<SEC-DOCUMENT>0000721371-20-000131.txt : 20201105
<SEC-HEADER>0000721371-20-000131.hdr.sgml : 20201105
<ACCEPTANCE-DATETIME>20201105161910
ACCESSION NUMBER:		0000721371-20-000131
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201105
DATE AS OF CHANGE:		20201105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		201290733

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:f4838a7d-79fc-48a1-8b7a-97e86b8356e3,g:0e31584d-c111-426d-9652-5609505543ae,d:84d08fd1ffc74d6494b61b46546492fc--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:cah="http://www.cardinal.com/20200930" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N18yLTEtMS0xLTA_65d228f3-1a86-4cff-accc-57dc5a687309">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N18zLTEtMS0xLTA_304e67de-87d6-4872-8ad8-d43bf7444c66">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N180LTEtMS0xLTA_3fa356af-f83d-4cac-89b7-f819897de1b1">2021</ix:nonNumeric><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N181LTEtMS0xLTA_d6b42868-1fb5-404e-9047-72fd57576d95">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N182LTEtMS0xLTA_c1782548-25b4-43c0-a363-d914ae4466c4">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib65a26413b874508a85f6777e242d835_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie14ef2e16a4341de83a616bd95c70060_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f40891839a4ff8ad0be8029fc7bfd7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a0d931ce9114013b82c3979d4b5e05b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294271bac59b4238aea6794f938ecb5e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia89288edcb8b47c297dde696b64571bb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f34ae0045b4d819eb72fa537be56f1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1773a34a7364c23ad4929d51cd3e157_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15805896000345a2aa639595943a623a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id41cee2cbbf94186823098ff6df8ac9d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab12b17254a47d586a4f825f9c57c99_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a8677c7cb741318b51781ad9f6c93d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0b0cb8b19e49fc80606766f904aa26_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff2fb339e24f483a8549de70efe24187_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86a90808957b4495abd9dc6d75d56f79_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7801ce08874014aa040090ccd71767_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i653c52bdb74a4a2a96fa0272a365cd9e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7475a55c7a2b497c85c0ca7944fc4f26_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8309f66561364b29839c307a5e8335a3_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e60c9a0ea354d95a50f7ca4fbb9cd93_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56ca687f7a1242d7bd026d4ff5c1e5ed_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b7f5e8f3b874a2eabbb08714f01af4c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49a22a27bb14af798584b89e48847e9_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7600f4c2e92b4932bd31018892472063_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd66c2d5fb84642b32933030ebed96e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09053d52c644470daa05bd64b11874a3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4663ceccbd74405690acfa2d2fb25056_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf2f42b91f3400680f775825de130a9_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e3bba2014545cda514af0b95f5bc4d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ac2341eaa1242f1aaba8d054128bda5_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id34905e19a1f4553a93dc88294b01178_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8807b0cd3a1a4aeca6c16a4e6b2aa3f7_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2cde32b3af84d33b1714302c8341607_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb6b2dd88864d668c5919feb00ee76c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c6be751ee64c558fe3494c112900ab_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2579521f524f83869e7f228bd84ff9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7037b2735b4e7f8e6c6f2d9b8d7038_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425faefcb193459095f9eb5f9e4acf2c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c1f80baf7644c585599ba8c1f2323c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8480697f2bdf44918df39a9f5e84e330_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48091522a54b466aaad728773c54a0a8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9da27597353943d181889c1d5456c85f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib649dc8198854be78403495cec1847cd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9929e41c0c24b0bba4c253330973f70_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0491c5bcabd34939b8a41c8f69eccb12_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i438081d1a6924fc1a9b6b1dd950a9fcd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021a5d537d2842cb817b9d054f4ff9b5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0adfa8f5d5214083a20b748280dfcefc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d951315c1c544ba967df1be4c66d58d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd2a95f5f2b4b88bbcc6c6297bc95d0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie926bbb0cbef440c994d8834ad4a9199_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf269ca481e4302b7d6164d95f0269a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia572b6f1eebf44cfbaeb9d8411357eca_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied58b175619b4bfebfb6b5b530246f5e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91fcd765710a4070b7c3c4036717d1cf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea560c27996450ea297ecbb41e9bf97_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bfc5884ee88416c9abb63244dab609c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i741ef9d887c94534a8eda6eccfbe2ad3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i119b91cee7ad43a3a902d392163cea9e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i771e1aea6b7f427a9df601aaf7660e54_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6561ef3f208042318b204d099ad1b0e0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939be74b35cc40a8969fcbc5e8654858_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reportable_segments"><xbrli:measure>cah:Reportable_Segments</xbrli:measure></xbrli:unit><xbrli:context id="i39e37f424f344ed4861a30e0289b675e_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1ec20ee64f4429a823a5f846ef8b554_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac21abb30a6046b1aaef99f6b707cbd5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd1e60e6ffd4307b7bf4207ea74288c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf9406084961493d9d4b3eb6d8055a86_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5b6097a61c849798a37a8304de056d5_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47435aa0ab74b408fd91dfc770477cc_D20201102-20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-02</xbrli:startDate><xbrli:endDate>2020-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if790e73672e840e5b0d954ff370e0e96_D20201102-20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-02</xbrli:startDate><xbrli:endDate>2020-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0a211a496049da89686dc5fe319089_D20201102-20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-02</xbrli:startDate><xbrli:endDate>2020-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefc77509e5de47719bffc603ae04f45c_D20201102-20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-02</xbrli:startDate><xbrli:endDate>2020-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f21d49611034f3fa4a6fb00669c782b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf6467237c464a1aa045646e1b87276b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia09951da05f64bf3a7732138bd69fdfc_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3306233e5db4b188aa16b734cd988cf_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f2e67b10f4d497fa601aa7acf5cafd5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia819620c77c04e44820e9270d0163402_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icee8303e1efb47e5b605a6d6693baa6d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i198d88ecb6cb419a8da8c55f4bdd2385_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90891cc2a4a8436bb9f99a47f2669996_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf6d9f7208624a0aa1b66fad4bab9571_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e11ec7b02f4f62aa657fb2116b44ad_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb4c3b745404fd9b199d24994707757_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821519601f81436faf796e3e48f6e226_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e14eef936ce478e977bd2365ab2dcc9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b43a414d2b4f6fa40be7cadc0a1262_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e3c7cc8bf8416a8084c477ef5ff7e1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f47cfe18fe54226a1df09ddb6efef0c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996aed144ffb4a48a0ee5fbb315c6670_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id645783b71294f05bb6047acb455691b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i269f7fc0ae604642a4a6a3d792040971_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6ccfc94660444b69cd33d2b61edc9e1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbaf94dcf17e4c03b40d6ee4e6a38630_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3ee5fbf2771456f9b16564e61ebe4f5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70de2fa7134c4f26a5575c7874c7dbc1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="id9465d58bd9c4791a0eb659e86c94043_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id083a10b766c4345a49d14f0632816a6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24179129a5974fea826c6897ed376db7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba45d8ce890d432cbb652a278df25802_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0d69c82422d48839b20ba8699842249_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76bcd37a41304f9a80edf0b488038276_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5672d212637f41acb8eb88dd1e16d3ab_I20191204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e8522d8b5645e79d6b9af6f3933166_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30acee2f999d4666aa8a690497305ee1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i364789c943c04565b9bde52a3752220d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e7580ef4ee445389920d8d3c96ab6c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d125daceaeb49239b6bf716b1f7b342_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia53329ae895148609299a5ce40e3c592_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cabdcfb164044c48c31dcddf5873c35_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i453407ee376d4fe78c2176a18171602c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic66e4cdcd5a046cfae01e323cbb8b418_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:context id="id8f75c382c1c4df691a419c0e178c753_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0defeec516474249b8995ba49880c24a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62af4253c8a346ccbeeba7311323f9a6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3b1bc368924c059f7e70628540e193_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2de354d09bc44a9fa3785d5625393d00_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3917f66b8f644838a6208b4c579c8bf_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09f112593ed04de0a5bb4ca0a2030c04_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b597f3573d47b49abc5302f1695a37_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecb54beca65c45029506df58645bad06_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a632d5955e4aa3866f348c953d8d08_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6e1c05bec24505be4e45733f808646_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781f2efb9025488d94dcbfda31c5bd48_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcebc361e52048eaba97198b6a5faba9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d88dbb2b05d4b1b89fa61aa66aedbad_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2cbf3fb2124481bec0997184cebcb1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d0e8c9c681b47eeb9760d46de31a6d1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52baa5c5a9654848bd9121d59999a39b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4974c67c114c848433b0dfc9102fde_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5632dcd9d2a4e40a78e375c76a736e3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c3a5767abd1403ab78e9bf2adee431c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dab659e59834b43b34ab0f7563c0c82_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7066c54e7dd4fceb8588adf471ba835_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i098156347d904aa088fa3e1e5127a1d4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75fa3de7c8a54b8b83706d76e4c35b76_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i857ee1bbc77f4af191655dfc896df4c3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2aeccd462de4b89be3251b77c14116a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7566b8915269491e8cf903384ee23182_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc62178c06b346f2a9d5381f46838f85_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad9b2879e704eba834be054682ed6c5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie19d22156ae648a3a872b2507b4de145_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc829ddfa7546fe9e92c22e0ea07a60_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ae4550dbfd4e139f3bcceb77e3e045_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e44ccff288b4a86886c5aab9864e13b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5efd6d972b064462a3d6638360713a1e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4631166cbef49ac95cee271f9ff8821_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72080d3b192041d29bdb612c6d87d607_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f40a80a6e5847bfa13e893d637f65d2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b231115e4c4896aea559547eb04df6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cdf4ef85d164520b43ff6d702fd42c4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i84d08fd1ffc74d6494b61b46546492fc_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF84NQ_2392e9e6-3f40-4967-b4f9-bfec65cb5cf7">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6NWQ5MzFmYjU2NmE5NDIyMGFkMjgwMzllMWNiNjFjNzcvdGFibGVyYW5nZTo1ZDkzMWZiNTY2YTk0MjIwYWQyODAzOWUxY2I2MWM3N18wLTAtMS0xLTA_c9a5e9fe-9ee2-428c-baaf-89b23565eb0a">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xMjI_546696f8-b79e-4788-9e68-93f653829630">September&#160;30, 2020</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6OGI0MzI0OTBkNWY4NDU4MjljZDM2ODc4NzliNmM5MDgvdGFibGVyYW5nZTo4YjQzMjQ5MGQ1Zjg0NTgyOWNkMzY4Nzg3OWI2YzkwOF8wLTAtMS0xLTA_a85b49aa-1fd4-4d81-bb2f-4b81674d7a79">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTA0_3d796855-157d-4575-96d9-0916d7dcd333">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTA1_7e15130d-e899-4588-9d99-a83671531a7a">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:566.25pt"><tr><td style="width:1.0pt"></td><td style="width:145.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:31.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8wLTAtMS0xLTA_c3df32ce-e458-4e21-aa78-7f333e6ff205">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8wLTYtMS0xLTA_b1d2ad4a-30be-4121-808f-fb3e32bffc29">31-0958666</ix:nonNumeric></span></td></tr><tr style="height:23pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8zLTAtMS0xLTA_d79b74f1-777b-4d5d-8bf0-5a8fe274d0d8">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8zLTItMS0xLTA_2398fc82-e68f-4b68-b1ac-3a3b43c6b7b3">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8zLTQtMS0xLTA_8b1490d4-5f9a-4677-b8db-4c868c62d537">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8zLTYtMS0xLTA_688f33d1-665c-46a9-be08-9bbb38b4f45b">43017</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTA2_b6858634-8381-4159-b4de-3e7862582e7d">614</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTAw_39e27a64-525c-45c2-88fd-7ac0608a18c9">757-5000</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:540.75pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:138.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6NGQwYmJhMmYwODQ1NGU1M2EwN2FmZTJkN2YyNzVkZWQvdGFibGVyYW5nZTo0ZDBiYmEyZjA4NDU0ZTUzYTA3YWZlMmQ3ZjI3NWRlZF8yLTAtMS0xLTA_964b5075-6324-424d-bc79-26394d2d7600">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6NGQwYmJhMmYwODQ1NGU1M2EwN2FmZTJkN2YyNzVkZWQvdGFibGVyYW5nZTo0ZDBiYmEyZjA4NDU0ZTUzYTA3YWZlMmQ3ZjI3NWRlZF8yLTEtMS0xLTA_6db00b44-db52-4574-b20d-7ab0d40daa1f">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6NGQwYmJhMmYwODQ1NGU1M2EwN2FmZTJkN2YyNzVkZWQvdGFibGVyYW5nZTo0ZDBiYmEyZjA4NDU0ZTUzYTA3YWZlMmQ3ZjI3NWRlZF8yLTItMS0xLTA_b38e02b7-29c9-4099-8a41-4de8c23f3645">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTAx_9168ad7f-61a3-46db-898f-967220bec7ce">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTAy_580a66ea-1b8d-4379-87c8-89d651cd6dec">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6MmVmMjM3MjRkOWNkNGM4YjliZjE5YTZkMWJkNWJhMDAvdGFibGVyYW5nZToyZWYyMzcyNGQ5Y2Q0YzhiOWJmMTlhNmQxYmQ1YmEwMF8wLTAtMS0xLTA_b765719a-f28c-47d8-9f71-060449f92b3c">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6MmVmMjM3MjRkOWNkNGM4YjliZjE5YTZkMWJkNWJhMDAvdGFibGVyYW5nZToyZWYyMzcyNGQ5Y2Q0YzhiOWJmMTlhNmQxYmQ1YmEwMF8xLTQtMS0xLTA_1e684231-b369-4f54-a684-9237c3e38b89">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6MmVmMjM3MjRkOWNkNGM4YjliZjE5YTZkMWJkNWJhMDAvdGFibGVyYW5nZToyZWYyMzcyNGQ5Y2Q0YzhiOWJmMTlhNmQxYmQ1YmEwMF8yLTQtMS0xLTA_8edf2660-0c99-4db1-912a-aa875f75c755">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTAz_72cbf7ca-7bc6-4930-bc3a-69c350ea562b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of October&#160;31, 2020, was the following: <ix:nonFraction unitRef="shares" contextRef="ib65a26413b874508a85f6777e242d835_I20201031" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xODk4_4af88f43-20bb-4d67-843c-7f597b54e4d3">293,420,561</ix:nonFraction>.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_7"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q1 Fiscal 2021 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.958%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:91.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_31">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_31">16</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_40">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_40">19</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_43">19</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_46">20</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_49">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_52">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_52">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_58">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_58">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_127">38</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_130">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_130">39</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_133">40</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc. is an Ohio corporation formed in 1979 and is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2021 and fiscal 2020 and to FY21 and FY20 are to the fiscal years ending or ended June&#160;30, 2021 and June 30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2020 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results, trends or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (our &#8220;2020 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations between the periods specified in our condensed consolidated balance sheets at September&#160;30, 2020 and June&#160;30, 2020, and in our condensed consolidated statements of loss for the three months ended September&#160;30, 2020 and 2019. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&amp;A included in our 2020 Form 10-K. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20200930_g1.jpg" alt="cah-20200930_g1.jpg" style="height:200px;width:250px;"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended September&#160;30, 2020 increased 5 percent to $39.1 billion due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings/(Loss)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating loss</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,264)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">618</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a GAAP operating loss of $624 million and $5.3 billion during the three months ended September&#160;30, 2020 and 2019, respectively, due to $1.02&#160;billion and $5.63&#160;billion pre-tax charges, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. See further description of opioid lawsuits in the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 7 percent increase in non-GAAP operating earnings to $618 million was primarily due to Medical segment cost savings.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.86)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.65)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.09</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.91</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.27&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS" or "diluted loss per share")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures". </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) First quarter fiscal 2021 and 2020 GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 and 296 million common shares, respectively, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the quarter. First quarter fiscal 2021 and 2020 non-GAAP diluted EPS is calculated using a weighted average of 295 and 297 million common shares, respectively, which includes potentially dilutive shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020 and 2019, we had GAAP diluted losses attributable to Cardinal Health, Inc. ("GAAP diluted EPS") of $(0.86) and $(16.65), respectively, due to the charges we recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. These opioid charges had a $(1.87) and $(17.40) after tax impact on GAAP diluted EPS during the three months ended September&#160;30, 2020 and 2019, respectively. Refer to Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A for additional detail. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, non-GAAP diluted EPS increased 19 percent to $1.51 per share. This increase was primarily due to the factors discussed above impacting non-GAAP operating earnings and lower interest expense due to less debt outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $2.7 billion at September&#160;30, 2020 compared to $2.8 billion at June&#160;30, 2020. Cash and equivalents were relatively unchanged during the three months ended September 30, 2020 with operating cash flow of $270 million offset primarily by $146 million paid in dividends and $78 million of capital expenditures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2021 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Opioid Lawsuits Development</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). Negotiations under the Settlement Framework continue to and have centered on the amount and timing for payment of the cash component as well as standards for settling distributors&#8217; controlled substance anti-diversion programs. Definitive terms for a settlement continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid lawsuits and these discussions, we recorded pre-tax charges of $1.02&#160;billion and $5.63&#160;billion during the three months ended September 30, 2020 and 2019, respectively, in litigation (recoveries)/charges, net, in the condensed consolidated statements of loss. We accrue for contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effect of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net tax benefits associated with the opioid litigation charges are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision/(benefit) for income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent.  Including the relatively lower tax benefit of the current quarter charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax benefit in the current quarter increased by approximately $450 million over the tax expense that would have been recognized without the impact of the opioid litigation charge and is expected to significantly increase our provision for income taxes during the remainder of fiscal 2021. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic associated with the novel strain of coronavirus ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As anticipated, Pharmaceutical segment profit was negatively impacted by COVID-19 during the three months ended September 30, 2020, largely due to volume declines in our generics program and Nuclear and Precision Health Solutions. Medical segment profit reflects an estimated minimal net impact from COVID-19 as the adverse effects of cancelled or deferred elective medical procedures were offset by the temporary reduction of certain costs and higher volumes in our laboratory business. Additionally, the impact of higher costs to source certain personal protective equipment ("PPE") was mostly mitigated by price increases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that the COVID-19 pandemic will have a further negative impact on fiscal 2021 consolidated operating earnings, and Pharmaceutical and Medical segment profit. However, we cannot estimate the length or severity of the COVID-19 pandemic or of the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related U.S. or global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow, and its impact may be greater or less than we anticipate.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20200930_g2.jpg" alt="cah-20200930_g2.jpg" style="height:200px;width:250px;"/><img src="cah-20200930_g3.jpg" alt="cah-20200930_g3.jpg" style="height:200px;width:250px;"/></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.705%"><tr><td style="width:1.0%"></td><td style="width:75.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,112</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,428&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,957</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,069</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,345&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 6.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,065</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,341&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-bottom:3pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment revenue increased during the three months ended September&#160;30, 2020 due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which together increased revenue by $1.7 billion.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue increased slightly during the three months ended September&#160;30, 2020 primarily due to sales growth from Cardinal Health at-Home Solutions, which increased revenue by $48 million. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold increased 5 percent to $37.4 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to the factors affecting the changes in revenue and gross margin.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><img src="cah-20200930_g4.jpg" alt="cah-20200930_g4.jpg" style="height:200px;width:250px;"/><img src="cah-20200930_g5.jpg" alt="cah-20200930_g5.jpg" style="height:200px;width:250px;"/></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,715</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin during the three months ended September&#160;30, 2020 increased slightly due to higher contribution from branded pharmaceutical sales mix.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gross margin rate declined 11 basis points during the three months ended September&#160;30, 2020 mainly due to changes in pharmaceutical distribution product mix. While branded pharmaceutical sales contributed positively to gross margin dollars during the three months ended September 30, 2020, they had a dilutive impact on our overall gross margin rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General, and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.705%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended September&#160;30, 2020, SG&amp;A expenses increased due to a judicial decision relating to a $41&#160;million assessment on prescription opioid medications that were sold or distributed in New York state in calendar year 2017 and 2018. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.  </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_118">Note 11</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20200930_g6.jpg" alt="cah-20200930_g6.jpg" style="height:200px;width:250px;"/><img src="cah-20200930_g7.jpg" alt="cah-20200930_g7.jpg" style="height:200px;width:250px;"/></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.705%"><tr><td style="width:1.0%"></td><td style="width:75.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">632</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,832)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,264)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, Pharmaceutical segment profit increased compared to the prior year period primarily due to higher contribution from branded pharmaceutical sales mix. Pharmaceutical segment profit was adversely impacted by COVID-19, primarily as a result of volume declines in our generics program and Nuclear and Precision Health Solutions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment financial results do not include the $1.02&#160;billion and $5.63&#160;billion charges associated with the opioid litigation during the three months ended September 30, 2020 and 2019, respectively. See the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note </a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. In addition, Pharmaceutical segment financial results do not include the $41&#160;million assessment on prescription opioid medications that were sold or distributed in New York state in calendar year 2017 and 2018. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The increase in Medical segment profit during the three months ended September&#160;30, 2020 was primarily due to cost savings, including global manufacturing efficiencies. Medical segment profit reflects an estimated minimal net impact from COVID-19 as the adverse effects of cancelled or deferred elective medical procedures were offset by the temporary reduction of certain costs and higher volumes in our  laboratory business. Additionally, the impact of higher costs to source certain PPE was mostly mitigated by price increases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three months ended September&#160;30, 2020 are due to the factors discussed in the Other Components of Consolidated Operating Loss section that follows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Loss</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin, and SG&amp;A expenses discussed previously, consolidated operating losses were impacted by the following:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:74.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020 and 2019, restructuring costs were primarily related to implementation of certain enterprise-wide cost-savings initiatives.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $115 million and $129 million for the three months ended September&#160;30, 2020 and 2019, respectively. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended September&#160;30, 2020 and 2019, we recognized pre-tax charges of $1.02&#160;billion and $5.63&#160;billion, respectively, associated with certain opioid matters. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of the "Notes to Condensed Consolidated Financial Statements" and the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Loss Before Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, loss before income taxes was impacted by the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income)/Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other (income)/expense, net during the three months ended September&#160;30, 2020 was primarily due to fluctuations in foreign exchange rates, and increased returns from investments, which offset fluctuations in deferred compensation liabilities that are included within SG&amp;A and discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_106">Note </a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_106">7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements".</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense during the three months ended September&#160;30, 2020 was primarily due to less debt outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for/(Benefit from) Income Taxes</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020 and 2019, the effective tax rate was 61.8 percent and 7.9 percent, respectively. The increase in the effective tax rate for the three months ended September 30, 2020 compared to the prior year period was primarily due to the treatment of the tax impacts of the opioid litigation accrual, partially offset by the prior-year benefit of discrete tax items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02 billion and $5.63&#160;billion pre-tax charges for the opioid litigation during the three months ended September&#160;30, 2020 and 2019, respectively, the net tax benefits are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision/(benefit) for income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent.  Including the relatively lower tax benefit of the current quarter charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax benefit in the current quarter increased by approximately $450 million over the tax expense that would have been recognized without the impact of the opioid litigation charge and is expected to significantly increase our provision for income taxes during the remainder of fiscal 2021. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations; tax payments; and current and projected debt service requirements, early extinguishment of debt, dividends and share repurchases as well as potential opioid litigation settlement payments associated with the Settlement Framework. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $2.7 billion at September&#160;30, 2020 compared to $2.8 billion at June&#160;30, 2020. At September&#160;30, 2020, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and equivalents were relatively unchanged during the three months ended September 30, 2020 with operating cash flow of $270 million offset primarily by $146 million paid in dividends and $78 million of capital expenditures. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases and payments to vendors in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at September&#160;30, 2020 included $573 million of cash held by subsidiaries outside of the United States. </span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at September&#160;30, 2020 include a $2.0 billion commercial paper program, backed by a&#160;$2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;September&#160;30, 2020, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit facility and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter from through December 2020, a consolidated net leverage ratio of&#160;no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every fiscal quarter thereafter. At September 30, 2020, we were in compliance with our financial covenants. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$6.7 billion and $6.8 billion at September&#160;30, 2020 and June&#160;30, 2020, respectively. During the three months ended September&#160;30, 2020, we repurchased a total of $37 million of notes due in 2022 with available cash. </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opioid Settlement Framework</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had $6.59 billion accrued at September 30, 2020 related to certain opioid litigation, as further described within the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of the "Notes to Condensed Consolidated Financial Statements." Negotiations under the Settlement Framework continue regarding, among other things, the amount and timing for payment of the cash component. If a definitive agreement is reached, and subject to participation by states and political subdivisions, we expect the majority of payment amounts to be spread over 18 years. We cannot currently predict when those payments might begin, and it is possible that all or part may ultimately be made over a different time period, or not at all. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the three months ended September&#160;30, 2020 and 2019 were $78 million and $72 million, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 11, 2020 and August 6, 2020, our Board of Directors approved a quarterly dividend of $0.4859 per share, or $1.94 per share on an annualized basis, which were paid on July 15, 2020 and October 15, 2020 to shareholders of record on July 1, 2020 and October 1, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2020, our Board of Directors approved a quarterly dividend of $0.4859 per share, or $1.94 per share on an annualized basis, payable on January 15, 2021 to shareholders of record on January 4, 2021.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in our 2020 Form 10-K addresses our contractual obligations and off-balance sheet arrangements, as of and for the fiscal year ended June 30, 2020.  There have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div id="i84d08fd1ffc74d6494b61b46546492fc_28"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below are supplemental disclosures to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheets at </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2020</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2020 Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as described further in the Significant Developments in Fiscal 2021 section in this MD&amp;A, we recorded pre-tax charges of $1.02 billion and $5.63 billion, during the three months ended September 30, 2020 and 2019, respectively. We accrue for contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02 billion and $5.63&#160;billion pre-tax charges for the opioid litigation during the three months ended September&#160;30, 2020 and 2019, respectively, the net tax benefits are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision/(benefit) for income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent.  Including the relatively lower tax benefit of the current quarter charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax benefit in the current quarter increased by approximately $450 million over the tax expense that would have been recognized without the impact of the opioid litigation charge and is expected to significantly increase our provision for income taxes during the remainder of fiscal 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, evaluate the balance sheet, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. We did not recognize any LIFO charges or credits during the periods presented.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Surgical gown recall costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes inventory write-offs and certain remediation and supply disruption costs arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Reversals of these accruals have occurred when the underlying assessments were invalidated by a Court.  </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Litigation recoveries or charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Transitional tax benefit, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.  </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> operating loss excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes: </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, and (8) loss on early extinguishment of debt. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ne</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t loss</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt, each net of tax, and (9) transitional tax benefit, net. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7)  litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt, and (9) transitional tax benefit, (net) divided by (loss before income taxes adjusted for the first eight items). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.703%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings/(Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) Before Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for/ (Benefit from) Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1,2</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(663)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(410)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(253)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.86)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.09</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">479</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">559</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.91</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">618</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">580</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">134</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">445</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,264)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,344)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,922)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.65)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.27&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">2&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:107%">First quarter fiscal 2021 and 2020 GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 and 296 million common shares, respectively, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the quarter. First quarter fiscal 2021 and 2020 non-GAAP diluted EPS is calculated using a weighted average of 295 and 297 million common shares, respectively, which includes potentially dilutive shares.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net includes pre-tax charges of $1.02 billion and $5.63 billion recorded in the first quarter of fiscal 2021 and 2020, respectively, related to the opioid litigation. For fiscal 2021, including the tax effects of opioid litigation charges in the calculation of the estimated annual effective tax rate  increased the amount of tax benefit in the current quarter by approximately $450 million and is expected to significantly increase the provision for income taxes during the remainder of the fiscal year. The current estimate of net tax benefits is $35 million and $488 million for fiscal 2021 and 2020 in connection with opioid lawsuit developments.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="i84d08fd1ffc74d6494b61b46546492fc_40"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in our&#160;2020&#160;Form 10-K since the end of fiscal&#160;2020&#160;through&#160;September&#160;30, 2020.</span></div><div id="i84d08fd1ffc74d6494b61b46546492fc_43"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of September&#160;30, 2020. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of September&#160;30, 2020, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended&#160;September&#160;30, 2020&#160;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Implementation of Business Improvement Initiatives</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business improvement initiatives underway that we expect to affect internal control over financial reporting beginning in the three months ended December 31, 2020. During fiscal 2021, as a part of an ongoing effort to optimize and simplify our operating model, we are in the process of transitioning portions of our finance operations to a global professional services firm. Additionally, the Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating information systems. If either of these initiatives are not effectively implemented, or fail to operate as intended, it could adversely affect our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeding described below, the legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court consolidated the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. The amended consolidated derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In June 2020, the defendants filed a motion to dismiss the complaint.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q and the risk factors discussed in "Risk Factors" and other risks discussed in our 2020 Form 10-K and our filings with the SEC since June&#160;30, 2020. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i84d08fd1ffc74d6494b61b46546492fc_52"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:15.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(2)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.25&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.63&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,489</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51.08</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">943</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects common shares purchased through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expires on December 31, 2021 and as of September 30, 2020, we have $943 million authorized for share repurchases remaining under this program.</span></div><div id="i84d08fd1ffc74d6494b61b46546492fc_55"></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Loss</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMi0xLTEtMS0w_afa53e97-0136-4996-b5ef-c1e56b19df1a">39,065</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMi0zLTEtMS0w_a9358593-699a-4bdf-918a-88fbc5876b12">37,341</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMy0xLTEtMS0w_ab9efb76-192e-476e-94c8-d44d11818a61">37,350</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMy0zLTEtMS0w_500a27b4-4278-4df8-b972-1e257ee90f2d">35,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfNC0xLTEtMS0w_d23b5a57-8f02-4893-80ed-f4a17942e8e4">1,715</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfNC0zLTEtMS0w_b3843f64-6b36-4fb3-af8f-03b8155ac044">1,679</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfNy0xLTEtMS0w_61bae5b7-0642-4cfd-bee8-bd9ab7bd5aca">1,137</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfNy0zLTEtMS0w_3e17e3e0-4176-499b-bb06-ce0158bf3682">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfOC0xLTEtMS0w_d77a4a0b-44d6-4690-b565-e942ccdb870f">37</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfOC0zLTEtMS0w_af0fbfc6-3037-41cf-b465-69896fb17fec">30</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfOS0xLTEtMS0w_10f6f738-bc34-40c4-b289-e9d8972fbeb0">118</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfOS0zLTEtMS0w_b54140ad-831a-427a-9597-8eff77645560">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTAtMS0xLTEtMA_f0a7715e-1911-4b84-8fda-51816f1e0c6c">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTAtMy0xLTEtMA_00e9d090-8963-4470-b568-8349778d14b4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTEtMS0xLTEtMA_05f35b6f-0918-4127-9d24-cafb7e2c137d">1,038</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTEtMy0xLTEtMA_cc86dda5-8d6b-407c-8455-c4e65e3a6459">5,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTItMS0xLTEtMA_acb98e8d-3839-4494-aa86-63ff78a2dbd2">624</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTItMy0xLTEtMA_2efd8bbd-a76d-41c3-9dd6-83b3b639f6d1">5,264</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTQtMS0xLTEtMA_e3edd258-a125-4296-a971-9ca5db196a65">7</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTQtMy0xLTEtMA_557f8e4a-f012-4fd0-8e44-bcf858f23fea">14</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTUtMS0xLTEtMA_64eb7b90-3b5f-497e-b247-d4278a7e3607">45</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTUtMy0xLTEtMA_f79722e2-4baf-4a7f-9416-f163d2831132">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTYtMS0xLTEtMA_89215112-1ccc-417c-9d94-eafb08a5b9d8">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTYtMy0xLTEtMA_cc37e363-c607-4a61-8d90-0e1e111ecc0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTctMS0xLTEtMA_bef17080-43c1-47f2-bbf0-1fb42eaf0e3d">663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTctMy0xLTEtMA_9d872721-d626-4716-912e-6814f1c2ec67">5,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for/(benefit from) income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTktMS0xLTEtMA_e8e5b488-1c27-4d13-baa5-e82e6acda9ad">410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTktMy0xLTEtMA_ae300862-41c4-4157-85a8-2aa5e604a81e">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjAtMS0xLTEtMA_b2490442-0a29-4a99-a0fd-204faf270df3">253</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjAtMy0xLTEtMA_2d8ad3d5-6657-45b7-83ae-8d18adac12ff">4,921</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Less: Net earnings attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjUtMS0xLTEtMA_bbe5a379-45b4-43f2-b118-574fd8965b56">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjUtMy0xLTEtMA_d3ef08b9-471b-4246-b1d3-a4f96a493e49">1</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss attributable to Cardinal Health, Inc. </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjYtMS0xLTEtMA_d247fec4-c37d-422e-b9e7-f11f8b28de6f">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjYtMy0xLTEtMA_838367ee-74ca-466b-a32a-86a26862eee0">4,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#c4c4c4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjktMS0xLTEtMA_0c20577a-dcf0-451b-be54-1641e0f3917f">0.86</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c4c4c4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjktMy0xLTEtMA_d57726b0-c9f7-4fa8-a171-9fc39de4f75a">16.65</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzAtMS0xLTEtMA_6db0d192-7215-4b35-b0e1-353f49d7e9f5">0.86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzAtMy0xLTEtMA_67e3e28e-183f-4a16-8b90-b651f9a116b4">16.65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzMtMS0xLTEtMA_434ed15b-fbf8-4d46-aa5c-4c33a66b4037">293</ix:nonFraction></span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzMtMy0xLTEtMA_fad8d6f8-c33e-421d-ab7e-bb46c41c9243">296</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzQtMS0xLTEtMA_2585ed94-b7b1-4dd7-acaf-eaab431c2877">293</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzQtMy0xLTEtMA_7f22aeb3-2c4e-4462-aa3a-e7c20a345b48">296</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzYtMS0xLTEtMA_2935d489-21f4-45ab-8dfa-b90b2995e1f1">0.4859</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzYtMy0xLTEtMA_e948f0e8-378f-4f0e-9574-5557855c679b">0.4811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMi0xLTEtMS0w_b2490442-0a29-4a99-a0fd-204faf270df3">253</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMi0zLTEtMS0w_2d8ad3d5-6657-45b7-83ae-8d18adac12ff">4,921</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNS0xLTEtMS0w_43ff63d6-8b09-4a0f-ac2d-b051f5a3d7b6">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNS0zLTEtMS0w_44297ab7-113f-4d89-b59d-3efbd93860be">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on derivative instruments, net of tax</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNi0xLTEtMS0w_29326c80-ddc0-43c9-bcb3-bef6c3ddc855">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNi0zLTEtMS0w_d793785f-7a65-4daa-af4f-5ef7bd967b08">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNy0xLTEtMS0w_0aa6b9d0-0a95-4cd8-a051-cb64f43e62a2">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNy0zLTEtMS0w_59fd98b5-230b-48f9-bd01-40b7711716c7">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfOS0xLTEtMS0w_13b37bc0-9f53-4398-b428-c18028a19b2b">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfOS0zLTEtMS0w_e5467240-ee58-48e8-bfc9-dbffe27fab0d">4,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMTEtMS0xLTEtMA_0742bf18-4cab-4d3e-aab5-7a1b6e9dd6a9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMTEtMy0xLTEtMA_a2a74775-ff99-48fa-9ae1-2255d52108ef">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive loss attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMTMtMS0xLTEtMA_4f01ee9f-efaa-4cf2-a794-684ee3fdbc1a">236</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMTMtMy0xLTEtMA_93eb34b3-a87e-484b-a73c-114eb53e12a2">4,944</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMy0xLTEtMS0w_2b244cf3-6228-4709-815d-fd58cd4e8a61">2,746</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMy0zLTEtMS0w_b8cb326a-86e2-410f-8863-1de26bad1ed6">2,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNC0xLTEtMS0w_c4592acc-0877-42bb-8d1b-9a5858ceadc6">8,637</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNC0zLTEtMS0w_a1a9a023-7dbb-4c93-851b-7cc40e8eff5a">8,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNS0xLTEtMS0w_e934cf45-5d74-470c-bbe0-99c2b2775ee1">13,439</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNS0zLTEtMS0w_277031c4-aa59-4662-9536-cd622f5c5dd4">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNi0xLTEtMS0w_3e99c390-a024-4316-9176-0e8d16ce66eb">2,208</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNi0zLTEtMS0w_0347ac32-4077-414c-aada-265924904da8">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfOC0xLTEtMS0w_d4464e85-cc74-47dc-8d41-4f731a1d49fc">27,030</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfOC0zLTEtMS0w_7c793fcc-6293-4191-a6d9-eb8904df29cb">25,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTAtMS0xLTEtMA_a8131361-4404-4063-9fa7-3e1a1a2c9f8a">2,369</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTAtMy0xLTEtMA_29345203-b642-4ad0-97a5-b562033decb2">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTEtMS0xLTEtMA_b0f1bd37-d3e1-4bfe-99a8-fb0c64932427">11,186</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTEtMy0xLTEtMA_143ff88b-fced-4d40-b7f0-c46a080026e9">11,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTMtMS0xLTEtMA_62227f2a-fe5b-427b-bf14-9f983f5868e6">1,142</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTMtMy0xLTEtMA_afe877aa-547d-4972-b1ed-90f2286c537b">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTQtMS0xLTEtMA_efe14f33-a52b-48c7-b352-067bd9689f4c">41,727</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTQtMy0xLTEtMA_84b682e4-0736-4f00-8f5f-82d277003fce">40,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTgtMS0xLTEtMA_171360c8-b90e-4ad8-a838-de8c0d5575a6">21,688</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTgtMy0xLTEtMA_74edffcb-f7b8-4459-80e6-aac1133c7fce">21,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTktMS0xLTEtMA_381244a6-0e54-47ec-85bd-88c8e5ac98e8">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTktMy0xLTEtMA_ee6c8603-e4eb-4102-b193-f8e58ac19d55">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjAtMS0xLTEtMA_a7b0aaa5-5dbf-4e59-bc78-3fbb34761507">2,316</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjAtMy0xLTEtMA_f8f78c91-c525-43f2-8268-66ba9896f689">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjItMS0xLTEtMA_3c1e6148-aaf5-4187-9de5-b5b582f79946">24,016</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjItMy0xLTEtMA_03e4c5e1-538e-43f9-b198-ca14b59dcdc0">23,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjQtMS0xLTEtMA_d1920119-b6f4-474e-a97c-4e8c4ab4dbd6">6,728</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjQtMy0xLTEtMA_6e986a12-ba0b-48cd-8a38-9247eedd42ae">6,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjUtMS0xLTEtMA_042ee7b3-19ec-4eab-a1f1-86f44e0a6be5">9,558</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjUtMy0xLTEtMA_b96b3f01-e9af-4cad-a23e-633240983b74">8,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmVjZWI1ZDBkNDgyMDQ0YzU4MzU4YmZhODM5MTViODhlXzgyNDYzMzcyMDgzODA_32a85c2b-cc05-44e9-9aba-7e72d86e1643"><ix:nonFraction unitRef="shares" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmVjZWI1ZDBkNDgyMDQ0YzU4MzU4YmZhODM5MTViODhlXzgyNDYzMzcyMDgzODA_7602f5dd-0fc2-42cc-ada6-1eba9dd139fe">500</ix:nonFraction></ix:nonFraction> thousand</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmVjZWI1ZDBkNDgyMDQ0YzU4MzU4YmZhODM5MTViODhlXzc2OTY1ODEzOTQ2OTY_80967284-98ae-493d-92e0-a15ee26e0cda"><ix:nonFraction unitRef="shares" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmVjZWI1ZDBkNDgyMDQ0YzU4MzU4YmZhODM5MTViODhlXzc2OTY1ODEzOTQ2OTY_a794d2d7-7822-4026-a211-df623f175e4e">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMS0xLTEtMA_05c4daf8-c65c-44da-82a0-e6b910eccee4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMy0xLTEtMA_8d621111-a8b3-4481-b1c7-054ab18ba1d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjhlOTBiNDdkYTZlZDRjYmY4MDBkNDcyMjkyMTg0ZDU1XzgyNDYzMzcyMDg0ODY_588edacd-672b-4aa3-85c7-e33a891bda26"><ix:nonFraction unitRef="shares" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjhlOTBiNDdkYTZlZDRjYmY4MDBkNDcyMjkyMTg0ZDU1XzgyNDYzMzcyMDg0ODY_5e339fbf-8763-4b55-8c5b-9f9fcc87483d">755</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjhlOTBiNDdkYTZlZDRjYmY4MDBkNDcyMjkyMTg0ZDU1XzgyNDYzMzcyMDg1MDE_43606707-242a-4df4-a77c-76840360c634"><ix:nonFraction unitRef="shares" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjhlOTBiNDdkYTZlZDRjYmY4MDBkNDcyMjkyMTg0ZDU1XzgyNDYzMzcyMDg1MDE_89b43bfa-5f1b-4591-a3b1-8871e34e3e9a">327</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">and June 30,2020, respectively</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMS0xLTEtMA_3db15bf0-4d33-4929-8334-eb87165ac0ce">2,760</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMy0xLTEtMA_90c93230-8767-4308-a635-73e0ada6edc1">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzItMS0xLTEtMA_e4575651-3e24-4750-ba90-31cebf1b0871">771</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzItMy0xLTEtMA_f294c95a-86fb-4d8f-9b05-0d13625df95b">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares in treasury, at cost:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> <ix:nonFraction unitRef="shares" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE0MjI4NjRiYjIxODRhYTRiNDFjNDgzNmQ0ODQ4NWU3Xzc2OTY1ODEzOTQ2MjA_2edc19de-1790-437c-a349-2e572b5dc730">33</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares and <ix:nonFraction unitRef="shares" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE0MjI4NjRiYjIxODRhYTRiNDFjNDgzNmQ0ODQ4NWU3Xzc2OTY1ODEzOTQ2MzQ_a8d10c2d-38eb-4887-b27b-9710e2f4824a">34</ix:nonFraction> million shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> and June 30, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzMtMS0xLTEtMA_f8e3e04e-2e6d-4aeb-b0b5-cb8ed4fc674d">2,022</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzMtMy0xLTEtMA_6b05184a-c42b-4196-a561-46253c504e2b">2,066</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzQtMS0xLTEtMA_16484406-f141-4012-afd7-6d5aad89878c">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzQtMy0xLTEtMA_bd6ed05f-9bb8-4d8f-9a35-3966d4e9e86f">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' equity</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzUtMS0xLTEtMA_ae5991e2-17c7-42ee-a821-9f5ad077fe7f">1,422</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzUtMy0xLTEtMA_b859cdcd-466b-47ad-9d1e-5f1918432bec">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzYtMS0xLTEtMA_75df4781-351a-4ad7-ba96-592588a478f7">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzYtMy0xLTEtMA_78e3e400-7430-4b74-8739-0aafc68b81ae">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzctMS0xLTEtMA_c83fe184-803c-47e5-aa06-1bf207ac8828">1,425</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzctMy0xLTEtMA_aa88c7e3-3c76-44c6-8ae5-2181cb531c8c">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzgtMS0xLTEtMA_fd02b521-a0b5-4ac3-a5ff-69f948310053">41,727</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzgtMy0xLTEtMA_cc41e1cd-123f-45f2-891b-59ef0951fb33">40,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' Equity</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46f40891839a4ff8ad0be8029fc7bfd7_I20200630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0xLTEtMS0w_ebc840b4-3b64-4862-92b8-89775e42eee6">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f40891839a4ff8ad0be8029fc7bfd7_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0zLTEtMS0w_ca76e8cc-41e3-46b5-8849-82ff85a42513">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0d931ce9114013b82c3979d4b5e05b_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy01LTEtMS0w_a8aca732-202d-4f0f-9282-60c54bf0ea29">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i294271bac59b4238aea6794f938ecb5e_I20200630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy03LTEtMS0w_493d25c1-1458-48a1-bb3a-c937c85923a2">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i294271bac59b4238aea6794f938ecb5e_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy05LTEtMS0w_eaa450e2-9e77-4390-9af1-8c46e5840375">2,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia89288edcb8b47c297dde696b64571bb_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0xMS0xLTEtMA_2fc1d1c3-4c4b-4ec9-bfee-05bd87ae0946">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f34ae0045b4d819eb72fa537be56f1_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0xMy0xLTEtMA_39e66775-7ad8-4855-b55c-d9df12acb353">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0xNS0xLTEtMA_a158e0ac-b7fe-4bcb-89dd-7d75faa923c2">1,792</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNC01LTEtMS0w_d247fec4-c37d-422e-b9e7-f11f8b28de6f">253</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1773a34a7364c23ad4929d51cd3e157_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNC0xMy0xLTEtMA_a78ed7b5-1292-4e12-ba3f-d5c9c634c7a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNC0xNS0xLTEtMA_1bc1880b-c546-4982-9333-216d3ea79bd5">253</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15805896000345a2aa639595943a623a_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNS0xMS0xLTEtMA_e073974a-808c-4410-a011-c4d72207b635">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNS0xNS0xLTEtMA_9e24c08b-0068-4555-b869-4ed93bcb7ca7">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id41cee2cbbf94186823098ff6df8ac9d_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNy0zLTEtMS0w_e9351c46-7c88-498b-9226-0b4ab13aeb63">29</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ab12b17254a47d586a4f825f9c57c99_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNy03LTEtMS0w_fa51cb3d-4b8a-4f6f-82ce-779dcd76a44f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab12b17254a47d586a4f825f9c57c99_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNy05LTEtMS0w_e00e4793-f2c9-4202-82e8-df3f2d8dca32">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNy0xNS0xLTEtMA_46ccc304-c1ae-40ae-bf1c-8b169bc23da2">15</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6a8677c7cb741318b51781ad9f6c93d_D20200701-20200930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfOS01LTEtMS0w_91f5de83-9107-430a-8a62-8c966dbf30bb">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfOS0xNS0xLTEtMA_f858a288-bf8b-4b18-a45e-4c20fff966ea">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb0b0cb8b19e49fc80606766f904aa26_I20200930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMS0xLTEtMA_bf37653e-1c05-4cf9-9b50-f7e67c95f776">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb0b0cb8b19e49fc80606766f904aa26_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMy0xLTEtMA_2c67ebff-e31f-4aad-af52-a87a7aba4542">2,760</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2fb339e24f483a8549de70efe24187_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItNS0xLTEtMA_3d19461a-464c-46f0-8d7c-d30d3a6b0a20">771</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i86a90808957b4495abd9dc6d75d56f79_I20200930" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItNy0xLTEtMA_cc2a7625-9223-45ee-9f7c-c269ad4a85d9">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86a90808957b4495abd9dc6d75d56f79_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItOS0xLTEtMA_c3f79926-4ecc-42e3-8128-6e85116e3a3d">2,022</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f7801ce08874014aa040090ccd71767_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMTEtMS0xLTA_fb67db12-d498-4895-8034-046714354cfc">87</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653c52bdb74a4a2a96fa0272a365cd9e_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMTMtMS0xLTA_7080de58-91ef-4bb7-af12-941f52528cc7">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMTUtMS0xLTA_a23446f2-da14-4028-bdd5-dceca41d82a4">1,425</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7475a55c7a2b497c85c0ca7944fc4f26_I20190630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0xLTEtMS0yOA_0ac39e6f-fd8a-444c-80d8-bf11a072e773">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7475a55c7a2b497c85c0ca7944fc4f26_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0zLTEtMS0xMjY_d4407d4c-2960-4015-a69e-f69350be5080">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8309f66561364b29839c307a5e8335a3_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS01LTEtMS0xMjk_dddd321d-621c-4819-a605-c4369ee7379e">5,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5e60c9a0ea354d95a50f7ca4fbb9cd93_I20190630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS03LTEtMS0xMzI_f79abcb2-e75a-4413-aca0-c1186eb9b930">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e60c9a0ea354d95a50f7ca4fbb9cd93_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS05LTEtMS0xMzU_f0e60a8d-072a-4e05-af06-b1f2b43e0552">1,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56ca687f7a1242d7bd026d4ff5c1e5ed_I20190630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0xMS0xLTEtMTM4_eb793af5-8f82-42f5-87ef-35321c1fc1b9">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b7f5e8f3b874a2eabbb08714f01af4c_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0xMy0xLTEtMTQx_d1cfc774-591f-4c90-9a97-402232cb2fb0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49a22a27bb14af798584b89e48847e9_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0xNS0xLTEtMTQ0_c43273e1-5e4f-4b0d-b691-4cd8b2f33c60">6,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMi01LTEtMS0xODc_70ab3979-f283-49af-8fca-e64d8740ccd2">4,922</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7600f4c2e92b4932bd31018892472063_D20190701-20190930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMi0xMy0xLTEtMTQxOA_f59498e9-8d8b-4d73-89b9-a38938f15503">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMi0xNS0xLTEtMTkx_b37fa2ba-cc56-4ce4-a73c-ff19e32fbaf7">4,921</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bd66c2d5fb84642b32933030ebed96e_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMy0xMS0xLTEtMTM2Mg_0095157c-7ae3-45ba-aff5-eb4ff966ecbe">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMy0xNS0xLTEtMTk0_b2bcdfbd-cbbc-4abe-8f0c-e0144c29602b">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09053d52c644470daa05bd64b11874a3_D20190701-20190930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNS0zLTEtMS00Njk_01659686-b953-4e3b-bea3-b1ef88b1a6cc">24</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNS05LTEtMS00NzI_43a7d6c9-dce9-4e54-b70f-fe88e57222b7">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNS0xNS0xLTEtMjAx_ff3c38e8-7db5-4069-b460-ff39eb126f92">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09053d52c644470daa05bd64b11874a3_D20190701-20190930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNi0zLTEtMS0xMzcx_54893a3d-402f-47af-9eeb-e690b2fe654c">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNi03LTEtMS0xMzc0_7fb7fe57-38a5-4a1a-b0aa-146f6dec274c">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNi05LTEtMS0xMzc3_27c49e65-3cf6-4448-a5dd-18e3271fe034">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNi0xNS0xLTEtMjA0_c37b62a3-78ef-4486-a125-901ce341304d">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4663ceccbd74405690acfa2d2fb25056_D20190701-20190930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNy01LTEtMS0xMzgw_8c6f7e61-786f-4b5c-9468-785d7c04004a">141</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNy0xNS0xLTEtMjA3_a521f01b-40c8-4f66-badd-b31fc266451c">141</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cf2f42b91f3400680f775825de130a9_I20190930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMS0xLTEtMTM5NA_4f975191-8a3a-401b-9684-b16d453dd754">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf2f42b91f3400680f775825de130a9_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMy0xLTEtMTM5Nw_587001b2-2492-4ed6-9c96-009286504eb7">2,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e3bba2014545cda514af0b95f5bc4d_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtNS0xLTEtMTQwMA_f2265a3e-a748-4edf-97bf-3413116a555a">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ac2341eaa1242f1aaba8d054128bda5_I20190930" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtNy0xLTEtMTQwMw_9d6aa5f9-6235-4a1d-9b29-d9851cd11a11">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ac2341eaa1242f1aaba8d054128bda5_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtOS0xLTEtMTQwNg_a5b55915-b101-4f51-b0ca-4a6c810bd005">2,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34905e19a1f4553a93dc88294b01178_I20190930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMTEtMS0xLTE0MDk_7b95b0c4-6fc0-4ad3-abc9-26e4d054f274">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8807b0cd3a1a4aeca6c16a4e6b2aa3f7_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMTMtMS0xLTE0MTI_12b6da7d-9dc7-4b81-97c9-a8668b6ecdcc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2cde32b3af84d33b1714302c8341607_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMTUtMS0xLTE0MTU_89a9f614-8bb9-4942-96bc-781c95b374d0">903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMy0xLTEtMS0w_b2490442-0a29-4a99-a0fd-204faf270df3">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMy0zLTEtMS0w_2d8ad3d5-6657-45b7-83ae-8d18adac12ff">4,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by/(used in) operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNi0xLTEtMS0w_85476d04-a067-4ab0-a314-e4719c4f6c20">205</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNi0zLTEtMS0w_501a8ca1-0671-4cf4-b480-12fb205c806e">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfOC0xLTEtMS0w_a10b325f-a0e4-4f70-b70f-874a51cdf775">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfOC0zLTEtMS0w_466c2cef-c903-4584-8410-2ef8bcc85563">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfOS0xLTEtMS0w_cdfbddcf-e704-4ee9-881e-240d7aa31385">28</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfOS0zLTEtMS0w_5eaec63c-1767-4c4d-96b6-61fb53764dd4">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTAtMS0xLTEtMA_fa6f51bf-b19d-40a9-8f0b-4a80e20af9e0">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTAtMy0xLTEtMA_2621561e-0e0e-478f-9d37-6a332d4cb004">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Increase)/decrease in trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTMtMS0xLTEtMA_cc08aeb7-c9fa-4662-9096-8c079adc7576">388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTMtMy0xLTEtMA_ead6ee3f-93cd-4f9a-b4ad-6789965f973b">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Increase)/decrease in inventories</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTQtMS0xLTEtMA_be2aaf81-81aa-4bdd-9785-3a48c3c9b455">245</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTQtMy0xLTEtMA_56fe2c78-1602-4c1c-80fe-577f37c248b1">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase/(decrease) in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTUtMS0xLTEtMA_1a95ed02-24be-4450-951f-19667b2a085d">313</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTUtMy0xLTEtMA_c96dd8a7-8f18-4284-8c59-f7aababb9a61">1,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTYtMS0xLTEtMA_0ada9aa7-aedc-44e6-9730-b5aec3fe4fec">585</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTYtMy0xLTEtMA_0084b2f3-4cbf-4603-86ac-5b77dd27c2da">5,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTctMS0xLTEtMA_fd2bc096-b069-412a-8294-750cdd7b1876">270</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTctMy0xLTEtMA_4d7dbece-c6d6-4cb4-8c45-9a995749d9bf">653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjEtMS0xLTEtMA_7fdfb87e-f696-423d-aaac-4ea0cef6d0fe">78</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjEtMy0xLTEtMA_01929fce-9583-497d-9582-3006532fd7ea">72</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjItMS0xLTEtMA_8ed720e7-768c-4807-a272-554ec63394d7">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjItMy0xLTEtMA_b43ede6b-1ba3-4ea4-af16-664e32d146b4">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjMtMS0xLTEtMA_7dc9181e-f6cf-4825-846f-0fc8ae906a90">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjMtMy0xLTEtMA_e0cac445-5f98-4693-b533-d687831d1bcb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjYtMS0xLTEtMA_59aa2b1e-a225-4770-b187-86d56c455858">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjYtMy0xLTEtMA_56df8c52-1edd-4996-ac4d-fd4761102db2">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzAtMS0xLTEtMA_36e47ba1-5140-437e-a566-d1af399ec487">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzAtMy0xLTEtMA_e4b2cece-4738-497e-a919-16248f1e98b9">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzEtMS0xLTEtMA_8cf98a99-b9da-429e-88c6-2b3e59e75ad3">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzEtMy0xLTEtMA_6913d0b7-a20d-454f-8f48-aba2456f636c">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax withholdings from share-based compensation</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzMtMS0xLTEtMA_61058849-fb9d-4e6d-b9c1-fc262af3f881">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzMtMy0xLTEtMA_65a81ade-5734-4df3-a0b3-b9d449f1a688">13</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzQtMS0xLTEtMA_550ebd7f-f945-4591-979b-ec6b2cdee35a">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzQtMy0xLTEtMA_1fb8d48a-84b8-47e5-b510-0210064089ee">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzUtMS0xLTEtMA_c3e89ae9-234a-4daa-ab68-84c346a698cd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzUtMy0xLTEtMA_503c3675-10d4-4925-a9f6-575001d590f4">350</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzYtMS0xLTEtMA_030bfcdb-7884-4db6-9243-31be4e9437c7">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzYtMy0xLTEtMA_b1f3bcf2-fce2-4d6d-8428-388bbd5ad037">585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzgtMS0xLTEtMA_b0c339b8-56f9-4bfd-9db8-cdaaa485eb82">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzgtMy0xLTEtMA_403623ed-3b17-49cb-bfaa-f2320e620b5c">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDAtMS0xLTEtMA_b05e792a-3cff-460f-b9cd-b0dc7fbe8452">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDAtMy0xLTEtMA_e24ec8e9-e746-4b93-882a-73e02b6138f3">1,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDEtMS0xLTEtMA_876e7b26-5d3a-4463-9ffb-91a724d8685d">2,771</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49a22a27bb14af798584b89e48847e9_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDEtMy0xLTEtMA_14ee07a0-5d05-448c-91ba-99656a218f7b">2,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDItMS0xLTEtMA_536c6b62-cd48-4a9d-b0eb-234c7df11103">2,746</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2cde32b3af84d33b1714302c8341607_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDItMy0xLTEtMA_f9c36ff9-bc1f-4236-8fb8-2f55dffee995">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements </span></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div id="i84d08fd1ffc74d6494b61b46546492fc_79"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183OS9mcmFnOmFiNzA5ZjAzM2IwYzQ2YTI5ZDg5N2NlNTFhZmI5YWRiL3RleHRyZWdpb246YWI3MDlmMDMzYjBjNDZhMjlkODk3Y2U1MWFmYjlhZGJfNDc3Mw_72e77671-1925-4cce-8a9b-349066a02a51" continuedAt="i83492dbd4b0648a3bec7ab9d4026d9e2" escape="true"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183OS9mcmFnOmFiNzA5ZjAzM2IwYzQ2YTI5ZDg5N2NlNTFhZmI5YWRiL3RleHRyZWdpb246YWI3MDlmMDMzYjBjNDZhMjlkODk3Y2U1MWFmYjlhZGJfNDc2OQ_043893d3-344f-4e4d-8384-44451ff8fceb" continuedAt="i8b9f06bad4be4bd3bcd7e1e3b204e5eb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2021 and June 30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual </span></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i83492dbd4b0648a3bec7ab9d4026d9e2"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b9f06bad4be4bd3bcd7e1e3b204e5eb">Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").</ix:continuation> </span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183OS9mcmFnOmFiNzA5ZjAzM2IwYzQ2YTI5ZDg5N2NlNTFhZmI5YWRiL3RleHRyZWdpb246YWI3MDlmMDMzYjBjNDZhMjlkODk3Y2U1MWFmYjlhZGJfODI0NjMzNzIyOTg3NA_9120f6c1-5045-4750-9b64-b70ae82e1f3f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i84d08fd1ffc74d6494b61b46546492fc_82"></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RleHRyZWdpb246ZGFlMGY1ZjJiNDNmNGNiY2I4M2I3M2ZiYWFjYWM2MmRfMTI3Nw_d61977eb-238c-4daf-be6d-12049a7b9b65" continuedAt="i3e770ca49d714a22b1eb613ab93af88c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Restructuring and Employee Severance </span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RleHRyZWdpb246ZGFlMGY1ZjJiNDNmNGNiY2I4M2I3M2ZiYWFjYWM2MmRfMTI3NA_9caa071c-c950-4fd7-b185-31065dcfa8ca" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfMi0xLTEtMS0w_06ef23ba-4495-421c-bfd3-164416376260">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfMi0zLTEtMS0w_84746d1e-38d3-4d17-909b-74ae173bf48e">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfMy0xLTEtMS0w_492a4a37-887b-4120-9eb1-6a515ba188b6">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfMy0zLTEtMS0w_cc6213f7-3f03-4599-97a3-0b17855f14c9">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfNC0xLTEtMS0w_d77a4a0b-44d6-4690-b565-e942ccdb870f">37</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfNC0zLTEtMS0w_af0fbfc6-3037-41cf-b465-69896fb17fec">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of lease costs associated with vacant facilities, accelerated depreciation, vendor transition fees, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020 and 2019, restructuring costs were primarily related to implementation of certain enterprise-wide cost-savings initiatives.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i3e770ca49d714a22b1eb613ab93af88c"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RleHRyZWdpb246ZGFlMGY1ZjJiNDNmNGNiY2I4M2I3M2ZiYWFjYWM2MmRfMTI1Mw_90247b90-c5cc-4126-8d24-a36191a937af" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb6b2dd88864d668c5919feb00ee76c_I20200630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMS0xLTEtMS0w_0362da77-0b3c-4ed3-b636-7c762a6e681a">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c6be751ee64c558fe3494c112900ab_I20200630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMS0zLTEtMS0w_7ce51a87-080c-4806-a58c-bb49723bc437">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMS01LTEtMS0w_8a8d3f2b-efd7-4644-bf5b-2d1f4ad90fb1">96</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2579521f524f83869e7f228bd84ff9_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMi0xLTEtMS0w_f375b81d-6755-4440-b13b-4fd122a985e1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7037b2735b4e7f8e6c6f2d9b8d7038_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMi0zLTEtMS0w_ebbd418f-3af7-435f-9e6d-3a2c1a7e627e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMi01LTEtMS0w_26e9a0c1-cddb-438d-a896-2dbda92d4f39">27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a2579521f524f83869e7f228bd84ff9_D20200701-20200930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMy0xLTEtMS0w_d7b09cc1-01b5-4ba2-988a-a698dd10b878">13</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief7037b2735b4e7f8e6c6f2d9b8d7038_D20200701-20200930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMy0zLTEtMS0w_fe8e4c94-4cd0-4716-9840-6180ba297f0a">11</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMy01LTEtMS0w_6a73125c-8549-4ac1-a2a6-ef6abefba304">24</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425faefcb193459095f9eb5f9e4acf2c_I20200930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfNC0xLTEtMS0w_b0747882-0c8d-4e30-b9a4-73db4248209f">72</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c1f80baf7644c585599ba8c1f2323c_I20200930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfNC0zLTEtMS0w_5c1303f6-6530-44af-b128-09e73183343c">27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfNC01LTEtMS0w_c129602b-9ad4-48ad-bdc6-fbce5026d8a6">99</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i84d08fd1ffc74d6494b61b46546492fc_85"></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNzY5NjU4MTM5NDk1NA_a856f25f-8fd9-41e4-85ca-347570317bce" continuedAt="idac472c249224ece899982eef82d0cad" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Goodwill and Other Intangible Assets </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDcx_09d8a113-7464-4ac5-bd0c-0c38a7e3556f" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8480697f2bdf44918df39a9f5e84e330_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMS0xLTEtMS0w_9aa6cfba-ff1d-49ca-bfa1-c20a725dc01f">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48091522a54b466aaad728773c54a0a8_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMS0zLTEtMS0w_a5b372e7-71c4-4ac5-9d1b-8ff031408335">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMS01LTEtMS0w_342cbdb0-db51-4f70-ab28-920d35b4a534">8,357</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da27597353943d181889c1d5456c85f_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMi0xLTEtMS0w_5543568d-b683-4e2d-92cc-2c9135a1f8b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib649dc8198854be78403495cec1847cd_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMi0zLTEtMS0w_5a1ea32f-655f-4eaa-81be-112470345a70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMi01LTEtMS0w_60e779ad-8a7b-49a4-a8be-d56cb83043ac">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da27597353943d181889c1d5456c85f_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMy0xLTEtMS0w_e96bf660-f397-40e7-bcc3-3d4e10084521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib649dc8198854be78403495cec1847cd_D20200701-20200930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMy0zLTEtMS0w_a5e72a0d-9ce7-45f3-bcc0-a0362bd7070f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMy01LTEtMS0w_1545f533-c69a-46dd-bd45-02959e5246ab">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9929e41c0c24b0bba4c253330973f70_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfNC0xLTEtMS0w_6c92ed62-112b-48ea-b3e9-89b85ae9458f">2,657</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0491c5bcabd34939b8a41c8f69eccb12_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfNC0zLTEtMS0w_3a74af75-c31b-4745-af7a-cdaab5e1a233">5,718</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfNC01LTEtMS0w_76b9e163-bad1-4675-b27c-89ea6ed86446">8,375</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDYw_594de549-60d6-46c4-aa7a-55cc000e915b" continuedAt="ia22710903076442ab4dea7cc49ee4ca0" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438081d1a6924fc1a9b6b1dd950a9fcd_I20200930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMy0xLTEtMS0w_0339a03f-0fa2-44bb-a305-394b4099fcef">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438081d1a6924fc1a9b6b1dd950a9fcd_I20200930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMy01LTEtMS0w_3c3234c2-35d3-45ad-8f2c-ebebadcf10e8">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNC0xLTEtMS0w_79166f84-f50e-4e6a-9af8-541d6ea8079b">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNC01LTEtMS0w_dcdbe54b-f2fe-4ab9-849e-49295b49e5b9">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021a5d537d2842cb817b9d054f4ff9b5_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNy0xLTEtMS0w_3a9d09eb-8047-42db-b222-dfcd90433295">3,565</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021a5d537d2842cb817b9d054f4ff9b5_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNy0zLTEtMS0w_1ae982a7-1f5b-4762-b378-92825a98820c">1,907</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021a5d537d2842cb817b9d054f4ff9b5_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNy01LTEtMS0w_45661cb7-72bd-4d93-9c56-e5015780e9c8">1,658</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0adfa8f5d5214083a20b748280dfcefc_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNy03LTEtMS0w_c4917cab-2897-494b-af29-fdc898a9b274">13</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d951315c1c544ba967df1be4c66d58d_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOC0xLTEtMS0w_fa82b88b-0227-4d4f-9686-332a4bbf96fa">674</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d951315c1c544ba967df1be4c66d58d_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOC0zLTEtMS0w_b95adbd6-7f0e-4024-8fae-4b3a8caad5ab">351</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d951315c1c544ba967df1be4c66d58d_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOC01LTEtMS0w_95e2a626-9127-4abc-84de-b5d3d4265498">323</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1dd2a95f5f2b4b88bbcc6c6297bc95d0_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOC03LTEtMS0w_d136b1e0-949e-4fcb-ab9f-4ba125353815">13</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie926bbb0cbef440c994d8834ad4a9199_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOS0xLTEtMS0w_7f33238f-c133-4a58-a10e-4f63b59f5092">1,605</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie926bbb0cbef440c994d8834ad4a9199_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOS0zLTEtMS0w_ed717271-5ac4-4637-ac97-24cca14ccfdb">798</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie926bbb0cbef440c994d8834ad4a9199_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOS01LTEtMS0w_476694a8-cc18-45e9-9228-1a8d6ef6fe35">807</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iccf269ca481e4302b7d6164d95f0269a_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOS03LTEtMS0w_51dc59b2-34de-497b-8d7b-c92f192baea0">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTAtMS0xLTEtMA_7a5521eb-e54c-4fbb-bfac-4ab2cec5428c">5,844</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTAtMy0xLTEtMA_097bba5a-a326-4b57-9897-b9ca0bcf5fe3">3,056</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTAtNS0xLTEtMA_dbec31ea-e2cf-4986-977b-3c947a3e9ac9">2,788</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTAtNy0xLTEtMA_aa0c8daa-b553-4c98-938a-eb53df3bf6ff">12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTEtMS0xLTEtMA_48d1c55a-1ace-405a-a88a-dd71dd82457b">5,867</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTEtMy0xLTEtMA_9afb7e77-24d8-4b88-9848-6109bd53a025">3,056</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTEtNS0xLTEtMA_8e80ac9b-2e1b-4c6b-8920-427c7f5bf2a3">2,811</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="idac472c249224ece899982eef82d0cad"><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><ix:continuation id="ia22710903076442ab4dea7cc49ee4ca0"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia572b6f1eebf44cfbaeb9d8411357eca_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMy0xLTEtMS0w_ae583957-a536-4eeb-b40a-1aa646dfa6b4">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia572b6f1eebf44cfbaeb9d8411357eca_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMy01LTEtMS0w_ef4fab37-78f7-4e7b-a889-d70d2d7db9af">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNC0xLTEtMS0w_d976b71d-0942-4499-a6e5-439da6c3b09b">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNC01LTEtMS0w_7b0aa5e7-6da1-4d1d-867d-c6b6b1dacd7c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied58b175619b4bfebfb6b5b530246f5e_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNy0xLTEtMS0w_363c8448-8116-4ad9-a3eb-ef235c58f978">3,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied58b175619b4bfebfb6b5b530246f5e_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNy0zLTEtMS0w_673797eb-da37-409c-91af-4ea2b2db19f8">1,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied58b175619b4bfebfb6b5b530246f5e_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNy01LTEtMS0w_e4781366-3b4d-40ec-855b-84632159bad7">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fcd765710a4070b7c3c4036717d1cf_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOC0xLTEtMS0w_32b35ece-1d90-45db-920c-6aa7689b0b6f">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fcd765710a4070b7c3c4036717d1cf_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOC0zLTEtMS0w_3112ca40-af2c-42dd-8e4e-5aec4be4b7fd">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fcd765710a4070b7c3c4036717d1cf_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOC01LTEtMS0w_3c5311f4-2079-40b2-b405-b2e8be4fd300">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea560c27996450ea297ecbb41e9bf97_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOS0xLTEtMS0w_5f84e260-89cb-4bc8-9bba-66cb32b68225">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea560c27996450ea297ecbb41e9bf97_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOS0zLTEtMS0w_0541ec0e-1983-4ffc-98df-ae0b41a8aab1">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea560c27996450ea297ecbb41e9bf97_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOS01LTEtMS0w_55b4b4b1-3326-4090-ad36-475080069a8c">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTAtMS0xLTEtMA_40a6ebf4-caa7-4b38-9fa7-52c7eb6218e9">5,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTAtMy0xLTEtMA_222a1dd1-23e3-4ca1-b7f7-6f55a32cc437">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTAtNS0xLTEtMA_7e6a106b-7194-4a60-b753-9d4b0a345de0">2,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTEtMS0xLTEtMA_a930d491-5759-435b-b9fe-0d7e4ea18932">5,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTEtMy0xLTEtMA_73fc57e5-ff9e-40e2-ab43-9027c988ddf0">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTEtNS0xLTEtMA_0a178cc0-7054-4c86-ab83-e14348794579">2,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfMjY0_d025b4b9-f99c-451a-9e22-4f676c6a70b5">115</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfMjcx_cec47a63-3fda-42a4-8282-4b92c9fbb113">129</ix:nonFraction> million for the three months ended September&#160;30, 2020 and 2019, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2021 through 2025 is as follows: $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDMz_40cb4f37-6247-4cbb-9655-9745744cdb88">333</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDM3_aa9aaa93-c999-45e5-9b9a-0fe8024e45ab">398</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDQx_3a7745c1-d3ea-4c64-9039-e683bdcc524a">358</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDQ1_5d98f187-257f-4595-8d8f-f93df6754ab7">329</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDUz_3343420c-6873-426f-91e9-107f36a61719">278</ix:nonFraction> million.</span></div></ix:continuation><div id="i84d08fd1ffc74d6494b61b46546492fc_94"></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNzY5NjU4MTM5NzIzMQ_b7fa1a6b-bfb0-40eb-8c34-e1ba35d242d5" continuedAt="i4a26c60c99714b1eb8a826742be44c22" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Long-Term Obligations and Other Short-Term Borrowings </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfMTI2_4a3c7517-4882-424d-b09a-e063939f4464">6.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfOTg5NTYwNDY1MTk4NQ_2706e1c4-856a-411f-a513-3899730a8ed8">6.8</ix:nonFraction> billion at September 30, 2020 and June 30, 2020, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNzY5NjU4MTM5NzQ5NA_eaef3f4b-5386-4437-81f1-d3f879e54f68">21.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNzY5NjU4MTM5NzUyNw_57d36fa6-aec0-4b5f-acd6-dfd59d082ce9">21.4</ix:nonFraction>&#160;billion at September 30, 2020 and June 30, 2020, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, we repurchased a total of $<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNjAy_35aa1069-b40b-4d17-b747-b4e54ff123f3">37</ix:nonFraction> million of notes due in 2022 with available cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$<ix:nonFraction unitRef="usd" contextRef="i3bfc5884ee88416c9abb63244dab609c_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNzgz_ed784e17-7a81-4ae3-b6af-f838184a1d74">2.0</ix:nonFraction> billion&#160;commercial paper program backed by a $<ix:nonFraction unitRef="usd" contextRef="i741ef9d887c94534a8eda6eccfbe2ad3_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfODIz_180eacd5-7b9d-4fde-86c9-7537342be2b9">2.0</ix:nonFraction> billion&#160;revolving credit facility. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="i119b91cee7ad43a3a902d392163cea9e_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfODY4_2860b0af-9b43-492e-b630-5e3b6ad801b9">1.0</ix:nonFraction> billion committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose-bankruptcy remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4a26c60c99714b1eb8a826742be44c22">Our revolving credit facility and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of&#160;no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every fiscal quarter thereafter. At September 30, 2020, we were in compliance with our financial covenants.</ix:continuation> </span></div><div id="i84d08fd1ffc74d6494b61b46546492fc_100"></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2Xzc2OTY1ODE0MzE4Njg_94682b5f-8f75-46eb-b477-8776946ccaa4" continuedAt="i08d8ed57dcfa4755996728f3fed8b94e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Commitments, Contingent Liabilities and Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="i771e1aea6b7f427a9df601aaf7660e54_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:LongtermPurchaseCommitmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzI1NA_e7dd65b8-c214-46c5-9ad5-3e689a16693f">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $<ix:nonFraction unitRef="usd" contextRef="i771e1aea6b7f427a9df601aaf7660e54_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="cah:MaximumQuarterlyPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzQ1NQ_ec386b93-f155-4df1-b625-09f7671e58ad">45.6</ix:nonFraction> million to CVS Health for the remainder of the initial term. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="i6561ef3f208042318b204d099ad1b0e0_I20200930" decimals="-6" format="ixt:numdotdecimal" name="cah:AggregateAnnualAssessment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzM5MTA3_025c0fed-5002-4125-bce6-bbbb42514ac9">100</ix:nonFraction> million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the U.S. District Court for the Southern District of New York ruled that the OSA was unconstitutional and enjoined its enforcement (the "Ruling"). In April 2019, the State, among other things, amended the OSA so that the assessment would only cover opioid sales in 2017 and 2018, subject to the State's appeal of the Ruling. In September 2020, the U.S. Court of Appeals for the Second Circuit reversed the Ruling and, as a result, New York will likely seek to collect amounts due from distributors and manufacturers for 2017 and 2018. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, at September 30, 2020, we recorded an aggregate accrual of $<ix:nonFraction unitRef="usd" contextRef="i939be74b35cc40a8969fcbc5e8654858_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzM5MTI2_36badba9-d99a-4290-8971-5f412cb4684f">41</ix:nonFraction> million for calendar year 2017 and 2018 based on the estimated payment amount. This is our best estimate of the OSA payments probable at September 30, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i08d8ed57dcfa4755996728f3fed8b94e" continuedAt="ifddc652ee1be448f933e2f90dc6d4c15"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of loss.</span></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="ifddc652ee1be448f933e2f90dc6d4c15" continuedAt="i56cbd4d5a940454f97fc1d20dfa93f1f"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately <ix:nonFraction unitRef="reportable_segments" contextRef="i39e37f424f344ed4861a30e0289b675e_I20201102" decimals="0" format="ixt:numdotdecimal" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTg2_61698846-f23f-4339-ab24-7ba4b3b79978">3,300</ix:nonFraction> lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="reportable_segments" contextRef="ie1ec20ee64f4429a823a5f846ef8b554_I20201102" decimals="0" format="ixt:numdotdecimal" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTA3_edafa46f-c4ad-4487-96bf-3e121ecd2a04">2,800</ix:nonFraction> of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;). In addition, <ix:nonFraction unitRef="reportable_segments" contextRef="i39e37f424f344ed4861a30e0289b675e_I20201102" decimals="0" name="cah:NumberofStateAttorneysGeneralfilinglawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQzMDAz_9e3daf13-211b-4fe9-aef2-6426b2772eb3">25</ix:nonFraction> state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in West Virginia in the Cabell County and City of Huntington cases is scheduled for January 2021, and a trial is scheduled to begin in Madison County, Ohio, in March 2021 in the case brought by the Ohio Attorney General. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is the basis for the ongoing negotiation of definitive terms and documentation. Negotiations under the Settlement Framework continue and have centered on the amount and timing for payment of the cash component as well as standards for settling distributors&#8217; controlled substance anti-diversion programs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these discussions, we have recorded total pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2ODkxMDc_a024248d-a20b-4a3e-8564-bf099edfdcee">1.02</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iac21abb30a6046b1aaef99f6b707cbd5_D20190701-20190930" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzM5MTc0_f08d9a18-6ca2-42fc-9fdc-b242c2cec640">5.63</ix:nonFraction> billion in litigation charges/(recoveries), net in the three months ended September 30, 2020 and 2019, respectively. In total, we have $<ix:nonFraction unitRef="usd" contextRef="i0dd1e60e6ffd4307b7bf4207ea74288c_I20200930" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LitigationReserve" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEzNzQzODk1NDEwMTM2_6437ba59-5b15-4383-9c7a-e86dffa06a3b">6.59</ix:nonFraction> billion accrued at September 30, 2020, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately <ix:nonFraction unitRef="reportable_segments" contextRef="iaf9406084961493d9d4b3eb6d8055a86_I20201102" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTky_e36a980d-2b1c-42a5-8e8d-5d5734f9260f">411</ix:nonFraction> lawsuits as of November 2, 2020. Of these, <ix:nonFraction unitRef="reportable_segments" contextRef="if5b6097a61c849798a37a8304de056d5_I20201102" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTk4_17cbe7b0-92f3-48b6-ace6-a37f76e726c3">116</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affirmative Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union Fire Insurance&#8221;), seeking a declaration that defense costs are recoverable under our insurance for certain of the lawsuits described above. We have not recorded a receivable for any recoveries related to the litigation against National Union Fire Insurance at September 30, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). The subpoenas seek documents relating to our anti-diversion policies, procedures and program, and our distribution of certain controlled substances. We are cooperating with these requests.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 2, 2020, we are named as a defendant in <ix:nonFraction unitRef="reportable_segments" contextRef="ie47435aa0ab74b408fd91dfc770477cc_D20201102-20201102" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTI0_1ec90024-1637-4d55-8e1c-468c1c386430">354</ix:nonFraction> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately <ix:nonFraction unitRef="reportable_segments" contextRef="if790e73672e840e5b0d954ff370e0e96_D20201102-20201102" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTI4_311c9600-08f4-45d0-9cb7-b46e111031b5">4,526</ix:nonFraction> plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another <ix:nonFraction unitRef="reportable_segments" contextRef="iab0a211a496049da89686dc5fe319089_D20201102-20201102" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTMy_d5724c96-b31e-477a-8a83-69d43789ae4c">31</ix:nonFraction> lawsuits involving similar claims by approximately <ix:nonFraction unitRef="reportable_segments" contextRef="iefc77509e5de47719bffc603ae04f45c_D20201102-20201102" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTM2_0448104b-779a-4061-8915-0876c806683a">36</ix:nonFraction> plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and are engaged in resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, we had a total of $<ix:nonFraction unitRef="usd" contextRef="i7f21d49611034f3fa4a6fb00669c782b_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzE1MTAz_0b54ffcf-d3ae-4684-a517-a9f0aa07df05">494</ix:nonFraction> million, net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i56cbd4d5a940454f97fc1d20dfa93f1f" continuedAt="i32794ecd4eff42d8b73231522a7c1c7f"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">end of the range to be approximately $<ix:nonFraction unitRef="usd" contextRef="ibf6467237c464a1aa045646e1b87276b_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzE1MTEx_9382d124-fc16-4cd0-b321-6c039e9eb24f">961</ix:nonFraction> million, net of estimated insurance recoveries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we received a civil subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with this request and are engaged in preliminary resolution discussions.  </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) </span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i32794ecd4eff42d8b73231522a7c1c7f">alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We were also named as a defendant in a Multidistrict Litigation alleging API impurities in Zantac and its generic form, ranitidine. We intend to vigorously defend ourselves in these matters.</ix:continuation></span></div><div id="i84d08fd1ffc74d6494b61b46546492fc_103"></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzc2OTY1ODE0MjI0OTM_341d2608-371b-4d95-9f9a-247a7e3e843d" continuedAt="i54e46ca390d64994a8f02410b9409047" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Income Taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pre-tax loss (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Settlement Framework</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $<ix:nonFraction unitRef="usd" contextRef="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzI4OQ_a024248d-a20b-4a3e-8564-bf099edfdcee">1.02</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iac21abb30a6046b1aaef99f6b707cbd5_D20190701-20190930" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzc2OTY1ODE0MDYxMDQ_2ddd8891-47bf-4a20-8bfa-c53ccc82e321">5.63</ix:nonFraction>&#160;billion pre-tax charges for the opioid litigation during the three months ended September 30, 2020 and 2019, respectively, the net tax benefits are $<ix:nonFraction unitRef="usd" contextRef="ia09951da05f64bf3a7732138bd69fdfc_D20200701-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2MzA0MDc2_a3e09a73-aa87-4ad3-922c-66120a1aecaa">35</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib3306233e5db4b188aa16b734cd988cf_D20190701-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2NDczMjc_e6c244d1-8fe1-4e73-89fe-25242809bb06">488</ix:nonFraction> million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i0f2e67b10f4d497fa601aa7acf5cafd5_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2NDczOTk_70a40d0a-8dac-454f-b9e1-0e7a139d7ac0">34</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia819620c77c04e44820e9270d0163402_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2NDc0MTM_676948d1-7814-4c31-8ad5-efa5d5ceb0d5">469</ix:nonFraction> million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision/(benefit) for income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent.  Including the relatively lower tax benefit of the current quarter charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax benefit in the current quarter increased by approximately $<ix:nonFraction unitRef="usd" contextRef="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2MzA0MDU4_732d852b-ac9b-4177-a0a5-be15a7d79736">450</ix:nonFraction> million over the tax expense that would have been recognized without the impact of the opioid litigation charge and is expected to </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i54e46ca390d64994a8f02410b9409047" continuedAt="i346d76beae904df29dcdf1801cf5be16"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly increase our provision for income taxes during the remainder of fiscal 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020 and 2019, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEzOTA_6b8508c6-0364-4015-9d4f-586048e1d4d7">61.8</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE0MDU_3d69f33e-86c9-49f5-843b-1105e4e57e3d">7.9</ix:nonFraction> percent, respectively. The increase in the effective tax rate for the three months ended September 30, 2020 compared to the prior year period was primarily due to the treatment of the tax impacts of the opioid litigation accrual, partially offset by the prior-year benefit of discrete tax items.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYxNzY_cba7bc2a-9d37-4ff3-9099-f4957945f18f">994</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYxNjg_ad35c2f3-ea47-4629-a1a1-eb28e8afbd77">998</ix:nonFraction> million of unrecognized tax benefits at September 30, 2020 and June&#160;30, 2020, respectively. The September 30, 2020 and June&#160;30, 2020 balances include $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYxODQ_9b2bb905-d574-4910-bf92-8bddfe94e41d">750</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYxOTY_ce9ec387-93c2-4451-9837-56d7fa79de70">753</ix:nonFraction> million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020 and June&#160;30, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMTI_9eb42a5f-00c1-41db-8b69-2cc24ceb8a79">147</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMDQ_903f4138-a5a2-4e96-abf2-f31ba63126af">146</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of loss. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="icee8303e1efb47e5b605a6d6693baa6d_I20200930" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzI3NzU_27c8120c-f939-4666-ac82-357b2736ab27">zero</ix:nonFraction> and a net decrease of $<ix:nonFraction unitRef="usd" contextRef="i198d88ecb6cb419a8da8c55f4bdd2385_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzI4MDA_0a57123e-6a99-4be1-9189-8eb94eac5ef3">370</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years <ix:nonNumeric contextRef="i90891cc2a4a8436bb9f99a47f2669996_D20200701-20200930" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzMwNzI_cac8a916-1f73-4db2-bada-d844722acc8f">2008</ix:nonNumeric> through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to </span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i346d76beae904df29dcdf1801cf5be16"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="icf6d9f7208624a0aa1b66fad4bab9571_I20200930" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMzA_958841f0-eddf-4a49-8c7f-8ee4ce26b5de">179</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i72e11ec7b02f4f62aa657fb2116b44ad_I20200630" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMjI_20f85c44-c335-4f02-a235-d4175b98cff8">176</ix:nonFraction> million at September&#160;30, 2020 and June&#160;30, 2020, respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition. The indemnification receivable was&#160;$<ix:nonFraction unitRef="usd" contextRef="i4fb4c3b745404fd9b199d24994707757_I20200630" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMzg_6d069194-8474-4eda-aa65-db6b7a29d62b"><ix:nonFraction unitRef="usd" contextRef="i821519601f81436faf796e3e48f6e226_I20200930" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMzg_81cb6e18-878d-45b3-acf4-d101f9472b03">19</ix:nonFraction></ix:nonFraction> million at both September&#160;30, 2020 and June&#160;30, 2020, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.</span></div></ix:continuation><div id="i84d08fd1ffc74d6494b61b46546492fc_106"></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90ZXh0cmVnaW9uOjdhYTViNzE4Njg3ZDQ2ZjA4NjAyZDZiZTY1YmQwNDllXzEyNjk_0804567d-22f0-41c2-8367-e5d9b278b74d" continuedAt="i6c56d84db6614f3cacd5a225a1e99f93" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Fair Value Measurements </span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90ZXh0cmVnaW9uOjdhYTViNzE4Njg3ZDQ2ZjA4NjAyZDZiZTY1YmQwNDllXzEyNTY_be1a186c-4c9f-4605-862a-5876df869d60" continuedAt="ifc6c6a80a9fe49bb907e00ffa2d9b259" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e14eef936ce478e977bd2365ab2dcc9_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzMtMS0xLTEtMA_de764bfd-4c0e-4f87-bde6-412339f43849">1,070</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b43a414d2b4f6fa40be7cadc0a1262_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzMtMy0xLTEtMA_20687f76-1345-42dc-ad37-9f219b515e3f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e3c7cc8bf8416a8084c477ef5ff7e1_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzMtNS0xLTEtMA_dde1990a-62a9-4edd-ba45-68bf0ae036d5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f47cfe18fe54226a1df09ddb6efef0c_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzMtNy0xLTEtMA_02a6f765-63ff-4b79-a2c4-cc2a38d0fb8b">1,070</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e14eef936ce478e977bd2365ab2dcc9_I20200930" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzQtMS0xLTEtMA_be03715a-1eef-4d11-abf6-51071948e5ef">111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b43a414d2b4f6fa40be7cadc0a1262_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzQtMy0xLTEtMA_5670bb0b-519a-42e9-9599-508f3ad1c6c5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e3c7cc8bf8416a8084c477ef5ff7e1_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzQtNS0xLTEtMA_c782f7c4-cb7b-4fad-861a-3bf86c4e64a4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996aed144ffb4a48a0ee5fbb315c6670_I20200930" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzQtNy0xLTEtMA_5cca1e42-4c2f-48f2-ae7b-aacf5628c3c9">111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e14eef936ce478e977bd2365ab2dcc9_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzYtMS0xLTEtMA_d0699fb4-40c4-428d-aa83-0c842ce238ae">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b43a414d2b4f6fa40be7cadc0a1262_I20200930" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzYtMy0xLTEtMA_9e39cc17-3499-442c-a98b-117844b0ec83">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e3c7cc8bf8416a8084c477ef5ff7e1_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzYtNS0xLTEtMA_c8207bb2-2a12-4738-addb-77d0124dab55">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996aed144ffb4a48a0ee5fbb315c6670_I20200930" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzYtNy0xLTEtMA_ee367fea-2347-4898-a181-38ddf3fcd140">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id645783b71294f05bb6047acb455691b_I20200630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzMtMS0xLTEtMA_37cb4dd9-b442-4289-8966-f216d3553371">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269f7fc0ae604642a4a6a3d792040971_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzMtMy0xLTEtMA_43604637-72c1-48c5-900b-95512fd5ae0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ccfc94660444b69cd33d2b61edc9e1_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzMtNS0xLTEtMA_5984d30f-30d7-4649-b00e-a93e31ad79dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbaf94dcf17e4c03b40d6ee4e6a38630_I20200630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzMtNy0xLTEtMA_ec7b83d7-3066-4533-9e2e-a8d90abcbd88">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id645783b71294f05bb6047acb455691b_I20200630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzQtMS0xLTEtMA_e0ea6394-91d8-4ce7-ac9c-204b0df6124a">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269f7fc0ae604642a4a6a3d792040971_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzQtMy0xLTEtMA_76661b96-1fb8-44de-a015-c3588522d178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ccfc94660444b69cd33d2b61edc9e1_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzQtNS0xLTEtMA_994e1e12-fbc4-4376-ad37-6163d2dc029d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ee5fbf2771456f9b16564e61ebe4f5_I20200630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzQtNy0xLTEtMA_2f4b00dc-05e3-43d0-9c1d-9c000a3df66a">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id645783b71294f05bb6047acb455691b_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzYtMS0xLTEtMA_6dad959c-4b72-4ad4-90b2-31cfe2ca910c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269f7fc0ae604642a4a6a3d792040971_I20200630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzYtMy0xLTEtMA_4b6e1e60-1791-48af-9e1d-556fbd3c6599">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ccfc94660444b69cd33d2b61edc9e1_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzYtNS0xLTEtMA_9ef2833c-4dc7-4547-9421-bf018d561498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ee5fbf2771456f9b16564e61ebe4f5_I20200630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzYtNy0xLTEtMA_03d286be-3112-455d-9150-6de07b8a2213">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i6c56d84db6614f3cacd5a225a1e99f93"><ix:continuation id="ifc6c6a80a9fe49bb907e00ffa2d9b259">(2)    The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</ix:continuation></ix:continuation> </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzc2OTY1ODE0MTM4MjY_801284e4-383e-4cf0-8a32-869488a022f9" continuedAt="i85ba7a4c042e45ac83eb7a22ee4deb9f" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of loss. For the three months ended September&#160;30, 2020 and 2019, there was <ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzMyNjM_f3517237-1b5d-45a0-961b-3d486f625784">no</ix:nonFraction> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2019, we entered into a forward interest rate swap with a total notional amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="i70de2fa7134c4f26a5575c7874c7dbc1_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzQxMzY_cd61ff4a-be42-4e2b-a67c-2d87bde3ce32">50</ix:nonFraction> million&#160;to hedge probable, but not firmly committed, future transactions associated with our debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses recognized in other comprehensive loss were immaterial during the three months ended September&#160;30, 2020 and 2019. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September&#160;30, 2020 and 2019. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended September 30, 2019, we entered into a &#165;<ix:nonFraction unitRef="eur" contextRef="id9465d58bd9c4791a0eb659e86c94043_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzQ5NzU_412c4f2c-1c14-4665-aa07-1e0769b4ba54">64.0</ix:nonFraction> billion ($600 million) cross-currency swap maturing in 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $<ix:nonFraction unitRef="usd" contextRef="id083a10b766c4345a49d14f0632816a6_D20200701-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzk4OTU2MDQ2NjkwNDU_580903e7-061c-4154-848d-e28bce358f68">25</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="i24179129a5974fea826c6897ed376db7_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzk4OTU2MDQ2NjkwNTg_bccb6ee5-8f8c-40ea-8aa3-edae928dcc2f">16</ix:nonFraction>&#160;million gain </span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i85ba7a4c042e45ac83eb7a22ee4deb9f"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended September&#160;30, 2020 and 2019, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of loss for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were immaterial during the three months ended September&#160;30, 2020 and 2019.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The gain and losses recognized in the three months ended September 30, 2020 and 2019 were immaterial. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, Brazilian real and Japanese yen.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2020 and June 30, 2020 approximate fair value due to their short-term maturities.</span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzcyOTc_41cb7222-7aa8-4950-bbd9-4f5cc408a3cf" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba45d8ce890d432cbb652a278df25802_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90YWJsZTplZmY2YWQzNGVhNGM0YzQ2OGU3MzQ5OWM1MDg0YmU0My90YWJsZXJhbmdlOmVmZjZhZDM0ZWE0YzRjNDY4ZTczNDk5YzUwODRiZTQzXzEtMS0xLTEtMA_310b57c4-d11f-47ea-81c2-3d12fc13ece0">7,245</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d69c82422d48839b20ba8699842249_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90YWJsZTplZmY2YWQzNGVhNGM0YzQ2OGU3MzQ5OWM1MDg0YmU0My90YWJsZXJhbmdlOmVmZjZhZDM0ZWE0YzRjNDY4ZTczNDk5YzUwODRiZTQzXzEtMy0xLTEtMA_721f7f80-077f-40c8-9396-f3062948648e">7,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90YWJsZTplZmY2YWQzNGVhNGM0YzQ2OGU3MzQ5OWM1MDg0YmU0My90YWJsZXJhbmdlOmVmZjZhZDM0ZWE0YzRjNDY4ZTczNDk5YzUwODRiZTQzXzItMS0xLTEtMA_8ea830c7-37de-4f20-b263-dabd236c6845">6,740</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90YWJsZTplZmY2YWQzNGVhNGM0YzQ2OGU3MzQ5OWM1MDg0YmU0My90YWJsZXJhbmdlOmVmZjZhZDM0ZWE0YzRjNDY4ZTczNDk5YzUwODRiZTQzXzItMy0xLTEtMA_f6028062-e49a-42a0-b494-dc5fcdbb0342">6,775</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="i84d08fd1ffc74d6494b61b46546492fc_112"></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzEyNjA_4f014aaa-8527-4706-a721-4b346424f3a7" continuedAt="ic0d9b735ee7944c8a633bdd2091bbfb6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Shareholders' Equity </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2019, we entered in an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i76bcd37a41304f9a80edf0b488038276_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzU5NA_0f64b863-7cb2-4f81-a59d-2b3a9f17ee4f">350</ix:nonFraction> million and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="cah:TreasuryStockAcquiredShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzYzMw_a9d92216-fe29-41e3-bb73-002afa751078">6.4</ix:nonFraction> million common shares having an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzY3OA_a615c606-a1dd-4412-81a5-10b026f4b461">280</ix:nonFraction> million. The average price paid per common share was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzcyNg_de8e9135-0b56-41ae-b45b-caf283c21136">43.76</ix:nonFraction>. The ASR program began on August 20, 2019 and was completed on December 4, 2019 when we received the final <ix:nonFraction unitRef="shares" contextRef="i5672d212637f41acb8eb88dd1e16d3ab_I20191204" decimals="-5" format="ixt:numdotdecimal" name="cah:FinalSharesReceivedfromASRProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1Xzc2OTY1ODEzOTY4MjU_91fb9ce3-6398-45dc-ae88-379e718bf888">0.9</ix:nonFraction>&#160;million common shares. We funded the repurchases with available cash and short-term borrowings. </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ic0d9b735ee7944c8a633bdd2091bbfb6"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzEyNjc_f53eeb74-7a5c-440b-b9f8-b60084339013" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67e8522d8b5645e79d6b9af6f3933166_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzEtMS0xLTEtMA_cf0e9a34-d56b-4963-9a80-8e1347fc2078">92</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30acee2f999d4666aa8a690497305ee1_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzEtMy0xLTEtMA_596dc188-da50-4304-bf65-947dde31fe3c">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i364789c943c04565b9bde52a3752220d_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzEtNS0xLTEtMA_1d8151c4-c81b-4f9c-86cf-4334894121ab">104</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e7580ef4ee445389920d8d3c96ab6c_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzItMS0xLTEtMA_9a2d8a34-d37d-43a6-85a5-b23ac5e03ba9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d125daceaeb49239b6bf716b1f7b342_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzItMy0xLTEtMA_a6764f1e-ebd5-4fb5-a5aa-f647f1f49467">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15805896000345a2aa639595943a623a_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzItNS0xLTEtMA_460e4ad8-72cd-4e58-a73b-2964481284b5">15</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e7580ef4ee445389920d8d3c96ab6c_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzMtMS0xLTEtMA_d9e0099e-74d6-4ffa-af63-958650f1de87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d125daceaeb49239b6bf716b1f7b342_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzMtMy0xLTEtMA_24457c62-4077-4302-afa4-d67ae1810de5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15805896000345a2aa639595943a623a_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzMtNS0xLTEtMA_ce176e94-d58a-4c99-988b-c0141793bf20">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e7580ef4ee445389920d8d3c96ab6c_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzQtMS0xLTEtMA_55c48161-087f-45cd-acad-2811dc3d397b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d125daceaeb49239b6bf716b1f7b342_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzQtMy0xLTEtMA_bdff1251-33f3-4c31-a658-0e96628316c7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53329ae895148609299a5ce40e3c592_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzQtNS0xLTEtMA_842f8e74-703a-4cf4-9f98-e00a9de03e2e">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cabdcfb164044c48c31dcddf5873c35_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzUtMS0xLTEtMA_4a446d20-e280-40d7-914c-5680fe1458e8">80</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i453407ee376d4fe78c2176a18171602c_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzUtMy0xLTEtMA_9e207ae5-76fd-4381-b6bc-06e99a524650">7</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic66e4cdcd5a046cfae01e323cbb8b418_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzUtNS0xLTEtMA_5b1ebb62-8642-44b7-ae5d-6cebceef5997">87</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i84d08fd1ffc74d6494b61b46546492fc_115"></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzU5OA_87e081e2-142a-48fa-8f2f-56bf0b69a4d0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Loss Per Share Attributable to Cardinal Health, Inc. </span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzU5NA_df4d7988-8f2b-46c2-8dd3-9984db5da5af" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzItMS0xLTEtMA_6ea12baa-63bf-44fb-b367-ffec31502b78">293</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzItMy0xLTEtMA_c80efc9c-36e9-4cfe-9538-17d6fdf982de">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzQtMS0xLTEtMA_6fd08cbb-c713-44bf-8a46-fa6bb5f95b13">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzQtMy0xLTEtMA_f3561939-a3c1-483a-9bc1-1a8bdfd27e2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzUtMS0xLTEtMA_b7f0a47b-3dbd-48ac-a980-a1d6c43c3af3">293</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzUtMy0xLTEtMA_63c0a157-f104-407b-8bab-c64873c4c93e">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for September 30, 2020 and 2019 were <ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="cah:Numberofsharesexcludedfromcalculationofdilutedshares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzEwOTk1MTE2MzA2ODg_3ac7b51e-9418-49d4-a609-3bfff3be079c">7</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="cah:Numberofsharesexcludedfromcalculationofdilutedshares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzEwOTk1MTE2MzA3MDc_4cba8e4a-41bd-4a33-83e4-7f5e1d0e2eb5">6</ix:nonFraction> million, respectively. For the three months ended September 30, 2020, and 2019, there were <ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="cah:Sharesthatwouldbeantidilutiveasaresultofnetloss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzEwOTk1MTE2MjgyMTE4_6d92e7fa-5a7e-4443-be1e-63aa91248f57">2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="cah:Sharesthatwouldbeantidilutiveasaresultofnetloss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzEwOTk1MTE2MzA3MTQ_34ef5ba9-fbd0-44ce-b80a-570450274b35">1</ix:nonFraction> million potentially dilutive employee stock options, restricted share units and performance share units, respectively, not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been anti-dilutive as a result of the net loss during that period.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3NDQ_bc6ee068-26d7-458a-8b54-2c68c5e1b1cf" continuedAt="i3a154e5af961447eb7f4ca2b52ad13a1" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Segment Information </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of <ix:nonFraction unitRef="segment" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzEwMg_501b2ce6-09e1-4c3f-beee-cff22bd03a01"><ix:nonFraction unitRef="segment" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzEwMg_d2903e3f-3f2d-4225-90c1-79d7b6d354cb">two</ix:nonFraction></ix:nonFraction> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3NDg_30f9bc0e-5884-4888-b7f2-00345b1690a2" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f75c382c1c4df691a419c0e178c753_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzItMS0xLTEtMA_955c2bce-8219-409a-8482-3b5c1052abbc">34,916</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0defeec516474249b8995ba49880c24a_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzItMy0xLTEtMA_039bc1fd-621a-454a-a446-641246e345af">33,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62af4253c8a346ccbeeba7311323f9a6_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzMtMS0xLTEtMA_116acb22-41dc-43de-8536-4446d01976bb">196</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e3b1bc368924c059f7e70628540e193_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzMtMy0xLTEtMA_643e917d-7524-42ba-b7ec-6625c5abd586">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de354d09bc44a9fa3785d5625393d00_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzQtMS0xLTEtMA_c7688e98-28a7-48d9-82ea-9c364b8572ba">35,112</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3917f66b8f644838a6208b4c579c8bf_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzQtMy0xLTEtMA_883a953d-6905-484d-94ec-ee59744c11a3">33,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09f112593ed04de0a5bb4ca0a2030c04_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzUtMS0xLTEtMA_71657f2c-8693-48f7-a25f-a8848f96a4a8">3,438</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b597f3573d47b49abc5302f1695a37_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzUtMy0xLTEtMA_f3154622-b4d9-4943-a42d-85860478f1b6">3,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb54beca65c45029506df58645bad06_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzYtMS0xLTEtMA_477244c9-73e0-4e68-bdb1-4948ccca5cfa">519</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a632d5955e4aa3866f348c953d8d08_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzYtMy0xLTEtMA_7fc6ca3b-da18-4860-a478-138447658fcb">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6e1c05bec24505be4e45733f808646_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzctMS0xLTEtMA_c32abd56-18a1-441a-b9ef-2c0c3157db2b">3,957</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781f2efb9025488d94dcbfda31c5bd48_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzctMy0xLTEtMA_72a5f112-316a-414c-90da-e79129c8445e">3,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcebc361e52048eaba97198b6a5faba9_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzgtMS0xLTEtMA_ffd2ff64-a0bf-4770-928b-089294ae0491">39,069</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d88dbb2b05d4b1b89fa61aa66aedbad_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzgtMy0xLTEtMA_8bfda17e-1a47-41b6-9a8f-aebed6c7f834">37,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee2cbf3fb2124481bec0997184cebcb1_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzktMS0xLTEtMA_9ed9a87e-ba96-4de5-9606-5340851913e5">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0e8c9c681b47eeb9760d46de31a6d1_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzktMy0xLTEtMA_4c21fe5e-575f-443b-bb74-1dae59219add">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzEwLTEtMS0xLTA_afa53e97-0136-4996-b5ef-c1e56b19df1a">39,065</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzEwLTMtMS0xLTA_f25a3b79-02da-4ea8-a545-0fd8f4977842">37,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3Mzk_b0d95ffa-ae6b-49e9-b36b-02df37beab30" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52baa5c5a9654848bd9121d59999a39b_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzItMS0xLTEtMA_aa490186-0742-439d-8a32-2bfc2e32eb72">37,976</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4974c67c114c848433b0dfc9102fde_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzItMy0xLTEtMA_c9e509e4-4246-4796-84ab-544d549f8d63">36,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5632dcd9d2a4e40a78e375c76a736e3_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzMtMS0xLTEtMA_80972585-26b0-4187-be7f-84df5f04fef7">1,093</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3a5767abd1403ab78e9bf2adee431c_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzMtMy0xLTEtMA_7336aaf1-008b-4a41-a416-aa1dd794c606">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcebc361e52048eaba97198b6a5faba9_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzQtMS0xLTEtMA_ffd2ff64-a0bf-4770-928b-089294ae0491">39,069</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d88dbb2b05d4b1b89fa61aa66aedbad_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzQtMy0xLTEtMA_569a7aea-9d19-4db7-b8a0-a97bd3cf29c5">37,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee2cbf3fb2124481bec0997184cebcb1_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzUtMS0xLTEtMA_9ed9a87e-ba96-4de5-9606-5340851913e5">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0e8c9c681b47eeb9760d46de31a6d1_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzUtMy0xLTEtMA_ca4ece9d-18e1-474a-a64b-effe7a6ee557">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzYtMS0xLTEtMA_afa53e97-0136-4996-b5ef-c1e56b19df1a">39,065</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzYtMy0xLTEtMA_c9d7089f-29aa-401b-90fc-d9d392cd61d1">37,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: last-in </span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i3a154e5af961447eb7f4ca2b52ad13a1"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQxNjg_436302ae-b6ac-4257-b84b-388e17db3540">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQxNzU_0302902b-97db-4904-a006-006a4dfa37de">3</ix:nonFraction> million for the three months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzk4OTU2MDQ2NTUzMTc_6cd5e1d0-c187-465b-bd9d-bbb9667aeb85">1.02</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="iac21abb30a6046b1aaef99f6b707cbd5_D20190701-20190930" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzk4OTU2MDQ2NTUzMjY_1bfcc83a-2153-45a1-b81f-773387d3c1ba">5.63</ix:nonFraction>&#160;billion during the three months ended September 30, 2020 and 2019, respectively, which was retained at Corporate. </span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3NDk_ce944219-e6b4-4ed8-95e0-f11c48d9a2b9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de354d09bc44a9fa3785d5625393d00_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzItMS0xLTEtMA_a4889358-7d4b-41cd-87ca-1705589deebc">402</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3917f66b8f644838a6208b4c579c8bf_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzItMy0xLTEtMA_663e8f28-5278-477f-a213-99b213b9e766">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6e1c05bec24505be4e45733f808646_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzMtMS0xLTEtMA_c0d1d208-ad96-4fe4-ab03-dec8d3119cfa">230</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781f2efb9025488d94dcbfda31c5bd48_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzMtMy0xLTEtMA_2b59a5c8-7442-4f52-8134-26c11d0a6b61">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcebc361e52048eaba97198b6a5faba9_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzQtMS0xLTEtMA_b4dac84e-00ff-4773-81b9-f61672df1ee5">632</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d88dbb2b05d4b1b89fa61aa66aedbad_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzQtMy0xLTEtMA_1a671ada-87cc-4ea6-8ea3-fb0b5f18ece3">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee2cbf3fb2124481bec0997184cebcb1_D20200701-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzUtMS0xLTEtMA_c818c16d-5629-4d6f-a317-a72baeb08166">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0e8c9c681b47eeb9760d46de31a6d1_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzUtMy0xLTEtMA_736907c9-8a03-425b-9b75-c36bbd3af158">5,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzYtMS0xLTEtMA_acb98e8d-3839-4494-aa86-63ff78a2dbd2">624</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzYtMy0xLTEtMA_33b21a32-839d-42fe-a2b2-d739cd272fac">5,264</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3NTE_d60a146c-63e9-4fe2-ae41-397212d6f850" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dab659e59834b43b34ab0f7563c0c82_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzEtMS0xLTEtMA_ed92c6ae-7be9-4b88-818c-75007a219aa9">22,809</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7066c54e7dd4fceb8588adf471ba835_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzEtMy0xLTEtMA_94dbe5b3-0e13-4e80-8cf2-b13a8f8cd042">22,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098156347d904aa088fa3e1e5127a1d4_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzItMS0xLTEtMA_8d5dd251-9363-48ab-b49c-560dc80f4438">14,985</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75fa3de7c8a54b8b83706d76e4c35b76_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzItMy0xLTEtMA_1bfe7103-6d56-4a41-9b09-a357a1f48e69">14,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857ee1bbc77f4af191655dfc896df4c3_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzMtMS0xLTEtMA_0b083e2d-82cd-4588-8e84-8015ab534a49">3,933</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2aeccd462de4b89be3251b77c14116a_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzMtMy0xLTEtMA_6d323ca2-aad3-49c1-b85c-d453feaf3adf">3,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzQtMS0xLTEtMA_efe14f33-a52b-48c7-b352-067bd9689f4c">41,727</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzQtMy0xLTEtMA_644853ba-d11d-4116-9bc3-54c3f15e4b33">40,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i84d08fd1ffc74d6494b61b46546492fc_124"></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzNDM_c8706d10-9f38-4f67-bee8-fa6e4adb0b2b" continuedAt="i57f900711d32429a81b2f1e1cbdd43be" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i57f900711d32429a81b2f1e1cbdd43be" continuedAt="icd2b1b81da9747948e015957387b5ac5"><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzNDg_e8c06f1b-d2c6-42ed-bc9e-131734444303" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzItMS0xLTEtMA_da3e26a5-639b-41be-869e-15dbf4eee4c9">19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc62178c06b346f2a9d5381f46838f85_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzItMy0xLTEtMA_829fa2de-5bb5-4ab7-a1e6-b346ec4be54d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzMtMS0xLTEtMA_b2287a00-252b-4303-b37d-523ae30c8199">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad9b2879e704eba834be054682ed6c5_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzMtMy0xLTEtMA_9e8d5fbf-ddbf-4ba9-9e88-ba4627044047">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzQtMS0xLTEtMA_10fbc1f5-59b4-450b-8a89-629b97cfcafc">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19d22156ae648a3a872b2507b4de145_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzQtMy0xLTEtMA_6c610239-f851-4045-8b20-74d21e7dde2a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzUtMS0xLTEtMA_1cfbe175-e44a-4a74-ae5c-8ceaabfaf8f2">28</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzUtMy0xLTEtMA_ef497ecd-1f43-476a-9c17-0645dec70b8a">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzI5MQ_b271b6b3-24ce-4b29-93c4-59d9fd67449d">4</ix:nonFraction> million for both the three months ended September&#160;30, 2020 and 2019. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzQ3Mw_fe12ef4d-4d55-473a-9c97-8c24a6ea11df">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzMzk_2681ecd7-05f3-4365-8c0e-a429e57bee4c" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cc829ddfa7546fe9e92c22e0ea07a60_I20200630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzEtMS0xLTEtMA_38559bb8-e0dd-43f7-a285-b22d063cdac4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7cc829ddfa7546fe9e92c22e0ea07a60_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzEtMy0xLTEtMA_7f9bbeb5-9f00-4d3d-971c-7b69244f3c9c">45.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzItMS0xLTEtMA_df1c2835-1f18-40d5-a855-cfcb5b42c9e4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzItMy0xLTEtMA_4dfe5503-e8a7-4136-8081-4afd7d1bac76">53.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzMtMS0xLTEtMA_eba5f094-b827-45ac-bded-1a0c6fd28468">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzMtMy0xLTEtMA_6a75503c-5002-41a5-94ef-c59080cf8668">48.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzQtMS0xLTEtMA_727a629d-3b3a-4573-91df-7ff5f73d4180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzQtMy0xLTEtMA_bb57b984-fb07-4838-b4c9-38acb13128c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5ae4550dbfd4e139f3bcceb77e3e045_I20200930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzUtMS0xLTEtMA_644607ff-8c9f-4381-bbdc-9487124a988e">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5ae4550dbfd4e139f3bcceb77e3e045_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzUtMy0xLTEtMA_486ee695-8ce0-4109-a27f-8303da5f8566">48.34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="ia5ae4550dbfd4e139f3bcceb77e3e045_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzgyMA_39843774-9280-4751-9ed7-7e67e9282ab2">124</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2Xzg5Mw_9b5c445d-16df-4a65-88b3-7ef9ecb84302">two years</ix:nonNumeric>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzEwMDc_ee73260a-4050-406a-bae2-5bbd358ef437">three years</ix:nonNumeric> and are exercisable for <ix:nonNumeric contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930" format="ixt-sec:durwordsen" name="cah:ExercisablePeriodOfPlansInYears" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzEwMzQ_d5b57c69-4a6d-4e4c-a0f5-b30e96512772">ten years</ix:nonNumeric> from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzNzA_cce3e0af-deec-4cdf-b219-aa766bbd4b1e" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:51.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzEtMS0xLTEtMA_deeb1c6d-aa6f-47d3-9a44-510a07838314">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzEtMy0xLTEtMA_d7897ba9-3020-4241-a1c3-83e3dc170f59">65.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzItMS0xLTEtMA_183343bb-b642-4c4f-af88-007ac92e2bfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzItMy0xLTEtMA_3f8f48ef-5188-4649-a60a-0876715ac8c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzMtMS0xLTEtMA_802681f1-26ff-4469-b27b-44b638633050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzMtMy0xLTEtMA_5645edb6-35ee-4507-8267-c1569d5e1b4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzQtMS0xLTEtMA_dbae5500-680e-496b-9bba-c4f1d90d62e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzQtMy0xLTEtMA_13413019-6f02-4aea-a8f2-3de839cccb87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzUtMS0xLTEtMA_5881b37f-88f6-47af-ad96-c0a03e8e49c5">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzUtMy0xLTEtMA_76b38402-67d9-4e3c-9231-ccb6557dfcd3">66.19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzYtMS0xLTEtMA_f694d174-89f1-484f-885b-06eb9bfd787c">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzYtMy0xLTEtMA_5932f263-137f-4ee4-8463-717c2f42885c">66.36</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet </span></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="icd2b1b81da9747948e015957387b5ac5"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized was $<ix:nonFraction unitRef="usd" contextRef="i6e44ccff288b4a86886c5aab9864e13b_I20200930" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE0MDM_c97d6af6-73f7-4dfd-bfdf-face6177b313">0.3</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE0NzY_15b27358-e8c0-47b9-bc8f-ebb44791261e">two years</ix:nonNumeric>. </span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="cah:AdditionalStockOptionPlanDataTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzMjU_0fe75f4d-ca9b-423f-8a01-e6e250718fd9" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e44ccff288b4a86886c5aab9864e13b_I20200930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpkOWFjZWFkZjBkMDc0MTVhYTM5MjUzMmIyYmI1Zjg2YS90YWJsZXJhbmdlOmQ5YWNlYWRmMGQwNzQxNWFhMzkyNTMyYjJiYjVmODZhXzEtMS0xLTEtMA_906af400-1bb3-4a16-9854-a0903d07dcdb">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efd6d972b064462a3d6638360713a1e_I20200630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpkOWFjZWFkZjBkMDc0MTVhYTM5MjUzMmIyYmI1Zjg2YS90YWJsZXJhbmdlOmQ5YWNlYWRmMGQwNzQxNWFhMzkyNTMyYjJiYjVmODZhXzEtMy0xLTEtMA_d21f36ff-8b05-4e5f-b9fb-d0145c73482a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e44ccff288b4a86886c5aab9864e13b_I20200930" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpkOWFjZWFkZjBkMDc0MTVhYTM5MjUzMmIyYmI1Zjg2YS90YWJsZXJhbmdlOmQ5YWNlYWRmMGQwNzQxNWFhMzkyNTMyYjJiYjVmODZhXzItMS0xLTEtMA_8c65ddf2-d834-4b34-95d2-224f127e1f51">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efd6d972b064462a3d6638360713a1e_I20200630" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpkOWFjZWFkZjBkMDc0MTVhYTM5MjUzMmIyYmI1Zjg2YS90YWJsZXJhbmdlOmQ5YWNlYWRmMGQwNzQxNWFhMzkyNTMyYjJiYjVmODZhXzItMy0xLTEtMA_997fbbf6-584a-4343-acac-3db46ee0442f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZToxYTRkNzczYjQ5NzY0NmQxYWUxOGFmZmQ1NDIyNWNkMC90YWJsZXJhbmdlOjFhNGQ3NzNiNDk3NjQ2ZDFhZTE4YWZmZDU0MjI1Y2QwXzEtMS0xLTEtMA_86bb5bd9-5cda-4163-b059-8ed69e16e1f9">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4631166cbef49ac95cee271f9ff8821_D20190701-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZToxYTRkNzczYjQ5NzY0NmQxYWUxOGFmZmQ1NDIyNWNkMC90YWJsZXJhbmdlOjFhNGQ3NzNiNDk3NjQ2ZDFhZTE4YWZmZDU0MjI1Y2QwXzEtMy0xLTEtMA_1aa0cfb4-8d62-4377-b400-9ebde18a339e">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZToxYTRkNzczYjQ5NzY0NmQxYWUxOGFmZmQ1NDIyNWNkMC90YWJsZXJhbmdlOjFhNGQ3NzNiNDk3NjQ2ZDFhZTE4YWZmZDU0MjI1Y2QwXzItMS0xLTEtMA_c705c046-d938-49fc-a52f-020f36eda0ef">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4631166cbef49ac95cee271f9ff8821_D20190701-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZToxYTRkNzczYjQ5NzY0NmQxYWUxOGFmZmQ1NDIyNWNkMC90YWJsZXJhbmdlOjFhNGQ3NzNiNDk3NjQ2ZDFhZTE4YWZmZDU0MjI1Y2QwXzItMy0xLTEtMA_1681fc04-a1d4-41ca-a919-032374c8c375">5</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="number" contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930" decimals="INF" name="cah:VestingPeriodinyearsforShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE2MTk_ec08373d-2e48-4446-abb3-2e637c89aa95">3</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from <ix:nonFraction unitRef="number" contextRef="i72080d3b192041d29bdb612c6d87d607_D20200701-20200930" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE3ODI_9d27f5ef-9226-4324-9913-ce99a145015e">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i4f40a80a6e5847bfa13e893d637f65d2_D20200701-20200930" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE3ODg_9df5b4d8-7a76-42b3-9d09-f204962a2f86">240</ix:nonFraction> percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzNTA_b88179c7-cdea-4deb-9931-3f42e85b549e" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7b231115e4c4896aea559547eb04df6_I20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzEtMS0xLTEtMA_bb33daa5-b87d-4607-87e1-602170f54a62">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7b231115e4c4896aea559547eb04df6_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzEtMy0xLTEtMA_cf1a207b-fb16-4c19-ba07-f0a2d5eca2ae">54.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzItMS0xLTEtMA_4c387bec-cad1-4ac7-aad3-a18180749261">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzItMy0xLTEtMA_0fd8dad6-5643-4775-930a-371cb835311d">55.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzMtMS0xLTEtMA_00d6560c-8f12-4c44-ade0-2b095ee22272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzMtMy0xLTEtMA_762f815c-7c5e-4cc5-801c-cd79df2ecf9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzQtMS0xLTEtMA_54f3bd1f-6835-4981-993f-8a6883d4fbf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzQtMy0xLTEtMA_f24600ce-ca8f-45a8-8622-537ee9cc59a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cdf4ef85d164520b43ff6d702fd42c4_I20200930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzUtMS0xLTEtMA_82bc2dae-5fa6-43ce-9277-a8035bbe980c">1.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cdf4ef85d164520b43ff6d702fd42c4_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzUtMy0xLTEtMA_ed800a1e-440a-47c6-86ad-a643650bab80">49.07</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i5cdf4ef85d164520b43ff6d702fd42c4_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIxOTc_ad24f0f9-8aa9-4a8b-a791-f88e703df798">39</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIyNzA_ca9ec556-e5e9-4c3c-9108-d7b3efc0ae94">two years</ix:nonNumeric> if the performance goals are achieved.</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.857%"><tr><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000072137119000129/exhibit32-restatedcode.htm">Cardinal Health, Inc. Restated Code of Regulations, as amended (incorporated by reference to Exhibit 3.2 to Cardinal Health's Current Report on Form 8-K filed on November 12, 2019, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q110q093020ex311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q110q093020ex312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q110q093020ex321.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q110q093020ex991.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases,&#160;SEC filings and certain other information on its website.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:27.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_58">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_58">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_40">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_40">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_43">19</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_46">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_49">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_52">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_52">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_127">38</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i84d08fd1ffc74d6494b61b46546492fc_133">40</a></span></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i84d08fd1ffc74d6494b61b46546492fc_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.005%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;MICHAEL C. KAUFMANN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael C. Kaufmann</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a21q110q093020ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i008517b9d4d64f088342e813686e51b8_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael C. Kaufmann, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;5, 2020 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a21q110q093020ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia9cec902afaa43679d15c23fe2bee019_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;5, 2020 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> JASON M. HOLLAR</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a21q110q093020ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i997cdcd45ca641f8a83519a3d55535b4_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael C. Kaufmann, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Jason M. Hollar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended September 30, 2020 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;5, 2020 </font></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>a21q110q093020ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic5d5fd9caa5e4c4ead19ceb3bca9e534_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2020 (the &#8220;2020 Form 10-K&#8221;), our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from the COVID-19 pandemic, including the possibility that our manufacturing or distribution facilities will be required to cease operations, whether from government regulation in the United States or internationally, or from reduction in available workforce due to illness&#59; the possibility that we could experience significant  delays or disruptions in our supply of medical or pharmaceutical products resulting in an inability to fulfill customer demand&#59; the risk that we will not be able to offset significant cost increases or that and price increases for these products could result in lost sales or customer losses or disputes&#59; the possibility that the widespread required cancellation or deferral of elective medical procedures will result in a sustained reduction in demand for our products&#59; and the potential for us to receive negative publicity resulting from prolonged supply shortages or our participation in industry-wide collaboration to increase the supply of personal protective equipment in the United States&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">with respect to our distribution services agreements with branded pharmaceutical manufacturers, changes in the amount of service fees we receive or, in cases where part of our compensation under these agreements is based on branded pharmaceutical price appreciation, changes in the frequency or magnitude of such price appreciation&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the risk that the outcome of these lawsuits and investigations could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the ongoing discussions regarding a potential global settlement of certain opioid lawsuits and investigations against us, including the risk that we could fail to reach a final settlement, that any final settlement reached could require us to pay more than we currently anticipate or could have a negative effect on our liquidity or ability to return money to shareholders and the risk that any injunctive or non-monetary remedies we may agree to could have unintended consequences&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential adverse impact to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from a quality issue related to the manufacture of some of our sterile surgical gowns, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">possible losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2020 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cah-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:f4838a7d-79fc-48a1-8b7a-97e86b8356e3,g:0e31584d-c111-426d-9652-5609505543ae-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statement of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>2104102 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance_1" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1">
        <link:definition>1306301 - Statement - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>2405402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>2406403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarrativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails">
        <link:definition>2407404 - Disclosure - Restructuring and Employee Severance Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>2108103 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>2309302 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>2410405 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2411406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>2412407 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>2113104 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails">
        <link:definition>2414408 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>2115105 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails">
        <link:definition>2416409 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2417410 - Disclosure - Income Taxes Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>2118106 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>2119107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>2320303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2421411 - Disclosure - Fair Value Measurements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>2122108 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>2323304 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2424412 - Disclosure - Financial Instruments Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>2425413 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>2126109 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>2327305 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2428414 - Disclosure - Shareholders' Equity Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2429415 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>2130110 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>2331306 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>2432416 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>2433417 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>2134111 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>2335307 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>2436418 - Disclosure - Segment Information Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>2437419 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>2438420 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>2439421 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails">
        <link:definition>2440422 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyGeographicalSegmentsDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails">
        <link:definition>2441423 - Disclosure - Segment Information Revenue by Geographical Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>2142112 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>2343308 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2444424 - Disclosure - Share-Based Compensation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>2445425 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails">
        <link:definition>2446426 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
        <link:definition>2447427 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>2448428 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>2449429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_TreasuryStockAcquiredShares" abstract="false" name="TreasuryStockAcquiredShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_MaximumQuarterlyPayment" abstract="false" name="MaximumQuarterlyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_FinalSharesReceivedfromASRProgram" abstract="false" name="FinalSharesReceivedfromASRProgram" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_NumberofStateAttorneysGeneralfilinglawsuits" abstract="false" name="NumberofStateAttorneysGeneralfilinglawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PharmaceuticalSegmentAxis" abstract="true" name="PharmaceuticalSegmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_PharmaceuticalSegmentDomain" abstract="true" name="PharmaceuticalSegmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_IndemnificationReceivable" abstract="false" name="IndemnificationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SegmentRevenuebyGeographicTable" abstract="true" name="SegmentRevenuebyGeographicTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_MedicalSegmentAxis" abstract="true" name="MedicalSegmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" abstract="false" name="Sharesthatwouldbeantidilutiveasaresultofnetloss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_OpioidLawsuitsStateDomain" abstract="true" name="OpioidLawsuitsStateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CareFusionMember" abstract="true" name="CareFusionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TaxMattersAgreementDomain" abstract="true" name="TaxMattersAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_LitigationTypeDomain" abstract="true" name="LitigationTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_Purchaseofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Purchaseofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_NuclearPrecisionHealthServicesMember" abstract="true" name="NuclearPrecisionHealthServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" abstract="false" name="EstimatedLiabilityForNewYorkOpioidStewardshipAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PharmaceuticalDistributionandSpecialtyMember" abstract="true" name="PharmaceuticalDistributionandSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_AlamedaCountyMember" abstract="true" name="AlamedaCountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_MedicalMember" abstract="true" name="MedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PatientRecoveryBusinessMember" abstract="true" name="PatientRecoveryBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_SegmentRevenuebyGeographicLineItems" abstract="true" name="SegmentRevenuebyGeographicLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_ExercisablePeriodOfPlansInYears" abstract="false" name="ExercisablePeriodOfPlansInYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Numberofsharesexcludedfromcalculationofdilutedshares" abstract="false" name="Numberofsharesexcludedfromcalculationofdilutedshares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_OtherJurisdictionsMember" abstract="true" name="OtherJurisdictionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_MedicaldistributionandproductsMember" abstract="true" name="MedicaldistributionandproductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_AdditionalStockOptionPlanDataTableTextBlock" abstract="false" name="AdditionalStockOptionPlanDataTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cah_MedicalSegmentDomain" abstract="true" name="MedicalSegmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CardinalHealthAtHomeSolutionsMember" abstract="true" name="CardinalHealthAtHomeSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" abstract="true" name="BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cah-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:f4838a7d-79fc-48a1-8b7a-97e86b8356e3,g:0e31584d-c111-426d-9652-5609505543ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_daa72c1a-cf1c-4a25-b7c5-247b871de6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4e91a440-42ae-4a91-9504-04b4a68b2639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_daa72c1a-cf1c-4a25-b7c5-247b871de6a1" xlink:to="loc_us-gaap_OperatingIncomeLoss_4e91a440-42ae-4a91-9504-04b4a68b2639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e7b28275-d49a-43ef-a6c9-b8c4a0ae8b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_daa72c1a-cf1c-4a25-b7c5-247b871de6a1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e7b28275-d49a-43ef-a6c9-b8c4a0ae8b83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f86021cd-d290-4e22-bc6d-07876c3b3756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_daa72c1a-cf1c-4a25-b7c5-247b871de6a1" xlink:to="loc_us-gaap_InterestExpense_f86021cd-d290-4e22-bc6d-07876c3b3756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3b3898b-71f2-459c-a301-ddd3ba9a0fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_3d2b1616-27c6-4e18-9132-62cac92c3028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b3898b-71f2-459c-a301-ddd3ba9a0fce" xlink:to="loc_us-gaap_GrossProfit_3d2b1616-27c6-4e18-9132-62cac92c3028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_948ee8a6-4e50-4f86-8501-e95298286f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b3898b-71f2-459c-a301-ddd3ba9a0fce" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_948ee8a6-4e50-4f86-8501-e95298286f5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_04884d1f-ec25-4cd2-bfc8-c29bcbe5487b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b3898b-71f2-459c-a301-ddd3ba9a0fce" xlink:to="loc_us-gaap_RestructuringCharges_04884d1f-ec25-4cd2-bfc8-c29bcbe5487b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_f1f34593-e59a-4260-bfa3-00ead40818d5" xlink:href="cah-20200930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b3898b-71f2-459c-a301-ddd3ba9a0fce" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_f1f34593-e59a-4260-bfa3-00ead40818d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_e8af96f4-c46d-484e-a4f6-844f816feac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b3898b-71f2-459c-a301-ddd3ba9a0fce" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_e8af96f4-c46d-484e-a4f6-844f816feac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_0d12f8f8-b778-4858-9740-bc2c0eae38c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b3898b-71f2-459c-a301-ddd3ba9a0fce" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_0d12f8f8-b778-4858-9740-bc2c0eae38c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aff054fd-42fc-4bc8-adf5-88a4991ac957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2c6962de-29ed-400e-8168-af5a0b409c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aff054fd-42fc-4bc8-adf5-88a4991ac957" xlink:to="loc_us-gaap_ProfitLoss_2c6962de-29ed-400e-8168-af5a0b409c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e85608d0-7d3d-4da6-bbe0-5ad4e28cf140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aff054fd-42fc-4bc8-adf5-88a4991ac957" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e85608d0-7d3d-4da6-bbe0-5ad4e28cf140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7b5d70ed-5489-4d86-8c33-1efcf88227eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ab07cb27-96de-4dcd-a1ec-f62a7d1d3439" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_7b5d70ed-5489-4d86-8c33-1efcf88227eb" xlink:to="loc_us-gaap_Revenues_ab07cb27-96de-4dcd-a1ec-f62a7d1d3439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_821651f1-e821-4468-a1fb-b4c780126dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_7b5d70ed-5489-4d86-8c33-1efcf88227eb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_821651f1-e821-4468-a1fb-b4c780126dc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_81fa1adf-67b6-43a0-93cb-3f0787d494cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_529395a7-2831-41ba-b9ba-6e4387e88d42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_81fa1adf-67b6-43a0-93cb-3f0787d494cc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_529395a7-2831-41ba-b9ba-6e4387e88d42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_37fdc289-194c-443f-b3d2-851dfe67ddcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_81fa1adf-67b6-43a0-93cb-3f0787d494cc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_37fdc289-194c-443f-b3d2-851dfe67ddcc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9521b210-b9ac-4e54-9292-6687c2b50276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_89b93854-9a61-433b-871a-ad85f1c70365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9521b210-b9ac-4e54-9292-6687c2b50276" xlink:to="loc_us-gaap_ProfitLoss_89b93854-9a61-433b-871a-ad85f1c70365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fc3e898d-43e4-4daf-8fa4-35603b580597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9521b210-b9ac-4e54-9292-6687c2b50276" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fc3e898d-43e4-4daf-8fa4-35603b580597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ed1ba7f9-0d9c-48cd-aca0-b180e832be89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bc61b609-acbc-41e5-9a46-4db86a41e2f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ed1ba7f9-0d9c-48cd-aca0-b180e832be89" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bc61b609-acbc-41e5-9a46-4db86a41e2f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_80b8cba6-16b8-48f6-bd2d-d6dd7f0f3be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ed1ba7f9-0d9c-48cd-aca0-b180e832be89" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_80b8cba6-16b8-48f6-bd2d-d6dd7f0f3be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d22ce8b2-b502-4734-8ff7-cf367d96a7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7b4e212f-3130-42a9-ad36-c487e0d70969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d22ce8b2-b502-4734-8ff7-cf367d96a7c7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7b4e212f-3130-42a9-ad36-c487e0d70969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_669f26ba-4ff9-45e3-b8f4-855c99a7d302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d22ce8b2-b502-4734-8ff7-cf367d96a7c7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_669f26ba-4ff9-45e3-b8f4-855c99a7d302" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_921efb93-4234-4126-bded-c3486719e7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_60ee3c53-adb8-4da8-9703-3ceac22fcd83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_921efb93-4234-4126-bded-c3486719e7ec" xlink:to="loc_us-gaap_AccountsPayableCurrent_60ee3c53-adb8-4da8-9703-3ceac22fcd83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7568d24d-5052-4079-8189-86d35e7038b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_921efb93-4234-4126-bded-c3486719e7ec" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7568d24d-5052-4079-8189-86d35e7038b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_587f468f-74a8-4d44-83b9-c1d3ba5ea2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_921efb93-4234-4126-bded-c3486719e7ec" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_587f468f-74a8-4d44-83b9-c1d3ba5ea2aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fddc9cf9-8988-4b40-8107-1d974909d59b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b6fa6f8e-0480-4ce2-8a46-ee2acdd1587d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fddc9cf9-8988-4b40-8107-1d974909d59b" xlink:to="loc_us-gaap_StockholdersEquity_b6fa6f8e-0480-4ce2-8a46-ee2acdd1587d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5b895486-eb9f-4f9e-abd2-9d7d438a2e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fddc9cf9-8988-4b40-8107-1d974909d59b" xlink:to="loc_us-gaap_MinorityInterest_5b895486-eb9f-4f9e-abd2-9d7d438a2e95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d71194fb-c465-4ad5-a5c7-f8928263d547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f8da8d3-3c06-44c1-8287-d5b8a95d834a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d71194fb-c465-4ad5-a5c7-f8928263d547" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f8da8d3-3c06-44c1-8287-d5b8a95d834a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_88c78724-fd8c-4bdf-a63f-6115d5669bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d71194fb-c465-4ad5-a5c7-f8928263d547" xlink:to="loc_us-gaap_ReceivablesNetCurrent_88c78724-fd8c-4bdf-a63f-6115d5669bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4d4f2329-5ace-458c-9e24-c41845e2b5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d71194fb-c465-4ad5-a5c7-f8928263d547" xlink:to="loc_us-gaap_InventoryNet_4d4f2329-5ace-458c-9e24-c41845e2b5e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3719376e-ebb4-43e0-a781-01d2efa823bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d71194fb-c465-4ad5-a5c7-f8928263d547" xlink:to="loc_us-gaap_OtherAssetsCurrent_3719376e-ebb4-43e0-a781-01d2efa823bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e512802f-3ff2-4c40-8f7a-0029b8e33e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f6616181-54a8-4900-a792-ced31d600b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e512802f-3ff2-4c40-8f7a-0029b8e33e80" xlink:to="loc_us-gaap_PreferredStockValue_f6616181-54a8-4900-a792-ced31d600b1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_34b91f8a-0e57-4dbe-937e-728369068c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e512802f-3ff2-4c40-8f7a-0029b8e33e80" xlink:to="loc_us-gaap_CommonStockValue_34b91f8a-0e57-4dbe-937e-728369068c97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b8c7c80-e4fa-4d51-9d1f-79ecb1ad51ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e512802f-3ff2-4c40-8f7a-0029b8e33e80" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b8c7c80-e4fa-4d51-9d1f-79ecb1ad51ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_08a1f5b1-d9dd-4490-94b8-1b2e19c672f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e512802f-3ff2-4c40-8f7a-0029b8e33e80" xlink:to="loc_us-gaap_TreasuryStockValue_08a1f5b1-d9dd-4490-94b8-1b2e19c672f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f00b683e-a89c-4c31-a37a-befb892b7ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e512802f-3ff2-4c40-8f7a-0029b8e33e80" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f00b683e-a89c-4c31-a37a-befb892b7ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b32849d-d2b1-41bf-ae16-e69aafdec693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_176349cf-c489-4f30-b5c6-2c3beb55cc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b32849d-d2b1-41bf-ae16-e69aafdec693" xlink:to="loc_us-gaap_LiabilitiesCurrent_176349cf-c489-4f30-b5c6-2c3beb55cc4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f2ad1858-adae-48dc-b7ce-59632f92d9d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b32849d-d2b1-41bf-ae16-e69aafdec693" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f2ad1858-adae-48dc-b7ce-59632f92d9d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_1368d89a-4b1d-453a-b505-4d85bdbbb993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b32849d-d2b1-41bf-ae16-e69aafdec693" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_1368d89a-4b1d-453a-b505-4d85bdbbb993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a2d11a9-02d2-402a-899c-8ec17b38d224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b32849d-d2b1-41bf-ae16-e69aafdec693" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a2d11a9-02d2-402a-899c-8ec17b38d224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f2588003-11b6-4dfb-a31b-9e4fa63ac80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_41293ca5-059f-492a-9eef-9a2df14b415b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f2588003-11b6-4dfb-a31b-9e4fa63ac80b" xlink:to="loc_us-gaap_AssetsCurrent_41293ca5-059f-492a-9eef-9a2df14b415b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_edd6cb6c-d541-44f4-8f07-fbf6ef07eb7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f2588003-11b6-4dfb-a31b-9e4fa63ac80b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_edd6cb6c-d541-44f4-8f07-fbf6ef07eb7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_84e907cd-2399-450b-8eb4-ff28282de153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f2588003-11b6-4dfb-a31b-9e4fa63ac80b" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_84e907cd-2399-450b-8eb4-ff28282de153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c1aadfa4-eb9e-4f1e-9d4e-548760867b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f2588003-11b6-4dfb-a31b-9e4fa63ac80b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c1aadfa4-eb9e-4f1e-9d4e-548760867b02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementofShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa278227-c797-46cf-8b9e-8215a1ab0230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b2b55d81-b1e8-468b-b5f8-fdc852446093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa278227-c797-46cf-8b9e-8215a1ab0230" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b2b55d81-b1e8-468b-b5f8-fdc852446093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4a764fa-41e0-4114-92dd-79a709d246f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa278227-c797-46cf-8b9e-8215a1ab0230" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4a764fa-41e0-4114-92dd-79a709d246f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6473c228-76a3-4fbc-8ded-4e142eda01de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa278227-c797-46cf-8b9e-8215a1ab0230" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6473c228-76a3-4fbc-8ded-4e142eda01de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7133f049-c41a-4fdc-9ce7-d07b09d68a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa278227-c797-46cf-8b9e-8215a1ab0230" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7133f049-c41a-4fdc-9ce7-d07b09d68a30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69d3b0e4-aba0-4717-9cdb-f1516af80f77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85194b96-a12b-4c9b-a881-02d174711eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69d3b0e4-aba0-4717-9cdb-f1516af80f77" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85194b96-a12b-4c9b-a881-02d174711eda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_336aa3bd-76fa-480c-813d-bfe15d934fd7" xlink:href="cah-20200930.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69d3b0e4-aba0-4717-9cdb-f1516af80f77" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_336aa3bd-76fa-480c-813d-bfe15d934fd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_1f2c97d7-eda1-44a3-9d71-5d4493e98f65" xlink:href="cah-20200930.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69d3b0e4-aba0-4717-9cdb-f1516af80f77" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_1f2c97d7-eda1-44a3-9d71-5d4493e98f65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34de9e9c-b140-45ae-926e-fbea16686525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_9eaeaf9f-2037-42ee-9edb-ef8db0642731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34de9e9c-b140-45ae-926e-fbea16686525" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_9eaeaf9f-2037-42ee-9edb-ef8db0642731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_48b63438-caf9-430e-8615-8eddd26473d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34de9e9c-b140-45ae-926e-fbea16686525" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_48b63438-caf9-430e-8615-8eddd26473d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_5ceedcdb-97f1-41ef-9b4e-d182994e70e4" xlink:href="cah-20200930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34de9e9c-b140-45ae-926e-fbea16686525" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_5ceedcdb-97f1-41ef-9b4e-d182994e70e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_72a0b77f-a13d-4b12-a0e5-3e9be5d81e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34de9e9c-b140-45ae-926e-fbea16686525" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_72a0b77f-a13d-4b12-a0e5-3e9be5d81e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3253c62b-e197-4a0a-bb04-c2294a29df46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34de9e9c-b140-45ae-926e-fbea16686525" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3253c62b-e197-4a0a-bb04-c2294a29df46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_166bd1cd-8f72-4452-8c5a-a6eb55ff9b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:to="loc_us-gaap_ProfitLoss_166bd1cd-8f72-4452-8c5a-a6eb55ff9b3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d27f2664-d4c1-4f69-a1d6-fe6a5f358a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d27f2664-d4c1-4f69-a1d6-fe6a5f358a3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_cd292701-2a6e-41f6-810b-ce2c755bc426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_cd292701-2a6e-41f6-810b-ce2c755bc426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9031bbf4-7feb-4e60-a5a8-aa4f36aa5f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:to="loc_us-gaap_ShareBasedCompensation_9031bbf4-7feb-4e60-a5a8-aa4f36aa5f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_beb061bd-533c-4eb1-a8c7-a31a6473655e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_beb061bd-533c-4eb1-a8c7-a31a6473655e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_14ac98fd-3b8e-47b4-8aeb-a6eac737a28a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_14ac98fd-3b8e-47b4-8aeb-a6eac737a28a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d3b3b885-2277-4a68-a433-a1fb0beaa0c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d3b3b885-2277-4a68-a433-a1fb0beaa0c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e1bc0dbf-7f57-4a32-9693-1325e9e9937b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e1bc0dbf-7f57-4a32-9693-1325e9e9937b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fea13212-1c03-4ac9-a499-6a9b11150ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e5a4927-232b-469a-8fc0-d25bb5f788ed" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fea13212-1c03-4ac9-a499-6a9b11150ccc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeverance"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeverance_1"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c55fb69e-f66e-406f-a922-48b86a1c3a80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_3760f5c5-0e13-4671-9f73-6a3de7649dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_c55fb69e-f66e-406f-a922-48b86a1c3a80" xlink:to="loc_us-gaap_SeveranceCosts1_3760f5c5-0e13-4671-9f73-6a3de7649dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_b054c561-3f15-48a5-a4bd-a1f19c3feacc" xlink:href="cah-20200930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_c55fb69e-f66e-406f-a922-48b86a1c3a80" xlink:to="loc_cah_FacilityExitAndOtherCosts_b054c561-3f15-48a5-a4bd-a1f19c3feacc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeveranceNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20200930.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20200930.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_90f36d26-083c-41fc-8ed1-2e048b295b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1c06002c-43cc-42cc-928f-abcc657a0897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_90f36d26-083c-41fc-8ed1-2e048b295b2a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1c06002c-43cc-42cc-928f-abcc657a0897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5c724b64-4d31-4a46-a34b-f04af549a20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_90f36d26-083c-41fc-8ed1-2e048b295b2a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5c724b64-4d31-4a46-a34b-f04af549a20c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_001f7bb0-ec59-49a4-beac-ef5c9025fe82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c84f9cd6-004e-4598-a5e3-8282f2af5222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_001f7bb0-ec59-49a4-beac-ef5c9025fe82" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c84f9cd6-004e-4598-a5e3-8282f2af5222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_326bbf7b-b8be-4a55-a5b5-0bd588b415d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_001f7bb0-ec59-49a4-beac-ef5c9025fe82" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_326bbf7b-b8be-4a55-a5b5-0bd588b415d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformation"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationRevenuebyGeographicalSegmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cah-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:f4838a7d-79fc-48a1-8b7a-97e86b8356e3,g:0e31584d-c111-426d-9652-5609505543ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended" id="i92b4aa6ce1a3438a91ecab8455cb84e3_CoverPage"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended" id="icd462dc297e1467f915fb22f6d3798a8_CondensedConsolidatedStatementsofEarnings"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended" id="i37b5fb5d14a3456a9219a25a6dbb9036_CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i73055f424ab448aea744d898f942b024_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="extended" id="ifb96cede25c2421c8bb02baeef2dd96e_CondensedConsolidatedStatementofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4a2890d9-120e-4d8f-8c87-016634be004b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_CommonStockSharesIssued_4a2890d9-120e-4d8f-8c87-016634be004b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d98d446a-7c55-43ce-97a7-25b2deee7838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d98d446a-7c55-43ce-97a7-25b2deee7838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_900e49f9-f319-4525-a05e-8a1f6a6d5b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_TreasuryStockShares_900e49f9-f319-4525-a05e-8a1f6a6d5b76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c09faf26-e70f-49b7-a738-1ae8047a616f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_TreasuryStockValue_c09faf26-e70f-49b7-a738-1ae8047a616f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49420316-d135-41f0-8722-fab8a58bcc24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_NetIncomeLoss_49420316-d135-41f0-8722-fab8a58bcc24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a9277f3d-eb19-41de-ad3b-fe1ea5b772ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_ProfitLoss_a9277f3d-eb19-41de-ad3b-fe1ea5b772ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f1b3df79-3a4f-4644-b07b-7ff7d01d7d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f1b3df79-3a4f-4644-b07b-7ff7d01d7d73" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_47113154-5478-429c-9f12-d77094e7d1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_47113154-5478-429c-9f12-d77094e7d1d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_82ad1874-0812-4cb9-8603-396d3c432abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_82ad1874-0812-4cb9-8603-396d3c432abe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_812abb0f-7cc1-4880-89ba-702bc2483ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_812abb0f-7cc1-4880-89ba-702bc2483ca7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d4cc7a2-76c6-41ef-bad6-e3b02e727584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d4cc7a2-76c6-41ef-bad6-e3b02e727584" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_db2ffab7-a698-421c-817a-bb581b16deb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_Dividends_db2ffab7-a698-421c-817a-bb581b16deb0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3e512ca8-5a5e-483d-9f54-6f6de6c9ae47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9bebb091-1cb9-426c-ad14-39c406662729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_d6fb3282-fc6c-4354-b757-caa01ccef99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b8efadf8-d392-4d49-97ee-2d59719f40aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_eeb8543f-f2dc-4d16-a5f2-afb84a0e0753" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_eeb8543f-f2dc-4d16-a5f2-afb84a0e0753" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30b3dcc5-58ed-42a6-9d0f-98b03990ee91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_eeb8543f-f2dc-4d16-a5f2-afb84a0e0753" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30b3dcc5-58ed-42a6-9d0f-98b03990ee91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30b3dcc5-58ed-42a6-9d0f-98b03990ee91_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30b3dcc5-58ed-42a6-9d0f-98b03990ee91" xlink:to="loc_us-gaap_EquityComponentDomain_30b3dcc5-58ed-42a6-9d0f-98b03990ee91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30b3dcc5-58ed-42a6-9d0f-98b03990ee91" xlink:to="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c2eded09-47e7-4a93-a3bf-b997ce508acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_CommonStockMember_c2eded09-47e7-4a93-a3bf-b997ce508acf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ee6480c7-125f-4f72-9dea-6216c6867876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_RetainedEarningsMember_ee6480c7-125f-4f72-9dea-6216c6867876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0122e8af-8974-4f50-8104-02300bc51873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_TreasuryStockMember_0122e8af-8974-4f50-8104-02300bc51873" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cacb349f-5b35-4084-9a4c-2ca223b81fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cacb349f-5b35-4084-9a4c-2ca223b81fff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9b0a6c8d-e306-458a-9610-bf99182863d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9b0a6c8d-e306-458a-9610-bf99182863d6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="id331811670ae43b7a3fff6dc3c1737ed_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i62bb5ede669046c6974ac63369e7ef35_BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i8954847b4cd44102b782e79fb59675e0_BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ice09cc94d7ec4f35aaccdf6db2f4ce0d_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeverance"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended" id="i69fe57d584704ffabf9fe17357cbbd6d_RestructuringandEmployeeSeverance"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeverance_1"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1" xlink:type="extended" id="i1357c23e542c474da2dde91ced3f7529_RestructuringandEmployeeSeverance_1"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended" id="ia6351a0e355644f7b9c6798ad13f2b29_RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended" id="i0b5a1d32e1c64db6a3f4357c55f9597c_RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_26e616c1-c32d-4e0c-807b-eac8ed5d09a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_26e616c1-c32d-4e0c-807b-eac8ed5d09a8" xlink:to="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_81d005fc-177e-4601-a3e4-9326a04857f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:to="loc_us-gaap_RestructuringReserve_81d005fc-177e-4601-a3e4-9326a04857f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_26d6cbfa-40e0-4381-ae07-5e48db2562dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:to="loc_us-gaap_RestructuringCosts_26d6cbfa-40e0-4381-ae07-5e48db2562dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_9865c72c-8b7a-4060-b2bd-5026827445bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:to="loc_us-gaap_PaymentsForRestructuring_9865c72c-8b7a-4060-b2bd-5026827445bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_686c9ad6-2de4-44e5-902b-e27fb189bb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_268160c8-8388-4c8e-9a2f-b4605727dafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_26e616c1-c32d-4e0c-807b-eac8ed5d09a8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_268160c8-8388-4c8e-9a2f-b4605727dafb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d1cee2f8-e0f2-4a7c-b2cb-a6e9780e4485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_268160c8-8388-4c8e-9a2f-b4605727dafb" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d1cee2f8-e0f2-4a7c-b2cb-a6e9780e4485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d1cee2f8-e0f2-4a7c-b2cb-a6e9780e4485_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d1cee2f8-e0f2-4a7c-b2cb-a6e9780e4485" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d1cee2f8-e0f2-4a7c-b2cb-a6e9780e4485_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f8590f6f-fa54-46b6-b545-3a248bd9011a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d1cee2f8-e0f2-4a7c-b2cb-a6e9780e4485" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f8590f6f-fa54-46b6-b545-3a248bd9011a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_d82d5175-fac5-41ed-a775-200453cd45c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f8590f6f-fa54-46b6-b545-3a248bd9011a" xlink:to="loc_us-gaap_EmployeeSeveranceMember_d82d5175-fac5-41ed-a775-200453cd45c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_bfd1760e-1308-494d-bc56-1feea0ac5f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f8590f6f-fa54-46b6-b545-3a248bd9011a" xlink:to="loc_us-gaap_FacilityClosingMember_bfd1760e-1308-494d-bc56-1feea0ac5f6e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeveranceNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="extended" id="i5be8ac89abb04b92b3b45178f47ff773_RestructuringandEmployeeSeveranceNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_2ae0d293-07dc-457a-81f5-1e27c938b0af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:to="loc_us-gaap_RestructuringCosts_2ae0d293-07dc-457a-81f5-1e27c938b0af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ca4d4413-7ea1-4988-9c0c-e854d0f6f433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:to="loc_us-gaap_SeveranceCosts1_ca4d4413-7ea1-4988-9c0c-e854d0f6f433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_a0656116-e0c2-4eff-9f64-51a15fa1f480" xlink:href="cah-20200930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:to="loc_cah_FacilityExitAndOtherCosts_a0656116-e0c2-4eff-9f64-51a15fa1f480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4679542-e419-454d-ae6f-4e75612821a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4679542-e419-454d-ae6f-4e75612821a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_9adb87b8-a529-43af-85f8-5694569bcd3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4679542-e419-454d-ae6f-4e75612821a4" xlink:to="loc_us-gaap_RestructuringPlanAxis_9adb87b8-a529-43af-85f8-5694569bcd3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_9adb87b8-a529-43af-85f8-5694569bcd3d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_9adb87b8-a529-43af-85f8-5694569bcd3d" xlink:to="loc_us-gaap_RestructuringPlanDomain_9adb87b8-a529-43af-85f8-5694569bcd3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_4ae07f01-d810-4abe-99d7-3db16f26a818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_9adb87b8-a529-43af-85f8-5694569bcd3d" xlink:to="loc_us-gaap_RestructuringPlanDomain_4ae07f01-d810-4abe-99d7-3db16f26a818" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended" id="ic50b065046fd4a1599ea271865a2de3f_GoodwillandOtherIntangibleAssets"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended" id="if37bfb2becbf46c8b7596a1462e80e38_GoodwillandOtherIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended" id="i09cc45e4052c4ef4be4509aaf657e1eb_GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ab87180d-df62-4377-a3fc-445e5d420567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers_d0dd524a-2d16-4dd1-b20f-0725a187d8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillTransfers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ab87180d-df62-4377-a3fc-445e5d420567" xlink:to="loc_us-gaap_GoodwillTransfers_d0dd524a-2d16-4dd1-b20f-0725a187d8c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b8effbc5-864e-4246-974b-f4a96624c3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ab87180d-df62-4377-a3fc-445e5d420567" xlink:to="loc_us-gaap_GoodwillRollForward_b8effbc5-864e-4246-974b-f4a96624c3fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_40631629-bc54-43a3-b815-4d3aee908f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b8effbc5-864e-4246-974b-f4a96624c3fa" xlink:to="loc_us-gaap_Goodwill_40631629-bc54-43a3-b815-4d3aee908f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c041f02e-b14a-4dc6-a117-5a3400ee55ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b8effbc5-864e-4246-974b-f4a96624c3fa" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c041f02e-b14a-4dc6-a117-5a3400ee55ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_955f12be-c21b-4fe3-a99b-b6db11f7b701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_24315df8-dc05-436f-9a83-99286a35e3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_ab87180d-df62-4377-a3fc-445e5d420567" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_24315df8-dc05-436f-9a83-99286a35e3b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5797e642-cca9-4026-9846-a86cfc90e190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_24315df8-dc05-436f-9a83-99286a35e3b0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5797e642-cca9-4026-9846-a86cfc90e190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5797e642-cca9-4026-9846-a86cfc90e190_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5797e642-cca9-4026-9846-a86cfc90e190" xlink:to="loc_us-gaap_SegmentDomain_5797e642-cca9-4026-9846-a86cfc90e190_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dce01a92-0247-46c1-937d-177ce55baea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5797e642-cca9-4026-9846-a86cfc90e190" xlink:to="loc_us-gaap_SegmentDomain_dce01a92-0247-46c1-937d-177ce55baea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_35a3b9a5-d5fb-4879-9f51-8d5186c42154" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dce01a92-0247-46c1-937d-177ce55baea6" xlink:to="loc_cah_PharmaceuticalMember_35a3b9a5-d5fb-4879-9f51-8d5186c42154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_83d1cbdb-9892-40ab-85d1-363b8940b3be" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dce01a92-0247-46c1-937d-177ce55baea6" xlink:to="loc_cah_MedicalMember_83d1cbdb-9892-40ab-85d1-363b8940b3be" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="ia1d5fdd6c5d4454f8789ba3f60d7ca7f_GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a587dcac-3f5a-44af-bd60-caa594847aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e280d406-6d02-49be-a093-48d2479a8a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a587dcac-3f5a-44af-bd60-caa594847aea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e280d406-6d02-49be-a093-48d2479a8a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e43627ff-cd35-468e-a41d-51ca735ab08b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a587dcac-3f5a-44af-bd60-caa594847aea" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e43627ff-cd35-468e-a41d-51ca735ab08b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f9a30411-8491-4963-bfec-5556468a4ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e43627ff-cd35-468e-a41d-51ca735ab08b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f9a30411-8491-4963-bfec-5556468a4ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f9a30411-8491-4963-bfec-5556468a4ded_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f9a30411-8491-4963-bfec-5556468a4ded" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f9a30411-8491-4963-bfec-5556468a4ded_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_33bd5e52-9b26-4b40-90cf-f5862ac570ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f9a30411-8491-4963-bfec-5556468a4ded" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_33bd5e52-9b26-4b40-90cf-f5862ac570ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_ce0211a6-bba0-4e34-a210-00febe637b68" xlink:href="cah-20200930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_33bd5e52-9b26-4b40-90cf-f5862ac570ea" xlink:to="loc_cah_IPRDTrademarksandOtherMember_ce0211a6-bba0-4e34-a210-00febe637b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_957994ab-17a6-4dba-bcd0-35bd76b3ea7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_957994ab-17a6-4dba-bcd0-35bd76b3ea7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f9f4f80f-be56-4144-8b07-ed7f1383bc51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f9f4f80f-be56-4144-8b07-ed7f1383bc51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3fc060cd-a892-43da-9d58-ae39a628dc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3fc060cd-a892-43da-9d58-ae39a628dc0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cf875c7a-12b2-4c22-a6db-ee159359da7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cf875c7a-12b2-4c22-a6db-ee159359da7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9fc50bf-37d6-4f27-8bc7-7c61291a883d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9fc50bf-37d6-4f27-8bc7-7c61291a883d" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_afbe958e-71e1-42ec-948e-b4356eef600c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9fc50bf-37d6-4f27-8bc7-7c61291a883d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_afbe958e-71e1-42ec-948e-b4356eef600c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_afbe958e-71e1-42ec-948e-b4356eef600c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_afbe958e-71e1-42ec-948e-b4356eef600c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_afbe958e-71e1-42ec-948e-b4356eef600c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_afbe958e-71e1-42ec-948e-b4356eef600c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c1224fe3-a06d-429d-a5b7-01ca59954e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c1224fe3-a06d-429d-a5b7-01ca59954e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_3b3e1031-ebad-4627-bf8b-1034734c90bb" xlink:href="cah-20200930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:to="loc_cah_TrademarksAndPatentsMember_3b3e1031-ebad-4627-bf8b-1034734c90bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cecb4dc6-ef99-458d-addd-8ad1d673fd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cecb4dc6-ef99-458d-addd-8ad1d673fd46" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i2e987ced877a4e18ba2355b0409aaec5_GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20200930.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended" id="ia86c0b75612f4a208c04e08efb57493e_LongTermObligationsandOtherShortTermBorrowings"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="extended" id="i2da84f88fc0d49acaae86326c3817692_LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_453d5a00-6043-4797-945b-acd8d570bb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_453d5a00-6043-4797-945b-acd8d570bb6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d7877a3f-f5bb-4dbc-80b7-b3c264af4e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d7877a3f-f5bb-4dbc-80b7-b3c264af4e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_d497be75-b36b-4240-b2eb-79c745f65709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_d497be75-b36b-4240-b2eb-79c745f65709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6dad0dae-201e-4967-b043-d23fa130fe9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_AccountsPayableCurrent_6dad0dae-201e-4967-b043-d23fa130fe9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2b9c371b-f553-49da-9c41-ee34a3e15d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2b9c371b-f553-49da-9c41-ee34a3e15d33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7f2d5028-91a0-41b4-a4c7-571f00a4da31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_CreditFacilityAxis_7f2d5028-91a0-41b4-a4c7-571f00a4da31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7f2d5028-91a0-41b4-a4c7-571f00a4da31_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7f2d5028-91a0-41b4-a4c7-571f00a4da31" xlink:to="loc_us-gaap_CreditFacilityDomain_7f2d5028-91a0-41b4-a4c7-571f00a4da31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7f2d5028-91a0-41b4-a4c7-571f00a4da31" xlink:to="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_19c222d0-3b30-452f-8087-64b584106d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:to="loc_us-gaap_CommercialPaperMember_19c222d0-3b30-452f-8087-64b584106d21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aa9d242d-d7b6-435a-a485-f7b3828c50c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aa9d242d-d7b6-435a-a485-f7b3828c50c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_888fb45b-33e0-4586-9600-06a7fb511fd6" xlink:href="cah-20200930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_888fb45b-33e0-4586-9600-06a7fb511fd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_7bd139d1-d279-4a87-833b-9260d24670a6" xlink:href="cah-20200930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShortTermCreditFacilitiesMember_888fb45b-33e0-4586-9600-06a7fb511fd6" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_7bd139d1-d279-4a87-833b-9260d24670a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c0ce3e27-e329-4874-b9a8-69b729e75492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c0ce3e27-e329-4874-b9a8-69b729e75492" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c0ce3e27-e329-4874-b9a8-69b729e75492_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c0ce3e27-e329-4874-b9a8-69b729e75492" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c0ce3e27-e329-4874-b9a8-69b729e75492_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3fda9608-c54d-4efe-a6ce-3398b6390349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c0ce3e27-e329-4874-b9a8-69b729e75492" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3fda9608-c54d-4efe-a6ce-3398b6390349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_93028d5a-aee2-49f6-ad54-7ba151bd1e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_DebtInstrumentAxis_93028d5a-aee2-49f6-ad54-7ba151bd1e86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_93028d5a-aee2-49f6-ad54-7ba151bd1e86_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_93028d5a-aee2-49f6-ad54-7ba151bd1e86" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_93028d5a-aee2-49f6-ad54-7ba151bd1e86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ed0bf1f-ff3e-4817-b49b-6930dab9a04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_93028d5a-aee2-49f6-ad54-7ba151bd1e86" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ed0bf1f-ff3e-4817-b49b-6930dab9a04c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_d9fa0520-11b2-41b2-af4c-eecd5708e5e1" xlink:href="cah-20200930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ed0bf1f-ff3e-4817-b49b-6930dab9a04c" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_d9fa0520-11b2-41b2-af4c-eecd5708e5e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e2a198d2-f680-48b7-82d4-89d6636e94ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_VariableRateAxis_e2a198d2-f680-48b7-82d4-89d6636e94ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e2a198d2-f680-48b7-82d4-89d6636e94ef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_e2a198d2-f680-48b7-82d4-89d6636e94ef" xlink:to="loc_us-gaap_VariableRateDomain_e2a198d2-f680-48b7-82d4-89d6636e94ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a5fe3cb0-bf76-438a-b0b7-b2855a78b3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_e2a198d2-f680-48b7-82d4-89d6636e94ef" xlink:to="loc_us-gaap_VariableRateDomain_a5fe3cb0-bf76-438a-b0b7-b2855a78b3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bcc4b92c-3862-4556-98f3-579a63465d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bcc4b92c-3862-4556-98f3-579a63465d22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_bcc4b92c-3862-4556-98f3-579a63465d22_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bcc4b92c-3862-4556-98f3-579a63465d22" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_bcc4b92c-3862-4556-98f3-579a63465d22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_97b28d6a-0cb8-4fab-85b0-1d7d0c750115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bcc4b92c-3862-4556-98f3-579a63465d22" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_97b28d6a-0cb8-4fab-85b0-1d7d0c750115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_294d3d07-5a74-49ff-b3d7-cb0b22d409da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_srt_RangeAxis_294d3d07-5a74-49ff-b3d7-cb0b22d409da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_294d3d07-5a74-49ff-b3d7-cb0b22d409da_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_294d3d07-5a74-49ff-b3d7-cb0b22d409da" xlink:to="loc_srt_RangeMember_294d3d07-5a74-49ff-b3d7-cb0b22d409da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3eba1af6-a73b-49ae-b6c6-f6a8a1cf1944" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_294d3d07-5a74-49ff-b3d7-cb0b22d409da" xlink:to="loc_srt_RangeMember_3eba1af6-a73b-49ae-b6c6-f6a8a1cf1944" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20200930.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended" id="i44c0eaa607674f12bc83db5098adf83e_CommitmentsContingentLiabilitiesandLitigation"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="extended" id="ie9c227a2ab694e038cef5af526da53a2_CommitmentsContingentLiabilitiesandLitigationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_45d48dc6-233e-442b-96dd-01163ce8487d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_45d48dc6-233e-442b-96dd-01163ce8487d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaximumQuarterlyPayment_2afdce85-4716-444a-90f7-43f8c3730e0b" xlink:href="cah-20200930.xsd#cah_MaximumQuarterlyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_MaximumQuarterlyPayment_2afdce85-4716-444a-90f7-43f8c3730e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_a1deb6ca-2d78-4ecc-9a51-2de89aac4fda" xlink:href="cah-20200930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_LossContingencyLawsuitsNumber_a1deb6ca-2d78-4ecc-9a51-2de89aac4fda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_4058e3cc-dcad-416e-9ed2-5c49d4f6fe05" xlink:href="cah-20200930.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_4058e3cc-dcad-416e-9ed2-5c49d4f6fe05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_6a598534-08eb-4cd0-ab6e-336fd763b331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LitigationReserve_6a598534-08eb-4cd0-ab6e-336fd763b331" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bc13ea5b-a808-4453-877f-be911337265f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bc13ea5b-a808-4453-877f-be911337265f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_1ecb06ad-1c91-4980-ae1c-2314a4900228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_1ecb06ad-1c91-4980-ae1c-2314a4900228" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_32f4e3e4-2e5d-42f7-8ae7-fdceb036d5b0" xlink:href="cah-20200930.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_AggregateAnnualAssessment_32f4e3e4-2e5d-42f7-8ae7-fdceb036d5b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_f3e2ec12-0aaa-4aee-9797-1a3c6049f9af" xlink:href="cah-20200930.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_f3e2ec12-0aaa-4aee-9797-1a3c6049f9af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b4fd3f6c-74e8-41c1-9c89-86572c0bbdad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b4fd3f6c-74e8-41c1-9c89-86572c0bbdad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_cca042a0-cdf5-4c96-b983-b548ca0f7d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LitigationSettlementExpense_cca042a0-cdf5-4c96-b983-b548ca0f7d2c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15e23e86-974e-4b30-91bb-3c463d0d43a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15e23e86-974e-4b30-91bb-3c463d0d43a5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_c2b8a54b-becc-4351-859e-a88f36fb9f44" xlink:href="cah-20200930.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_cah_LawsuitTypeAxis_c2b8a54b-becc-4351-859e-a88f36fb9f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_c2b8a54b-becc-4351-859e-a88f36fb9f44_default" xlink:href="cah-20200930.xsd#cah_LitigationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_c2b8a54b-becc-4351-859e-a88f36fb9f44" xlink:to="loc_cah_LitigationTypeDomain_c2b8a54b-becc-4351-859e-a88f36fb9f44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_37ae487c-b23c-4b44-b550-bfbe299dc4ec" xlink:href="cah-20200930.xsd#cah_LitigationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_c2b8a54b-becc-4351-859e-a88f36fb9f44" xlink:to="loc_cah_LitigationTypeDomain_37ae487c-b23c-4b44-b550-bfbe299dc4ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_9a47a808-7454-430b-869d-a912800711a2" xlink:href="cah-20200930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LitigationTypeDomain_37ae487c-b23c-4b44-b550-bfbe299dc4ec" xlink:to="loc_cah_ClassActionLawsuitsMember_9a47a808-7454-430b-869d-a912800711a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_4a933e3a-aa18-40f4-872c-6b5b0383496f" xlink:href="cah-20200930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LitigationTypeDomain_37ae487c-b23c-4b44-b550-bfbe299dc4ec" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_4a933e3a-aa18-40f4-872c-6b5b0383496f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_5170e57e-9caf-405d-a60f-f27c2433deea" xlink:href="cah-20200930.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_cah_PlaintiffTypeAxis_5170e57e-9caf-405d-a60f-f27c2433deea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_5170e57e-9caf-405d-a60f-f27c2433deea_default" xlink:href="cah-20200930.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_5170e57e-9caf-405d-a60f-f27c2433deea" xlink:to="loc_cah_PlaintiffTypeDomain_5170e57e-9caf-405d-a60f-f27c2433deea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_831530f8-ff6f-4e0e-8cef-685d06986322" xlink:href="cah-20200930.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_5170e57e-9caf-405d-a60f-f27c2433deea" xlink:to="loc_cah_PlaintiffTypeDomain_831530f8-ff6f-4e0e-8cef-685d06986322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_8e905d94-3e23-41c7-952f-6a5c94139fb3" xlink:href="cah-20200930.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_831530f8-ff6f-4e0e-8cef-685d06986322" xlink:to="loc_cah_PrivatePartiesMember_8e905d94-3e23-41c7-952f-6a5c94139fb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_c868ddf4-c14b-42f1-9092-89445e118207" xlink:href="cah-20200930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_cah_OpioidLitigationAxis_c868ddf4-c14b-42f1-9092-89445e118207" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_c868ddf4-c14b-42f1-9092-89445e118207_default" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_c868ddf4-c14b-42f1-9092-89445e118207" xlink:to="loc_cah_TaxMattersAgreementDomain_c868ddf4-c14b-42f1-9092-89445e118207_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_45f40c92-d28c-46e0-94e9-e01cc3c6fb3e" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_c868ddf4-c14b-42f1-9092-89445e118207" xlink:to="loc_cah_TaxMattersAgreementDomain_45f40c92-d28c-46e0-94e9-e01cc3c6fb3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_a9f2964c-b382-417e-aeb1-e2584b72266a" xlink:href="cah-20200930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_45f40c92-d28c-46e0-94e9-e01cc3c6fb3e" xlink:to="loc_cah_TotalOpioidLitigationMember_a9f2964c-b382-417e-aeb1-e2584b72266a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9ad9b17d-d9ed-4402-a905-292c3f680b12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_StatementGeographicalAxis_9ad9b17d-d9ed-4402-a905-292c3f680b12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9ad9b17d-d9ed-4402-a905-292c3f680b12_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9ad9b17d-d9ed-4402-a905-292c3f680b12" xlink:to="loc_srt_SegmentGeographicalDomain_9ad9b17d-d9ed-4402-a905-292c3f680b12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_aed731d8-77db-4754-a31b-7d0ae91911cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9ad9b17d-d9ed-4402-a905-292c3f680b12" xlink:to="loc_srt_SegmentGeographicalDomain_aed731d8-77db-4754-a31b-7d0ae91911cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_d7270f6f-d3e4-4393-ace0-630811317cb0" xlink:href="cah-20200930.xsd#cah_AlamedaCountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_aed731d8-77db-4754-a31b-7d0ae91911cf" xlink:to="loc_cah_AlamedaCountyMember_d7270f6f-d3e4-4393-ace0-630811317cb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_32ad0b11-268a-4a15-9201-769b3133520f" xlink:href="cah-20200930.xsd#cah_OtherJurisdictionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_aed731d8-77db-4754-a31b-7d0ae91911cf" xlink:to="loc_cah_OtherJurisdictionsMember_32ad0b11-268a-4a15-9201-769b3133520f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_514d4e6d-239d-400b-8e89-d55b2d3877ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_RangeAxis_514d4e6d-239d-400b-8e89-d55b2d3877ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_514d4e6d-239d-400b-8e89-d55b2d3877ae_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_514d4e6d-239d-400b-8e89-d55b2d3877ae" xlink:to="loc_srt_RangeMember_514d4e6d-239d-400b-8e89-d55b2d3877ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb670a59-970b-4848-a02c-45563c63dd08" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_514d4e6d-239d-400b-8e89-d55b2d3877ae" xlink:to="loc_srt_RangeMember_eb670a59-970b-4848-a02c-45563c63dd08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b0bd0672-3e83-4da3-b05c-ef4090df2c59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb670a59-970b-4848-a02c-45563c63dd08" xlink:to="loc_srt_MinimumMember_b0bd0672-3e83-4da3-b05c-ef4090df2c59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f794dff0-b812-46be-bc81-7bfc771a0a5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb670a59-970b-4848-a02c-45563c63dd08" xlink:to="loc_srt_MaximumMember_f794dff0-b812-46be-bc81-7bfc771a0a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_547e4362-2ed4-4401-8c61-aeb590151830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_547e4362-2ed4-4401-8c61-aeb590151830" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_547e4362-2ed4-4401-8c61-aeb590151830_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_547e4362-2ed4-4401-8c61-aeb590151830" xlink:to="loc_us-gaap_LossContingencyNatureDomain_547e4362-2ed4-4401-8c61-aeb590151830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d893136a-adab-4096-bc66-47f607940bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_547e4362-2ed4-4401-8c61-aeb590151830" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d893136a-adab-4096-bc66-47f607940bb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_f8983050-f64e-45b2-b4ce-8c8b066e8f85" xlink:href="cah-20200930.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d893136a-adab-4096-bc66-47f607940bb2" xlink:to="loc_cah_OpioidLawsuitsMember_f8983050-f64e-45b2-b4ce-8c8b066e8f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_ce97cfca-1126-47f1-bb3e-ecc9111fbe03" xlink:href="cah-20200930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d893136a-adab-4096-bc66-47f607940bb2" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_ce97cfca-1126-47f1-bb3e-ecc9111fbe03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_8c63d441-a080-4c43-a9e8-17a5611e4f4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_MajorCustomersAxis_8c63d441-a080-4c43-a9e8-17a5611e4f4d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8c63d441-a080-4c43-a9e8-17a5611e4f4d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_8c63d441-a080-4c43-a9e8-17a5611e4f4d" xlink:to="loc_srt_NameOfMajorCustomerDomain_8c63d441-a080-4c43-a9e8-17a5611e4f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0d1ce684-c710-4744-9dc4-75a115e96b9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_8c63d441-a080-4c43-a9e8-17a5611e4f4d" xlink:to="loc_srt_NameOfMajorCustomerDomain_0d1ce684-c710-4744-9dc4-75a115e96b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_b92c1511-7605-416e-be3e-5c130e817a0b" xlink:href="cah-20200930.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d1ce684-c710-4744-9dc4-75a115e96b9e" xlink:to="loc_cah_CVSHealthMember_b92c1511-7605-416e-be3e-5c130e817a0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cbadfeda-e27d-403f-8655-2f4361e95474" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_LitigationCaseAxis_cbadfeda-e27d-403f-8655-2f4361e95474" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_cbadfeda-e27d-403f-8655-2f4361e95474_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_cbadfeda-e27d-403f-8655-2f4361e95474" xlink:to="loc_srt_LitigationCaseTypeDomain_cbadfeda-e27d-403f-8655-2f4361e95474_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_cbadfeda-e27d-403f-8655-2f4361e95474" xlink:to="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_811c1b06-db69-4e97-84ce-48be8fad8a07" xlink:href="cah-20200930.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_OpioidLawsuitsMember_811c1b06-db69-4e97-84ce-48be8fad8a07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_b9655a35-f286-44c7-ae2a-85f761a6562b" xlink:href="cah-20200930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_ClassActionLawsuitsMember_b9655a35-f286-44c7-ae2a-85f761a6562b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_97fd0268-a0d2-4808-b621-1b3b2d6e23bd" xlink:href="cah-20200930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_97fd0268-a0d2-4808-b621-1b3b2d6e23bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_227ea0ff-718d-4d26-8d27-7f17e6373718" xlink:href="cah-20200930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_227ea0ff-718d-4d26-8d27-7f17e6373718" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain_2797a5e9-d67d-4047-b40a-583958fae9b3" xlink:href="cah-20200930.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_OpioidLawsuitsStateDomain_2797a5e9-d67d-4047-b40a-583958fae9b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5749232c-6f41-4fe6-9ba1-5d9ac238895e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5749232c-6f41-4fe6-9ba1-5d9ac238895e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5749232c-6f41-4fe6-9ba1-5d9ac238895e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5749232c-6f41-4fe6-9ba1-5d9ac238895e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5749232c-6f41-4fe6-9ba1-5d9ac238895e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c086857e-bdf9-474d-bb72-52e4c2319313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5749232c-6f41-4fe6-9ba1-5d9ac238895e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c086857e-bdf9-474d-bb72-52e4c2319313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f0bc89bd-d9ec-484c-b257-0068b28e860c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c086857e-bdf9-474d-bb72-52e4c2319313" xlink:to="loc_us-gaap_SubsequentEventMember_f0bc89bd-d9ec-484c-b257-0068b28e860c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e2a0f2fd-209a-4f3e-8095-ccf604394917" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_StatementScenarioAxis_e2a0f2fd-209a-4f3e-8095-ccf604394917" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e2a0f2fd-209a-4f3e-8095-ccf604394917_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_e2a0f2fd-209a-4f3e-8095-ccf604394917" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e2a0f2fd-209a-4f3e-8095-ccf604394917_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a18d2df6-58ea-4de2-a3e4-89a854b90ef6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_e2a0f2fd-209a-4f3e-8095-ccf604394917" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a18d2df6-58ea-4de2-a3e4-89a854b90ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5a65d556-74fc-4ac9-bb56-c7f183865f3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a18d2df6-58ea-4de2-a3e4-89a854b90ef6" xlink:to="loc_srt_ScenarioForecastMember_5a65d556-74fc-4ac9-bb56-c7f183865f3a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="if91a1c1ba1d74ab6b3b6ada479ea66a1_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_aeca067f-edc1-4b8b-a557-baa5e5334906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_LitigationReserve_aeca067f-edc1-4b8b-a557-baa5e5334906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0e19fdfe-22ac-450f-b14c-aa29cee421c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0e19fdfe-22ac-450f-b14c-aa29cee421c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_79247814-7734-4a20-a322-3b62c2ef3d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_79247814-7734-4a20-a322-3b62c2ef3d24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f2a18f4a-f5eb-4538-b1ae-46e0e74500f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f2a18f4a-f5eb-4538-b1ae-46e0e74500f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1f4fbe4e-bf80-41cd-b604-da93fb47f4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1f4fbe4e-bf80-41cd-b604-da93fb47f4c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9b6695e2-c814-4d0b-be03-e4ef9d0c935b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9b6695e2-c814-4d0b-be03-e4ef9d0c935b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e0513b24-020a-40fd-9a60-85df0182368e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e0513b24-020a-40fd-9a60-85df0182368e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_51002541-a89c-4f25-aaba-66f2b50230eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_OpenTaxYear_51002541-a89c-4f25-aaba-66f2b50230eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_e7822157-95e4-49cb-a580-47dc2ba42499" xlink:href="cah-20200930.xsd#cah_IndemnificationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_cah_IndemnificationReceivable_e7822157-95e4-49cb-a580-47dc2ba42499" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_59bc0b2a-35ce-4ebc-957d-c4dcf59ae477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_59bc0b2a-35ce-4ebc-957d-c4dcf59ae477" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_76fd0e99-05b7-4006-95e9-d5461ea63aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_LitigationSettlementExpense_76fd0e99-05b7-4006-95e9-d5461ea63aea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_7be36e96-9236-4ef3-8ca6-64364d79014a" xlink:href="cah-20200930.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_cah_TaxMatterAxis_7be36e96-9236-4ef3-8ca6-64364d79014a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_7be36e96-9236-4ef3-8ca6-64364d79014a_default" xlink:href="cah-20200930.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_7be36e96-9236-4ef3-8ca6-64364d79014a" xlink:to="loc_cah_TaxMatterDomain_7be36e96-9236-4ef3-8ca6-64364d79014a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_1604d0e0-e79a-4b13-96ba-26720e207454" xlink:href="cah-20200930.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_7be36e96-9236-4ef3-8ca6-64364d79014a" xlink:to="loc_cah_TaxMatterDomain_1604d0e0-e79a-4b13-96ba-26720e207454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_4b6f4a82-784b-4c34-a939-978e9d48c667" xlink:href="cah-20200930.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_1604d0e0-e79a-4b13-96ba-26720e207454" xlink:to="loc_cah_CareFusionMember_4b6f4a82-784b-4c34-a939-978e9d48c667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_4bbdbf60-add3-4e06-8df3-5f415cafad08" xlink:href="cah-20200930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_1604d0e0-e79a-4b13-96ba-26720e207454" xlink:to="loc_cah_PatientRecoveryBusinessMember_4bbdbf60-add3-4e06-8df3-5f415cafad08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_728bb327-4843-4e25-bcc0-bc33bc1abcc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_728bb327-4843-4e25-bcc0-bc33bc1abcc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_728bb327-4843-4e25-bcc0-bc33bc1abcc0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_728bb327-4843-4e25-bcc0-bc33bc1abcc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_728bb327-4843-4e25-bcc0-bc33bc1abcc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_968dc8a0-394a-4164-a557-ca892377d81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_728bb327-4843-4e25-bcc0-bc33bc1abcc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_968dc8a0-394a-4164-a557-ca892377d81d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_c65ecf8b-6a6f-4ec2-8112-085c6da60425" xlink:href="cah-20200930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_968dc8a0-394a-4164-a557-ca892377d81d" xlink:to="loc_cah_PatientRecoveryBusinessMember_c65ecf8b-6a6f-4ec2-8112-085c6da60425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_cf530fe4-bbd2-4b26-9f54-5359c8019a54" xlink:href="cah-20200930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_cah_OpioidLitigationAxis_cf530fe4-bbd2-4b26-9f54-5359c8019a54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_cf530fe4-bbd2-4b26-9f54-5359c8019a54_default" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_cf530fe4-bbd2-4b26-9f54-5359c8019a54" xlink:to="loc_cah_TaxMattersAgreementDomain_cf530fe4-bbd2-4b26-9f54-5359c8019a54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_cf530fe4-bbd2-4b26-9f54-5359c8019a54" xlink:to="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_4b75aa63-98df-465f-b73d-ebc44890f392" xlink:href="cah-20200930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:to="loc_cah_TotalOpioidLitigationMember_4b75aa63-98df-465f-b73d-ebc44890f392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_0766493e-96cf-40c5-8f55-01d7a7740104" xlink:href="cah-20200930.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:to="loc_cah_CareFusionMember_0766493e-96cf-40c5-8f55-01d7a7740104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_7ca4cee8-4d5c-459a-a8ff-e7de7d343806" xlink:href="cah-20200930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:to="loc_cah_PatientRecoveryBusinessMember_7ca4cee8-4d5c-459a-a8ff-e7de7d343806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2a18c58a-4628-4562-bcd8-f3dceae99cb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2a18c58a-4628-4562-bcd8-f3dceae99cb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2a18c58a-4628-4562-bcd8-f3dceae99cb9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2a18c58a-4628-4562-bcd8-f3dceae99cb9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2a18c58a-4628-4562-bcd8-f3dceae99cb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d159daa5-8834-45f5-be98-ca2249cbf218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2a18c58a-4628-4562-bcd8-f3dceae99cb9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d159daa5-8834-45f5-be98-ca2249cbf218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_82aea9ff-58fe-4843-956e-27a61199a85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_82aea9ff-58fe-4843-956e-27a61199a85a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_82aea9ff-58fe-4843-956e-27a61199a85a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82aea9ff-58fe-4843-956e-27a61199a85a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_82aea9ff-58fe-4843-956e-27a61199a85a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_53ce29d2-4d34-4930-8a53-88a2abf3c1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82aea9ff-58fe-4843-956e-27a61199a85a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_53ce29d2-4d34-4930-8a53-88a2abf3c1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_5271190e-b62a-4cc7-8a68-286b30382295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_53ce29d2-4d34-4930-8a53-88a2abf3c1f4" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_5271190e-b62a-4cc7-8a68-286b30382295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1d77e75-2359-40ae-93b7-97a4e81b0f29" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_srt_RangeAxis_b1d77e75-2359-40ae-93b7-97a4e81b0f29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1d77e75-2359-40ae-93b7-97a4e81b0f29_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1d77e75-2359-40ae-93b7-97a4e81b0f29" xlink:to="loc_srt_RangeMember_b1d77e75-2359-40ae-93b7-97a4e81b0f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a52e4c4d-1da2-4fa9-be37-ad4f1e8f4260" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1d77e75-2359-40ae-93b7-97a4e81b0f29" xlink:to="loc_srt_RangeMember_a52e4c4d-1da2-4fa9-be37-ad4f1e8f4260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f9d8bebf-06e1-4788-9ae7-d9462a0f593a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a52e4c4d-1da2-4fa9-be37-ad4f1e8f4260" xlink:to="loc_srt_MinimumMember_f9d8bebf-06e1-4788-9ae7-d9462a0f593a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3d6585ae-844f-46d7-80b1-cbabf217d3e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a52e4c4d-1da2-4fa9-be37-ad4f1e8f4260" xlink:to="loc_srt_MaximumMember_3d6585ae-844f-46d7-80b1-cbabf217d3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3f3f7cfa-5e7b-49d8-948b-c70c90bb987f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_srt_StatementScenarioAxis_3f3f7cfa-5e7b-49d8-948b-c70c90bb987f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3f3f7cfa-5e7b-49d8-948b-c70c90bb987f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3f3f7cfa-5e7b-49d8-948b-c70c90bb987f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3f3f7cfa-5e7b-49d8-948b-c70c90bb987f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f3e9528b-3ece-49f1-9586-dbd1ab52d877" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3f3f7cfa-5e7b-49d8-948b-c70c90bb987f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f3e9528b-3ece-49f1-9586-dbd1ab52d877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b900f501-ef78-4744-a11f-75ac8a863c53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f3e9528b-3ece-49f1-9586-dbd1ab52d877" xlink:to="loc_srt_ScenarioForecastMember_b900f501-ef78-4744-a11f-75ac8a863c53" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20200930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended" id="if84edb3601d843ac881ad25503960898_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended" id="i0cae4427b30e4a9697ec9d1b43047b5e_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i90b8ee2d4b4b4298bbde14bc660d828b_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i6d515a4414654f57b8f4b2dfd0b6a1f4_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e26b74cf-6d57-4cc7-8cd1-2d22dc225fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8543eaf0-754c-4478-b6a7-059edd890c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e26b74cf-6d57-4cc7-8cd1-2d22dc225fb9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8543eaf0-754c-4478-b6a7-059edd890c2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_fbdc2912-0bce-4355-9a15-ee320d480c77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8543eaf0-754c-4478-b6a7-059edd890c2a" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_fbdc2912-0bce-4355-9a15-ee320d480c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5c09dd2f-465c-4ed4-9f18-cdfdfe451e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8543eaf0-754c-4478-b6a7-059edd890c2a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5c09dd2f-465c-4ed4-9f18-cdfdfe451e9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2a66875b-354d-48f3-841e-8dc4d4a647f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e26b74cf-6d57-4cc7-8cd1-2d22dc225fb9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2a66875b-354d-48f3-841e-8dc4d4a647f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_12024bb0-ce38-471e-9433-4ce9bc3976af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2a66875b-354d-48f3-841e-8dc4d4a647f4" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_12024bb0-ce38-471e-9433-4ce9bc3976af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a99f2f-973d-4cbc-af8c-9ff1c06bd86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e26b74cf-6d57-4cc7-8cd1-2d22dc225fb9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a99f2f-973d-4cbc-af8c-9ff1c06bd86d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1a653ca7-91ec-4889-b7c3-23880f430e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a99f2f-973d-4cbc-af8c-9ff1c06bd86d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1a653ca7-91ec-4889-b7c3-23880f430e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1a653ca7-91ec-4889-b7c3-23880f430e96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1a653ca7-91ec-4889-b7c3-23880f430e96" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1a653ca7-91ec-4889-b7c3-23880f430e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7754dfd7-62e4-4701-bd89-cf8c3753db00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1a653ca7-91ec-4889-b7c3-23880f430e96" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7754dfd7-62e4-4701-bd89-cf8c3753db00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f0b71516-4cd6-4b45-b9e1-a5212f5711ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7754dfd7-62e4-4701-bd89-cf8c3753db00" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f0b71516-4cd6-4b45-b9e1-a5212f5711ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bcecbe72-3571-4c76-9205-a070fc5aafb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a99f2f-973d-4cbc-af8c-9ff1c06bd86d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bcecbe72-3571-4c76-9205-a070fc5aafb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bcecbe72-3571-4c76-9205-a070fc5aafb3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bcecbe72-3571-4c76-9205-a070fc5aafb3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bcecbe72-3571-4c76-9205-a070fc5aafb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bcecbe72-3571-4c76-9205-a070fc5aafb3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9f5e2c48-4f89-423a-9847-ed4eca357e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9f5e2c48-4f89-423a-9847-ed4eca357e0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_41a6558a-a57e-4c08-a960-e0c1b15daa9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_41a6558a-a57e-4c08-a960-e0c1b15daa9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74159aee-50cd-4670-be0d-bf9296845c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74159aee-50cd-4670-be0d-bf9296845c87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_35abb15a-d787-4fcf-86ba-bdd7ea7c1c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_35abb15a-d787-4fcf-86ba-bdd7ea7c1c8b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended" id="i1ef660d21bdb4a9ca5c53d588579ecff_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended" id="iffc0817119f54fe39d68b6054993913d_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="id8ff2bb57bf24b289d9d052a6973f36d_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_65d55ffb-fdf6-4839-bf76-0ac21ba452e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_65d55ffb-fdf6-4839-bf76-0ac21ba452e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_6bce23d5-2ff7-4068-82ee-1ae65a3c7e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_6bce23d5-2ff7-4068-82ee-1ae65a3c7e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_a1dc73a2-7b9f-43e8-8cb4-6a2b171fcef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_a1dc73a2-7b9f-43e8-8cb4-6a2b171fcef1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:to="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4d2d1c02-8cd5-4351-b4d1-c0952b875b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4d2d1c02-8cd5-4351-b4d1-c0952b875b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d2d1c02-8cd5-4351-b4d1-c0952b875b5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4d2d1c02-8cd5-4351-b4d1-c0952b875b5b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d2d1c02-8cd5-4351-b4d1-c0952b875b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b37337e1-f434-4d80-9982-db0987ba9469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4d2d1c02-8cd5-4351-b4d1-c0952b875b5b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b37337e1-f434-4d80-9982-db0987ba9469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0469e4f8-cf29-494f-978a-38040fe31f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:to="loc_us-gaap_HedgingDesignationAxis_0469e4f8-cf29-494f-978a-38040fe31f45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0469e4f8-cf29-494f-978a-38040fe31f45_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_0469e4f8-cf29-494f-978a-38040fe31f45" xlink:to="loc_us-gaap_HedgingDesignationDomain_0469e4f8-cf29-494f-978a-38040fe31f45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b0a35a77-cb91-4867-8136-8c4025238ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_0469e4f8-cf29-494f-978a-38040fe31f45" xlink:to="loc_us-gaap_HedgingDesignationDomain_b0a35a77-cb91-4867-8136-8c4025238ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a48ccf4-55f1-4025-abf4-bf2090d0fc02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a48ccf4-55f1-4025-abf4-bf2090d0fc02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5a48ccf4-55f1-4025-abf4-bf2090d0fc02_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a48ccf4-55f1-4025-abf4-bf2090d0fc02" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5a48ccf4-55f1-4025-abf4-bf2090d0fc02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4a3504ca-cf78-4ad0-99cb-03abfa51f163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a48ccf4-55f1-4025-abf4-bf2090d0fc02" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4a3504ca-cf78-4ad0-99cb-03abfa51f163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ce44af7e-4c91-40e1-8fb6-14ee4383a461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ce44af7e-4c91-40e1-8fb6-14ee4383a461" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ce44af7e-4c91-40e1-8fb6-14ee4383a461_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ce44af7e-4c91-40e1-8fb6-14ee4383a461" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ce44af7e-4c91-40e1-8fb6-14ee4383a461_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ce44af7e-4c91-40e1-8fb6-14ee4383a461" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_bf1dc737-3be8-4ef6-9ee1-232c85ab2da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:to="loc_us-gaap_CashFlowHedgingMember_bf1dc737-3be8-4ef6-9ee1-232c85ab2da2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_408700cb-ef0c-4c42-8bf4-6216162a10ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:to="loc_us-gaap_CurrencySwapMember_408700cb-ef0c-4c42-8bf4-6216162a10ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a1d26d3f-230b-4072-b379-d106533e654b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a1d26d3f-230b-4072-b379-d106533e654b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended" id="i6f7dddab24354e5a92e78f55f52ba937_FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e4959aab-9ce3-4455-82a4-1f714817c77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_49ab40e2-51af-4dd6-a353-019471a415cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e4959aab-9ce3-4455-82a4-1f714817c77b" xlink:to="loc_us-gaap_DebtInstrumentFairValue_49ab40e2-51af-4dd6-a353-019471a415cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_2d866f2c-d4c4-4e8d-a6bf-2a7d700ec874" xlink:href="cah-20200930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e4959aab-9ce3-4455-82a4-1f714817c77b" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_2d866f2c-d4c4-4e8d-a6bf-2a7d700ec874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f3e026ab-8f56-409b-8058-c7addcd755e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e4959aab-9ce3-4455-82a4-1f714817c77b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f3e026ab-8f56-409b-8058-c7addcd755e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6a6fefd-1586-4d93-9d65-ac6e61db2cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f3e026ab-8f56-409b-8058-c7addcd755e0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6a6fefd-1586-4d93-9d65-ac6e61db2cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6a6fefd-1586-4d93-9d65-ac6e61db2cb1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6a6fefd-1586-4d93-9d65-ac6e61db2cb1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6a6fefd-1586-4d93-9d65-ac6e61db2cb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ccba66e-2158-429c-a29c-0a1f30ffd4cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6a6fefd-1586-4d93-9d65-ac6e61db2cb1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ccba66e-2158-429c-a29c-0a1f30ffd4cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1ba1b1ad-bb3a-43ab-a24c-1bf754fe4049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ccba66e-2158-429c-a29c-0a1f30ffd4cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1ba1b1ad-bb3a-43ab-a24c-1bf754fe4049" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended" id="i42e37cc100944821a336e29086f92cb4_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended" id="i4f5bdde1abc4447faa3805612336f2b6_ShareholdersEquityTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="i435e4e2a7cb94c19905fd1fd831cec3f_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d5d8d158-d025-4751-92ca-fc477e96f86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d5d8d158-d025-4751-92ca-fc477e96f86d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ab0538aa-a4a1-4754-8dbd-0e9d64c6e666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ab0538aa-a4a1-4754-8dbd-0e9d64c6e666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c43106e6-912b-43e8-a260-ba337ba6f8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c43106e6-912b-43e8-a260-ba337ba6f8b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_055dfaea-3d93-42c2-b0d7-45ab66765858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_055dfaea-3d93-42c2-b0d7-45ab66765858" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TreasuryStockAcquiredShares_4393f334-d181-421b-a327-812455a8b84f" xlink:href="cah-20200930.xsd#cah_TreasuryStockAcquiredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_cah_TreasuryStockAcquiredShares_4393f334-d181-421b-a327-812455a8b84f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FinalSharesReceivedfromASRProgram_e05b4a84-283b-40d7-b0bc-101ddee9f165" xlink:href="cah-20200930.xsd#cah_FinalSharesReceivedfromASRProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_cah_FinalSharesReceivedfromASRProgram_e05b4a84-283b-40d7-b0bc-101ddee9f165" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_785ff706-542a-4285-9ca0-5e3090ce44eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_785ff706-542a-4285-9ca0-5e3090ce44eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_785ff706-542a-4285-9ca0-5e3090ce44eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_785ff706-542a-4285-9ca0-5e3090ce44eb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_785ff706-542a-4285-9ca0-5e3090ce44eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_40e048aa-4cbd-4230-9bb1-72c609e352f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_785ff706-542a-4285-9ca0-5e3090ce44eb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_40e048aa-4cbd-4230-9bb1-72c609e352f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f0ba198c-9765-4a44-b464-445581c8c48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f0ba198c-9765-4a44-b464-445581c8c48c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f0ba198c-9765-4a44-b464-445581c8c48c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f0ba198c-9765-4a44-b464-445581c8c48c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f0ba198c-9765-4a44-b464-445581c8c48c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8bf36cf7-bac0-42bf-b405-52893fb71975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f0ba198c-9765-4a44-b464-445581c8c48c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8bf36cf7-bac0-42bf-b405-52893fb71975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ecff1e69-424b-494f-98dd-218d3c9e9b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8bf36cf7-bac0-42bf-b405-52893fb71975" xlink:to="loc_us-gaap_SubsequentEventMember_ecff1e69-424b-494f-98dd-218d3c9e9b27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04a51d38-a585-4c17-bf1a-e0e7338030ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04a51d38-a585-4c17-bf1a-e0e7338030ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04a51d38-a585-4c17-bf1a-e0e7338030ef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04a51d38-a585-4c17-bf1a-e0e7338030ef" xlink:to="loc_us-gaap_EquityComponentDomain_04a51d38-a585-4c17-bf1a-e0e7338030ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f795e3c-071d-4ad2-af41-b996a9879229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04a51d38-a585-4c17-bf1a-e0e7338030ef" xlink:to="loc_us-gaap_EquityComponentDomain_8f795e3c-071d-4ad2-af41-b996a9879229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_41ec151d-d010-4091-8c4a-fbfd57310958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f795e3c-071d-4ad2-af41-b996a9879229" xlink:to="loc_us-gaap_TreasuryStockMember_41ec151d-d010-4091-8c4a-fbfd57310958" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="icb5e9de0047e407cba32940975bdaca9_ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_31c8aaa6-8a55-417b-8880-81c409e6008e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_31c8aaa6-8a55-417b-8880-81c409e6008e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ebdf2ddc-21c1-423e-8e22-1748b8f75990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ebdf2ddc-21c1-423e-8e22-1748b8f75990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_c8c348ae-e602-474a-8eeb-cfc9984ec4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_c8c348ae-e602-474a-8eeb-cfc9984ec4aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_448266a6-6c7a-43f7-b9cd-1cdfb94cb50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_448266a6-6c7a-43f7-b9cd-1cdfb94cb50f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb73281e-c853-4436-8490-35de3ac10aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb73281e-c853-4436-8490-35de3ac10aec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ed4365a-0713-4af5-a960-7e196ce62248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7e4779b8-3b5d-475d-8381-44b1b090e4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_31c8aaa6-8a55-417b-8880-81c409e6008e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7e4779b8-3b5d-475d-8381-44b1b090e4b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68ec9b2a-dfaf-40c2-8f87-0f1f4a21783c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7e4779b8-3b5d-475d-8381-44b1b090e4b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68ec9b2a-dfaf-40c2-8f87-0f1f4a21783c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_68ec9b2a-dfaf-40c2-8f87-0f1f4a21783c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68ec9b2a-dfaf-40c2-8f87-0f1f4a21783c" xlink:to="loc_us-gaap_EquityComponentDomain_68ec9b2a-dfaf-40c2-8f87-0f1f4a21783c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68ec9b2a-dfaf-40c2-8f87-0f1f4a21783c" xlink:to="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_88e934b4-6ca5-4404-9aaa-f1480c9cbded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_88e934b4-6ca5-4404-9aaa-f1480c9cbded" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_dc2edeb0-9bf0-48ab-9a63-92ee0a61f312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_dc2edeb0-9bf0-48ab-9a63-92ee0a61f312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c81839cc-96ce-4894-ac0a-9adb7a55bdea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c81839cc-96ce-4894-ac0a-9adb7a55bdea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4345c39c-6f7b-4434-92c6-7043afbe58c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4345c39c-6f7b-4434-92c6-7043afbe58c5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended" id="i2ca05f0fd7dd4ca09c497d4da46b1522_EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended" id="i416d8aac0d8545309072fa86759c75ab_EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended" id="ib93ad5253fe548909609a2e277a97824_EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended" id="i2bbace794cf54c099f3e63506b0bff64_EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformation"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended" id="if3cc2de256d64a5b850c64f2dd0f3e49_SegmentInformation"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended" id="i763d72ba20a0483f99a9c6b179511d08_SegmentInformationTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_1ad4544e-5179-4c44-9159-3df89dd914e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_56266a74-e890-486e-b13e-b79d77639b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_1ad4544e-5179-4c44-9159-3df89dd914e7" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_56266a74-e890-486e-b13e-b79d77639b08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_1ad4544e-5179-4c44-9159-3df89dd914e7" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3366bd03-de07-4b1a-8757-3b4d834a7b02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:to="loc_srt_ConsolidationItemsAxis_3366bd03-de07-4b1a-8757-3b4d834a7b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3366bd03-de07-4b1a-8757-3b4d834a7b02_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_3366bd03-de07-4b1a-8757-3b4d834a7b02" xlink:to="loc_srt_ConsolidationItemsDomain_3366bd03-de07-4b1a-8757-3b4d834a7b02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d2ce5999-4dab-48aa-88d1-ba9d8ad40070" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_3366bd03-de07-4b1a-8757-3b4d834a7b02" xlink:to="loc_srt_ConsolidationItemsDomain_d2ce5999-4dab-48aa-88d1-ba9d8ad40070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f4f0f01e-26d4-4865-ab34-cef0f2cabf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f4f0f01e-26d4-4865-ab34-cef0f2cabf15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f4f0f01e-26d4-4865-ab34-cef0f2cabf15_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f4f0f01e-26d4-4865-ab34-cef0f2cabf15" xlink:to="loc_us-gaap_SegmentDomain_f4f0f01e-26d4-4865-ab34-cef0f2cabf15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dc6a06e9-8253-467f-8a1f-68d60324ad0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f4f0f01e-26d4-4865-ab34-cef0f2cabf15" xlink:to="loc_us-gaap_SegmentDomain_dc6a06e9-8253-467f-8a1f-68d60324ad0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_284d4ff2-0a95-42c7-8cf4-b734be307c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:to="loc_us-gaap_SubsegmentsAxis_284d4ff2-0a95-42c7-8cf4-b734be307c69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_284d4ff2-0a95-42c7-8cf4-b734be307c69_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_284d4ff2-0a95-42c7-8cf4-b734be307c69" xlink:to="loc_us-gaap_SubsegmentsDomain_284d4ff2-0a95-42c7-8cf4-b734be307c69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_882fa42c-a960-4894-8617-6feb13f07e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_284d4ff2-0a95-42c7-8cf4-b734be307c69" xlink:to="loc_us-gaap_SubsegmentsDomain_882fa42c-a960-4894-8617-6feb13f07e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5eb6cc13-bb8b-46f7-86b6-9c494dbecc00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5eb6cc13-bb8b-46f7-86b6-9c494dbecc00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_5eb6cc13-bb8b-46f7-86b6-9c494dbecc00_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5eb6cc13-bb8b-46f7-86b6-9c494dbecc00" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_5eb6cc13-bb8b-46f7-86b6-9c494dbecc00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_b1ce4ed7-3799-4322-874b-7f5c19a51f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5eb6cc13-bb8b-46f7-86b6-9c494dbecc00" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_b1ce4ed7-3799-4322-874b-7f5c19a51f6f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="i15f0494887254f69b19c6935d070665b_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ff243cb6-8ea3-44da-be7f-142e989090bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_6079173d-691f-4841-980f-71c8bcfd670b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ff243cb6-8ea3-44da-be7f-142e989090bc" xlink:to="loc_us-gaap_LitigationReserve_6079173d-691f-4841-980f-71c8bcfd670b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_9e590120-0620-4bcd-89aa-da155ca3cc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ff243cb6-8ea3-44da-be7f-142e989090bc" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_9e590120-0620-4bcd-89aa-da155ca3cc8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_008f5866-f554-402e-bccc-4f5463713348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ff243cb6-8ea3-44da-be7f-142e989090bc" xlink:to="loc_us-gaap_StatementTable_008f5866-f554-402e-bccc-4f5463713348" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_66ded5f7-9a85-45f7-bcbe-a28658641bc3" xlink:href="cah-20200930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_008f5866-f554-402e-bccc-4f5463713348" xlink:to="loc_cah_OpioidLitigationAxis_66ded5f7-9a85-45f7-bcbe-a28658641bc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_66ded5f7-9a85-45f7-bcbe-a28658641bc3_default" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_66ded5f7-9a85-45f7-bcbe-a28658641bc3" xlink:to="loc_cah_TaxMattersAgreementDomain_66ded5f7-9a85-45f7-bcbe-a28658641bc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_c1a26f10-6e11-4ce9-ba9d-62567dcfc554" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_66ded5f7-9a85-45f7-bcbe-a28658641bc3" xlink:to="loc_cah_TaxMattersAgreementDomain_c1a26f10-6e11-4ce9-ba9d-62567dcfc554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_c6ce09c2-4883-47de-ae9b-b8128817a94e" xlink:href="cah-20200930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_c1a26f10-6e11-4ce9-ba9d-62567dcfc554" xlink:to="loc_cah_TotalOpioidLitigationMember_c6ce09c2-4883-47de-ae9b-b8128817a94e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended" id="i3e2e4735df4a4cba85bba46b63aeb040_SegmentInformationRevenuebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_52a1cd03-4870-4da4-a117-867a00bc4f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_410d4a51-d1e6-48d4-92ef-a5d366e5bed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52a1cd03-4870-4da4-a117-867a00bc4f87" xlink:to="loc_us-gaap_Revenues_410d4a51-d1e6-48d4-92ef-a5d366e5bed9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52a1cd03-4870-4da4-a117-867a00bc4f87" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_0b5fb9c3-a899-47a7-8677-66a4e3f601d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:to="loc_us-gaap_SubsegmentsAxis_0b5fb9c3-a899-47a7-8677-66a4e3f601d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_0b5fb9c3-a899-47a7-8677-66a4e3f601d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_0b5fb9c3-a899-47a7-8677-66a4e3f601d3" xlink:to="loc_us-gaap_SubsegmentsDomain_0b5fb9c3-a899-47a7-8677-66a4e3f601d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_0b5fb9c3-a899-47a7-8677-66a4e3f601d3" xlink:to="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_9500859c-0592-40d6-b286-c0ce154ef010" xlink:href="cah-20200930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_9500859c-0592-40d6-b286-c0ce154ef010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_3e7d14ae-a092-4e81-8d8e-360c56a9f7cb" xlink:href="cah-20200930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_3e7d14ae-a092-4e81-8d8e-360c56a9f7cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_433f77dd-18d1-4f07-bf74-2f24390bcfea" xlink:href="cah-20200930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:to="loc_cah_MedicaldistributionandproductsMember_433f77dd-18d1-4f07-bf74-2f24390bcfea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeSolutionsMember_8f61bd26-39aa-45d7-857d-2d74c6031909" xlink:href="cah-20200930.xsd#cah_CardinalHealthAtHomeSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:to="loc_cah_CardinalHealthAtHomeSolutionsMember_8f61bd26-39aa-45d7-857d-2d74c6031909" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9e0cd095-72eb-46a2-8bc3-cd3786bf62cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:to="loc_srt_ConsolidationItemsAxis_9e0cd095-72eb-46a2-8bc3-cd3786bf62cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9e0cd095-72eb-46a2-8bc3-cd3786bf62cd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9e0cd095-72eb-46a2-8bc3-cd3786bf62cd" xlink:to="loc_srt_ConsolidationItemsDomain_9e0cd095-72eb-46a2-8bc3-cd3786bf62cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4657a3d0-1422-4306-9458-583a9c6efbff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9e0cd095-72eb-46a2-8bc3-cd3786bf62cd" xlink:to="loc_srt_ConsolidationItemsDomain_4657a3d0-1422-4306-9458-583a9c6efbff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_734d8de6-4dad-4328-a5c9-37bee35e509a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4657a3d0-1422-4306-9458-583a9c6efbff" xlink:to="loc_us-gaap_OperatingSegmentsMember_734d8de6-4dad-4328-a5c9-37bee35e509a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_5c732202-8de3-4c76-a242-77e828f8b3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4657a3d0-1422-4306-9458-583a9c6efbff" xlink:to="loc_us-gaap_CorporateNonSegmentMember_5c732202-8de3-4c76-a242-77e828f8b3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_877b3846-ab73-4843-b690-75d37b3194dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_877b3846-ab73-4843-b690-75d37b3194dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_877b3846-ab73-4843-b690-75d37b3194dd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_877b3846-ab73-4843-b690-75d37b3194dd" xlink:to="loc_us-gaap_SegmentDomain_877b3846-ab73-4843-b690-75d37b3194dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cfde29b3-4833-408d-84a0-345aee8f9dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_877b3846-ab73-4843-b690-75d37b3194dd" xlink:to="loc_us-gaap_SegmentDomain_cfde29b3-4833-408d-84a0-345aee8f9dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_cb6c2461-e6e0-430e-93f9-a476591d60f7" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cfde29b3-4833-408d-84a0-345aee8f9dcb" xlink:to="loc_cah_PharmaceuticalMember_cb6c2461-e6e0-430e-93f9-a476591d60f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_69b3feb8-41df-4c4d-9e4d-e5ba43e40d0a" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cfde29b3-4833-408d-84a0-345aee8f9dcb" xlink:to="loc_cah_MedicalMember_69b3feb8-41df-4c4d-9e4d-e5ba43e40d0a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended" id="i4c633150224b424fa878e9eb8ee73923_SegmentInformationSegmentProfitbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_bc392e46-78f6-4dbc-b40d-ef5caea6fa97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b2701aaa-1976-45fc-9b38-35f173ad1cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_bc392e46-78f6-4dbc-b40d-ef5caea6fa97" xlink:to="loc_us-gaap_OperatingIncomeLoss_b2701aaa-1976-45fc-9b38-35f173ad1cf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_cdfa662e-a02e-43be-93b0-ef204baa0d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_bc392e46-78f6-4dbc-b40d-ef5caea6fa97" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_cdfa662e-a02e-43be-93b0-ef204baa0d5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1a7558b6-564c-4dea-9ab1-d7280988de6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_cdfa662e-a02e-43be-93b0-ef204baa0d5d" xlink:to="loc_srt_ConsolidationItemsAxis_1a7558b6-564c-4dea-9ab1-d7280988de6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1a7558b6-564c-4dea-9ab1-d7280988de6e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_1a7558b6-564c-4dea-9ab1-d7280988de6e" xlink:to="loc_srt_ConsolidationItemsDomain_1a7558b6-564c-4dea-9ab1-d7280988de6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f344fb53-6d32-405f-9de5-3c9c005d1e26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_1a7558b6-564c-4dea-9ab1-d7280988de6e" xlink:to="loc_srt_ConsolidationItemsDomain_f344fb53-6d32-405f-9de5-3c9c005d1e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d6ef3222-b93a-4968-a5cc-3a115b6763e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f344fb53-6d32-405f-9de5-3c9c005d1e26" xlink:to="loc_us-gaap_OperatingSegmentsMember_d6ef3222-b93a-4968-a5cc-3a115b6763e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d447d684-7704-4790-8c07-492152ea46f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f344fb53-6d32-405f-9de5-3c9c005d1e26" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d447d684-7704-4790-8c07-492152ea46f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_bb9fe0e3-5722-4cfc-9457-53233000003f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_cdfa662e-a02e-43be-93b0-ef204baa0d5d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_bb9fe0e3-5722-4cfc-9457-53233000003f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb9fe0e3-5722-4cfc-9457-53233000003f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bb9fe0e3-5722-4cfc-9457-53233000003f" xlink:to="loc_us-gaap_SegmentDomain_bb9fe0e3-5722-4cfc-9457-53233000003f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b4c81469-a177-4449-9fda-e501b7ef952b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bb9fe0e3-5722-4cfc-9457-53233000003f" xlink:to="loc_us-gaap_SegmentDomain_b4c81469-a177-4449-9fda-e501b7ef952b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_7e36a76d-77d4-4202-a519-eb40dd99de0f" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4c81469-a177-4449-9fda-e501b7ef952b" xlink:to="loc_cah_PharmaceuticalMember_7e36a76d-77d4-4202-a519-eb40dd99de0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_dc49a8c7-77ca-4694-83db-d1b3bf0a73fa" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4c81469-a177-4449-9fda-e501b7ef952b" xlink:to="loc_cah_MedicalMember_dc49a8c7-77ca-4694-83db-d1b3bf0a73fa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended" id="id76a9bdd2cb1498f917cb4fb4907ecc9_SegmentInformationAssetsbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_70fd1969-71b5-42e2-a856-3dad2f82fae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cb670e92-6329-4fa9-848b-33e833a48739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_70fd1969-71b5-42e2-a856-3dad2f82fae2" xlink:to="loc_us-gaap_Assets_cb670e92-6329-4fa9-848b-33e833a48739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f3be18-f3c8-451e-94c2-3631e7d870ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_70fd1969-71b5-42e2-a856-3dad2f82fae2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f3be18-f3c8-451e-94c2-3631e7d870ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f8a5a519-1a23-4651-bf66-a3a0543f5a1a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f3be18-f3c8-451e-94c2-3631e7d870ef" xlink:to="loc_srt_ConsolidationItemsAxis_f8a5a519-1a23-4651-bf66-a3a0543f5a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f8a5a519-1a23-4651-bf66-a3a0543f5a1a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f8a5a519-1a23-4651-bf66-a3a0543f5a1a" xlink:to="loc_srt_ConsolidationItemsDomain_f8a5a519-1a23-4651-bf66-a3a0543f5a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7408e579-0f26-416b-9d92-36a440f9ef34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f8a5a519-1a23-4651-bf66-a3a0543f5a1a" xlink:to="loc_srt_ConsolidationItemsDomain_7408e579-0f26-416b-9d92-36a440f9ef34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e492cc56-41dc-4696-9fbb-01ff9b946354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7408e579-0f26-416b-9d92-36a440f9ef34" xlink:to="loc_us-gaap_OperatingSegmentsMember_e492cc56-41dc-4696-9fbb-01ff9b946354" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2b78942d-6614-4fbd-97b0-902425f351f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7408e579-0f26-416b-9d92-36a440f9ef34" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2b78942d-6614-4fbd-97b0-902425f351f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d04607f6-a13c-48ab-8252-2908abf33485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f3be18-f3c8-451e-94c2-3631e7d870ef" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d04607f6-a13c-48ab-8252-2908abf33485" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d04607f6-a13c-48ab-8252-2908abf33485_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d04607f6-a13c-48ab-8252-2908abf33485" xlink:to="loc_us-gaap_SegmentDomain_d04607f6-a13c-48ab-8252-2908abf33485_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_62c30974-28ee-45ef-9f6f-5db66b2a24e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d04607f6-a13c-48ab-8252-2908abf33485" xlink:to="loc_us-gaap_SegmentDomain_62c30974-28ee-45ef-9f6f-5db66b2a24e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_58790c51-184a-4d0a-a061-969f9553be0b" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_62c30974-28ee-45ef-9f6f-5db66b2a24e4" xlink:to="loc_cah_PharmaceuticalMember_58790c51-184a-4d0a-a061-969f9553be0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_6ef4a04a-7dc5-4b6f-865a-9b7127331169" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_62c30974-28ee-45ef-9f6f-5db66b2a24e4" xlink:to="loc_cah_MedicalMember_6ef4a04a-7dc5-4b6f-865a-9b7127331169" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="extended" id="iaa425a4450d442cc889be0cf6c9e9fc9_SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_10fde879-0ccc-4110-b74b-86925d1ad74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3ebd5a51-9df0-4cdf-8144-5641b282f8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_10fde879-0ccc-4110-b74b-86925d1ad74e" xlink:to="loc_us-gaap_Revenues_3ebd5a51-9df0-4cdf-8144-5641b282f8c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_10fde879-0ccc-4110-b74b-86925d1ad74e" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentAxis_87633315-4366-4c60-8ef2-9759c3e18bf9" xlink:href="cah-20200930.xsd#cah_MedicalSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_cah_MedicalSegmentAxis_87633315-4366-4c60-8ef2-9759c3e18bf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain_87633315-4366-4c60-8ef2-9759c3e18bf9_default" xlink:href="cah-20200930.xsd#cah_MedicalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_MedicalSegmentAxis_87633315-4366-4c60-8ef2-9759c3e18bf9" xlink:to="loc_cah_MedicalSegmentDomain_87633315-4366-4c60-8ef2-9759c3e18bf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain_43b7a069-9023-4eea-9250-279ab2764c62" xlink:href="cah-20200930.xsd#cah_MedicalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_MedicalSegmentAxis_87633315-4366-4c60-8ef2-9759c3e18bf9" xlink:to="loc_cah_MedicalSegmentDomain_43b7a069-9023-4eea-9250-279ab2764c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_a3f10513-00bb-4e5c-92a2-a17bd84c24d2" xlink:href="cah-20200930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MedicalSegmentDomain_43b7a069-9023-4eea-9250-279ab2764c62" xlink:to="loc_cah_MedicaldistributionandproductsMember_a3f10513-00bb-4e5c-92a2-a17bd84c24d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentAxis_c1af2646-74b3-45c8-90d0-8716090d8fdf" xlink:href="cah-20200930.xsd#cah_PharmaceuticalSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_cah_PharmaceuticalSegmentAxis_c1af2646-74b3-45c8-90d0-8716090d8fdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain_c1af2646-74b3-45c8-90d0-8716090d8fdf_default" xlink:href="cah-20200930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PharmaceuticalSegmentAxis_c1af2646-74b3-45c8-90d0-8716090d8fdf" xlink:to="loc_cah_PharmaceuticalSegmentDomain_c1af2646-74b3-45c8-90d0-8716090d8fdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain_f160cac4-3b2d-4283-9c11-bccf3625b237" xlink:href="cah-20200930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PharmaceuticalSegmentAxis_c1af2646-74b3-45c8-90d0-8716090d8fdf" xlink:to="loc_cah_PharmaceuticalSegmentDomain_f160cac4-3b2d-4283-9c11-bccf3625b237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_57be8708-4d86-4a16-8a16-e43f91177fdd" xlink:href="cah-20200930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PharmaceuticalSegmentDomain_f160cac4-3b2d-4283-9c11-bccf3625b237" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_57be8708-4d86-4a16-8a16-e43f91177fdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_3b371006-d8ce-4f26-b112-3dd058f310a9" xlink:href="cah-20200930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PharmaceuticalSegmentDomain_f160cac4-3b2d-4283-9c11-bccf3625b237" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_3b371006-d8ce-4f26-b112-3dd058f310a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_688c2fa0-91a3-4823-9e4d-9573d6f87633" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_srt_ConsolidationItemsAxis_688c2fa0-91a3-4823-9e4d-9573d6f87633" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_688c2fa0-91a3-4823-9e4d-9573d6f87633_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_688c2fa0-91a3-4823-9e4d-9573d6f87633" xlink:to="loc_srt_ConsolidationItemsDomain_688c2fa0-91a3-4823-9e4d-9573d6f87633_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4516724f-1a0e-4700-9442-430a9e8e522f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_688c2fa0-91a3-4823-9e4d-9573d6f87633" xlink:to="loc_srt_ConsolidationItemsDomain_4516724f-1a0e-4700-9442-430a9e8e522f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_55ccb25c-c71d-40d1-b9f4-7a08c248bc4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4516724f-1a0e-4700-9442-430a9e8e522f" xlink:to="loc_us-gaap_OperatingSegmentsMember_55ccb25c-c71d-40d1-b9f4-7a08c248bc4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e1a4783c-1aad-47bb-b678-6d9decc47137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4516724f-1a0e-4700-9442-430a9e8e522f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e1a4783c-1aad-47bb-b678-6d9decc47137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_546253bd-2b0b-49df-8d4a-49869d554921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_546253bd-2b0b-49df-8d4a-49869d554921" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_546253bd-2b0b-49df-8d4a-49869d554921_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_546253bd-2b0b-49df-8d4a-49869d554921" xlink:to="loc_us-gaap_SegmentDomain_546253bd-2b0b-49df-8d4a-49869d554921_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_26419207-d889-415a-94dd-9f991e9e699f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_546253bd-2b0b-49df-8d4a-49869d554921" xlink:to="loc_us-gaap_SegmentDomain_26419207-d889-415a-94dd-9f991e9e699f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_489f8a2b-010b-42c7-ba58-73e7bbb8711d" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_26419207-d889-415a-94dd-9f991e9e699f" xlink:to="loc_cah_PharmaceuticalMember_489f8a2b-010b-42c7-ba58-73e7bbb8711d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_fb25eb3d-edd9-464c-b18b-f0fec0604694" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_26419207-d889-415a-94dd-9f991e9e699f" xlink:to="loc_cah_MedicalMember_fb25eb3d-edd9-464c-b18b-f0fec0604694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_665a0d05-0e4b-49af-83d4-585c3497a111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_us-gaap_SubsegmentsAxis_665a0d05-0e4b-49af-83d4-585c3497a111" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_665a0d05-0e4b-49af-83d4-585c3497a111_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_665a0d05-0e4b-49af-83d4-585c3497a111" xlink:to="loc_us-gaap_SubsegmentsDomain_665a0d05-0e4b-49af-83d4-585c3497a111_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_665a0d05-0e4b-49af-83d4-585c3497a111" xlink:to="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_6ef7d45f-1435-4cd2-bc97-88071aee12a5" xlink:href="cah-20200930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:to="loc_cah_MedicaldistributionandproductsMember_6ef7d45f-1435-4cd2-bc97-88071aee12a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_266e7e04-0960-4d19-bc1d-56e0092418f1" xlink:href="cah-20200930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_266e7e04-0960-4d19-bc1d-56e0092418f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_c2c1d950-8872-4c5d-a31c-d3d52a4bd99b" xlink:href="cah-20200930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_c2c1d950-8872-4c5d-a31c-d3d52a4bd99b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_0f2ff824-70c8-46a2-bd5e-92b7023b89e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_0f2ff824-70c8-46a2-bd5e-92b7023b89e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_0f2ff824-70c8-46a2-bd5e-92b7023b89e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_0f2ff824-70c8-46a2-bd5e-92b7023b89e3" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_0f2ff824-70c8-46a2-bd5e-92b7023b89e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_edbefc2d-3a6d-4d6a-bc0e-ee17c89927f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_0f2ff824-70c8-46a2-bd5e-92b7023b89e3" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_edbefc2d-3a6d-4d6a-bc0e-ee17c89927f0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationRevenuebyGeographicalSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="extended" id="i45ee97fde5c745d19680d091ef46d08d_SegmentInformationRevenuebyGeographicalSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems_e5264783-9791-4224-854a-924096dbb04d" xlink:href="cah-20200930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a74f7f4b-c22a-4060-b3f3-d2549c96ff8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_e5264783-9791-4224-854a-924096dbb04d" xlink:to="loc_us-gaap_Revenues_a74f7f4b-c22a-4060-b3f3-d2549c96ff8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable_21379822-a0ae-4387-87a6-9aff1fe544ae" xlink:href="cah-20200930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_e5264783-9791-4224-854a-924096dbb04d" xlink:to="loc_cah_SegmentRevenuebyGeographicTable_21379822-a0ae-4387-87a6-9aff1fe544ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8dd0e847-d8d8-4782-9dc5-90ceb17c8d78" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_21379822-a0ae-4387-87a6-9aff1fe544ae" xlink:to="loc_srt_ConsolidationItemsAxis_8dd0e847-d8d8-4782-9dc5-90ceb17c8d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8dd0e847-d8d8-4782-9dc5-90ceb17c8d78_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_8dd0e847-d8d8-4782-9dc5-90ceb17c8d78" xlink:to="loc_srt_ConsolidationItemsDomain_8dd0e847-d8d8-4782-9dc5-90ceb17c8d78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4ac9ecd0-4137-4957-af5a-ce32f0b5663f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_8dd0e847-d8d8-4782-9dc5-90ceb17c8d78" xlink:to="loc_srt_ConsolidationItemsDomain_4ac9ecd0-4137-4957-af5a-ce32f0b5663f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f9eada84-949e-4f21-913f-4f9b3fe414e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4ac9ecd0-4137-4957-af5a-ce32f0b5663f" xlink:to="loc_us-gaap_OperatingSegmentsMember_f9eada84-949e-4f21-913f-4f9b3fe414e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_7cb950dd-909c-46b3-a440-8e7c47bc7f15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingSegmentsMember_f9eada84-949e-4f21-913f-4f9b3fe414e8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_7cb950dd-909c-46b3-a440-8e7c47bc7f15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9507731e-aa1d-4f63-9b89-3073c6b05483" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_21379822-a0ae-4387-87a6-9aff1fe544ae" xlink:to="loc_srt_StatementGeographicalAxis_9507731e-aa1d-4f63-9b89-3073c6b05483" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9507731e-aa1d-4f63-9b89-3073c6b05483_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9507731e-aa1d-4f63-9b89-3073c6b05483" xlink:to="loc_srt_SegmentGeographicalDomain_9507731e-aa1d-4f63-9b89-3073c6b05483_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f84ccf56-8786-4331-b59c-1050a638bb45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9507731e-aa1d-4f63-9b89-3073c6b05483" xlink:to="loc_srt_SegmentGeographicalDomain_f84ccf56-8786-4331-b59c-1050a638bb45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0c0e0125-02f5-4876-8c30-816654e10dc6" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f84ccf56-8786-4331-b59c-1050a638bb45" xlink:to="loc_country_US_0c0e0125-02f5-4876-8c30-816654e10dc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_90cdcbb7-412a-4630-bd4e-ce60e5e78fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f84ccf56-8786-4331-b59c-1050a638bb45" xlink:to="loc_us-gaap_NonUsMember_90cdcbb7-412a-4630-bd4e-ce60e5e78fd8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended" id="i2b5b7795eefb48faaa37ab07ced728bf_ShareBasedCompensation"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended" id="i814dd80786444644af0a14f1b499a205_ShareBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i849fad73d05a4abc872435a2e9cdea75_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_3004dcb4-50e8-43b9-89a0-bc11b4eb720c" xlink:href="cah-20200930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_cah_VestingPeriodinyearsforShares_3004dcb4-50e8-43b9-89a0-bc11b4eb720c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_cfde0790-08e6-48f4-b17d-2ed0f74ff209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_cfde0790-08e6-48f4-b17d-2ed0f74ff209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8c6840c-c6f4-42ad-927e-854660e8d2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8c6840c-c6f4-42ad-927e-854660e8d2ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f32e26c1-3e10-41f7-acd2-1549c3faf26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f32e26c1-3e10-41f7-acd2-1549c3faf26b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d367a7bd-e7ef-47ce-ac81-135f06bf5d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d367a7bd-e7ef-47ce-ac81-135f06bf5d91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_f8a57708-5ab3-4632-a944-ff250d32ac69" xlink:href="cah-20200930.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_f8a57708-5ab3-4632-a944-ff250d32ac69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0eac8d84-3eca-4869-adfa-99bc2690d4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0eac8d84-3eca-4869-adfa-99bc2690d4ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd2207f-215e-4292-a9e7-dbea090c8900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd2207f-215e-4292-a9e7-dbea090c8900" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_222a7cb8-a98b-49f4-877b-7fd524b88d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd2207f-215e-4292-a9e7-dbea090c8900" xlink:to="loc_us-gaap_AwardTypeAxis_222a7cb8-a98b-49f4-877b-7fd524b88d21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_222a7cb8-a98b-49f4-877b-7fd524b88d21_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_222a7cb8-a98b-49f4-877b-7fd524b88d21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_222a7cb8-a98b-49f4-877b-7fd524b88d21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_222a7cb8-a98b-49f4-877b-7fd524b88d21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_39c935dd-cb6e-46e1-9ef9-10af25a6d10a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:to="loc_us-gaap_EmployeeStockOptionMember_39c935dd-cb6e-46e1-9ef9-10af25a6d10a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_79c6a15d-3f60-48c9-8cda-30e08150edd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_79c6a15d-3f60-48c9-8cda-30e08150edd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_818e3ee9-414d-4e5c-bc83-f58540862c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:to="loc_us-gaap_PerformanceSharesMember_818e3ee9-414d-4e5c-bc83-f58540862c44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0ae2b2c6-e29c-4033-90de-1de9c300d26b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd2207f-215e-4292-a9e7-dbea090c8900" xlink:to="loc_srt_RangeAxis_0ae2b2c6-e29c-4033-90de-1de9c300d26b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ae2b2c6-e29c-4033-90de-1de9c300d26b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0ae2b2c6-e29c-4033-90de-1de9c300d26b" xlink:to="loc_srt_RangeMember_0ae2b2c6-e29c-4033-90de-1de9c300d26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79737746-07f3-44a5-b489-cd5cfe933cd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0ae2b2c6-e29c-4033-90de-1de9c300d26b" xlink:to="loc_srt_RangeMember_79737746-07f3-44a5-b489-cd5cfe933cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f405c400-e57c-4705-a1f1-beb825be5ed4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79737746-07f3-44a5-b489-cd5cfe933cd2" xlink:to="loc_srt_MinimumMember_f405c400-e57c-4705-a1f1-beb825be5ed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af0dd597-0c96-4c64-8038-75e3f5e2e376" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79737746-07f3-44a5-b489-cd5cfe933cd2" xlink:to="loc_srt_MaximumMember_af0dd597-0c96-4c64-8038-75e3f5e2e376" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended" id="i2542f6fdedf94ded9bfbbd45ccfe55e8_ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb1e886-ddca-4fe3-86b9-6ebcd1f94e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ebcd6c2-3b51-463c-96cc-5e5b406f8130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb1e886-ddca-4fe3-86b9-6ebcd1f94e59" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ebcd6c2-3b51-463c-96cc-5e5b406f8130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_622b9d36-6689-4a86-890a-7eecaf42a8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb1e886-ddca-4fe3-86b9-6ebcd1f94e59" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_622b9d36-6689-4a86-890a-7eecaf42a8b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_63bfc0f9-e846-4b4f-87c5-d455f4b3dddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_622b9d36-6689-4a86-890a-7eecaf42a8b0" xlink:to="loc_us-gaap_AwardTypeAxis_63bfc0f9-e846-4b4f-87c5-d455f4b3dddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63bfc0f9-e846-4b4f-87c5-d455f4b3dddc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_63bfc0f9-e846-4b4f-87c5-d455f4b3dddc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63bfc0f9-e846-4b4f-87c5-d455f4b3dddc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_63bfc0f9-e846-4b4f-87c5-d455f4b3dddc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a63ada13-1658-4592-a90e-f2181eea1031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a63ada13-1658-4592-a90e-f2181eea1031" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29c5d512-c5ec-414c-b30c-e66912b87192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29c5d512-c5ec-414c-b30c-e66912b87192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d222274a-25b8-4464-a098-c74954499c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:to="loc_us-gaap_PerformanceSharesMember_d222274a-25b8-4464-a098-c74954499c78" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended" id="i88f111cb18a54e15843ac1f089084cca_ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended" id="i72e4091dc0974442b2edc0cf6d8514d0_ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7dca6ec0-4423-40be-b9f2-3e38a956cb55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7dca6ec0-4423-40be-b9f2-3e38a956cb55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_73fc9cac-d06d-4e6b-8c70-58360181a7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_73fc9cac-d06d-4e6b-8c70-58360181a7aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4634b537-6a12-4dc5-9cf6-fce5d5da67fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4634b537-6a12-4dc5-9cf6-fce5d5da67fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_747f071f-42a1-493a-9de0-a3f9a3c3c6db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_747f071f-42a1-493a-9de0-a3f9a3c3c6db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c3cf9e79-a58c-43d9-8143-2ea7eb6457f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c3cf9e79-a58c-43d9-8143-2ea7eb6457f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_62333225-f3e1-40db-8d6a-ba18f506e076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_62333225-f3e1-40db-8d6a-ba18f506e076" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639f79b2-3d3f-43da-8783-318d03947866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639f79b2-3d3f-43da-8783-318d03947866" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7fcfc840-0b79-4627-87fb-3feafc7cf269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639f79b2-3d3f-43da-8783-318d03947866" xlink:to="loc_us-gaap_AwardTypeAxis_7fcfc840-0b79-4627-87fb-3feafc7cf269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7fcfc840-0b79-4627-87fb-3feafc7cf269_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7fcfc840-0b79-4627-87fb-3feafc7cf269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7fcfc840-0b79-4627-87fb-3feafc7cf269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52b28902-7e5a-4f73-968c-e1708c0234a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7fcfc840-0b79-4627-87fb-3feafc7cf269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52b28902-7e5a-4f73-968c-e1708c0234a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7daf1b29-8165-46c5-9992-1a70e5f27460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52b28902-7e5a-4f73-968c-e1708c0234a2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7daf1b29-8165-46c5-9992-1a70e5f27460" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended" id="i4136cb4b605f442eab01fc93c3f82cd5_ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc769b6a-6032-40fc-9a9a-590adb0db5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc769b6a-6032-40fc-9a9a-590adb0db5d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d2a8857b-6c26-4641-b0ec-90f2f0c5b431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d2a8857b-6c26-4641-b0ec-90f2f0c5b431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bc025273-7c1a-4f9c-a2d6-35ece1bd5754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bc025273-7c1a-4f9c-a2d6-35ece1bd5754" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8389232f-ad05-467c-b915-d95b113c7e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8389232f-ad05-467c-b915-d95b113c7e07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1290f408-c702-4108-a6aa-cb9ef6f0663c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1290f408-c702-4108-a6aa-cb9ef6f0663c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_19cac6a0-ad94-4ff1-88bc-61268f6a5e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ec72136-7796-4670-a8c4-4fa4b35a0789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ec72136-7796-4670-a8c4-4fa4b35a0789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d7a96cbb-ba93-4677-a67b-0bbb947bee55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d7a96cbb-ba93-4677-a67b-0bbb947bee55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4c182a19-df85-4165-9c69-697295fe03e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4c182a19-df85-4165-9c69-697295fe03e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0d7c6fe8-b939-4f0c-b835-9ec55ca2537a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0d7c6fe8-b939-4f0c-b835-9ec55ca2537a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_eabd4dcd-f0c5-4fd6-bdca-22f5e2ee8081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ce7a3c7-65e5-4a4f-8356-0d91f6349de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ce7a3c7-65e5-4a4f-8356-0d91f6349de7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e707d2c-11fd-4127-80ea-747a6146b8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ce7a3c7-65e5-4a4f-8356-0d91f6349de7" xlink:to="loc_us-gaap_AwardTypeAxis_6e707d2c-11fd-4127-80ea-747a6146b8d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e707d2c-11fd-4127-80ea-747a6146b8d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6e707d2c-11fd-4127-80ea-747a6146b8d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e707d2c-11fd-4127-80ea-747a6146b8d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c9a76a0-7c61-412e-a78f-27f464abff78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6e707d2c-11fd-4127-80ea-747a6146b8d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c9a76a0-7c61-412e-a78f-27f464abff78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd344128-ecd2-4b8a-85b0-eaa193a172fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c9a76a0-7c61-412e-a78f-27f464abff78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd344128-ecd2-4b8a-85b0-eaa193a172fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended" id="id5597bd145994a7bbb49c74fdfc009f1_ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5006a714-c731-4873-ba46-ff8bdf7b29f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5006a714-c731-4873-ba46-ff8bdf7b29f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29748ff3-4d44-4f94-b106-62cbb514cd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29748ff3-4d44-4f94-b106-62cbb514cd3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7a50a9f5-a37f-44c9-8054-ece6bd10cefb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7a50a9f5-a37f-44c9-8054-ece6bd10cefb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_09ef85b8-d2d5-48c0-8328-5ed7ebef30d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_09ef85b8-d2d5-48c0-8328-5ed7ebef30d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_338fdcd4-59ad-44ba-9af9-1830d05c2f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_338fdcd4-59ad-44ba-9af9-1830d05c2f05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fef26c6c-84d6-4606-8454-b112ea43d4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d2bf8f04-ca2d-44d2-94b8-8c663116a750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d2bf8f04-ca2d-44d2-94b8-8c663116a750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_416c0a46-751b-4a5b-9f0c-66e63ecf285e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_416c0a46-751b-4a5b-9f0c-66e63ecf285e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c2bc1595-7152-4ed6-84bc-3c2342b66bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c2bc1595-7152-4ed6-84bc-3c2342b66bd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_483c3c62-40a3-4756-9fb0-7dd41f2a7a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_483c3c62-40a3-4756-9fb0-7dd41f2a7a33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c0fa2224-022e-4eff-b0a9-4f05826b7395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4761577-cb5f-4bbd-b168-c4e7a4b4f362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4761577-cb5f-4bbd-b168-c4e7a4b4f362" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be11daba-0736-4bf9-ab88-cf04cf565a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be11daba-0736-4bf9-ab88-cf04cf565a0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d85eff2f-6882-4fd2-8e08-78c422726813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d85eff2f-6882-4fd2-8e08-78c422726813" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e813aa3-4e62-4fd0-a2f6-34fab2c0f147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d85eff2f-6882-4fd2-8e08-78c422726813" xlink:to="loc_us-gaap_AwardTypeAxis_0e813aa3-4e62-4fd0-a2f6-34fab2c0f147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e813aa3-4e62-4fd0-a2f6-34fab2c0f147_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0e813aa3-4e62-4fd0-a2f6-34fab2c0f147" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e813aa3-4e62-4fd0-a2f6-34fab2c0f147_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b510cee0-b53f-4351-a6da-8ebaea60fd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0e813aa3-4e62-4fd0-a2f6-34fab2c0f147" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b510cee0-b53f-4351-a6da-8ebaea60fd0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cc6ec924-c4a1-49dc-b465-d06bf9617e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b510cee0-b53f-4351-a6da-8ebaea60fd0b" xlink:to="loc_us-gaap_PerformanceSharesMember_cc6ec924-c4a1-49dc-b465-d06bf9617e02" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cah-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:f4838a7d-79fc-48a1-8b7a-97e86b8356e3,g:0e31584d-c111-426d-9652-5609505543ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9326980a-3693-46eb-bee1-c6116ed69b1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4c695cb5-d31c-495f-9f30-0b7dffc3060a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5945c2c2-3867-4558-a1fb-8729e56fa024_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of outstanding options at period end</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_fad44286-3604-4f8e-80a0-d5c7eff76286_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6748de18-eec8-4ed1-a1e8-57e6ab36bf12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bb767354-67ad-4ba9-be36-34dcfa50c36f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9e2c3874-a9ce-47d8-b01e-2eeaf6a84a9f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_b77df559-5097-4bf1-8959-e320c8e1a311_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_86a2cf9b-5a78-4d68-9285-87047eb06ff0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_98d32757-c1b6-4262-be17-e77e6f6ba003_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_ff577e6d-a26f-42d0-914c-eac6ae967712_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_ab3f230f-6375-4a2f-9235-a81fb1f59b9a_terseLabel_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_label_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_documentation_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:href="cah-20200930.xsd#cah_Sharesthatwouldbeantidilutiveasaresultofnetloss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:to="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_d1957225-5e3a-4969-acb7-f3fee1c3b759_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain/(loss) on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bd7d5464-4842-48f7-9d7b-c60d524c23a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_4586723f-9f1f-4a7c-a5e5-511c5328c590_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c5ca61aa-34db-4253-9134-c1524cc55a6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a908fc47-9c74-4d6a-a3e9-d0af44eb0263_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalMember_f1eafdb5-7ab7-45b8-b873-44f5466d551b_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_label_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Member</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalMember" xlink:to="lab_cah_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_df7e367d-2380-4305-9bb0-f22801bfe772_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bba65c1-ae4d-4a23-99a6-0adf9a7c41bd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f69d46d9-858a-4310-91b9-988f547b951b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalSegmentAxis_be2238ec-94bc-4633-8dd1-6f0ed6c78cc2_terseLabel_en-US" xlink:label="lab_cah_MedicalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Axis]</link:label>
    <link:label id="lab_cah_MedicalSegmentAxis_label_en-US" xlink:label="lab_cah_MedicalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Axis]</link:label>
    <link:label id="lab_cah_MedicalSegmentAxis_documentation_en-US" xlink:label="lab_cah_MedicalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentAxis" xlink:href="cah-20200930.xsd#cah_MedicalSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalSegmentAxis" xlink:to="lab_cah_MedicalSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_10b6dd7a-0391-499b-9fbe-7bcf013addc1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_044d77cf-5579-4382-9664-ea4a665530a0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2528eb40-a30a-40e2-9f3b-c9479cea4bfc_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_7255efc0-8395-46a9-bdaa-c3835b31e984_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20200930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5d8f6c03-cc39-4911-b55f-72270fc5c035_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1034af54-991e-41c4-8ff0-f09f7cc48035_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_454bb1f1-1945-48b6-a24e-1e8b50238d63_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20200930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b6e8ed1d-583c-4e29-ba58-2a74c7704176_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_99aacfd6-b01f-4b5e-b556-85399ac421e5_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20200930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_b1ea7515-f569-4b7a-abe1-b1122df0da2b_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_ebd96b24-b4c7-43c2-883b-040582366db2_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_42def72d-b356-4cce-a042-5a756be0e915_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_18259276-f03e-4c3a-9ce3-a767d0e0a8d8_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c8f9ba3-0c3f-4a3b-9cbd-f3c966900965_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2500aaa4-86d7-4154-9a19-48141a9f32e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a0f394bb-d9c6-4a44-9e2b-b6883bed9a90_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_2d48340c-3bc0-4d8c-9172-82094dc9216c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_5288719d-02c7-45ef-b94d-76431eef116c_terseLabel_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuits Against Distributors</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_label_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_documentation_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:href="cah-20200930.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:to="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_9fb5236e-80f7-4a0a-a9a5-e420bbb6d782_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2a295f32-a5f8-4e2b-b8c6-3e01f2555766_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_255fd7df-25c4-4565-9478-beb13e8326e6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7e85ad71-1983-4016-8241-ca3b09d8f4aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f9e463cc-24e9-48da-a67c-ff30c7cde6fc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c859c9e7-116f-46bf-845a-3d43bab61fc1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock plans activity, net of shares withheld for employee taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bbdeee9d-5f78-48af-9aac-e9e0e69b5305_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_257fbb61-5e51-4e3a-bbbf-1c2ba842254e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e64eb82a-3530-40eb-86f5-9a291130dfcb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_047f90d7-2eed-440e-866c-594c6006a3c0_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_c0c6cd83-b860-4440-99bb-d20bf7c42a8e_terseLabel_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_label_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_documentation_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember" xlink:href="cah-20200930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearPrecisionHealthServicesMember" xlink:to="lab_cah_NuclearPrecisionHealthServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_ba7122c7-5a3e-40c9-96fd-7396b7455ff4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c1f0d259-ab49-4089-a3d5-625d69664fd8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_c3ef0c40-41bb-4bb9-98f8-a7d1828035e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_c7908311-96fc-4bd4-ac0e-64a9dd37645d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired (using cost method), shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12b397aa-1ce1-4163-9259-fdeaf372cdb5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_748b9dbe-7017-439e-b7d2-9e59311ee65f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_07f1f494-c920-4bc1-b577-055ce82a1fcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1f468834-8038-4a85-91ff-19d74df4e077_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_5664486a-aeb3-4648-b3b3-44ba9ccd2b84_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_ebb0684f-321c-4ec6-b4db-2f495baf3b3f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_e0f95f8e-1a48-4b4f-8c3f-d56fca878b4f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ed348b0d-4277-4325-8c9d-8adb2137a661_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_347d31d8-5ea9-4489-8f99-f48ef2a1700c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a70c64cd-37a5-4bdb-b46b-41fbfc0c3e8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d7de4819-ec12-429f-9763-37b72bb458b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_6e2d8801-a006-45c9-ace0-4d5ca0544c33_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20200930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_242ab24e-6133-43aa-8e8f-ade0038b6ba8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7bc6f53d-da13-46d1-a96f-b10030cfa803_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_3e98b44e-f172-4b6e-b7f4-0a0b1e5ddcf4_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20200930.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalMember_7c4eb64b-0229-4e84-8de9-b7c704f04990_terseLabel_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical</link:label>
    <link:label id="lab_cah_MedicalMember_label_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Member</link:label>
    <link:label id="lab_cah_MedicalMember_documentation_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalMember" xlink:to="lab_cah_MedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_815eed73-b1c5-41e2-9026-d6e392f448c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ba0ae3ad-a491-4730-b30e-2a714164c4a0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1fb0ffd1-529c-4cf5-9a11-cfd7934681e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IndemnificationReceivable_be8cd86e-bd5b-457f-a1d0-a44ea7893d4b_terseLabel_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_label_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_documentation_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable" xlink:href="cah-20200930.xsd#cah_IndemnificationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IndemnificationReceivable" xlink:to="lab_cah_IndemnificationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a4b84de1-52c4-455c-825b-f47900ae7661_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ec7754a5-7eb1-4add-b626-fc238cc347a0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_1dd10023-88f3-4381-87b9-952aeca1aaca_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net tax withholdings from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20200930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_27c1f869-235f-4248-b514-5973cefa73a5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_ec0710c1-d0fb-4d0c-ab36-659d416b2516_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_27962ce2-2c1f-4b3a-a805-3d8e61980da2_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20200930.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_132a4c48-633c-4d19-91ac-858d77e2d276_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_757fe7f0-3407-4140-85c3-4c7167edce95_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_f016d20c-2c6b-4173-ac4b-9697288a3e33_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_a7191320-fd97-4e49-b3e9-2f6273b5cf9b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_c5d5a2eb-0537-4c1c-a8df-a8fa2fb7a07c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6579ab9d-3f5e-4cac-914e-b439b76efa9f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_893d4745-d922-434e-ad13-a8c6a1088445_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_f83623d5-b957-4b94-90e1-2cdb72b48e52_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_375ae8bd-4fd0-48f9-9984-a327a7be6250_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d03aa5f-ecca-4d77-b290-b21f1e7e33e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_0f8ee9ff-b880-406e-965e-569f64c806d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_aec71e15-27c0-458a-992c-5c7cf17601e8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_ce4259d6-8cc7-45b1-9e91-e682785f44d1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_eb1cd5f0-be8b-4983-a422-503d993a0eb6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_82625e75-7a19-4554-ad51-0595cc1b95b8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_a557f619-f5e2-4ef8-a3c3-11491aa1230d_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from sales of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20200930.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a58f0647-b1a6-4628-b0e5-2efb0baa943c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillTransfers_4aecf109-788e-4e82-8928-9a970b98d49e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillTransfers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:label id="lab_us-gaap_GoodwillTransfers_label_en-US" xlink:label="lab_us-gaap_GoodwillTransfers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillTransfers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillTransfers" xlink:to="lab_us-gaap_GoodwillTransfers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_1532f5ff-5406-4749-85ea-6d3c46b1f4d1_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_ab224abe-24a1-4d16-8a98-6d7c5f22b1f6_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a4ae4337-d4fc-47c4-829c-dab35c758e2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1193249-870d-4871-aa27-84b12e0fdd9d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_34410a88-92cc-41ea-911b-c32e64708570_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ac75f52c-1d44-419e-a21b-b3f5aaa90570_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6704f4b1-2f9c-4914-98a1-0f5c00e9e144_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_3edc8c23-a53a-4bf9-960a-1ff31137ef4b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Charges</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_5705eb01-d63e-4373-b82c-b5c81c8bd0ec_terseLabel_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="cah-20200930.xsd#cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_f41f4400-477a-4360-8b29-cfe45012e267_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_3fdc0244-f6a8-4c94-8a38-a0fb2c94936a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4fa156f5-2255-4397-9790-14389641d977_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_1d5ad55e-687b-476d-9e16-742a7cfbf2e8_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20200930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CardinalHealthAtHomeSolutionsMember_2d631321-1299-4915-8147-147d7283f80a_terseLabel_en-US" xlink:label="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home Solutions [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeSolutionsMember_label_en-US" xlink:label="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home Solutions [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeSolutionsMember_documentation_en-US" xlink:label="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeSolutionsMember" xlink:href="cah-20200930.xsd#cah_CardinalHealthAtHomeSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CardinalHealthAtHomeSolutionsMember" xlink:to="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_8f79a1c8-48a7-4356-9cf8-17e1fb0798be_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_label_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable" xlink:href="cah-20200930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuebyGeographicTable" xlink:to="lab_cah_SegmentRevenuebyGeographicTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_35d9ead2-14bf-40a1-8ef1-3f6134e7adff_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_4a3b7252-61da-473e-a42e-4e074842b882_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_39239db2-feca-4e17-864a-681f094c3f7d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_680bd114-048e-4274-9a43-136100325e25_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_c1d31801-923c-45a0-bbf3-b02b8bae6257_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_537325f9-600e-4ad3-936e-a72840822f3a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b4d4e380-1f09-411a-91e6-0bba5542617a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_41cd6b5c-275d-4c9e-b3b7-998c56665099_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_230865db-9ef4-42ce-b97b-6235d81eb345_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20200930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_79a3325c-b8d4-4746-909d-84ad9842eeeb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5951b392-4d58-43d2-8799-a50fcbbebd62_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f591c072-286f-4d63-b8ac-2405c4101cf7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_221cfcf7-aaa8-443a-b252-9f0f09e6b9a7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_70671c06-abb5-4fe3-be3f-a8abda6d80ba_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_843bcfaa-65da-4291-848a-8b51651bb0aa_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_946e97c5-b353-4b5c-b1c7-155b912647a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4cd22e6d-9f27-40ee-8337-3243fe8b9e15_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3e90f25-71b6-4c0c-a73c-d205686eaad0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_54f0ca1d-5dec-4302-8448-5662715ce39e_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6104ff61-f7f9-40a6-8d62-a8f621ac15ef_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_87b113ec-d3a2-490a-b179-84a6b73986a8_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_9f1edc1a-dd04-4449-9f6e-5d6f00c7f8d4_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_205304b8-eb76-4fd6-b173-5a393e6c92f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1a10f82-10ec-44bc-a45c-46e0e25174b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c79b36cf-5e0b-44f6-bd10-6e0dc35c365a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_694b089f-7189-4aae-a87f-b32c895cab5f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0a3ad1e8-f3a3-47fd-8db6-052ba3527b9b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d41d5708-9ab7-48ef-9051-d33098578f60_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FinalSharesReceivedfromASRProgram_1cf92cbf-0b5a-4880-8425-229d97823921_terseLabel_en-US" xlink:label="lab_cah_FinalSharesReceivedfromASRProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Shares Received from ASR Program</link:label>
    <link:label id="lab_cah_FinalSharesReceivedfromASRProgram_label_en-US" xlink:label="lab_cah_FinalSharesReceivedfromASRProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Shares Received from ASR Program</link:label>
    <link:label id="lab_cah_FinalSharesReceivedfromASRProgram_documentation_en-US" xlink:label="lab_cah_FinalSharesReceivedfromASRProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Shares Received from ASR Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FinalSharesReceivedfromASRProgram" xlink:href="cah-20200930.xsd#cah_FinalSharesReceivedfromASRProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FinalSharesReceivedfromASRProgram" xlink:to="lab_cah_FinalSharesReceivedfromASRProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a317e387-9a58-4f76-8ea2-91030d4e7aa5_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e3dd2615-7354-45ec-a9fd-348974097c48_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_54ba30d4-8077-463b-b373-a9667bd906dd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_79265d72-5f93-40d1-950e-3290b9e1579d_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_0981a880-2c0b-4489-9ec5-38046940c53f_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20200930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4ec814b2-85b5-4674-b56e-ffe51011199b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6b6c444f-c309-4c04-b95f-1349efac8e50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_aa061a5b-0502-4caa-bab4-2179544eaa75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/decrease in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5774a150-402b-4985-8344-4616610cb463_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_d59623ae-ae4c-4fc9-bb16-79e8999be008_terseLabel_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_label_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_documentation_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:href="cah-20200930.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:to="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5ca72823-ead5-4a39-9f0d-b0d9413ddc3e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2d173acb-ca32-4fd5-b3b2-f64d6191ab46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_cc3b853d-8478-4a74-8c75-3492a4dd17ce_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_3f4a0962-a461-4166-ab72-18307a9c4cbf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0f28590e-974b-49e0-a069-3b18c1ec2990_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_11841240-7c18-447d-a6fe-e270ebe78d3c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_5224eaf2-440e-4beb-83b4-95ec31b639e5_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5b2248ae-2af0-4757-b476-3b36d868a454_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_ccb7baaa-602e-481a-9340-3e27cec78c1b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d62cd887-93fd-476b-a2ed-d212f12941f9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by/(used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6a61ab55-8d6d-4ec7-a384-ed8a85707e5f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_350e2ba5-ccda-4f47-9d58-43cb34ca5704_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20200930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_4a6c42de-aa89-4903-9aa7-1960e7c34c1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_b0c22a24-7b4b-43b9-806e-506eb9e4f523_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_b6fe86cc-6d0f-4235-9c17-f08fcbc8f368_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_93f6e8e4-4dc8-43fb-9238-b53a126c25d7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b6187641-db58-4573-b0a4-8504186d53e5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6a72050-0858-4228-9aeb-ad55a963bfe4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70ee9d3d-6254-4b20-9b6c-110906b17b51_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b8551cb3-a7ea-46c6-8c84-6a5df93375e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a7708302-f4d2-44d6-bba0-4dc7c3a2e9db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_ea263989-5cb8-465f-87b7-66018b9bbe03_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9c6f332c-6e90-4c26-a114-b95ae350ef59_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_ddb0ce57-48b4-4c7a-b6e6-20ab12090d01_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_460a3a97-303c-4740-a941-667fe88df110_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_330f13c9-d4c9-4d66-b93f-3793351f2096_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D, trademarks and other</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20200930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3cb0dc09-f22d-4f55-ad71-28a1d1b55e34_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ba8e9959-41eb-47da-a52f-2caf362122e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_e227f778-2b4f-4e1d-aeac-676d893ef396_terseLabel_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:href="cah-20200930.xsd#cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:to="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_14a5ec2c-1a6b-420a-9e0a-8763b975707f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalSegmentDomain_4e3f0cf9-56a3-4ad0-ae5e-033f11c1197a_terseLabel_en-US" xlink:label="lab_cah_MedicalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Domain]</link:label>
    <link:label id="lab_cah_MedicalSegmentDomain_label_en-US" xlink:label="lab_cah_MedicalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Domain]</link:label>
    <link:label id="lab_cah_MedicalSegmentDomain_documentation_en-US" xlink:label="lab_cah_MedicalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Medical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain" xlink:href="cah-20200930.xsd#cah_MedicalSegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalSegmentDomain" xlink:to="lab_cah_MedicalSegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_82550d03-b538-4d29-bd83-a121582d5bfb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_a5c0da8a-cd3f-42bf-85cc-70c08d9ca795_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6997e43a-2c15-4e86-8020-a1759289f716_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_421ecfff-5ccc-438e-9ae3-8b296088ca89_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_74cebdb9-0d15-494e-bd3d-b2c4772b67e2_terseLabel_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_label_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_documentation_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember" xlink:href="cah-20200930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicaldistributionandproductsMember" xlink:to="lab_cah_MedicaldistributionandproductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_6c2d9d95-5eef-472e-b573-31211427a280_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_42a32638-374b-4e75-941a-b05451627422_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20200930.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_048c3062-3d54-43ff-9bdd-193fdebe5330_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_79c17323-e7be-4cd4-99a5-ce5f2909ed6d_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_67fdfa3e-02f1-48c9-859a-e1475f9600f7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8b2a762b-7177-4eb5-ab1b-175efa13d324_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_d72cc420-1d4a-4804-b503-c077ed936993_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_a9c9c2e1-fffc-43b0-8289-1b8a837bc970_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_fe5b1378-62db-4eb3-82b2-047817d3ff41_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4401aee2-7c57-4cdc-8521-b6296a72ab37_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9d0623f2-bd7c-4b55-9788-879befc3a262_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_9917ad22-bd8f-4aa2-b971-cc603c6370ae_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9c8c16a0-b6fd-4b0b-9cca-4c363ab49c0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b443e2f9-d10b-48d4-a615-916b650efcbf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_c687bf95-cb44-41ea-9c32-6f9275d4ad59_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Statement of Shareholders' Equity</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8dbf6407-aa06-4a72-864b-bbcd713e799f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_188d14f5-cfb5-4b8f-8240-8fb112d62788_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_a10cdea2-125a-4d17-9c2a-647194be28c6_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Domain]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_label_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Domain]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain" xlink:href="cah-20200930.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsStateDomain" xlink:to="lab_cah_OpioidLawsuitsStateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_bb13d1da-cd85-4132-9e3b-4e48bc83ec93_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8678067c-6c4f-48f5-8fa6-cf5b9b3ddfaa_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_6d465a37-7058-4f47-9a11-b45731df276a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_bcaff222-9d19-4152-b69e-b4f766000433_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaximumQuarterlyPayment_36fd25e7-6dff-419f-9b63-fb1474f04c55_terseLabel_en-US" xlink:label="lab_cah_MaximumQuarterlyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum quarterly payment</link:label>
    <link:label id="lab_cah_MaximumQuarterlyPayment_label_en-US" xlink:label="lab_cah_MaximumQuarterlyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Quarterly Payment</link:label>
    <link:label id="lab_cah_MaximumQuarterlyPayment_documentation_en-US" xlink:label="lab_cah_MaximumQuarterlyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaximumQuarterlyPayment" xlink:href="cah-20200930.xsd#cah_MaximumQuarterlyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaximumQuarterlyPayment" xlink:to="lab_cah_MaximumQuarterlyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_90051641-f9e6-476a-856f-479701ceb322_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_0e0aaca1-7930-423e-b26d-3bb8d450f86e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified to earnings</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_db8e6929-4406-43a0-b7f5-dedba818d142_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OtherJurisdictionsMember_dcb2b592-428c-4dc4-a4eb-c8328c028239_terseLabel_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_label_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_documentation_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember" xlink:href="cah-20200930.xsd#cah_OtherJurisdictionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OtherJurisdictionsMember" xlink:to="lab_cah_OtherJurisdictionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_19618fd9-b839-4506-8120-17abc8486292_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a3dc9a3f-7389-48a7-9d19-cceea0abe292_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_fa114835-2e99-4d3b-bee9-b245303c654f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_4d7e24e4-5c87-4ce2-a116-467fca5af4fc_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20200930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_5fab0cc0-d78c-4516-ac9b-447ea31d2468_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_1a727c39-13d4-4847-b263-2347946b5045_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_a160ebf5-5fe2-4521-b853-416e13307049_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_def05454-688f-40cd-9829-c41160dda6e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_85abcd9c-b2f2-48cb-a5ca-a23553ab30dc_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5c8b5900-d5c8-4869-9e38-b013eb08b469_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CareFusionMember_525d7813-6b98-4a41-9c7b-c776705e93db_terseLabel_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_label_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_documentation_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember" xlink:href="cah-20200930.xsd#cah_CareFusionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CareFusionMember" xlink:to="lab_cah_CareFusionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LitigationTypeDomain_9994a101-dfbe-4a38-b40a-e5ab68181ae7_terseLabel_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Type [Domain]</link:label>
    <link:label id="lab_cah_LitigationTypeDomain_label_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Type [Domain]</link:label>
    <link:label id="lab_cah_LitigationTypeDomain_documentation_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Litigation Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain" xlink:href="cah-20200930.xsd#cah_LitigationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LitigationTypeDomain" xlink:to="lab_cah_LitigationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_3b62330d-0539-4843-aec2-98778e9aefd9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a31c6baf-51fb-414a-8d68-885f07b9b2e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_d37818f0-77e2-4e61-8e0c-c55a9e6fa697_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_ee52fd1b-c722-451b-baeb-e85fc8bece88_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3965d489-c151-4044-bc8d-1c0501a779b2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0172796a-9cdd-4d9c-b006-2b0fe41b0f40_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a1481a1-c15f-4390-9861-9320206e65b1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_bcf746d9-3693-4b6a-a60e-36692a12c630_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4fda6732-ffda-42c3-91c9-24279bdd23a9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_0c981173-8856-4a4c-a118-d0d8c6ae63c6_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_701c01a1-4102-4f49-93cf-9944ce471987_terseLabel_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_label_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_documentation_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember" xlink:href="cah-20200930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PatientRecoveryBusinessMember" xlink:to="lab_cah_PatientRecoveryBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_717b1549-317b-4334-aac1-a938be4c3262_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_705e5c04-a30d-40c5-8396-4e6e2794e97e_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_44c01ea7-ed6a-463d-8fbf-37f70bb7278a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_09806aa3-8136-4bf4-8a4c-9844d9fe6232_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_121c6dbc-3df0-4c41-82b5-9545b625449e_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fc99f5c6-6fdb-41a8-92d1-2443e627a8f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_3c577fe3-30ef-434b-9f14-55f301191785_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_label_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:href="cah-20200930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:to="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f2802a4c-e898-4a86-b3a9-6b2768cd8201_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9af44b6f-c219-46d1-90f5-37c74d474b7d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_117c0a2e-daa9-4fc6-aa15-fb8d77d0de7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_804dc9dd-7dcc-4736-b6ab-a6db812a84ee_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_c4a89958-bfca-4c73-99c8-b322e686e17e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_12a5cbab-3434-4010-8635-f4c3d096668b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_6ee7bff1-b006-4dfc-8872-4e5016b9612b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_ce27730b-dfe3-4910-b414-ef5726915f3e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fac65615-94f0-4ce1-8308-9988913e7d5b_verboseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c893920f-8ef3-400a-ac71-dc03871d3dbe_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b6ed3499-643e-469c-9657-b7b83649d3ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_65bfe824-e19f-4445-919b-7fc0a2956dc0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_30cd2b30-1c86-4001-9c25-52312027f032_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_bfd9c262-ad30-4ee5-aa89-4a44186d7ea3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_56cebd60-b12c-49b2-9462-fa690aae68a1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_21979289-540f-491a-8d07-144e8cab684d_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_68100c9f-cc03-48db-b64e-793b707e6e2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Common Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dd0f54d8-a972-434b-a754-e78c4882d78e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_bf552bea-2464-4780-b758-490e0b9ab82f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2bdfd4eb-3862-44b2-8f17-51b69fdf24fe_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_0283a386-e084-41de-b450-0dbe1715d8c1_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_f5e6cd9a-4f4a-49af-a5e9-db3e83882209_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_6d6c8cd9-a339-41a8-bfba-b33992de38b1_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_074b1d54-2be3-4be6-a905-59da369a9fb5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f5aa4b76-00fb-40b5-b5c0-3be4609b1375_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_8458c6f7-f09e-45e8-aed9-69047494b43b_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_97df5e7f-50f9-43dd-bffe-b0e50c9c1ec6_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_e0e1f283-cdf9-4fc8-97dd-27a18135bb1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalSegmentAxis_88dac44c-95e1-4255-a9ba-52310261ac80_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Axis]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentAxis_label_en-US" xlink:label="lab_cah_PharmaceuticalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Axis]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentAxis_documentation_en-US" xlink:label="lab_cah_PharmaceuticalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentAxis" xlink:href="cah-20200930.xsd#cah_PharmaceuticalSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalSegmentAxis" xlink:to="lab_cah_PharmaceuticalSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_db0bcaf8-0ef7-4da7-b1fa-518f3aee768c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ad8ce9f1-f545-4d79-9262-1f0827ccb9c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_7b6eae90-ccf3-4e94-ab93-79444252cfe4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_20bca1e8-3654-4206-ba11-1a12790e91ea_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_2a498697-fe54-45ac-875f-4ed8e8096c30_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_3f04308f-472a-4bdc-9f2b-4c7e1aa24863_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_cde1d0d7-fab5-482c-9c03-5788aa7a02b0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_12881979-a1a1-498a-abd3-4fdcafa044ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_6e92abfc-e46d-43b3-8c99-20b52f346315_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_19d926c1-fbfc-472f-aabb-a53535b6d899_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_dcbc63b3-d931-4b9f-86a9-6e935501edba_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_d04bdb50-e190-442f-9858-338d744ebd2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_a6809952-8b3a-42f9-ab5d-b337950be5fc_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20200930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_a9b24593-c057-4c87-b7a4-00b41ac2da44_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_617b636e-9722-48a7-aaa8-55124182e2bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0292fc60-6368-4d7a-ab96-9bc505775771_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_af706e99-c9f4-47db-a2a6-5df7f8ae698e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_6eb22e71-07ec-460d-81e1-877e15ed97ec_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_cc7c6d11-0931-4a9e-971d-6ee46891fc9c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b0b355a6-21ce-4f3c-80ad-2e4c3b9a4f20_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_0b877098-3a9a-4717-8f06-43eb3477a9d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/decrease in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_85fc9f11-0627-4cf1-9a10-77261b8c8905_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20200930.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5dd3f166-ffc9-410d-9da3-646cf1fa7a9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_144cb3fd-8c29-41af-b992-ddf8ffd3b545_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a869a470-17e7-4de6-a112-a6f8d27f49d5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69161697-aecb-44df-9b92-3516dab0e2a3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6892b9bd-56b4-4a10-b353-9109f1a603bf_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_1079e027-e643-4dc7-97d1-de6a3f236ca4_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_03f52c8c-0319-45d5-94e4-7dbe52b4b41b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_ceb677a7-d7f1-4fbf-9e32-eed7b51915fa_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Segment Revenue by Geographic [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems" xlink:href="cah-20200930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems" xlink:to="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_33df3de5-3b62-492b-8625-9d686468961a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_dab91302-bf17-414c-84be-2e15060502a2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1fc16e3a-37d5-4d41-a42b-0a3fcf406d87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9a9334b3-99d9-4e89-a4d4-18847cfec4bc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d7d11aa4-d05d-46e5-8510-537ccca3ba97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_ecbb79df-6972-4f70-8cde-407f551f8f45_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_2cf8d734-d892-4e34-8ceb-dce330fdcf1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_128af331-b901-48f9-aeb5-b921b37f7a1a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_14d1dbe8-3f82-4062-bf56-63926961fb3f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8aa46cb3-8f35-4d77-ac61-ee65b8ad605a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_475c05cc-b722-465c-a47c-22e9983ad862_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_99a3a331-e632-46d2-ab8a-b94c7f2d7d1b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e3b34e5f-a199-4df9-a58e-af86a6867c38_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cce732bd-15c0-47f2-a7ed-98ec783defe6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_59473add-5da7-4cf2-a11f-8e0b056d4da8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_dcf4c1e7-6788-420c-bc7b-7c62f87d99f6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_66bdf8fc-4c6b-4341-89ab-523e729e181d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_81e99685-6418-456c-b776-66c4d29bf7f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f23b61b2-6d0c-46a7-8114-ed56608a8246_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of exercisable options at period end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1bd75c3a-9938-4a11-90c3-e993aae34032_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2a44881e-84ea-4224-bbad-13e7c7c8b982_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_d95bde4a-7bf5-4fa2-9dd4-52fe5415fdf9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_cdc63b14-bb11-499a-8dc7-116f676eae5f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_514e50cd-54bd-40cb-a6ef-b630eb85be75_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5b456f64-5835-4dec-b30e-4ae35d3cae33_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3c002662-0af0-4cd8-838c-ae782fddf354_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d58a185c-583c-4129-a3b6-d874049ce1b9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a369d10f-2b32-46ca-ac26-965561813cfa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ab24eb62-8601-4e1a-9529-32ed0438a22f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8b86f7e1-056b-402a-9449-e28da9af17d2_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac81783e-a4e5-40cb-b724-5bbf03b73443_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_36222618-5d59-4cf5-b9e5-3def73c5947b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0971ac69-2901-4871-8671-fd10dbcbdca6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_58a0d244-1ec4-4200-ac88-c8b991abcb17_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_44291160-c585-4357-bc80-d190cf9f58b8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_77305b25-b301-4dc2-9d39-3e45e9758f39_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_eab17b1b-d1f6-446b-affd-d43c6aba947a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_4328e966-10a5-4e20-aff0-5ec16d3da14d_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">litigation settlement liability recorded</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_ae1a2c75-a0fe-48c0-a46a-8e89887ba5f0_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_f8fc4462-2cb3-417c-ab2c-2e9ce696e434_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_c076fabc-a0f3-436d-9066-a4c112e753d5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f532ecee-c5ba-4307-9179-8eac1cacbb9a_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_61482519-dc95-45d8-a07d-39b2c1406114_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c649e7d3-52aa-470b-8f73-ae6a8ffac7b1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_08319749-ee28-4d54-b77c-ccc56523d56e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_5de0c5b8-ff70-4ce5-b71f-0c07cf4d176c_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20200930.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_1cc943a1-d5cc-4b4d-9a92-ffeda49feb80_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20200930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_81c95d5e-85ce-42fe-872d-b0d259d723a7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_2c6e9a11-3406-413c-8cab-2be21513d35a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fd2d4adc-c636-42f6-8d50-7a5b7046d59a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_0b7d3aa8-3183-4a08-981e-4a87ff9e1f00_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8c2e75f3-05df-4e12-bd00-6adcf6ccbe46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_269a034f-fe95-44ca-9fd2-501b53740b7f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_a07e8f74-b2ba-45a1-9b88-4af2c21242a1_terseLabel_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans (in years)</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_label_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans, in years</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_documentation_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The instrument's contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears" xlink:href="cah-20200930.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ExercisablePeriodOfPlansInYears" xlink:to="lab_cah_ExercisablePeriodOfPlansInYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8af46b90-28c7-4e8d-86db-60e627cd115b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a987e9a8-a889-42f8-8cfd-782d18398b7b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5b3effef-2801-4bdd-bf3f-e53f151a017a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1c51590d-08f8-4d4f-941b-2f018900d958_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0e86cdd6-0629-4eb5-9196-864d764487b4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_72a02314-4667-4bb9-9c7e-592e152d8a89_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_0090300d-dbd0-4cd5-ac1f-3cd557a7041f_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_5a7655a0-8bd9-4ac0-8ec1-2c98d930cd08_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_eea3784e-33f3-4b28-b189-8d0db88c137b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ae35ef04-bc46-4632-b7d0-e3ed18ced586_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1d902087-af9e-465d-ba50-00c269dad515_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_65e8120a-2fbe-4acb-b675-9fe8e985b0a5_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3d8d23be-fa83-4e02-bd3f-720e8ed875a6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_873b0bed-ff12-4e08-b48e-d48ac5fe5ff1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings/(Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f3b84ddc-039e-4b5b-b990-4e8a81ab30bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2db13ddd-4f0b-4c3b-985b-2ddb9aac53d8_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_159ae801-9fdf-4913-851a-82ddddf61422_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_dd2444be-4835-47ab-b970-04175a291240_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1c519301-b11a-4f5f-b227-bce7e1b93a19_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_dc21d9c7-e6a8-4d22-9317-9d2f02cce8cd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5caff76d-0749-443d-bf18-164ca0a8f929_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_3fd9f81b-7551-4ecd-b817-8e1f18c903e5_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_1a55bfa0-685e-42c1-85f6-63defe542c69_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_3788dec4-28f5-46b9-8d24-81dd3049e8b9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_16fb51e7-bb6d-4436-a2a1-27b72d26d73e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_6f3ec786-f59f-44f4-8039-49313c8220e6_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dac04ec3-d6c9-4f10-957a-a7a74fce9c02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TreasuryStockAcquiredShares_dac24b97-1e27-4c51-9018-7ff03d137b1a_terseLabel_en-US" xlink:label="lab_cah_TreasuryStockAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired Shares</link:label>
    <link:label id="lab_cah_TreasuryStockAcquiredShares_label_en-US" xlink:label="lab_cah_TreasuryStockAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired Shares</link:label>
    <link:label id="lab_cah_TreasuryStockAcquiredShares_documentation_en-US" xlink:label="lab_cah_TreasuryStockAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TreasuryStockAcquiredShares" xlink:href="cah-20200930.xsd#cah_TreasuryStockAcquiredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TreasuryStockAcquiredShares" xlink:to="lab_cah_TreasuryStockAcquiredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a24f4610-5916-4c29-9906-1fc76763c1c6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_a2e79c2f-0acd-44f1-b6c8-535b3f883e71_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20200930.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_ea3ed376-ee15-459a-9fe5-a1cca6f898a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_55b38326-5b9c-4639-990d-6b4d95223b42_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_0064a4dc-c317-4134-bc5a-a676980b0d1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1, 2 and 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1, 2 and 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:to="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_abf907c0-9468-45ae-8f72-be033d8fde3c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_22099386-de09-4eff-99c0-dea8b8437c27_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1ef845f1-5fc7-4580-9d58-a26a13c520d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_174d47fe-eedf-47ce-ba37-b852b07e74cc_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20200930.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_6fe20c18-907b-4713-b84d-f83aa2f3186b_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20200930.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AlamedaCountyMember_6c488273-6b35-4f41-852a-ee6118e0467d_terseLabel_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_label_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_documentation_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember" xlink:href="cah-20200930.xsd#cah_AlamedaCountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AlamedaCountyMember" xlink:to="lab_cah_AlamedaCountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_b5b81c93-a9df-4ad5-af79-a0801dccf53c_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20200930.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_66275750-29fd-4777-9773-356f765de37e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_571d23ac-d9ce-4212-8efe-97af24777cfb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_bfa529e4-f70c-49a4-bf7a-6eee0ae4a0ae_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_bac7b8f9-03e1-46f9-b3c5-8a6916f7da74_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_46dfed16-ebbc-403d-98c7-3f61d77a7603_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_84d41da7-c4a3-4980-807d-0b42b10a1ca2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_11d7b15e-b223-496a-9744-aff98bb5a690_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_a4f36ce4-3042-4d39-ad18-1612591b0dbb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bc9e6690-9f58-471e-976d-618e1923ed7b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_672418cc-a5bf-4a12-a8ae-6f83d53fc086_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_96290670-9374-4a4e-bf48-ddaa3f6e5de2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_90f8f739-73fc-4eb3-b0da-5a242092427c_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20200930.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_7090caca-79ff-4755-a82d-3313ef66de0b_terseLabel_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Data Related to Stock Option Activity</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_label_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock Option Plan Data [Table Text Block]</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_documentation_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A disclosure of additional data related to all stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:href="cah-20200930.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:to="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_858ceb22-13e3-4f45-a911-329d1d92d2bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_2e7fe3d1-ba8e-43d9-97fa-c1876d3c4d9b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bef4334a-212c-4b5a-9fd0-82f36bd27135_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c46ba99b-5cce-4be2-936e-49b947009315_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_4a959ed5-bcbc-4cfd-b7ae-15d27be8bf7d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_84d28f7a-1516-4330-a30d-40f1115365b7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_03b90766-afc7-4205-ba63-6c6cab033242_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_c94f4c8c-061e-4225-86fb-cc684e7a062d_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_247503ee-9302-4c61-b848-d230f0cdc7b2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_5fb6fca0-a4d0-4a14-81cf-47b977fb7b20_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20200930.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_8ff502ba-13a3-4e28-94c7-df5f64cfc8d2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_de53e2d7-746a-4dfa-977a-d3aef4cb0d20_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_2a32773f-9454-4694-87a3-aa3353c718e0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_a4827e56-09a8-4d54-a1bf-860f2b9f63b4_negatedLabel_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from purchases of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20200930.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares_c2d4b7f1-c642-4b81-bc07-3a39d462f7f5_terseLabel_en-US" xlink:label="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:label id="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares_label_en-US" xlink:label="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares excluded from calculation of diluted shares</link:label>
    <link:label id="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares_documentation_en-US" xlink:label="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares excluded from calculation of diluted shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:href="cah-20200930.xsd#cah_Numberofsharesexcludedfromcalculationofdilutedshares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:to="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b318a927-14c0-42c5-8264-15cd8a8f4414_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_871c8633-daf1-421c-aef0-8a03cbd4951c_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_186bb165-aa47-43dd-b836-e3be7cd048e7_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d41bb3f9-efe3-4488-aa95-6e75e69b2176_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40835071-7660-4a54-9c97-38b8c3fbc918_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2011f5ad-834c-4ca9-91bb-0080410af176_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_c410e2a8-6d3c-4cae-9f48-9319f1c72047_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_78bd59cf-e25f-46ea-a072-55505c6f7aeb_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4b6b5f66-cc75-4262-a0b7-d244abe96d2a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for/(benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_91b886d7-65f5-443e-88ad-496a504cac77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_59985ad3-8b0d-4eb2-b0a6-7a0cf9b94122_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_c6d32be7-b07a-4d71-a135-ecbf4cf7cb9a_terseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20200930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a2a27427-d476-4caf-af0e-395943c74e41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7b3028aa-84c4-4355-ad6e-34c59a5b0158_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_af71323b-5865-428c-aa04-a036e168665c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_947512ff-cb94-4d30-981e-392e9689b291_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_66debc67-4fa2-4b58-8f1f-fddddcd613a6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_a4896d1e-073c-48e1-95a9-b8f1dd94f721_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d35865d7-523e-47fb-b4df-3c1c516ca9a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_c91573f2-aa2a-4745-9e1f-05eb09a10342_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5947398c-9370-4273-93ec-899b4fc85ade_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_aa4f6591-bb18-4c21-aac0-a083c0471484_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_48aeb07f-a26e-496d-9fe7-6837556b2912_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0a349277-0865-463e-b8f9-27d5de1917f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalSegmentDomain_044ee57b-19d4-4937-8400-6773da0dc947_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Domain]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentDomain_label_en-US" xlink:label="lab_cah_PharmaceuticalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Domain]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentDomain_documentation_en-US" xlink:label="lab_cah_PharmaceuticalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Pharmaceutical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain" xlink:href="cah-20200930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalSegmentDomain" xlink:to="lab_cah_PharmaceuticalSegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9deb9204-fa92-4003-9330-098aa34690f7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_df2d20e3-3010-4ae5-9703-7b6d261346a5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_69435daf-2fd6-46a5-a269-a1e1da221b0d_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8fbd53e4-5906-444e-9486-148580081981_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b474a067-5f4a-4ffe-bd42-cbb09c642342_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9d44c9c1-161d-4200-bda4-23416a6cae9b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_74f68489-c28b-4233-a585-93187c79403d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7819a157-fe02-4b6e-a7f3-bcef7d2667c0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_87899d2f-94da-4142-9a94-ebae1d4bfc9e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_08fa3bee-f00a-46a3-92a3-95b1d738b798_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_57995e1f-61f1-41a6-a2b8-ec01592ad578_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d71e7b69-ff01-44b3-80f8-1183e5485b5d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b6ee176c-310b-4bc0-9ac0-b1330e4e7142_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_80b43047-bbfb-406e-9dba-c55162bd369f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_93db040c-b6ad-4376-a633-e379aac476ca_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dcc344ca-14dc-41b5-8972-81228467d057_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5232021-6029-42ab-8e53-626f893fca11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23f720cf-9d7e-43a5-b763-c895ff9ee503_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e479422d-ec62-4498-968b-1fdc1d3711e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4a703ccd-a004-4760-a8b0-982bc87965c7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a80032aa-13bd-4405-a222-a15e62ce6278_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_39e25fe1-4e99-4457-b1a0-f2297004f4e1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementDomain_e10501c7-6b0c-4a9a-8199-680d55cc96bf_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_label_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementDomain" xlink:to="lab_cah_TaxMattersAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_6dce2ed6-bde1-4db5-b194-3bb1c8ad3288_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_bd02bd34-35f0-4ea9-8134-ca0ed8bb4c74_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_a0e8d841-f348-40d2-ba41-357ae4a2e5d4_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_74da0f07-8070-440f-bfdd-1508c4545bed_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5b822a13-7f33-4333-a89c-70037c5beb35_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_3ad3391d-b500-426f-8b22-3c7dd3dacc58_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b001bdc8-13b3-4049-a29c-0f47c0ed34d0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_636d3499-cda7-471e-8591-e77a57f62523_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_5401f110-67e6-4417-8271-9f3d7deb7fcf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4f9e5e07-7f2e-41ab-8e74-1a06a77f7020_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_40b4c085-616f-4cde-82de-278639cfa078_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0256cacc-24e3-4423-bf9f-9f0829c63119_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_06e9309f-4ff2-4a0a-8868-b90df77e9117_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_d04e0f8d-8263-4c4e-8ac8-2afe3c271e79_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cah-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:f4838a7d-79fc-48a1-8b7a-97e86b8356e3,g:0e31584d-c111-426d-9652-5609505543ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_56221198-9ce2-4625-ae85-6fc6e3283572" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_DocumentType_56221198-9ce2-4625-ae85-6fc6e3283572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_bf62325c-adc7-45a1-a74c-14351e07bd46" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_DocumentQuarterlyReport_bf62325c-adc7-45a1-a74c-14351e07bd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_06730b0c-f164-4c69-97f7-4a4d3edde072" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_DocumentPeriodEndDate_06730b0c-f164-4c69-97f7-4a4d3edde072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2da62b42-0b64-479c-b1fd-48917e77eb1a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_DocumentTransitionReport_2da62b42-0b64-479c-b1fd-48917e77eb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c386843d-cb1a-4d5a-b771-2a376e42d604" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityFileNumber_c386843d-cb1a-4d5a-b771-2a376e42d604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_24deabbe-8419-48ac-b0ef-09b6c7fc7288" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityRegistrantName_24deabbe-8419-48ac-b0ef-09b6c7fc7288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ef7a4e27-7048-443b-bf11-e7e2e5000a7b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityCentralIndexKey_ef7a4e27-7048-443b-bf11-e7e2e5000a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d496cf87-fde6-4a78-8f7a-fc8f748a05b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_CurrentFiscalYearEndDate_d496cf87-fde6-4a78-8f7a-fc8f748a05b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_791d8ce8-5017-4979-854d-bd8d2ae7e875" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_DocumentFiscalYearFocus_791d8ce8-5017-4979-854d-bd8d2ae7e875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_26bc1cbc-1104-40f0-92de-f78c9443e137" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_DocumentFiscalPeriodFocus_26bc1cbc-1104-40f0-92de-f78c9443e137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_bbddee30-09a0-4bb1-912b-b44bcf554ee1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_AmendmentFlag_bbddee30-09a0-4bb1-912b-b44bcf554ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2d6af8b7-2be7-470b-aff5-30800fa4a69f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2d6af8b7-2be7-470b-aff5-30800fa4a69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fff9c732-f897-4e86-82c0-aabf87cf673f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityTaxIdentificationNumber_fff9c732-f897-4e86-82c0-aabf87cf673f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_29951fbe-d2f6-4061-83a7-04b905f719c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityAddressAddressLine1_29951fbe-d2f6-4061-83a7-04b905f719c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ef02a6c7-7273-4fd6-b604-3898a0bd5887" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityAddressCityOrTown_ef02a6c7-7273-4fd6-b604-3898a0bd5887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_40d57afd-891c-44a7-a25e-fc01fb383c87" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityAddressStateOrProvince_40d57afd-891c-44a7-a25e-fc01fb383c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5c4fffa2-8529-4a29-82de-8d459b7c5809" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityAddressPostalZipCode_5c4fffa2-8529-4a29-82de-8d459b7c5809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_221407fc-b14e-4d74-b240-6936f6147943" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_CityAreaCode_221407fc-b14e-4d74-b240-6936f6147943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_389958ce-1a78-429e-8d26-d1446d38e2b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_LocalPhoneNumber_389958ce-1a78-429e-8d26-d1446d38e2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e9ee932b-2247-4694-9828-540f503f82f2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityCurrentReportingStatus_e9ee932b-2247-4694-9828-540f503f82f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7de78992-b574-42bb-bd76-22daea29305f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityInteractiveDataCurrent_7de78992-b574-42bb-bd76-22daea29305f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a14d4a62-ecc4-4818-8f1d-184a6d7bccb2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityFilerCategory_a14d4a62-ecc4-4818-8f1d-184a6d7bccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e7551a01-ed59-4219-9c15-684d34061dfe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntitySmallBusiness_e7551a01-ed59-4219-9c15-684d34061dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_234afa37-d526-41aa-bdc2-8493937c6a15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityEmergingGrowthCompany_234afa37-d526-41aa-bdc2-8493937c6a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b58d39d1-b66e-4b08-8f41-fcbd3295b5d2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityShellCompany_b58d39d1-b66e-4b08-8f41-fcbd3295b5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_683f3669-4324-4386-bb88-b831e76b53af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_Security12bTitle_683f3669-4324-4386-bb88-b831e76b53af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_abebf65a-fe0f-40e3-a5f0-09ba2f900241" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_TradingSymbol_abebf65a-fe0f-40e3-a5f0-09ba2f900241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_92ad6035-ed13-4a0a-a3df-15177a997c04" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_SecurityExchangeName_92ad6035-ed13-4a0a-a3df-15177a997c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e63a8522-bbb0-4a9d-8f42-2935209177f8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_852d3f35-df20-4bfd-9340-4d2343304118" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e63a8522-bbb0-4a9d-8f42-2935209177f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_48dec836-190d-49fa-8e41-9d7fcf11ac2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_Revenues_48dec836-190d-49fa-8e41-9d7fcf11ac2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0597fdaa-f271-43f9-8985-5e4cfbf6638f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0597fdaa-f271-43f9-8985-5e4cfbf6638f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_654b93f0-82e5-4e50-8ea1-4cd6cbc006b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_GrossProfit_654b93f0-82e5-4e50-8ea1-4cd6cbc006b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_58694071-7ac1-4c2e-b794-419b7a35a15d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_58694071-7ac1-4c2e-b794-419b7a35a15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23e9f18e-aaae-4f34-a314-aaae1de4f4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_58694071-7ac1-4c2e-b794-419b7a35a15d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23e9f18e-aaae-4f34-a314-aaae1de4f4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_777eb633-5393-435a-92a9-da6de19d953f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_58694071-7ac1-4c2e-b794-419b7a35a15d" xlink:to="loc_us-gaap_RestructuringCharges_777eb633-5393-435a-92a9-da6de19d953f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_38b2d834-be22-46ef-8be8-fad708250ff6" xlink:href="cah-20200930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_58694071-7ac1-4c2e-b794-419b7a35a15d" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_38b2d834-be22-46ef-8be8-fad708250ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_cda0b3eb-8bc1-4dde-9d48-d7ce26e27884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_58694071-7ac1-4c2e-b794-419b7a35a15d" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_cda0b3eb-8bc1-4dde-9d48-d7ce26e27884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_e06681dd-0e21-40ab-a13b-663cb20fb7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_58694071-7ac1-4c2e-b794-419b7a35a15d" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_e06681dd-0e21-40ab-a13b-663cb20fb7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8dce0b27-018b-4aa0-93bb-d081bad88ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_OperatingIncomeLoss_8dce0b27-018b-4aa0-93bb-d081bad88ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7ef663f0-77d9-450d-a0b9-a14cd42d3edf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7ef663f0-77d9-450d-a0b9-a14cd42d3edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_35fc9d09-3065-426e-ac26-6dd704e33115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_InterestExpense_35fc9d09-3065-426e-ac26-6dd704e33115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_ce37b7c2-60c3-44de-9e52-43526d678918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_ce37b7c2-60c3-44de-9e52-43526d678918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b8ba4b1e-4690-4d8e-976d-2e73fc46e43a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b8ba4b1e-4690-4d8e-976d-2e73fc46e43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_767ba129-c100-4395-badb-47ef8785731a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_767ba129-c100-4395-badb-47ef8785731a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ed4172b5-7318-4b0d-83a4-7d8a09c15dcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_ProfitLoss_ed4172b5-7318-4b0d-83a4-7d8a09c15dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1aed3b08-5c29-4c66-ba37-6cb89af46c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1aed3b08-5c29-4c66-ba37-6cb89af46c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b75d6618-85b2-4c21-88cb-dedd5fc61730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_NetIncomeLoss_b75d6618-85b2-4c21-88cb-dedd5fc61730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_263c0ba8-c025-4f6d-9d6e-29ba4ba9c8c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_263c0ba8-c025-4f6d-9d6e-29ba4ba9c8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d9011414-c6f6-4c6d-aaae-8de4e80959a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_263c0ba8-c025-4f6d-9d6e-29ba4ba9c8c5" xlink:to="loc_us-gaap_EarningsPerShareBasic_d9011414-c6f6-4c6d-aaae-8de4e80959a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ced10129-9532-48fb-9157-565e2ea53e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_263c0ba8-c025-4f6d-9d6e-29ba4ba9c8c5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ced10129-9532-48fb-9157-565e2ea53e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c849d7c2-b990-42f4-a5f6-91882aeb0ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c849d7c2-b990-42f4-a5f6-91882aeb0ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_06640438-9f2a-4d92-ad01-cf4ba3e3084a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c849d7c2-b990-42f4-a5f6-91882aeb0ff9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_06640438-9f2a-4d92-ad01-cf4ba3e3084a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4ea02f60-5045-4b85-93b1-83d7e2c650e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c849d7c2-b990-42f4-a5f6-91882aeb0ff9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4ea02f60-5045-4b85-93b1-83d7e2c650e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_5dc5586b-e9e8-450a-98d8-1a95f3ade6c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ce61d3e8-6365-43bc-bddc-c858deadfc6c" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_5dc5586b-e9e8-450a-98d8-1a95f3ade6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab20b55a-50f1-4d53-a37f-44348e9c3491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b532d85d-7aa7-4e90-856f-e48de0520d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab20b55a-50f1-4d53-a37f-44348e9c3491" xlink:to="loc_us-gaap_ProfitLoss_b532d85d-7aa7-4e90-856f-e48de0520d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_faa31881-16d6-4266-84ac-fb97be8add04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab20b55a-50f1-4d53-a37f-44348e9c3491" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_faa31881-16d6-4266-84ac-fb97be8add04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_82340219-040e-40e2-9bd1-50158d660653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_faa31881-16d6-4266-84ac-fb97be8add04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_82340219-040e-40e2-9bd1-50158d660653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_c017f9d9-b81a-4086-a5a7-d49679e4541e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_faa31881-16d6-4266-84ac-fb97be8add04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_c017f9d9-b81a-4086-a5a7-d49679e4541e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_028e2071-89be-4b21-9c1b-d061ee6d3dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_faa31881-16d6-4266-84ac-fb97be8add04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_028e2071-89be-4b21-9c1b-d061ee6d3dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2d57ffdc-c6d1-4f08-bb48-c7d2058bb571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab20b55a-50f1-4d53-a37f-44348e9c3491" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2d57ffdc-c6d1-4f08-bb48-c7d2058bb571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6d0bf0da-0060-459c-910d-d49823fefcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab20b55a-50f1-4d53-a37f-44348e9c3491" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6d0bf0da-0060-459c-910d-d49823fefcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_45d8fa07-9480-4958-b430-4fef81f559bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab20b55a-50f1-4d53-a37f-44348e9c3491" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_45d8fa07-9480-4958-b430-4fef81f559bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ed9f9227-3dbd-4461-b3b8-abf739424619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bdbb98ff-fe80-4e6c-a756-bb140a7e551b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed9f9227-3dbd-4461-b3b8-abf739424619" xlink:to="loc_us-gaap_AssetsAbstract_bdbb98ff-fe80-4e6c-a756-bb140a7e551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bd01ef66-abe7-4b74-a01d-79dac18e99b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bdbb98ff-fe80-4e6c-a756-bb140a7e551b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bd01ef66-abe7-4b74-a01d-79dac18e99b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_afc4533c-8017-4af0-b0f5-8baa5b3cadf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd01ef66-abe7-4b74-a01d-79dac18e99b4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_afc4533c-8017-4af0-b0f5-8baa5b3cadf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_aff293c5-c9ce-4880-b502-d119fb1d95fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd01ef66-abe7-4b74-a01d-79dac18e99b4" xlink:to="loc_us-gaap_ReceivablesNetCurrent_aff293c5-c9ce-4880-b502-d119fb1d95fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d4475451-99c2-47a4-9335-29ca75f74731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd01ef66-abe7-4b74-a01d-79dac18e99b4" xlink:to="loc_us-gaap_InventoryNet_d4475451-99c2-47a4-9335-29ca75f74731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_98f9451f-64c2-4068-bbc7-08110a0e7bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd01ef66-abe7-4b74-a01d-79dac18e99b4" xlink:to="loc_us-gaap_OtherAssetsCurrent_98f9451f-64c2-4068-bbc7-08110a0e7bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a5f784ca-8af2-4f4c-9f07-a8470b701a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd01ef66-abe7-4b74-a01d-79dac18e99b4" xlink:to="loc_us-gaap_AssetsCurrent_a5f784ca-8af2-4f4c-9f07-a8470b701a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5d5fae8c-1299-4dc4-91d4-fe1e392136b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bdbb98ff-fe80-4e6c-a756-bb140a7e551b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5d5fae8c-1299-4dc4-91d4-fe1e392136b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1db3a62c-13e0-443b-96ef-a0ba709d522b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bdbb98ff-fe80-4e6c-a756-bb140a7e551b" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1db3a62c-13e0-443b-96ef-a0ba709d522b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_aa6d3bc9-160c-436c-ba11-f3b7942f8aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bdbb98ff-fe80-4e6c-a756-bb140a7e551b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_aa6d3bc9-160c-436c-ba11-f3b7942f8aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9e2ee86a-945b-4839-9ba4-1d7ce550c834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bdbb98ff-fe80-4e6c-a756-bb140a7e551b" xlink:to="loc_us-gaap_Assets_9e2ee86a-945b-4839-9ba4-1d7ce550c834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_879b5ffb-c0d5-41a9-9a69-ce4a8979fb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed9f9227-3dbd-4461-b3b8-abf739424619" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_879b5ffb-c0d5-41a9-9a69-ce4a8979fb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_842f893d-9034-46be-9b52-407038f610d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_879b5ffb-c0d5-41a9-9a69-ce4a8979fb57" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_842f893d-9034-46be-9b52-407038f610d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d8397d65-7bb7-45d7-8ae4-4c0b1205e2ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_842f893d-9034-46be-9b52-407038f610d2" xlink:to="loc_us-gaap_AccountsPayableCurrent_d8397d65-7bb7-45d7-8ae4-4c0b1205e2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1eaaec13-7484-42ed-8e13-6bff95e9ba85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_842f893d-9034-46be-9b52-407038f610d2" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1eaaec13-7484-42ed-8e13-6bff95e9ba85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4b40c6cb-4209-41e4-ad3b-b41101a36d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_842f893d-9034-46be-9b52-407038f610d2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4b40c6cb-4209-41e4-ad3b-b41101a36d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d104f73f-81a9-471a-8c05-76fd14bf0a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_842f893d-9034-46be-9b52-407038f610d2" xlink:to="loc_us-gaap_LiabilitiesCurrent_d104f73f-81a9-471a-8c05-76fd14bf0a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_7facdf4e-f459-4b02-b463-681ed445d051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_879b5ffb-c0d5-41a9-9a69-ce4a8979fb57" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_7facdf4e-f459-4b02-b463-681ed445d051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_ae57cd1c-7af5-4a20-991d-faf225bdf823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_879b5ffb-c0d5-41a9-9a69-ce4a8979fb57" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_ae57cd1c-7af5-4a20-991d-faf225bdf823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_879b5ffb-c0d5-41a9-9a69-ce4a8979fb57" xlink:to="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_b9cd14a4-a3e9-4834-9815-52d7da39332c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_b9cd14a4-a3e9-4834-9815-52d7da39332c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4fa69baf-1526-4981-8da2-0fa588407c8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4fa69baf-1526-4981-8da2-0fa588407c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_97076cef-314f-4db6-867f-668706d72e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_97076cef-314f-4db6-867f-668706d72e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7082f849-c88e-44f5-8a87-6a57265a79c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_PreferredStockValue_7082f849-c88e-44f5-8a87-6a57265a79c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_2411a6e4-e8b4-44b0-a228-5bdc976129a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_2411a6e4-e8b4-44b0-a228-5bdc976129a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0e300e31-24ae-474b-8f08-3a711021c819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0e300e31-24ae-474b-8f08-3a711021c819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1c15cd53-e104-467b-9e73-96c654e870d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_CommonStockSharesIssued_1c15cd53-e104-467b-9e73-96c654e870d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8fe13b99-136e-4398-97ab-30230394d343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_CommonStockValue_8fe13b99-136e-4398-97ab-30230394d343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99b672b8-b50d-44fe-9219-924f1d6d1211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99b672b8-b50d-44fe-9219-924f1d6d1211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_27395c7c-9077-4a44-94fb-58cfdcaa7093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_TreasuryStockValue_27395c7c-9077-4a44-94fb-58cfdcaa7093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_0d01d851-8070-4277-aba5-124a454046b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_TreasuryStockShares_0d01d851-8070-4277-aba5-124a454046b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1125c9a3-06ad-4bdc-a5c4-70c4e2d15621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1125c9a3-06ad-4bdc-a5c4-70c4e2d15621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_29723849-8649-455d-a8db-9458541db821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_StockholdersEquity_29723849-8649-455d-a8db-9458541db821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_86d4ebed-6f08-43f2-9501-fa748245ffc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_MinorityInterest_86d4ebed-6f08-43f2-9501-fa748245ffc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e80a0483-a8c1-4259-8067-217c12354046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_86623c44-427d-484a-834e-bd31401e1f1c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e80a0483-a8c1-4259-8067-217c12354046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_067b64aa-a6df-428f-9a83-ae9d38ac74e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_879b5ffb-c0d5-41a9-9a69-ce4a8979fb57" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_067b64aa-a6df-428f-9a83-ae9d38ac74e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1a585bea-fe5c-4cc3-a45a-93297521fce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_eeb8543f-f2dc-4d16-a5f2-afb84a0e0753" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1a585bea-fe5c-4cc3-a45a-93297521fce5" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_eeb8543f-f2dc-4d16-a5f2-afb84a0e0753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30b3dcc5-58ed-42a6-9d0f-98b03990ee91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_eeb8543f-f2dc-4d16-a5f2-afb84a0e0753" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30b3dcc5-58ed-42a6-9d0f-98b03990ee91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30b3dcc5-58ed-42a6-9d0f-98b03990ee91" xlink:to="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c2eded09-47e7-4a93-a3bf-b997ce508acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_CommonStockMember_c2eded09-47e7-4a93-a3bf-b997ce508acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ee6480c7-125f-4f72-9dea-6216c6867876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_RetainedEarningsMember_ee6480c7-125f-4f72-9dea-6216c6867876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0122e8af-8974-4f50-8104-02300bc51873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_TreasuryStockMember_0122e8af-8974-4f50-8104-02300bc51873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cacb349f-5b35-4084-9a4c-2ca223b81fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cacb349f-5b35-4084-9a4c-2ca223b81fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9b0a6c8d-e306-458a-9610-bf99182863d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6db539b-35b9-4a34-9500-3a3da9c51e9c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9b0a6c8d-e306-458a-9610-bf99182863d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_eeb8543f-f2dc-4d16-a5f2-afb84a0e0753" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4a2890d9-120e-4d8f-8c87-016634be004b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_CommonStockSharesIssued_4a2890d9-120e-4d8f-8c87-016634be004b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d98d446a-7c55-43ce-97a7-25b2deee7838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d98d446a-7c55-43ce-97a7-25b2deee7838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_900e49f9-f319-4525-a05e-8a1f6a6d5b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_TreasuryStockShares_900e49f9-f319-4525-a05e-8a1f6a6d5b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c09faf26-e70f-49b7-a738-1ae8047a616f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_TreasuryStockValue_c09faf26-e70f-49b7-a738-1ae8047a616f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49420316-d135-41f0-8722-fab8a58bcc24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_NetIncomeLoss_49420316-d135-41f0-8722-fab8a58bcc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a9277f3d-eb19-41de-ad3b-fe1ea5b772ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_ProfitLoss_a9277f3d-eb19-41de-ad3b-fe1ea5b772ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f1b3df79-3a4f-4644-b07b-7ff7d01d7d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f1b3df79-3a4f-4644-b07b-7ff7d01d7d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_47113154-5478-429c-9f12-d77094e7d1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_47113154-5478-429c-9f12-d77094e7d1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_82ad1874-0812-4cb9-8603-396d3c432abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_82ad1874-0812-4cb9-8603-396d3c432abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_812abb0f-7cc1-4880-89ba-702bc2483ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_812abb0f-7cc1-4880-89ba-702bc2483ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d4cc7a2-76c6-41ef-bad6-e3b02e727584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d4cc7a2-76c6-41ef-bad6-e3b02e727584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_db2ffab7-a698-421c-817a-bb581b16deb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_Dividends_db2ffab7-a698-421c-817a-bb581b16deb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3e512ca8-5a5e-483d-9f54-6f6de6c9ae47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_CommonStockSharesIssued_3e512ca8-5a5e-483d-9f54-6f6de6c9ae47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9bebb091-1cb9-426c-ad14-39c406662729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9bebb091-1cb9-426c-ad14-39c406662729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_d6fb3282-fc6c-4354-b757-caa01ccef99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_TreasuryStockShares_d6fb3282-fc6c-4354-b757-caa01ccef99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b8efadf8-d392-4d49-97ee-2d59719f40aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7e75e9b6-fdb5-4ff0-b050-d3210ae881d9" xlink:to="loc_us-gaap_TreasuryStockValue_b8efadf8-d392-4d49-97ee-2d59719f40aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_cebaa858-8fa3-4b76-8ad3-7e40260c1be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4915b166-277a-4b27-85e1-46e003098348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cebaa858-8fa3-4b76-8ad3-7e40260c1be7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4915b166-277a-4b27-85e1-46e003098348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_961cda26-dadd-4c33-823a-1c68ea7ecc7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4915b166-277a-4b27-85e1-46e003098348" xlink:to="loc_us-gaap_ProfitLoss_961cda26-dadd-4c33-823a-1c68ea7ecc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2c6d3ff-b3b6-4596-b6da-314d65af2e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4915b166-277a-4b27-85e1-46e003098348" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2c6d3ff-b3b6-4596-b6da-314d65af2e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_266199b7-0fb8-44db-8e34-a472ae270daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2c6d3ff-b3b6-4596-b6da-314d65af2e26" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_266199b7-0fb8-44db-8e34-a472ae270daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_e76f65d7-aca8-472a-929b-5ee247f615cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2c6d3ff-b3b6-4596-b6da-314d65af2e26" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_e76f65d7-aca8-472a-929b-5ee247f615cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_80893127-4925-45ab-abb8-9b05d96eafd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2c6d3ff-b3b6-4596-b6da-314d65af2e26" xlink:to="loc_us-gaap_ShareBasedCompensation_80893127-4925-45ab-abb8-9b05d96eafd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_3d6b2cae-9962-476d-8f39-1e10be5fb766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2c6d3ff-b3b6-4596-b6da-314d65af2e26" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_3d6b2cae-9962-476d-8f39-1e10be5fb766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_693bdb3e-9194-4983-ad7a-ff04e3350b70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c2c6d3ff-b3b6-4596-b6da-314d65af2e26" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_693bdb3e-9194-4983-ad7a-ff04e3350b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_65ac0b98-0089-42a8-8543-e916bbaf0830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_693bdb3e-9194-4983-ad7a-ff04e3350b70" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_65ac0b98-0089-42a8-8543-e916bbaf0830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fa50b6f7-a772-4bf7-9535-803cbac739e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_693bdb3e-9194-4983-ad7a-ff04e3350b70" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fa50b6f7-a772-4bf7-9535-803cbac739e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9cb59bab-0dc4-4b9d-be2e-101a56733b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_693bdb3e-9194-4983-ad7a-ff04e3350b70" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9cb59bab-0dc4-4b9d-be2e-101a56733b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_17db8f3c-ddef-45b1-b8b4-f58b0ac7b5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_693bdb3e-9194-4983-ad7a-ff04e3350b70" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_17db8f3c-ddef-45b1-b8b4-f58b0ac7b5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_199c9a0e-7285-4124-b717-cd73c5f36e55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4915b166-277a-4b27-85e1-46e003098348" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_199c9a0e-7285-4124-b717-cd73c5f36e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_493229b7-5740-4fbc-84b7-541a582d3b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cebaa858-8fa3-4b76-8ad3-7e40260c1be7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_493229b7-5740-4fbc-84b7-541a582d3b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_144c2007-9639-41c5-b357-79d08ad271fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_493229b7-5740-4fbc-84b7-541a582d3b59" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_144c2007-9639-41c5-b357-79d08ad271fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_65d71932-789f-4322-bfa7-077d489bc8f4" xlink:href="cah-20200930.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_493229b7-5740-4fbc-84b7-541a582d3b59" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_65d71932-789f-4322-bfa7-077d489bc8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_e60a486a-5391-47a8-8ae3-51134393680c" xlink:href="cah-20200930.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_493229b7-5740-4fbc-84b7-541a582d3b59" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_e60a486a-5391-47a8-8ae3-51134393680c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fabb8e44-81d2-43ac-9bd4-13d3d1873be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cebaa858-8fa3-4b76-8ad3-7e40260c1be7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fabb8e44-81d2-43ac-9bd4-13d3d1873be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_876571af-1311-4dc4-810f-43d195b17049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cebaa858-8fa3-4b76-8ad3-7e40260c1be7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_876571af-1311-4dc4-810f-43d195b17049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_3fcd1101-7f32-405f-8212-108edd8f8c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_876571af-1311-4dc4-810f-43d195b17049" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_3fcd1101-7f32-405f-8212-108edd8f8c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2bd5d584-de38-415b-a2c0-d3030ec214fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_876571af-1311-4dc4-810f-43d195b17049" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2bd5d584-de38-415b-a2c0-d3030ec214fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_2e45aceb-ac50-4334-9d1f-4c2798e3c8f8" xlink:href="cah-20200930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_876571af-1311-4dc4-810f-43d195b17049" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_2e45aceb-ac50-4334-9d1f-4c2798e3c8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_4f703dde-3ab6-4299-8ddb-ad564f629633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_876571af-1311-4dc4-810f-43d195b17049" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_4f703dde-3ab6-4299-8ddb-ad564f629633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c6106f53-c0e0-4280-9eee-ca4dc5e00278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_876571af-1311-4dc4-810f-43d195b17049" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c6106f53-c0e0-4280-9eee-ca4dc5e00278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a5a21e6-43c0-433a-bbe3-2dbf7cc398cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_876571af-1311-4dc4-810f-43d195b17049" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a5a21e6-43c0-433a-bbe3-2dbf7cc398cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_d65cade7-9f9f-4ea4-b5e4-f5f5c42ec04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cebaa858-8fa3-4b76-8ad3-7e40260c1be7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_d65cade7-9f9f-4ea4-b5e4-f5f5c42ec04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_98d42948-07e3-4709-b8a2-fa3fab33e73c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cebaa858-8fa3-4b76-8ad3-7e40260c1be7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_98d42948-07e3-4709-b8a2-fa3fab33e73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ac7399d9-ec74-494c-8a7e-78627c1064f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cebaa858-8fa3-4b76-8ad3-7e40260c1be7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ac7399d9-ec74-494c-8a7e-78627c1064f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d08fbab8-08be-41d6-8d64-760f68595f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cebaa858-8fa3-4b76-8ad3-7e40260c1be7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d08fbab8-08be-41d6-8d64-760f68595f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2d456405-52fc-41c1-b313-e00f5c9c0557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e77c4dfd-7d60-4b36-aec1-81965e06ba87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d456405-52fc-41c1-b313-e00f5c9c0557" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e77c4dfd-7d60-4b36-aec1-81965e06ba87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_545f41fc-7a40-41bc-94d6-d03981b285a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ec3a49fd-4a93-4cff-875e-b2615bca9d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545f41fc-7a40-41bc-94d6-d03981b285a8" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ec3a49fd-4a93-4cff-875e-b2615bca9d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_aa072ae1-d364-4e10-a8d8-148536636026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545f41fc-7a40-41bc-94d6-d03981b285a8" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_aa072ae1-d364-4e10-a8d8-148536636026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_69285126-938e-4b00-abd4-a97b3d9c7b37" xlink:href="cah-20200930.xsd#cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_4db610c1-9d6d-419e-b5be-4b6c9c7c6d74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_20702d8b-54b7-4d6d-8b31-cd775f104dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_4db610c1-9d6d-419e-b5be-4b6c9c7c6d74" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_20702d8b-54b7-4d6d-8b31-cd775f104dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeverance_1"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_198964f4-d3bf-44dc-86b5-7f56ee2ccdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f856bb8b-4025-423f-9c38-963a034c3fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_198964f4-d3bf-44dc-86b5-7f56ee2ccdc8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f856bb8b-4025-423f-9c38-963a034c3fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f48e6118-c894-4d51-8c46-e165d546f651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_198964f4-d3bf-44dc-86b5-7f56ee2ccdc8" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f48e6118-c894-4d51-8c46-e165d546f651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_ccc8c04c-ddc6-4797-af63-781c303c8454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_2002aa3f-68ca-44ba-93d7-fc13b0a7b25f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_ccc8c04c-ddc6-4797-af63-781c303c8454" xlink:to="loc_us-gaap_SeveranceCosts1_2002aa3f-68ca-44ba-93d7-fc13b0a7b25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_387f1c4e-f882-405c-877f-f0c68710415c" xlink:href="cah-20200930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_ccc8c04c-ddc6-4797-af63-781c303c8454" xlink:to="loc_cah_FacilityExitAndOtherCosts_387f1c4e-f882-405c-877f-f0c68710415c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ae920861-4702-410d-9898-9acd2423bd74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_ccc8c04c-ddc6-4797-af63-781c303c8454" xlink:to="loc_us-gaap_RestructuringCharges_ae920861-4702-410d-9898-9acd2423bd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_8eb1a802-630a-4107-89ff-21343fd73de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_268160c8-8388-4c8e-9a2f-b4605727dafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_8eb1a802-630a-4107-89ff-21343fd73de0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_268160c8-8388-4c8e-9a2f-b4605727dafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d1cee2f8-e0f2-4a7c-b2cb-a6e9780e4485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_268160c8-8388-4c8e-9a2f-b4605727dafb" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d1cee2f8-e0f2-4a7c-b2cb-a6e9780e4485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f8590f6f-fa54-46b6-b545-3a248bd9011a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d1cee2f8-e0f2-4a7c-b2cb-a6e9780e4485" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f8590f6f-fa54-46b6-b545-3a248bd9011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_d82d5175-fac5-41ed-a775-200453cd45c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f8590f6f-fa54-46b6-b545-3a248bd9011a" xlink:to="loc_us-gaap_EmployeeSeveranceMember_d82d5175-fac5-41ed-a775-200453cd45c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_bfd1760e-1308-494d-bc56-1feea0ac5f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f8590f6f-fa54-46b6-b545-3a248bd9011a" xlink:to="loc_us-gaap_FacilityClosingMember_bfd1760e-1308-494d-bc56-1feea0ac5f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_26e616c1-c32d-4e0c-807b-eac8ed5d09a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_268160c8-8388-4c8e-9a2f-b4605727dafb" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_26e616c1-c32d-4e0c-807b-eac8ed5d09a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_26e616c1-c32d-4e0c-807b-eac8ed5d09a8" xlink:to="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_81d005fc-177e-4601-a3e4-9326a04857f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:to="loc_us-gaap_RestructuringReserve_81d005fc-177e-4601-a3e4-9326a04857f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_26d6cbfa-40e0-4381-ae07-5e48db2562dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:to="loc_us-gaap_RestructuringCosts_26d6cbfa-40e0-4381-ae07-5e48db2562dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_9865c72c-8b7a-4060-b2bd-5026827445bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:to="loc_us-gaap_PaymentsForRestructuring_9865c72c-8b7a-4060-b2bd-5026827445bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_686c9ad6-2de4-44e5-902b-e27fb189bb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_bfbbc896-5531-4320-938a-ff654123f011" xlink:to="loc_us-gaap_RestructuringReserve_686c9ad6-2de4-44e5-902b-e27fb189bb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#RestructuringandEmployeeSeveranceNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c9db8e32-25ce-4599-b9a9-6e7ae7cc9698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4679542-e419-454d-ae6f-4e75612821a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c9db8e32-25ce-4599-b9a9-6e7ae7cc9698" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4679542-e419-454d-ae6f-4e75612821a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_9adb87b8-a529-43af-85f8-5694569bcd3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4679542-e419-454d-ae6f-4e75612821a4" xlink:to="loc_us-gaap_RestructuringPlanAxis_9adb87b8-a529-43af-85f8-5694569bcd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_4ae07f01-d810-4abe-99d7-3db16f26a818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_9adb87b8-a529-43af-85f8-5694569bcd3d" xlink:to="loc_us-gaap_RestructuringPlanDomain_4ae07f01-d810-4abe-99d7-3db16f26a818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4679542-e419-454d-ae6f-4e75612821a4" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_2ae0d293-07dc-457a-81f5-1e27c938b0af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:to="loc_us-gaap_RestructuringCosts_2ae0d293-07dc-457a-81f5-1e27c938b0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ca4d4413-7ea1-4988-9c0c-e854d0f6f433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:to="loc_us-gaap_SeveranceCosts1_ca4d4413-7ea1-4988-9c0c-e854d0f6f433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_a0656116-e0c2-4eff-9f64-51a15fa1f480" xlink:href="cah-20200930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18103edd-ce15-4ba3-9c55-e926cb7e7f8e" xlink:to="loc_cah_FacilityExitAndOtherCosts_a0656116-e0c2-4eff-9f64-51a15fa1f480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8311f8b9-8b03-4ffe-989a-59a7c4f325d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_be708bbb-49b3-403b-8456-eea5e36efd08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8311f8b9-8b03-4ffe-989a-59a7c4f325d1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_be708bbb-49b3-403b-8456-eea5e36efd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0e95ac55-62b7-41da-8760-13f227506e34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e8712d5f-5610-4aa3-abb0-16f93629c81c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0e95ac55-62b7-41da-8760-13f227506e34" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e8712d5f-5610-4aa3-abb0-16f93629c81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_6fe9c352-db43-4af1-8694-d4401645cd95" xlink:href="cah-20200930.xsd#cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0e95ac55-62b7-41da-8760-13f227506e34" xlink:to="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_6fe9c352-db43-4af1-8694-d4401645cd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_94a8bdf3-2060-40df-b710-4a0115e0fb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_24315df8-dc05-436f-9a83-99286a35e3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_94a8bdf3-2060-40df-b710-4a0115e0fb17" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_24315df8-dc05-436f-9a83-99286a35e3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5797e642-cca9-4026-9846-a86cfc90e190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_24315df8-dc05-436f-9a83-99286a35e3b0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5797e642-cca9-4026-9846-a86cfc90e190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dce01a92-0247-46c1-937d-177ce55baea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5797e642-cca9-4026-9846-a86cfc90e190" xlink:to="loc_us-gaap_SegmentDomain_dce01a92-0247-46c1-937d-177ce55baea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_35a3b9a5-d5fb-4879-9f51-8d5186c42154" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dce01a92-0247-46c1-937d-177ce55baea6" xlink:to="loc_cah_PharmaceuticalMember_35a3b9a5-d5fb-4879-9f51-8d5186c42154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_83d1cbdb-9892-40ab-85d1-363b8940b3be" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dce01a92-0247-46c1-937d-177ce55baea6" xlink:to="loc_cah_MedicalMember_83d1cbdb-9892-40ab-85d1-363b8940b3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ab87180d-df62-4377-a3fc-445e5d420567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_24315df8-dc05-436f-9a83-99286a35e3b0" xlink:to="loc_us-gaap_GoodwillLineItems_ab87180d-df62-4377-a3fc-445e5d420567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers_d0dd524a-2d16-4dd1-b20f-0725a187d8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillTransfers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ab87180d-df62-4377-a3fc-445e5d420567" xlink:to="loc_us-gaap_GoodwillTransfers_d0dd524a-2d16-4dd1-b20f-0725a187d8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b8effbc5-864e-4246-974b-f4a96624c3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ab87180d-df62-4377-a3fc-445e5d420567" xlink:to="loc_us-gaap_GoodwillRollForward_b8effbc5-864e-4246-974b-f4a96624c3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_40631629-bc54-43a3-b815-4d3aee908f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b8effbc5-864e-4246-974b-f4a96624c3fa" xlink:to="loc_us-gaap_Goodwill_40631629-bc54-43a3-b815-4d3aee908f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c041f02e-b14a-4dc6-a117-5a3400ee55ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b8effbc5-864e-4246-974b-f4a96624c3fa" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c041f02e-b14a-4dc6-a117-5a3400ee55ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_955f12be-c21b-4fe3-a99b-b6db11f7b701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b8effbc5-864e-4246-974b-f4a96624c3fa" xlink:to="loc_us-gaap_Goodwill_955f12be-c21b-4fe3-a99b-b6db11f7b701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1fbfca8-ec79-41c4-b77c-fed60248049e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e43627ff-cd35-468e-a41d-51ca735ab08b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1fbfca8-ec79-41c4-b77c-fed60248049e" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e43627ff-cd35-468e-a41d-51ca735ab08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f9a30411-8491-4963-bfec-5556468a4ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e43627ff-cd35-468e-a41d-51ca735ab08b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f9a30411-8491-4963-bfec-5556468a4ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_33bd5e52-9b26-4b40-90cf-f5862ac570ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f9a30411-8491-4963-bfec-5556468a4ded" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_33bd5e52-9b26-4b40-90cf-f5862ac570ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_ce0211a6-bba0-4e34-a210-00febe637b68" xlink:href="cah-20200930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_33bd5e52-9b26-4b40-90cf-f5862ac570ea" xlink:to="loc_cah_IPRDTrademarksandOtherMember_ce0211a6-bba0-4e34-a210-00febe637b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a587dcac-3f5a-44af-bd60-caa594847aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e43627ff-cd35-468e-a41d-51ca735ab08b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a587dcac-3f5a-44af-bd60-caa594847aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e280d406-6d02-49be-a093-48d2479a8a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a587dcac-3f5a-44af-bd60-caa594847aea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e280d406-6d02-49be-a093-48d2479a8a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9fc50bf-37d6-4f27-8bc7-7c61291a883d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1fbfca8-ec79-41c4-b77c-fed60248049e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9fc50bf-37d6-4f27-8bc7-7c61291a883d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_afbe958e-71e1-42ec-948e-b4356eef600c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9fc50bf-37d6-4f27-8bc7-7c61291a883d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_afbe958e-71e1-42ec-948e-b4356eef600c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_afbe958e-71e1-42ec-948e-b4356eef600c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c1224fe3-a06d-429d-a5b7-01ca59954e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c1224fe3-a06d-429d-a5b7-01ca59954e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_3b3e1031-ebad-4627-bf8b-1034734c90bb" xlink:href="cah-20200930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:to="loc_cah_TrademarksAndPatentsMember_3b3e1031-ebad-4627-bf8b-1034734c90bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cecb4dc6-ef99-458d-addd-8ad1d673fd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_230433d5-fb7b-450c-a336-74959660ac61" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cecb4dc6-ef99-458d-addd-8ad1d673fd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f9fc50bf-37d6-4f27-8bc7-7c61291a883d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_957994ab-17a6-4dba-bcd0-35bd76b3ea7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_957994ab-17a6-4dba-bcd0-35bd76b3ea7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f9f4f80f-be56-4144-8b07-ed7f1383bc51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f9f4f80f-be56-4144-8b07-ed7f1383bc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3fc060cd-a892-43da-9d58-ae39a628dc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3fc060cd-a892-43da-9d58-ae39a628dc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cf875c7a-12b2-4c22-a6db-ee159359da7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a3fe13bc-146b-4a09-a1c2-5767a4958993" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cf875c7a-12b2-4c22-a6db-ee159359da7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5b5c2651-6fe3-46b2-9f59-612b6c30a992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1fbfca8-ec79-41c4-b77c-fed60248049e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5b5c2651-6fe3-46b2-9f59-612b6c30a992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c2d6f5c-a5c9-4154-83e3-e6f3f9aca734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1fbfca8-ec79-41c4-b77c-fed60248049e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c2d6f5c-a5c9-4154-83e3-e6f3f9aca734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7cc12b80-773b-4eb2-a4f5-7510d1862ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7aa4321b-2482-4ab5-b6fa-aa0fb2e1a749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7cc12b80-773b-4eb2-a4f5-7510d1862ebb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7aa4321b-2482-4ab5-b6fa-aa0fb2e1a749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_75e0b6bd-7876-4ccc-b9fe-e517bb687317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7cc12b80-773b-4eb2-a4f5-7510d1862ebb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_75e0b6bd-7876-4ccc-b9fe-e517bb687317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3280e367-dcd5-4bba-a116-7dc56366e0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7cc12b80-773b-4eb2-a4f5-7510d1862ebb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3280e367-dcd5-4bba-a116-7dc56366e0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d5e667cd-c250-444b-8810-e03797864bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7cc12b80-773b-4eb2-a4f5-7510d1862ebb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d5e667cd-c250-444b-8810-e03797864bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f916459f-a7cb-4e07-a718-11a24d6893c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7cc12b80-773b-4eb2-a4f5-7510d1862ebb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f916459f-a7cb-4e07-a718-11a24d6893c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_68b865b8-8ef7-4e79-9810-bc5af0638ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7cc12b80-773b-4eb2-a4f5-7510d1862ebb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_68b865b8-8ef7-4e79-9810-bc5af0638ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20200930.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_65b9217d-7bd7-423b-b9d5-f670680d0847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4a57980b-16e6-4922-b667-46c362aab422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65b9217d-7bd7-423b-b9d5-f670680d0847" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4a57980b-16e6-4922-b667-46c362aab422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4732ac49-7c01-427a-9572-9108d000413a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4732ac49-7c01-427a-9572-9108d000413a" xlink:to="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7f2d5028-91a0-41b4-a4c7-571f00a4da31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_CreditFacilityAxis_7f2d5028-91a0-41b4-a4c7-571f00a4da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7f2d5028-91a0-41b4-a4c7-571f00a4da31" xlink:to="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_19c222d0-3b30-452f-8087-64b584106d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:to="loc_us-gaap_CommercialPaperMember_19c222d0-3b30-452f-8087-64b584106d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aa9d242d-d7b6-435a-a485-f7b3828c50c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aa9d242d-d7b6-435a-a485-f7b3828c50c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_888fb45b-33e0-4586-9600-06a7fb511fd6" xlink:href="cah-20200930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dd60491a-3b5d-4b0a-a147-9e8df63ecba6" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_888fb45b-33e0-4586-9600-06a7fb511fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_7bd139d1-d279-4a87-833b-9260d24670a6" xlink:href="cah-20200930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShortTermCreditFacilitiesMember_888fb45b-33e0-4586-9600-06a7fb511fd6" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_7bd139d1-d279-4a87-833b-9260d24670a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c0ce3e27-e329-4874-b9a8-69b729e75492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c0ce3e27-e329-4874-b9a8-69b729e75492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3fda9608-c54d-4efe-a6ce-3398b6390349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c0ce3e27-e329-4874-b9a8-69b729e75492" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3fda9608-c54d-4efe-a6ce-3398b6390349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_93028d5a-aee2-49f6-ad54-7ba151bd1e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_DebtInstrumentAxis_93028d5a-aee2-49f6-ad54-7ba151bd1e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ed0bf1f-ff3e-4817-b49b-6930dab9a04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_93028d5a-aee2-49f6-ad54-7ba151bd1e86" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ed0bf1f-ff3e-4817-b49b-6930dab9a04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_d9fa0520-11b2-41b2-af4c-eecd5708e5e1" xlink:href="cah-20200930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ed0bf1f-ff3e-4817-b49b-6930dab9a04c" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_d9fa0520-11b2-41b2-af4c-eecd5708e5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e2a198d2-f680-48b7-82d4-89d6636e94ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_VariableRateAxis_e2a198d2-f680-48b7-82d4-89d6636e94ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a5fe3cb0-bf76-438a-b0b7-b2855a78b3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_e2a198d2-f680-48b7-82d4-89d6636e94ef" xlink:to="loc_us-gaap_VariableRateDomain_a5fe3cb0-bf76-438a-b0b7-b2855a78b3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bcc4b92c-3862-4556-98f3-579a63465d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bcc4b92c-3862-4556-98f3-579a63465d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_97b28d6a-0cb8-4fab-85b0-1d7d0c750115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bcc4b92c-3862-4556-98f3-579a63465d22" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_97b28d6a-0cb8-4fab-85b0-1d7d0c750115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_294d3d07-5a74-49ff-b3d7-cb0b22d409da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_srt_RangeAxis_294d3d07-5a74-49ff-b3d7-cb0b22d409da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3eba1af6-a73b-49ae-b6c6-f6a8a1cf1944" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_294d3d07-5a74-49ff-b3d7-cb0b22d409da" xlink:to="loc_srt_RangeMember_3eba1af6-a73b-49ae-b6c6-f6a8a1cf1944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0840bad6-2da6-40be-99a2-a62eeaeb7a70" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_453d5a00-6043-4797-945b-acd8d570bb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_453d5a00-6043-4797-945b-acd8d570bb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d7877a3f-f5bb-4dbc-80b7-b3c264af4e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d7877a3f-f5bb-4dbc-80b7-b3c264af4e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_d497be75-b36b-4240-b2eb-79c745f65709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_d497be75-b36b-4240-b2eb-79c745f65709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6dad0dae-201e-4967-b043-d23fa130fe9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_AccountsPayableCurrent_6dad0dae-201e-4967-b043-d23fa130fe9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2b9c371b-f553-49da-9c41-ee34a3e15d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5c6e079-a192-48ac-92fb-0b5ce7f45e02" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2b9c371b-f553-49da-9c41-ee34a3e15d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20200930.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_802f74a7-67f5-4198-a12e-7499c8dfdf69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_33177cdb-9b04-4414-8c02-41ea29bf38e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_802f74a7-67f5-4198-a12e-7499c8dfdf69" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_33177cdb-9b04-4414-8c02-41ea29bf38e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_716e29a3-1d25-4a4f-9446-0eb4a8a301d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_716e29a3-1d25-4a4f-9446-0eb4a8a301d3" xlink:to="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_c2b8a54b-becc-4351-859e-a88f36fb9f44" xlink:href="cah-20200930.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_cah_LawsuitTypeAxis_c2b8a54b-becc-4351-859e-a88f36fb9f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_37ae487c-b23c-4b44-b550-bfbe299dc4ec" xlink:href="cah-20200930.xsd#cah_LitigationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_c2b8a54b-becc-4351-859e-a88f36fb9f44" xlink:to="loc_cah_LitigationTypeDomain_37ae487c-b23c-4b44-b550-bfbe299dc4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_9a47a808-7454-430b-869d-a912800711a2" xlink:href="cah-20200930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LitigationTypeDomain_37ae487c-b23c-4b44-b550-bfbe299dc4ec" xlink:to="loc_cah_ClassActionLawsuitsMember_9a47a808-7454-430b-869d-a912800711a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_4a933e3a-aa18-40f4-872c-6b5b0383496f" xlink:href="cah-20200930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LitigationTypeDomain_37ae487c-b23c-4b44-b550-bfbe299dc4ec" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_4a933e3a-aa18-40f4-872c-6b5b0383496f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_5170e57e-9caf-405d-a60f-f27c2433deea" xlink:href="cah-20200930.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_cah_PlaintiffTypeAxis_5170e57e-9caf-405d-a60f-f27c2433deea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_831530f8-ff6f-4e0e-8cef-685d06986322" xlink:href="cah-20200930.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_5170e57e-9caf-405d-a60f-f27c2433deea" xlink:to="loc_cah_PlaintiffTypeDomain_831530f8-ff6f-4e0e-8cef-685d06986322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_8e905d94-3e23-41c7-952f-6a5c94139fb3" xlink:href="cah-20200930.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_831530f8-ff6f-4e0e-8cef-685d06986322" xlink:to="loc_cah_PrivatePartiesMember_8e905d94-3e23-41c7-952f-6a5c94139fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_c868ddf4-c14b-42f1-9092-89445e118207" xlink:href="cah-20200930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_cah_OpioidLitigationAxis_c868ddf4-c14b-42f1-9092-89445e118207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_45f40c92-d28c-46e0-94e9-e01cc3c6fb3e" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_c868ddf4-c14b-42f1-9092-89445e118207" xlink:to="loc_cah_TaxMattersAgreementDomain_45f40c92-d28c-46e0-94e9-e01cc3c6fb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_a9f2964c-b382-417e-aeb1-e2584b72266a" xlink:href="cah-20200930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_45f40c92-d28c-46e0-94e9-e01cc3c6fb3e" xlink:to="loc_cah_TotalOpioidLitigationMember_a9f2964c-b382-417e-aeb1-e2584b72266a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9ad9b17d-d9ed-4402-a905-292c3f680b12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_StatementGeographicalAxis_9ad9b17d-d9ed-4402-a905-292c3f680b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_aed731d8-77db-4754-a31b-7d0ae91911cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9ad9b17d-d9ed-4402-a905-292c3f680b12" xlink:to="loc_srt_SegmentGeographicalDomain_aed731d8-77db-4754-a31b-7d0ae91911cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_d7270f6f-d3e4-4393-ace0-630811317cb0" xlink:href="cah-20200930.xsd#cah_AlamedaCountyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_aed731d8-77db-4754-a31b-7d0ae91911cf" xlink:to="loc_cah_AlamedaCountyMember_d7270f6f-d3e4-4393-ace0-630811317cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_32ad0b11-268a-4a15-9201-769b3133520f" xlink:href="cah-20200930.xsd#cah_OtherJurisdictionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_aed731d8-77db-4754-a31b-7d0ae91911cf" xlink:to="loc_cah_OtherJurisdictionsMember_32ad0b11-268a-4a15-9201-769b3133520f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_514d4e6d-239d-400b-8e89-d55b2d3877ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_RangeAxis_514d4e6d-239d-400b-8e89-d55b2d3877ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb670a59-970b-4848-a02c-45563c63dd08" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_514d4e6d-239d-400b-8e89-d55b2d3877ae" xlink:to="loc_srt_RangeMember_eb670a59-970b-4848-a02c-45563c63dd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b0bd0672-3e83-4da3-b05c-ef4090df2c59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb670a59-970b-4848-a02c-45563c63dd08" xlink:to="loc_srt_MinimumMember_b0bd0672-3e83-4da3-b05c-ef4090df2c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f794dff0-b812-46be-bc81-7bfc771a0a5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb670a59-970b-4848-a02c-45563c63dd08" xlink:to="loc_srt_MaximumMember_f794dff0-b812-46be-bc81-7bfc771a0a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_547e4362-2ed4-4401-8c61-aeb590151830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_547e4362-2ed4-4401-8c61-aeb590151830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d893136a-adab-4096-bc66-47f607940bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_547e4362-2ed4-4401-8c61-aeb590151830" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d893136a-adab-4096-bc66-47f607940bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_f8983050-f64e-45b2-b4ce-8c8b066e8f85" xlink:href="cah-20200930.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d893136a-adab-4096-bc66-47f607940bb2" xlink:to="loc_cah_OpioidLawsuitsMember_f8983050-f64e-45b2-b4ce-8c8b066e8f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_ce97cfca-1126-47f1-bb3e-ecc9111fbe03" xlink:href="cah-20200930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d893136a-adab-4096-bc66-47f607940bb2" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_ce97cfca-1126-47f1-bb3e-ecc9111fbe03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_8c63d441-a080-4c43-a9e8-17a5611e4f4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_MajorCustomersAxis_8c63d441-a080-4c43-a9e8-17a5611e4f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0d1ce684-c710-4744-9dc4-75a115e96b9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_8c63d441-a080-4c43-a9e8-17a5611e4f4d" xlink:to="loc_srt_NameOfMajorCustomerDomain_0d1ce684-c710-4744-9dc4-75a115e96b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_b92c1511-7605-416e-be3e-5c130e817a0b" xlink:href="cah-20200930.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d1ce684-c710-4744-9dc4-75a115e96b9e" xlink:to="loc_cah_CVSHealthMember_b92c1511-7605-416e-be3e-5c130e817a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cbadfeda-e27d-403f-8655-2f4361e95474" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_LitigationCaseAxis_cbadfeda-e27d-403f-8655-2f4361e95474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_cbadfeda-e27d-403f-8655-2f4361e95474" xlink:to="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_811c1b06-db69-4e97-84ce-48be8fad8a07" xlink:href="cah-20200930.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_OpioidLawsuitsMember_811c1b06-db69-4e97-84ce-48be8fad8a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_b9655a35-f286-44c7-ae2a-85f761a6562b" xlink:href="cah-20200930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_ClassActionLawsuitsMember_b9655a35-f286-44c7-ae2a-85f761a6562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_97fd0268-a0d2-4808-b621-1b3b2d6e23bd" xlink:href="cah-20200930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_97fd0268-a0d2-4808-b621-1b3b2d6e23bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_227ea0ff-718d-4d26-8d27-7f17e6373718" xlink:href="cah-20200930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_227ea0ff-718d-4d26-8d27-7f17e6373718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain_2797a5e9-d67d-4047-b40a-583958fae9b3" xlink:href="cah-20200930.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2ee47c72-e162-47d4-9bcb-5686d3e13a1e" xlink:to="loc_cah_OpioidLawsuitsStateDomain_2797a5e9-d67d-4047-b40a-583958fae9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5749232c-6f41-4fe6-9ba1-5d9ac238895e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5749232c-6f41-4fe6-9ba1-5d9ac238895e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c086857e-bdf9-474d-bb72-52e4c2319313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5749232c-6f41-4fe6-9ba1-5d9ac238895e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c086857e-bdf9-474d-bb72-52e4c2319313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f0bc89bd-d9ec-484c-b257-0068b28e860c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c086857e-bdf9-474d-bb72-52e4c2319313" xlink:to="loc_us-gaap_SubsequentEventMember_f0bc89bd-d9ec-484c-b257-0068b28e860c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e2a0f2fd-209a-4f3e-8095-ccf604394917" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_srt_StatementScenarioAxis_e2a0f2fd-209a-4f3e-8095-ccf604394917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a18d2df6-58ea-4de2-a3e4-89a854b90ef6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_e2a0f2fd-209a-4f3e-8095-ccf604394917" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a18d2df6-58ea-4de2-a3e4-89a854b90ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5a65d556-74fc-4ac9-bb56-c7f183865f3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a18d2df6-58ea-4de2-a3e4-89a854b90ef6" xlink:to="loc_srt_ScenarioForecastMember_5a65d556-74fc-4ac9-bb56-c7f183865f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_06b4e147-ca9b-405c-85d6-d9decee66e71" xlink:to="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_45d48dc6-233e-442b-96dd-01163ce8487d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_45d48dc6-233e-442b-96dd-01163ce8487d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaximumQuarterlyPayment_2afdce85-4716-444a-90f7-43f8c3730e0b" xlink:href="cah-20200930.xsd#cah_MaximumQuarterlyPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_MaximumQuarterlyPayment_2afdce85-4716-444a-90f7-43f8c3730e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_a1deb6ca-2d78-4ecc-9a51-2de89aac4fda" xlink:href="cah-20200930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_LossContingencyLawsuitsNumber_a1deb6ca-2d78-4ecc-9a51-2de89aac4fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_4058e3cc-dcad-416e-9ed2-5c49d4f6fe05" xlink:href="cah-20200930.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_4058e3cc-dcad-416e-9ed2-5c49d4f6fe05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_6a598534-08eb-4cd0-ab6e-336fd763b331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LitigationReserve_6a598534-08eb-4cd0-ab6e-336fd763b331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bc13ea5b-a808-4453-877f-be911337265f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bc13ea5b-a808-4453-877f-be911337265f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_1ecb06ad-1c91-4980-ae1c-2314a4900228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_1ecb06ad-1c91-4980-ae1c-2314a4900228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_32f4e3e4-2e5d-42f7-8ae7-fdceb036d5b0" xlink:href="cah-20200930.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_AggregateAnnualAssessment_32f4e3e4-2e5d-42f7-8ae7-fdceb036d5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_f3e2ec12-0aaa-4aee-9797-1a3c6049f9af" xlink:href="cah-20200930.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_f3e2ec12-0aaa-4aee-9797-1a3c6049f9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b4fd3f6c-74e8-41c1-9c89-86572c0bbdad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b4fd3f6c-74e8-41c1-9c89-86572c0bbdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_cca042a0-cdf5-4c96-b983-b548ca0f7d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_LitigationSettlementExpense_cca042a0-cdf5-4c96-b983-b548ca0f7d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15e23e86-974e-4b30-91bb-3c463d0d43a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7d51e6cd-31ff-4f13-86ff-179243fd5201" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15e23e86-974e-4b30-91bb-3c463d0d43a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d49effab-470f-452a-a003-a38a2c8c1518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d49effab-470f-452a-a003-a38a2c8c1518" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_7be36e96-9236-4ef3-8ca6-64364d79014a" xlink:href="cah-20200930.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_cah_TaxMatterAxis_7be36e96-9236-4ef3-8ca6-64364d79014a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_1604d0e0-e79a-4b13-96ba-26720e207454" xlink:href="cah-20200930.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_7be36e96-9236-4ef3-8ca6-64364d79014a" xlink:to="loc_cah_TaxMatterDomain_1604d0e0-e79a-4b13-96ba-26720e207454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_4b6f4a82-784b-4c34-a939-978e9d48c667" xlink:href="cah-20200930.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_1604d0e0-e79a-4b13-96ba-26720e207454" xlink:to="loc_cah_CareFusionMember_4b6f4a82-784b-4c34-a939-978e9d48c667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_4bbdbf60-add3-4e06-8df3-5f415cafad08" xlink:href="cah-20200930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_1604d0e0-e79a-4b13-96ba-26720e207454" xlink:to="loc_cah_PatientRecoveryBusinessMember_4bbdbf60-add3-4e06-8df3-5f415cafad08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_728bb327-4843-4e25-bcc0-bc33bc1abcc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_728bb327-4843-4e25-bcc0-bc33bc1abcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_968dc8a0-394a-4164-a557-ca892377d81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_728bb327-4843-4e25-bcc0-bc33bc1abcc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_968dc8a0-394a-4164-a557-ca892377d81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_c65ecf8b-6a6f-4ec2-8112-085c6da60425" xlink:href="cah-20200930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_968dc8a0-394a-4164-a557-ca892377d81d" xlink:to="loc_cah_PatientRecoveryBusinessMember_c65ecf8b-6a6f-4ec2-8112-085c6da60425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_cf530fe4-bbd2-4b26-9f54-5359c8019a54" xlink:href="cah-20200930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_cah_OpioidLitigationAxis_cf530fe4-bbd2-4b26-9f54-5359c8019a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_cf530fe4-bbd2-4b26-9f54-5359c8019a54" xlink:to="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_4b75aa63-98df-465f-b73d-ebc44890f392" xlink:href="cah-20200930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:to="loc_cah_TotalOpioidLitigationMember_4b75aa63-98df-465f-b73d-ebc44890f392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_0766493e-96cf-40c5-8f55-01d7a7740104" xlink:href="cah-20200930.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:to="loc_cah_CareFusionMember_0766493e-96cf-40c5-8f55-01d7a7740104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_7ca4cee8-4d5c-459a-a8ff-e7de7d343806" xlink:href="cah-20200930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_7280887d-b678-426b-94cc-0ec60efb877c" xlink:to="loc_cah_PatientRecoveryBusinessMember_7ca4cee8-4d5c-459a-a8ff-e7de7d343806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2a18c58a-4628-4562-bcd8-f3dceae99cb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2a18c58a-4628-4562-bcd8-f3dceae99cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d159daa5-8834-45f5-be98-ca2249cbf218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2a18c58a-4628-4562-bcd8-f3dceae99cb9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d159daa5-8834-45f5-be98-ca2249cbf218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_82aea9ff-58fe-4843-956e-27a61199a85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_82aea9ff-58fe-4843-956e-27a61199a85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_53ce29d2-4d34-4930-8a53-88a2abf3c1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82aea9ff-58fe-4843-956e-27a61199a85a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_53ce29d2-4d34-4930-8a53-88a2abf3c1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_5271190e-b62a-4cc7-8a68-286b30382295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_53ce29d2-4d34-4930-8a53-88a2abf3c1f4" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_5271190e-b62a-4cc7-8a68-286b30382295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1d77e75-2359-40ae-93b7-97a4e81b0f29" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_srt_RangeAxis_b1d77e75-2359-40ae-93b7-97a4e81b0f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a52e4c4d-1da2-4fa9-be37-ad4f1e8f4260" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1d77e75-2359-40ae-93b7-97a4e81b0f29" xlink:to="loc_srt_RangeMember_a52e4c4d-1da2-4fa9-be37-ad4f1e8f4260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f9d8bebf-06e1-4788-9ae7-d9462a0f593a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a52e4c4d-1da2-4fa9-be37-ad4f1e8f4260" xlink:to="loc_srt_MinimumMember_f9d8bebf-06e1-4788-9ae7-d9462a0f593a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3d6585ae-844f-46d7-80b1-cbabf217d3e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a52e4c4d-1da2-4fa9-be37-ad4f1e8f4260" xlink:to="loc_srt_MaximumMember_3d6585ae-844f-46d7-80b1-cbabf217d3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3f3f7cfa-5e7b-49d8-948b-c70c90bb987f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_srt_StatementScenarioAxis_3f3f7cfa-5e7b-49d8-948b-c70c90bb987f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f3e9528b-3ece-49f1-9586-dbd1ab52d877" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3f3f7cfa-5e7b-49d8-948b-c70c90bb987f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f3e9528b-3ece-49f1-9586-dbd1ab52d877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b900f501-ef78-4744-a11f-75ac8a863c53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f3e9528b-3ece-49f1-9586-dbd1ab52d877" xlink:to="loc_srt_ScenarioForecastMember_b900f501-ef78-4744-a11f-75ac8a863c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f08de9ee-940c-446b-923d-5d1746753863" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_aeca067f-edc1-4b8b-a557-baa5e5334906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_LitigationReserve_aeca067f-edc1-4b8b-a557-baa5e5334906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0e19fdfe-22ac-450f-b14c-aa29cee421c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0e19fdfe-22ac-450f-b14c-aa29cee421c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_79247814-7734-4a20-a322-3b62c2ef3d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_79247814-7734-4a20-a322-3b62c2ef3d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f2a18f4a-f5eb-4538-b1ae-46e0e74500f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f2a18f4a-f5eb-4538-b1ae-46e0e74500f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1f4fbe4e-bf80-41cd-b604-da93fb47f4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1f4fbe4e-bf80-41cd-b604-da93fb47f4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9b6695e2-c814-4d0b-be03-e4ef9d0c935b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9b6695e2-c814-4d0b-be03-e4ef9d0c935b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e0513b24-020a-40fd-9a60-85df0182368e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e0513b24-020a-40fd-9a60-85df0182368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_51002541-a89c-4f25-aaba-66f2b50230eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_OpenTaxYear_51002541-a89c-4f25-aaba-66f2b50230eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_e7822157-95e4-49cb-a580-47dc2ba42499" xlink:href="cah-20200930.xsd#cah_IndemnificationReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_cah_IndemnificationReceivable_e7822157-95e4-49cb-a580-47dc2ba42499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_59bc0b2a-35ce-4ebc-957d-c4dcf59ae477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_59bc0b2a-35ce-4ebc-957d-c4dcf59ae477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_76fd0e99-05b7-4006-95e9-d5461ea63aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0cceb77d-a92a-4815-a569-a9f66eb6438e" xlink:to="loc_us-gaap_LitigationSettlementExpense_76fd0e99-05b7-4006-95e9-d5461ea63aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20200930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8a6293c1-bb95-456a-8f49-41524bddd323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a48da027-6479-4ea8-9fc3-fb7edc11e1c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a6293c1-bb95-456a-8f49-41524bddd323" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a48da027-6479-4ea8-9fc3-fb7edc11e1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8a37ce26-fc09-44b5-a65a-2c81c44e79ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_4767ecec-3c86-4c10-845b-183d393c9a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8a37ce26-fc09-44b5-a65a-2c81c44e79ab" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_4767ecec-3c86-4c10-845b-183d393c9a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7e386ae3-2d28-42c8-bc9d-0af199d0e31d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7581c9d7-a594-4ba4-aa4c-17223dcfc7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7e386ae3-2d28-42c8-bc9d-0af199d0e31d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7581c9d7-a594-4ba4-aa4c-17223dcfc7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fbfb8ff4-8f64-4ea2-b21c-f4c4a0c26edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a99f2f-973d-4cbc-af8c-9ff1c06bd86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fbfb8ff4-8f64-4ea2-b21c-f4c4a0c26edd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a99f2f-973d-4cbc-af8c-9ff1c06bd86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1a653ca7-91ec-4889-b7c3-23880f430e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a99f2f-973d-4cbc-af8c-9ff1c06bd86d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1a653ca7-91ec-4889-b7c3-23880f430e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7754dfd7-62e4-4701-bd89-cf8c3753db00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1a653ca7-91ec-4889-b7c3-23880f430e96" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7754dfd7-62e4-4701-bd89-cf8c3753db00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f0b71516-4cd6-4b45-b9e1-a5212f5711ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7754dfd7-62e4-4701-bd89-cf8c3753db00" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f0b71516-4cd6-4b45-b9e1-a5212f5711ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bcecbe72-3571-4c76-9205-a070fc5aafb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a99f2f-973d-4cbc-af8c-9ff1c06bd86d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bcecbe72-3571-4c76-9205-a070fc5aafb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bcecbe72-3571-4c76-9205-a070fc5aafb3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9f5e2c48-4f89-423a-9847-ed4eca357e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9f5e2c48-4f89-423a-9847-ed4eca357e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_41a6558a-a57e-4c08-a960-e0c1b15daa9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_41a6558a-a57e-4c08-a960-e0c1b15daa9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74159aee-50cd-4670-be0d-bf9296845c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74159aee-50cd-4670-be0d-bf9296845c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_35abb15a-d787-4fcf-86ba-bdd7ea7c1c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e8aff7b-62b5-4631-b354-8ab1cda16eaa" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_35abb15a-d787-4fcf-86ba-bdd7ea7c1c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e26b74cf-6d57-4cc7-8cd1-2d22dc225fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a99f2f-973d-4cbc-af8c-9ff1c06bd86d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e26b74cf-6d57-4cc7-8cd1-2d22dc225fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8543eaf0-754c-4478-b6a7-059edd890c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e26b74cf-6d57-4cc7-8cd1-2d22dc225fb9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8543eaf0-754c-4478-b6a7-059edd890c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_fbdc2912-0bce-4355-9a15-ee320d480c77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8543eaf0-754c-4478-b6a7-059edd890c2a" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_fbdc2912-0bce-4355-9a15-ee320d480c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5c09dd2f-465c-4ed4-9f18-cdfdfe451e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8543eaf0-754c-4478-b6a7-059edd890c2a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5c09dd2f-465c-4ed4-9f18-cdfdfe451e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2a66875b-354d-48f3-841e-8dc4d4a647f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e26b74cf-6d57-4cc7-8cd1-2d22dc225fb9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2a66875b-354d-48f3-841e-8dc4d4a647f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_12024bb0-ce38-471e-9433-4ce9bc3976af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2a66875b-354d-48f3-841e-8dc4d4a647f4" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_12024bb0-ce38-471e-9433-4ce9bc3976af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2f7ecbe9-2c36-4305-b04e-2b78b92294f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_c65e5055-ead9-4050-90a8-f5e0a08f056b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2f7ecbe9-2c36-4305-b04e-2b78b92294f7" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_c65e5055-ead9-4050-90a8-f5e0a08f056b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a4a34cdb-42a2-4cf7-9126-92cd60899d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_2c607bcc-5926-4f57-b928-dc280b89c861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a4a34cdb-42a2-4cf7-9126-92cd60899d85" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_2c607bcc-5926-4f57-b928-dc280b89c861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9327b273-5ef7-4715-bccf-8d25f8edc1bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9327b273-5ef7-4715-bccf-8d25f8edc1bc" xlink:to="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4d2d1c02-8cd5-4351-b4d1-c0952b875b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4d2d1c02-8cd5-4351-b4d1-c0952b875b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b37337e1-f434-4d80-9982-db0987ba9469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4d2d1c02-8cd5-4351-b4d1-c0952b875b5b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b37337e1-f434-4d80-9982-db0987ba9469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0469e4f8-cf29-494f-978a-38040fe31f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:to="loc_us-gaap_HedgingDesignationAxis_0469e4f8-cf29-494f-978a-38040fe31f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b0a35a77-cb91-4867-8136-8c4025238ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_0469e4f8-cf29-494f-978a-38040fe31f45" xlink:to="loc_us-gaap_HedgingDesignationDomain_b0a35a77-cb91-4867-8136-8c4025238ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a48ccf4-55f1-4025-abf4-bf2090d0fc02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a48ccf4-55f1-4025-abf4-bf2090d0fc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4a3504ca-cf78-4ad0-99cb-03abfa51f163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a48ccf4-55f1-4025-abf4-bf2090d0fc02" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4a3504ca-cf78-4ad0-99cb-03abfa51f163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ce44af7e-4c91-40e1-8fb6-14ee4383a461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ce44af7e-4c91-40e1-8fb6-14ee4383a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ce44af7e-4c91-40e1-8fb6-14ee4383a461" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_bf1dc737-3be8-4ef6-9ee1-232c85ab2da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:to="loc_us-gaap_CashFlowHedgingMember_bf1dc737-3be8-4ef6-9ee1-232c85ab2da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_408700cb-ef0c-4c42-8bf4-6216162a10ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:to="loc_us-gaap_CurrencySwapMember_408700cb-ef0c-4c42-8bf4-6216162a10ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a1d26d3f-230b-4072-b379-d106533e654b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9071a2d1-ded5-4eb3-aaa1-3e7dd1f16ddb" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a1d26d3f-230b-4072-b379-d106533e654b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_12f45827-e501-43f1-b72e-c0487c0bee56" xlink:to="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_65d55ffb-fdf6-4839-bf76-0ac21ba452e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_65d55ffb-fdf6-4839-bf76-0ac21ba452e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_6bce23d5-2ff7-4068-82ee-1ae65a3c7e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_6bce23d5-2ff7-4068-82ee-1ae65a3c7e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_a1dc73a2-7b9f-43e8-8cb4-6a2b171fcef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f2099f66-2c99-40cd-973e-a1ea8a5764dc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_a1dc73a2-7b9f-43e8-8cb4-6a2b171fcef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c90f682-4d24-471f-8dd0-4cc2f6b6b22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f3e026ab-8f56-409b-8058-c7addcd755e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c90f682-4d24-471f-8dd0-4cc2f6b6b22c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f3e026ab-8f56-409b-8058-c7addcd755e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6a6fefd-1586-4d93-9d65-ac6e61db2cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f3e026ab-8f56-409b-8058-c7addcd755e0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6a6fefd-1586-4d93-9d65-ac6e61db2cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ccba66e-2158-429c-a29c-0a1f30ffd4cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6a6fefd-1586-4d93-9d65-ac6e61db2cb1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ccba66e-2158-429c-a29c-0a1f30ffd4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1ba1b1ad-bb3a-43ab-a24c-1bf754fe4049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ccba66e-2158-429c-a29c-0a1f30ffd4cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1ba1b1ad-bb3a-43ab-a24c-1bf754fe4049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e4959aab-9ce3-4455-82a4-1f714817c77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f3e026ab-8f56-409b-8058-c7addcd755e0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e4959aab-9ce3-4455-82a4-1f714817c77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_49ab40e2-51af-4dd6-a353-019471a415cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e4959aab-9ce3-4455-82a4-1f714817c77b" xlink:to="loc_us-gaap_DebtInstrumentFairValue_49ab40e2-51af-4dd6-a353-019471a415cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_2d866f2c-d4c4-4e8d-a6bf-2a7d700ec874" xlink:href="cah-20200930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e4959aab-9ce3-4455-82a4-1f714817c77b" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_2d866f2c-d4c4-4e8d-a6bf-2a7d700ec874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_29ea617e-aa02-4867-9b80-108caa1bbdfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_324ce02c-1dd0-4724-b38b-7990914aa7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_29ea617e-aa02-4867-9b80-108caa1bbdfa" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_324ce02c-1dd0-4724-b38b-7990914aa7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ade0422d-65dc-4830-9f69-c8f16eaf9f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b68e4714-7e92-4fd2-ab7b-5f509a501b70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ade0422d-65dc-4830-9f69-c8f16eaf9f17" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b68e4714-7e92-4fd2-ab7b-5f509a501b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5456e767-aa15-4d89-8104-b99bebd4ee13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5456e767-aa15-4d89-8104-b99bebd4ee13" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_785ff706-542a-4285-9ca0-5e3090ce44eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_785ff706-542a-4285-9ca0-5e3090ce44eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_40e048aa-4cbd-4230-9bb1-72c609e352f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_785ff706-542a-4285-9ca0-5e3090ce44eb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_40e048aa-4cbd-4230-9bb1-72c609e352f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f0ba198c-9765-4a44-b464-445581c8c48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f0ba198c-9765-4a44-b464-445581c8c48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8bf36cf7-bac0-42bf-b405-52893fb71975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f0ba198c-9765-4a44-b464-445581c8c48c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8bf36cf7-bac0-42bf-b405-52893fb71975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ecff1e69-424b-494f-98dd-218d3c9e9b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8bf36cf7-bac0-42bf-b405-52893fb71975" xlink:to="loc_us-gaap_SubsequentEventMember_ecff1e69-424b-494f-98dd-218d3c9e9b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04a51d38-a585-4c17-bf1a-e0e7338030ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04a51d38-a585-4c17-bf1a-e0e7338030ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f795e3c-071d-4ad2-af41-b996a9879229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04a51d38-a585-4c17-bf1a-e0e7338030ef" xlink:to="loc_us-gaap_EquityComponentDomain_8f795e3c-071d-4ad2-af41-b996a9879229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_41ec151d-d010-4091-8c4a-fbfd57310958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f795e3c-071d-4ad2-af41-b996a9879229" xlink:to="loc_us-gaap_TreasuryStockMember_41ec151d-d010-4091-8c4a-fbfd57310958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_141b178d-16e3-42ca-9a70-344cda4caa0d" xlink:to="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d5d8d158-d025-4751-92ca-fc477e96f86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d5d8d158-d025-4751-92ca-fc477e96f86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ab0538aa-a4a1-4754-8dbd-0e9d64c6e666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ab0538aa-a4a1-4754-8dbd-0e9d64c6e666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c43106e6-912b-43e8-a260-ba337ba6f8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c43106e6-912b-43e8-a260-ba337ba6f8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_055dfaea-3d93-42c2-b0d7-45ab66765858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_055dfaea-3d93-42c2-b0d7-45ab66765858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TreasuryStockAcquiredShares_4393f334-d181-421b-a327-812455a8b84f" xlink:href="cah-20200930.xsd#cah_TreasuryStockAcquiredShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_cah_TreasuryStockAcquiredShares_4393f334-d181-421b-a327-812455a8b84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FinalSharesReceivedfromASRProgram_e05b4a84-283b-40d7-b0bc-101ddee9f165" xlink:href="cah-20200930.xsd#cah_FinalSharesReceivedfromASRProgram"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_09fa3bea-e851-4880-8082-9764f6f3abaf" xlink:to="loc_cah_FinalSharesReceivedfromASRProgram_e05b4a84-283b-40d7-b0bc-101ddee9f165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cc5c9e98-0e61-400a-9e73-0fb27ae7a985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7e4779b8-3b5d-475d-8381-44b1b090e4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cc5c9e98-0e61-400a-9e73-0fb27ae7a985" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7e4779b8-3b5d-475d-8381-44b1b090e4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68ec9b2a-dfaf-40c2-8f87-0f1f4a21783c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7e4779b8-3b5d-475d-8381-44b1b090e4b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68ec9b2a-dfaf-40c2-8f87-0f1f4a21783c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68ec9b2a-dfaf-40c2-8f87-0f1f4a21783c" xlink:to="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_88e934b4-6ca5-4404-9aaa-f1480c9cbded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_88e934b4-6ca5-4404-9aaa-f1480c9cbded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_dc2edeb0-9bf0-48ab-9a63-92ee0a61f312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_dc2edeb0-9bf0-48ab-9a63-92ee0a61f312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c81839cc-96ce-4894-ac0a-9adb7a55bdea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c81839cc-96ce-4894-ac0a-9adb7a55bdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4345c39c-6f7b-4434-92c6-7043afbe58c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec3f4dd5-e632-4086-95d2-392406876b0f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4345c39c-6f7b-4434-92c6-7043afbe58c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_31c8aaa6-8a55-417b-8880-81c409e6008e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7e4779b8-3b5d-475d-8381-44b1b090e4b2" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_31c8aaa6-8a55-417b-8880-81c409e6008e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_31c8aaa6-8a55-417b-8880-81c409e6008e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ebdf2ddc-21c1-423e-8e22-1748b8f75990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ebdf2ddc-21c1-423e-8e22-1748b8f75990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_c8c348ae-e602-474a-8eeb-cfc9984ec4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_c8c348ae-e602-474a-8eeb-cfc9984ec4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_448266a6-6c7a-43f7-b9cd-1cdfb94cb50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_448266a6-6c7a-43f7-b9cd-1cdfb94cb50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb73281e-c853-4436-8490-35de3ac10aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb73281e-c853-4436-8490-35de3ac10aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ed4365a-0713-4af5-a960-7e196ce62248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_073c827b-7a0b-4fa5-8bb3-3335f01fa26b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ed4365a-0713-4af5-a960-7e196ce62248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b5976054-2bb4-4784-a0c4-11330dc6008d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7a4fc5d9-5058-4eb4-b3e5-14c36e2de55f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b5976054-2bb4-4784-a0c4-11330dc6008d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7a4fc5d9-5058-4eb4-b3e5-14c36e2de55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_51fd9dbd-8da6-4f83-9e57-6878ec16f3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e5a039b5-14e9-4424-b133-6d20ee2c8955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51fd9dbd-8da6-4f83-9e57-6878ec16f3df" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e5a039b5-14e9-4424-b133-6d20ee2c8955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3ee9dcb2-2fe7-4e59-9863-617a1a75f532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e8dfc76-63c8-4e60-88db-2bb4211989e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3ee9dcb2-2fe7-4e59-9863-617a1a75f532" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e8dfc76-63c8-4e60-88db-2bb4211989e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_f95908e4-8a87-4dac-b236-b3e410518150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3ee9dcb2-2fe7-4e59-9863-617a1a75f532" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_f95908e4-8a87-4dac-b236-b3e410518150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_df8f399f-ff76-4ffd-be3a-87c017f5c2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3ee9dcb2-2fe7-4e59-9863-617a1a75f532" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_df8f399f-ff76-4ffd-be3a-87c017f5c2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2f65a05a-5e8a-4fe7-9934-e3413a94f7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3ee9dcb2-2fe7-4e59-9863-617a1a75f532" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2f65a05a-5e8a-4fe7-9934-e3413a94f7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_41fd13f5-0afc-4ca7-9545-1f3e252ce327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares_92fb7a08-e66f-47e8-86e1-81790a7dd7a3" xlink:href="cah-20200930.xsd#cah_Numberofsharesexcludedfromcalculationofdilutedshares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41fd13f5-0afc-4ca7-9545-1f3e252ce327" xlink:to="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares_92fb7a08-e66f-47e8-86e1-81790a7dd7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_97d842c4-c38e-4022-a91b-0d7c5a23c911" xlink:href="cah-20200930.xsd#cah_Sharesthatwouldbeantidilutiveasaresultofnetloss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41fd13f5-0afc-4ca7-9545-1f3e252ce327" xlink:to="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_97d842c4-c38e-4022-a91b-0d7c5a23c911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_abdee298-5e93-4364-9a79-33d147373d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_0a29b7a5-7e77-40ae-a3ba-376b1c39e9df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_abdee298-5e93-4364-9a79-33d147373d81" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_0a29b7a5-7e77-40ae-a3ba-376b1c39e9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d69a0908-0065-4cac-89f1-37b4ae822614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d69a0908-0065-4cac-89f1-37b4ae822614" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3366bd03-de07-4b1a-8757-3b4d834a7b02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:to="loc_srt_ConsolidationItemsAxis_3366bd03-de07-4b1a-8757-3b4d834a7b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d2ce5999-4dab-48aa-88d1-ba9d8ad40070" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_3366bd03-de07-4b1a-8757-3b4d834a7b02" xlink:to="loc_srt_ConsolidationItemsDomain_d2ce5999-4dab-48aa-88d1-ba9d8ad40070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f4f0f01e-26d4-4865-ab34-cef0f2cabf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f4f0f01e-26d4-4865-ab34-cef0f2cabf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dc6a06e9-8253-467f-8a1f-68d60324ad0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f4f0f01e-26d4-4865-ab34-cef0f2cabf15" xlink:to="loc_us-gaap_SegmentDomain_dc6a06e9-8253-467f-8a1f-68d60324ad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_284d4ff2-0a95-42c7-8cf4-b734be307c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:to="loc_us-gaap_SubsegmentsAxis_284d4ff2-0a95-42c7-8cf4-b734be307c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_882fa42c-a960-4894-8617-6feb13f07e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_284d4ff2-0a95-42c7-8cf4-b734be307c69" xlink:to="loc_us-gaap_SubsegmentsDomain_882fa42c-a960-4894-8617-6feb13f07e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5eb6cc13-bb8b-46f7-86b6-9c494dbecc00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5eb6cc13-bb8b-46f7-86b6-9c494dbecc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_b1ce4ed7-3799-4322-874b-7f5c19a51f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5eb6cc13-bb8b-46f7-86b6-9c494dbecc00" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_b1ce4ed7-3799-4322-874b-7f5c19a51f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_1ad4544e-5179-4c44-9159-3df89dd914e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_611c6ec9-fb33-4ef0-a0c2-1f131939332f" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_1ad4544e-5179-4c44-9159-3df89dd914e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_56266a74-e890-486e-b13e-b79d77639b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_1ad4544e-5179-4c44-9159-3df89dd914e7" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_56266a74-e890-486e-b13e-b79d77639b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_125b77c9-1fe6-4e39-b099-feda3e441177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d69a0908-0065-4cac-89f1-37b4ae822614" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_125b77c9-1fe6-4e39-b099-feda3e441177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_5188b24d-1cb7-4007-9580-3e837aa362c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d69a0908-0065-4cac-89f1-37b4ae822614" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_5188b24d-1cb7-4007-9580-3e837aa362c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_6c271b64-d6ae-4cff-8a56-07d28531a5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d69a0908-0065-4cac-89f1-37b4ae822614" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_6c271b64-d6ae-4cff-8a56-07d28531a5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_465b267f-6248-46df-96e6-12e3afdb38cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_008f5866-f554-402e-bccc-4f5463713348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_465b267f-6248-46df-96e6-12e3afdb38cf" xlink:to="loc_us-gaap_StatementTable_008f5866-f554-402e-bccc-4f5463713348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_66ded5f7-9a85-45f7-bcbe-a28658641bc3" xlink:href="cah-20200930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_008f5866-f554-402e-bccc-4f5463713348" xlink:to="loc_cah_OpioidLitigationAxis_66ded5f7-9a85-45f7-bcbe-a28658641bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_c1a26f10-6e11-4ce9-ba9d-62567dcfc554" xlink:href="cah-20200930.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_66ded5f7-9a85-45f7-bcbe-a28658641bc3" xlink:to="loc_cah_TaxMattersAgreementDomain_c1a26f10-6e11-4ce9-ba9d-62567dcfc554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_c6ce09c2-4883-47de-ae9b-b8128817a94e" xlink:href="cah-20200930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_c1a26f10-6e11-4ce9-ba9d-62567dcfc554" xlink:to="loc_cah_TotalOpioidLitigationMember_c6ce09c2-4883-47de-ae9b-b8128817a94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ff243cb6-8ea3-44da-be7f-142e989090bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_008f5866-f554-402e-bccc-4f5463713348" xlink:to="loc_us-gaap_StatementLineItems_ff243cb6-8ea3-44da-be7f-142e989090bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_6079173d-691f-4841-980f-71c8bcfd670b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ff243cb6-8ea3-44da-be7f-142e989090bc" xlink:to="loc_us-gaap_LitigationReserve_6079173d-691f-4841-980f-71c8bcfd670b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_9e590120-0620-4bcd-89aa-da155ca3cc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ff243cb6-8ea3-44da-be7f-142e989090bc" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_9e590120-0620-4bcd-89aa-da155ca3cc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_520e48ef-f8c4-4454-95d5-86495de5cc7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_465b267f-6248-46df-96e6-12e3afdb38cf" xlink:to="loc_us-gaap_NumberOfOperatingSegments_520e48ef-f8c4-4454-95d5-86495de5cc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_a983d391-8fd6-4e9e-91af-38f390f7f299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_465b267f-6248-46df-96e6-12e3afdb38cf" xlink:to="loc_us-gaap_NumberOfReportableSegments_a983d391-8fd6-4e9e-91af-38f390f7f299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_1fc6ebb5-f72a-42a0-9675-c5d7e6959d8f" xlink:href="cah-20200930.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_465b267f-6248-46df-96e6-12e3afdb38cf" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_1fc6ebb5-f72a-42a0-9675-c5d7e6959d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4ccde3c2-bf3c-41b9-882a-a2d5e456e011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4ccde3c2-bf3c-41b9-882a-a2d5e456e011" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_0b5fb9c3-a899-47a7-8677-66a4e3f601d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:to="loc_us-gaap_SubsegmentsAxis_0b5fb9c3-a899-47a7-8677-66a4e3f601d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_0b5fb9c3-a899-47a7-8677-66a4e3f601d3" xlink:to="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_9500859c-0592-40d6-b286-c0ce154ef010" xlink:href="cah-20200930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_9500859c-0592-40d6-b286-c0ce154ef010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_3e7d14ae-a092-4e81-8d8e-360c56a9f7cb" xlink:href="cah-20200930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_3e7d14ae-a092-4e81-8d8e-360c56a9f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_433f77dd-18d1-4f07-bf74-2f24390bcfea" xlink:href="cah-20200930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:to="loc_cah_MedicaldistributionandproductsMember_433f77dd-18d1-4f07-bf74-2f24390bcfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeSolutionsMember_8f61bd26-39aa-45d7-857d-2d74c6031909" xlink:href="cah-20200930.xsd#cah_CardinalHealthAtHomeSolutionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b4d6a45f-317d-4fcc-9401-4a2035cf994b" xlink:to="loc_cah_CardinalHealthAtHomeSolutionsMember_8f61bd26-39aa-45d7-857d-2d74c6031909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9e0cd095-72eb-46a2-8bc3-cd3786bf62cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:to="loc_srt_ConsolidationItemsAxis_9e0cd095-72eb-46a2-8bc3-cd3786bf62cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4657a3d0-1422-4306-9458-583a9c6efbff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9e0cd095-72eb-46a2-8bc3-cd3786bf62cd" xlink:to="loc_srt_ConsolidationItemsDomain_4657a3d0-1422-4306-9458-583a9c6efbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_734d8de6-4dad-4328-a5c9-37bee35e509a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4657a3d0-1422-4306-9458-583a9c6efbff" xlink:to="loc_us-gaap_OperatingSegmentsMember_734d8de6-4dad-4328-a5c9-37bee35e509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_5c732202-8de3-4c76-a242-77e828f8b3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4657a3d0-1422-4306-9458-583a9c6efbff" xlink:to="loc_us-gaap_CorporateNonSegmentMember_5c732202-8de3-4c76-a242-77e828f8b3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_877b3846-ab73-4843-b690-75d37b3194dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_877b3846-ab73-4843-b690-75d37b3194dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cfde29b3-4833-408d-84a0-345aee8f9dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_877b3846-ab73-4843-b690-75d37b3194dd" xlink:to="loc_us-gaap_SegmentDomain_cfde29b3-4833-408d-84a0-345aee8f9dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_cb6c2461-e6e0-430e-93f9-a476591d60f7" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cfde29b3-4833-408d-84a0-345aee8f9dcb" xlink:to="loc_cah_PharmaceuticalMember_cb6c2461-e6e0-430e-93f9-a476591d60f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_69b3feb8-41df-4c4d-9e4d-e5ba43e40d0a" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cfde29b3-4833-408d-84a0-345aee8f9dcb" xlink:to="loc_cah_MedicalMember_69b3feb8-41df-4c4d-9e4d-e5ba43e40d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_52a1cd03-4870-4da4-a117-867a00bc4f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d0895097-833b-4964-b8b3-b61ddda0e220" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_52a1cd03-4870-4da4-a117-867a00bc4f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_410d4a51-d1e6-48d4-92ef-a5d366e5bed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52a1cd03-4870-4da4-a117-867a00bc4f87" xlink:to="loc_us-gaap_Revenues_410d4a51-d1e6-48d4-92ef-a5d366e5bed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bba705c6-718e-4bc5-af37-51815ca0f311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_cdfa662e-a02e-43be-93b0-ef204baa0d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bba705c6-718e-4bc5-af37-51815ca0f311" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_cdfa662e-a02e-43be-93b0-ef204baa0d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1a7558b6-564c-4dea-9ab1-d7280988de6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_cdfa662e-a02e-43be-93b0-ef204baa0d5d" xlink:to="loc_srt_ConsolidationItemsAxis_1a7558b6-564c-4dea-9ab1-d7280988de6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f344fb53-6d32-405f-9de5-3c9c005d1e26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_1a7558b6-564c-4dea-9ab1-d7280988de6e" xlink:to="loc_srt_ConsolidationItemsDomain_f344fb53-6d32-405f-9de5-3c9c005d1e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d6ef3222-b93a-4968-a5cc-3a115b6763e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f344fb53-6d32-405f-9de5-3c9c005d1e26" xlink:to="loc_us-gaap_OperatingSegmentsMember_d6ef3222-b93a-4968-a5cc-3a115b6763e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d447d684-7704-4790-8c07-492152ea46f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f344fb53-6d32-405f-9de5-3c9c005d1e26" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d447d684-7704-4790-8c07-492152ea46f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_bb9fe0e3-5722-4cfc-9457-53233000003f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_cdfa662e-a02e-43be-93b0-ef204baa0d5d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_bb9fe0e3-5722-4cfc-9457-53233000003f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b4c81469-a177-4449-9fda-e501b7ef952b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bb9fe0e3-5722-4cfc-9457-53233000003f" xlink:to="loc_us-gaap_SegmentDomain_b4c81469-a177-4449-9fda-e501b7ef952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_7e36a76d-77d4-4202-a519-eb40dd99de0f" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4c81469-a177-4449-9fda-e501b7ef952b" xlink:to="loc_cah_PharmaceuticalMember_7e36a76d-77d4-4202-a519-eb40dd99de0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_dc49a8c7-77ca-4694-83db-d1b3bf0a73fa" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4c81469-a177-4449-9fda-e501b7ef952b" xlink:to="loc_cah_MedicalMember_dc49a8c7-77ca-4694-83db-d1b3bf0a73fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_bc392e46-78f6-4dbc-b40d-ef5caea6fa97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_cdfa662e-a02e-43be-93b0-ef204baa0d5d" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_bc392e46-78f6-4dbc-b40d-ef5caea6fa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b2701aaa-1976-45fc-9b38-35f173ad1cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_bc392e46-78f6-4dbc-b40d-ef5caea6fa97" xlink:to="loc_us-gaap_OperatingIncomeLoss_b2701aaa-1976-45fc-9b38-35f173ad1cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6114aff9-bd8e-4d32-a614-0c867454e854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f3be18-f3c8-451e-94c2-3631e7d870ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6114aff9-bd8e-4d32-a614-0c867454e854" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f3be18-f3c8-451e-94c2-3631e7d870ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f8a5a519-1a23-4651-bf66-a3a0543f5a1a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f3be18-f3c8-451e-94c2-3631e7d870ef" xlink:to="loc_srt_ConsolidationItemsAxis_f8a5a519-1a23-4651-bf66-a3a0543f5a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7408e579-0f26-416b-9d92-36a440f9ef34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f8a5a519-1a23-4651-bf66-a3a0543f5a1a" xlink:to="loc_srt_ConsolidationItemsDomain_7408e579-0f26-416b-9d92-36a440f9ef34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e492cc56-41dc-4696-9fbb-01ff9b946354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7408e579-0f26-416b-9d92-36a440f9ef34" xlink:to="loc_us-gaap_OperatingSegmentsMember_e492cc56-41dc-4696-9fbb-01ff9b946354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2b78942d-6614-4fbd-97b0-902425f351f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7408e579-0f26-416b-9d92-36a440f9ef34" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2b78942d-6614-4fbd-97b0-902425f351f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d04607f6-a13c-48ab-8252-2908abf33485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f3be18-f3c8-451e-94c2-3631e7d870ef" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d04607f6-a13c-48ab-8252-2908abf33485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_62c30974-28ee-45ef-9f6f-5db66b2a24e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d04607f6-a13c-48ab-8252-2908abf33485" xlink:to="loc_us-gaap_SegmentDomain_62c30974-28ee-45ef-9f6f-5db66b2a24e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_58790c51-184a-4d0a-a061-969f9553be0b" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_62c30974-28ee-45ef-9f6f-5db66b2a24e4" xlink:to="loc_cah_PharmaceuticalMember_58790c51-184a-4d0a-a061-969f9553be0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_6ef4a04a-7dc5-4b6f-865a-9b7127331169" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_62c30974-28ee-45ef-9f6f-5db66b2a24e4" xlink:to="loc_cah_MedicalMember_6ef4a04a-7dc5-4b6f-865a-9b7127331169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_70fd1969-71b5-42e2-a856-3dad2f82fae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f3be18-f3c8-451e-94c2-3631e7d870ef" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_70fd1969-71b5-42e2-a856-3dad2f82fae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cb670e92-6329-4fa9-848b-33e833a48739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_70fd1969-71b5-42e2-a856-3dad2f82fae2" xlink:to="loc_us-gaap_Assets_cb670e92-6329-4fa9-848b-33e833a48739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2f0b01d9-01ae-4535-84ba-8e8ade9c79bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2f0b01d9-01ae-4535-84ba-8e8ade9c79bd" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentAxis_87633315-4366-4c60-8ef2-9759c3e18bf9" xlink:href="cah-20200930.xsd#cah_MedicalSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_cah_MedicalSegmentAxis_87633315-4366-4c60-8ef2-9759c3e18bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain_43b7a069-9023-4eea-9250-279ab2764c62" xlink:href="cah-20200930.xsd#cah_MedicalSegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MedicalSegmentAxis_87633315-4366-4c60-8ef2-9759c3e18bf9" xlink:to="loc_cah_MedicalSegmentDomain_43b7a069-9023-4eea-9250-279ab2764c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_a3f10513-00bb-4e5c-92a2-a17bd84c24d2" xlink:href="cah-20200930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MedicalSegmentDomain_43b7a069-9023-4eea-9250-279ab2764c62" xlink:to="loc_cah_MedicaldistributionandproductsMember_a3f10513-00bb-4e5c-92a2-a17bd84c24d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentAxis_c1af2646-74b3-45c8-90d0-8716090d8fdf" xlink:href="cah-20200930.xsd#cah_PharmaceuticalSegmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_cah_PharmaceuticalSegmentAxis_c1af2646-74b3-45c8-90d0-8716090d8fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain_f160cac4-3b2d-4283-9c11-bccf3625b237" xlink:href="cah-20200930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PharmaceuticalSegmentAxis_c1af2646-74b3-45c8-90d0-8716090d8fdf" xlink:to="loc_cah_PharmaceuticalSegmentDomain_f160cac4-3b2d-4283-9c11-bccf3625b237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_57be8708-4d86-4a16-8a16-e43f91177fdd" xlink:href="cah-20200930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PharmaceuticalSegmentDomain_f160cac4-3b2d-4283-9c11-bccf3625b237" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_57be8708-4d86-4a16-8a16-e43f91177fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_3b371006-d8ce-4f26-b112-3dd058f310a9" xlink:href="cah-20200930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PharmaceuticalSegmentDomain_f160cac4-3b2d-4283-9c11-bccf3625b237" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_3b371006-d8ce-4f26-b112-3dd058f310a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_688c2fa0-91a3-4823-9e4d-9573d6f87633" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_srt_ConsolidationItemsAxis_688c2fa0-91a3-4823-9e4d-9573d6f87633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4516724f-1a0e-4700-9442-430a9e8e522f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_688c2fa0-91a3-4823-9e4d-9573d6f87633" xlink:to="loc_srt_ConsolidationItemsDomain_4516724f-1a0e-4700-9442-430a9e8e522f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_55ccb25c-c71d-40d1-b9f4-7a08c248bc4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4516724f-1a0e-4700-9442-430a9e8e522f" xlink:to="loc_us-gaap_OperatingSegmentsMember_55ccb25c-c71d-40d1-b9f4-7a08c248bc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e1a4783c-1aad-47bb-b678-6d9decc47137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4516724f-1a0e-4700-9442-430a9e8e522f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e1a4783c-1aad-47bb-b678-6d9decc47137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_546253bd-2b0b-49df-8d4a-49869d554921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_546253bd-2b0b-49df-8d4a-49869d554921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_26419207-d889-415a-94dd-9f991e9e699f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_546253bd-2b0b-49df-8d4a-49869d554921" xlink:to="loc_us-gaap_SegmentDomain_26419207-d889-415a-94dd-9f991e9e699f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_489f8a2b-010b-42c7-ba58-73e7bbb8711d" xlink:href="cah-20200930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_26419207-d889-415a-94dd-9f991e9e699f" xlink:to="loc_cah_PharmaceuticalMember_489f8a2b-010b-42c7-ba58-73e7bbb8711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_fb25eb3d-edd9-464c-b18b-f0fec0604694" xlink:href="cah-20200930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_26419207-d889-415a-94dd-9f991e9e699f" xlink:to="loc_cah_MedicalMember_fb25eb3d-edd9-464c-b18b-f0fec0604694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_665a0d05-0e4b-49af-83d4-585c3497a111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_us-gaap_SubsegmentsAxis_665a0d05-0e4b-49af-83d4-585c3497a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_665a0d05-0e4b-49af-83d4-585c3497a111" xlink:to="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_6ef7d45f-1435-4cd2-bc97-88071aee12a5" xlink:href="cah-20200930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:to="loc_cah_MedicaldistributionandproductsMember_6ef7d45f-1435-4cd2-bc97-88071aee12a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_266e7e04-0960-4d19-bc1d-56e0092418f1" xlink:href="cah-20200930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_266e7e04-0960-4d19-bc1d-56e0092418f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_c2c1d950-8872-4c5d-a31c-d3d52a4bd99b" xlink:href="cah-20200930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_52008281-a0b8-4edc-8e0f-3b6470e54330" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_c2c1d950-8872-4c5d-a31c-d3d52a4bd99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_0f2ff824-70c8-46a2-bd5e-92b7023b89e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_0f2ff824-70c8-46a2-bd5e-92b7023b89e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_edbefc2d-3a6d-4d6a-bc0e-ee17c89927f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_0f2ff824-70c8-46a2-bd5e-92b7023b89e3" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_edbefc2d-3a6d-4d6a-bc0e-ee17c89927f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_10fde879-0ccc-4110-b74b-86925d1ad74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_83241af5-9db9-4581-9b94-6f99940bec98" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_10fde879-0ccc-4110-b74b-86925d1ad74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3ebd5a51-9df0-4cdf-8144-5641b282f8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_10fde879-0ccc-4110-b74b-86925d1ad74e" xlink:to="loc_us-gaap_Revenues_3ebd5a51-9df0-4cdf-8144-5641b282f8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#SegmentInformationRevenuebyGeographicalSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c498e677-0293-498f-93c1-ae7fdd6f5f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable_21379822-a0ae-4387-87a6-9aff1fe544ae" xlink:href="cah-20200930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c498e677-0293-498f-93c1-ae7fdd6f5f0f" xlink:to="loc_cah_SegmentRevenuebyGeographicTable_21379822-a0ae-4387-87a6-9aff1fe544ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8dd0e847-d8d8-4782-9dc5-90ceb17c8d78" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_21379822-a0ae-4387-87a6-9aff1fe544ae" xlink:to="loc_srt_ConsolidationItemsAxis_8dd0e847-d8d8-4782-9dc5-90ceb17c8d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4ac9ecd0-4137-4957-af5a-ce32f0b5663f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_8dd0e847-d8d8-4782-9dc5-90ceb17c8d78" xlink:to="loc_srt_ConsolidationItemsDomain_4ac9ecd0-4137-4957-af5a-ce32f0b5663f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f9eada84-949e-4f21-913f-4f9b3fe414e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4ac9ecd0-4137-4957-af5a-ce32f0b5663f" xlink:to="loc_us-gaap_OperatingSegmentsMember_f9eada84-949e-4f21-913f-4f9b3fe414e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_7cb950dd-909c-46b3-a440-8e7c47bc7f15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingSegmentsMember_f9eada84-949e-4f21-913f-4f9b3fe414e8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_7cb950dd-909c-46b3-a440-8e7c47bc7f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9507731e-aa1d-4f63-9b89-3073c6b05483" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_21379822-a0ae-4387-87a6-9aff1fe544ae" xlink:to="loc_srt_StatementGeographicalAxis_9507731e-aa1d-4f63-9b89-3073c6b05483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f84ccf56-8786-4331-b59c-1050a638bb45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9507731e-aa1d-4f63-9b89-3073c6b05483" xlink:to="loc_srt_SegmentGeographicalDomain_f84ccf56-8786-4331-b59c-1050a638bb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0c0e0125-02f5-4876-8c30-816654e10dc6" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f84ccf56-8786-4331-b59c-1050a638bb45" xlink:to="loc_country_US_0c0e0125-02f5-4876-8c30-816654e10dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_90cdcbb7-412a-4630-bd4e-ce60e5e78fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f84ccf56-8786-4331-b59c-1050a638bb45" xlink:to="loc_us-gaap_NonUsMember_90cdcbb7-412a-4630-bd4e-ce60e5e78fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems_e5264783-9791-4224-854a-924096dbb04d" xlink:href="cah-20200930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_21379822-a0ae-4387-87a6-9aff1fe544ae" xlink:to="loc_cah_SegmentRevenuebyGeographicLineItems_e5264783-9791-4224-854a-924096dbb04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a74f7f4b-c22a-4060-b3f3-d2549c96ff8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_e5264783-9791-4224-854a-924096dbb04d" xlink:to="loc_us-gaap_Revenues_a74f7f4b-c22a-4060-b3f3-d2549c96ff8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce22df65-8106-406d-8f07-1fd64c1f3f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7789f6da-ef22-4bce-9cc7-0b1ed162b0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce22df65-8106-406d-8f07-1fd64c1f3f4d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7789f6da-ef22-4bce-9cc7-0b1ed162b0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00fc27f6-d45d-4044-a774-0dd046ab8705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b250254e-88a9-4e3a-81cf-8a9ec5bb74eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00fc27f6-d45d-4044-a774-0dd046ab8705" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b250254e-88a9-4e3a-81cf-8a9ec5bb74eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_52383c8a-10ca-429c-b94a-2b37fd5b2d02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00fc27f6-d45d-4044-a774-0dd046ab8705" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_52383c8a-10ca-429c-b94a-2b37fd5b2d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_de41114d-f979-4d13-8c52-c095d662b742" xlink:href="cah-20200930.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00fc27f6-d45d-4044-a774-0dd046ab8705" xlink:to="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_de41114d-f979-4d13-8c52-c095d662b742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_6f548cd9-44d4-40fd-aba2-ce1993c91da6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00fc27f6-d45d-4044-a774-0dd046ab8705" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_6f548cd9-44d4-40fd-aba2-ce1993c91da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_c94f1773-b4ff-44b8-a18b-677c5db350ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00fc27f6-d45d-4044-a774-0dd046ab8705" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_c94f1773-b4ff-44b8-a18b-677c5db350ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_148f21df-5c5f-4fec-954a-e209e2722235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd2207f-215e-4292-a9e7-dbea090c8900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_148f21df-5c5f-4fec-954a-e209e2722235" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd2207f-215e-4292-a9e7-dbea090c8900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_222a7cb8-a98b-49f4-877b-7fd524b88d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd2207f-215e-4292-a9e7-dbea090c8900" xlink:to="loc_us-gaap_AwardTypeAxis_222a7cb8-a98b-49f4-877b-7fd524b88d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_222a7cb8-a98b-49f4-877b-7fd524b88d21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_39c935dd-cb6e-46e1-9ef9-10af25a6d10a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:to="loc_us-gaap_EmployeeStockOptionMember_39c935dd-cb6e-46e1-9ef9-10af25a6d10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_79c6a15d-3f60-48c9-8cda-30e08150edd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_79c6a15d-3f60-48c9-8cda-30e08150edd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_818e3ee9-414d-4e5c-bc83-f58540862c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a86f511-8195-470c-a16f-060c8d5d0408" xlink:to="loc_us-gaap_PerformanceSharesMember_818e3ee9-414d-4e5c-bc83-f58540862c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0ae2b2c6-e29c-4033-90de-1de9c300d26b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd2207f-215e-4292-a9e7-dbea090c8900" xlink:to="loc_srt_RangeAxis_0ae2b2c6-e29c-4033-90de-1de9c300d26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79737746-07f3-44a5-b489-cd5cfe933cd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0ae2b2c6-e29c-4033-90de-1de9c300d26b" xlink:to="loc_srt_RangeMember_79737746-07f3-44a5-b489-cd5cfe933cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f405c400-e57c-4705-a1f1-beb825be5ed4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79737746-07f3-44a5-b489-cd5cfe933cd2" xlink:to="loc_srt_MinimumMember_f405c400-e57c-4705-a1f1-beb825be5ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af0dd597-0c96-4c64-8038-75e3f5e2e376" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79737746-07f3-44a5-b489-cd5cfe933cd2" xlink:to="loc_srt_MaximumMember_af0dd597-0c96-4c64-8038-75e3f5e2e376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd2207f-215e-4292-a9e7-dbea090c8900" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_3004dcb4-50e8-43b9-89a0-bc11b4eb720c" xlink:href="cah-20200930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_cah_VestingPeriodinyearsforShares_3004dcb4-50e8-43b9-89a0-bc11b4eb720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_cfde0790-08e6-48f4-b17d-2ed0f74ff209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_cfde0790-08e6-48f4-b17d-2ed0f74ff209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8c6840c-c6f4-42ad-927e-854660e8d2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e8c6840c-c6f4-42ad-927e-854660e8d2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f32e26c1-3e10-41f7-acd2-1549c3faf26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f32e26c1-3e10-41f7-acd2-1549c3faf26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d367a7bd-e7ef-47ce-ac81-135f06bf5d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d367a7bd-e7ef-47ce-ac81-135f06bf5d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_f8a57708-5ab3-4632-a944-ff250d32ac69" xlink:href="cah-20200930.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_f8a57708-5ab3-4632-a944-ff250d32ac69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0eac8d84-3eca-4869-adfa-99bc2690d4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e0ddba-0f49-42fc-b832-f88c841c7c29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0eac8d84-3eca-4869-adfa-99bc2690d4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07149207-a215-4882-b9a5-da3bbd06969b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_622b9d36-6689-4a86-890a-7eecaf42a8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07149207-a215-4882-b9a5-da3bbd06969b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_622b9d36-6689-4a86-890a-7eecaf42a8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_63bfc0f9-e846-4b4f-87c5-d455f4b3dddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_622b9d36-6689-4a86-890a-7eecaf42a8b0" xlink:to="loc_us-gaap_AwardTypeAxis_63bfc0f9-e846-4b4f-87c5-d455f4b3dddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_63bfc0f9-e846-4b4f-87c5-d455f4b3dddc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a63ada13-1658-4592-a90e-f2181eea1031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a63ada13-1658-4592-a90e-f2181eea1031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29c5d512-c5ec-414c-b30c-e66912b87192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29c5d512-c5ec-414c-b30c-e66912b87192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d222274a-25b8-4464-a098-c74954499c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e174f4c-dddd-438e-bead-c37ead0b6a1c" xlink:to="loc_us-gaap_PerformanceSharesMember_d222274a-25b8-4464-a098-c74954499c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb1e886-ddca-4fe3-86b9-6ebcd1f94e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_622b9d36-6689-4a86-890a-7eecaf42a8b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb1e886-ddca-4fe3-86b9-6ebcd1f94e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ebcd6c2-3b51-463c-96cc-5e5b406f8130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb1e886-ddca-4fe3-86b9-6ebcd1f94e59" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ebcd6c2-3b51-463c-96cc-5e5b406f8130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1400ad7-0768-4eab-972f-39fc0b1cf9a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_42a9af92-2349-4ffd-a11a-d117a6fb8877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1400ad7-0768-4eab-972f-39fc0b1cf9a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_42a9af92-2349-4ffd-a11a-d117a6fb8877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dd0cca88-801a-4a1e-8b3e-1e1161ccc68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_42a9af92-2349-4ffd-a11a-d117a6fb8877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dd0cca88-801a-4a1e-8b3e-1e1161ccc68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7770f059-1319-40af-88ac-c40ab13816cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_42a9af92-2349-4ffd-a11a-d117a6fb8877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7770f059-1319-40af-88ac-c40ab13816cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49cb1745-b0d9-4058-931d-f630e762ef37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_42a9af92-2349-4ffd-a11a-d117a6fb8877" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49cb1745-b0d9-4058-931d-f630e762ef37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_db4d0063-d89e-4d56-9147-5f68680d0a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_42a9af92-2349-4ffd-a11a-d117a6fb8877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_db4d0063-d89e-4d56-9147-5f68680d0a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e860c736-6275-4781-ab43-193c26a59501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_42a9af92-2349-4ffd-a11a-d117a6fb8877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e860c736-6275-4781-ab43-193c26a59501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_081cd014-7061-4641-9d52-185dc47f7f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1400ad7-0768-4eab-972f-39fc0b1cf9a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_081cd014-7061-4641-9d52-185dc47f7f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2fb47e7-7ed6-41f4-b654-e9e2f65131d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1400ad7-0768-4eab-972f-39fc0b1cf9a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2fb47e7-7ed6-41f4-b654-e9e2f65131d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10ed532f-7046-4131-b868-54a8d85c5a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2fb47e7-7ed6-41f4-b654-e9e2f65131d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10ed532f-7046-4131-b868-54a8d85c5a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b3cb9bc3-7571-4e3f-83b2-572ca1400431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2fb47e7-7ed6-41f4-b654-e9e2f65131d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b3cb9bc3-7571-4e3f-83b2-572ca1400431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_83d10c85-8e4e-4257-9acd-28338d56b8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2fb47e7-7ed6-41f4-b654-e9e2f65131d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_83d10c85-8e4e-4257-9acd-28338d56b8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_476b6aea-b997-4cbd-af2c-d49f1fc467d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2fb47e7-7ed6-41f4-b654-e9e2f65131d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_476b6aea-b997-4cbd-af2c-d49f1fc467d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7e859615-c2a9-4b06-a769-216f54c88edf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2fb47e7-7ed6-41f4-b654-e9e2f65131d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7e859615-c2a9-4b06-a769-216f54c88edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7dac0838-3e90-4c53-bf2e-e185c9aca5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2fb47e7-7ed6-41f4-b654-e9e2f65131d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7dac0838-3e90-4c53-bf2e-e185c9aca5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64781b16-5000-4288-a619-00ab70575eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639f79b2-3d3f-43da-8783-318d03947866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64781b16-5000-4288-a619-00ab70575eec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639f79b2-3d3f-43da-8783-318d03947866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7fcfc840-0b79-4627-87fb-3feafc7cf269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639f79b2-3d3f-43da-8783-318d03947866" xlink:to="loc_us-gaap_AwardTypeAxis_7fcfc840-0b79-4627-87fb-3feafc7cf269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52b28902-7e5a-4f73-968c-e1708c0234a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7fcfc840-0b79-4627-87fb-3feafc7cf269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52b28902-7e5a-4f73-968c-e1708c0234a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7daf1b29-8165-46c5-9992-1a70e5f27460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52b28902-7e5a-4f73-968c-e1708c0234a2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7daf1b29-8165-46c5-9992-1a70e5f27460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639f79b2-3d3f-43da-8783-318d03947866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7dca6ec0-4423-40be-b9f2-3e38a956cb55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7dca6ec0-4423-40be-b9f2-3e38a956cb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_73fc9cac-d06d-4e6b-8c70-58360181a7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_73fc9cac-d06d-4e6b-8c70-58360181a7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4634b537-6a12-4dc5-9cf6-fce5d5da67fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4634b537-6a12-4dc5-9cf6-fce5d5da67fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_747f071f-42a1-493a-9de0-a3f9a3c3c6db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_747f071f-42a1-493a-9de0-a3f9a3c3c6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c3cf9e79-a58c-43d9-8143-2ea7eb6457f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c3cf9e79-a58c-43d9-8143-2ea7eb6457f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_62333225-f3e1-40db-8d6a-ba18f506e076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4020ba31-914e-4e3b-89ad-60c4eca8cf81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_62333225-f3e1-40db-8d6a-ba18f506e076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c90664e4-7f56-43df-9cc1-0c40b934590c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ce7a3c7-65e5-4a4f-8356-0d91f6349de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c90664e4-7f56-43df-9cc1-0c40b934590c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ce7a3c7-65e5-4a4f-8356-0d91f6349de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e707d2c-11fd-4127-80ea-747a6146b8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ce7a3c7-65e5-4a4f-8356-0d91f6349de7" xlink:to="loc_us-gaap_AwardTypeAxis_6e707d2c-11fd-4127-80ea-747a6146b8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c9a76a0-7c61-412e-a78f-27f464abff78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6e707d2c-11fd-4127-80ea-747a6146b8d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c9a76a0-7c61-412e-a78f-27f464abff78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd344128-ecd2-4b8a-85b0-eaa193a172fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c9a76a0-7c61-412e-a78f-27f464abff78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd344128-ecd2-4b8a-85b0-eaa193a172fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ce7a3c7-65e5-4a4f-8356-0d91f6349de7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc769b6a-6032-40fc-9a9a-590adb0db5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc769b6a-6032-40fc-9a9a-590adb0db5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d2a8857b-6c26-4641-b0ec-90f2f0c5b431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d2a8857b-6c26-4641-b0ec-90f2f0c5b431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bc025273-7c1a-4f9c-a2d6-35ece1bd5754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bc025273-7c1a-4f9c-a2d6-35ece1bd5754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8389232f-ad05-467c-b915-d95b113c7e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8389232f-ad05-467c-b915-d95b113c7e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1290f408-c702-4108-a6aa-cb9ef6f0663c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1290f408-c702-4108-a6aa-cb9ef6f0663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_19cac6a0-ad94-4ff1-88bc-61268f6a5e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_527431e9-4c87-47a1-b844-a1f10c113abd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_19cac6a0-ad94-4ff1-88bc-61268f6a5e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b517a3e-ebe7-4e3a-aa0e-4c60f7463187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ec72136-7796-4670-a8c4-4fa4b35a0789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ec72136-7796-4670-a8c4-4fa4b35a0789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d7a96cbb-ba93-4677-a67b-0bbb947bee55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d7a96cbb-ba93-4677-a67b-0bbb947bee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4c182a19-df85-4165-9c69-697295fe03e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4c182a19-df85-4165-9c69-697295fe03e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0d7c6fe8-b939-4f0c-b835-9ec55ca2537a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0d7c6fe8-b939-4f0c-b835-9ec55ca2537a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_eabd4dcd-f0c5-4fd6-bdca-22f5e2ee8081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6926aaad-a02a-413f-ae02-2c46241cef84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_eabd4dcd-f0c5-4fd6-bdca-22f5e2ee8081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20200930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc46aac6-8691-4f58-958d-0a04ddb6281d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d85eff2f-6882-4fd2-8e08-78c422726813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc46aac6-8691-4f58-958d-0a04ddb6281d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d85eff2f-6882-4fd2-8e08-78c422726813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e813aa3-4e62-4fd0-a2f6-34fab2c0f147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d85eff2f-6882-4fd2-8e08-78c422726813" xlink:to="loc_us-gaap_AwardTypeAxis_0e813aa3-4e62-4fd0-a2f6-34fab2c0f147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b510cee0-b53f-4351-a6da-8ebaea60fd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0e813aa3-4e62-4fd0-a2f6-34fab2c0f147" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b510cee0-b53f-4351-a6da-8ebaea60fd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cc6ec924-c4a1-49dc-b465-d06bf9617e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b510cee0-b53f-4351-a6da-8ebaea60fd0b" xlink:to="loc_us-gaap_PerformanceSharesMember_cc6ec924-c4a1-49dc-b465-d06bf9617e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d85eff2f-6882-4fd2-8e08-78c422726813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5006a714-c731-4873-ba46-ff8bdf7b29f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5006a714-c731-4873-ba46-ff8bdf7b29f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29748ff3-4d44-4f94-b106-62cbb514cd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29748ff3-4d44-4f94-b106-62cbb514cd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7a50a9f5-a37f-44c9-8054-ece6bd10cefb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7a50a9f5-a37f-44c9-8054-ece6bd10cefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_09ef85b8-d2d5-48c0-8328-5ed7ebef30d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_09ef85b8-d2d5-48c0-8328-5ed7ebef30d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_338fdcd4-59ad-44ba-9af9-1830d05c2f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_338fdcd4-59ad-44ba-9af9-1830d05c2f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fef26c6c-84d6-4606-8454-b112ea43d4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a73dd601-8a91-4e4e-b3e4-cb225402707b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fef26c6c-84d6-4606-8454-b112ea43d4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d2bf8f04-ca2d-44d2-94b8-8c663116a750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d2bf8f04-ca2d-44d2-94b8-8c663116a750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_416c0a46-751b-4a5b-9f0c-66e63ecf285e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_416c0a46-751b-4a5b-9f0c-66e63ecf285e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c2bc1595-7152-4ed6-84bc-3c2342b66bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c2bc1595-7152-4ed6-84bc-3c2342b66bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_483c3c62-40a3-4756-9fb0-7dd41f2a7a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_483c3c62-40a3-4756-9fb0-7dd41f2a7a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c0fa2224-022e-4eff-b0a9-4f05826b7395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10805525-a4a1-4c6c-9c98-6d7bac738bcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c0fa2224-022e-4eff-b0a9-4f05826b7395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4761577-cb5f-4bbd-b168-c4e7a4b4f362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4761577-cb5f-4bbd-b168-c4e7a4b4f362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be11daba-0736-4bf9-ab88-cf04cf565a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f3ee234-4302-4daa-ab2f-80dfe09aa9b9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be11daba-0736-4bf9-ab88-cf04cf565a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cah-20200930_g1.jpg
<TEXT>
begin 644 cah-20200930_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P $AOV,=.^#FLZCJ/A"WT^PC\*ZAK$*QW=UIJZ!;BVEG10 LK0A&90  Q(
M%=A_P=;?\G3_ +!?_8P7O_I=H% '[6>+_P!HS]GOX>_$C1_@WX^^._@S0_%_
MB%8VT#PKK'BBTMM2U,22-'&;>VDD$LP:1'1=BG+*0.01795^6?\ P4X\$_\
M!-C6?^"[7[,GB;]HOXS_ !(T?XTV5GH8^'7AKP[HT$VBZ@BZS>M;F[F>,O&6
MN#,K;6&$53U.:^MO^"C?_!6S]B3_ ()9^$M-\0_M6_$:XM]1UP2'P_X4T&Q-
MYJNI*A =XX055(U) ,DKQIGY0Q;B@#Z6HKXR_P"";W_!>C_@GC_P5%\97?PN
M_9]\;ZUI'C*VM7NH_!_C72EL;Z[MT^_+;F.26&<*.61)"ZJ"Q4*":U?VB/\
M@M]_P3S_ &3_ -JC6/V0_P!H/XIWWAGQ-H'AAM>U6^OM'D.GPV@M3<@"9<EY
M70!4B16=Y&5%!9@" ?7%%?!_[ W_  <:_P#!-C_@HK^T$/V8_@OXB\5Z-XLO
M$G?P_;>,M!2SBUSR4:21;5XYI07$:-)LD\MRJM@$@@;W_!2+_@OE_P $\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4_8Z^%/_  F'B?2_C!I^MWVF?V[8:?Y5A'I6JP/-YE]/#&V);F!=H8L=^0"
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MVT*T\3>%_ACX=+^'O"6M1B:RGCL;"T\B!XG&)(OM%Y->&,Y5G+;@R$J?I_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_#XO_JW3_R[O_N2@#[:HKXE_P"'Q?\ U;I_Y=W_ -R4?\/B_P#JW3_R[O\
M[DH ^VJ*\8_8\_:\_P"&L+'7KW_A7O\ 8']AS6Z;?[6^U>=YHD.<^5'MQY?O
MG/;%>ST %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK_D!>/?^OO3O_0;BOL^@ HHHH **** "BBB@ HHHH **** "BBB@#Q#XJ?\
M(_ZC_P!=$_\ 1:USU=#\5/\ D?\ 4?\ KHG_ *+6N>H **** "BBB@ HHHH
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MS3;UAGB*J^57&\X6-0=Q&:[/]M#]F+_AKWX#WWP2_P"$W_X1[[;?6UQ_:?\
M9OVO9Y,@?;Y?F1YSC&=PQ[UZO10!'96_V2SBM-^[RHE3=C&<#&:DHHH ^Y?^
M"/7_ " O'O\ U]Z=_P"@W%?9]?&'_!'K_D!>/?\ K[T[_P!!N*^SZ "BBB@
MHHHH **** "BBB@ HHHH **** /$/BI_R/\ J/\ UT3_ -%K7E_[0/BSXE^
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MZCX._P#(_P!I_P!<Y?\ T6U<O74?!W_D?[3_ *YR_P#HMJ /:**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH J:__P @*]_Z])/_ $$U^*U?M3K_ /R KW_KTD_]!-?BM0 4444
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M_A0+_P#&J /HFBOG;_AV5\!/^AP\;_\ A0+_ /&J/^'97P$_Z'#QO_X4"_\
MQJ@#W[7_ /D!7O\ UZ2?^@FOQ6K]*_\ AV5\!/\ H</&_P#X4"__ !JC_AV5
M\!/^AP\;_P#A0+_\:H _-2BOTK_X=E? 3_H</&__ (4"_P#QJC_AV5\!/^AP
M\;_^% O_ ,:H _-2BOTK_P"'97P$_P"AP\;_ /A0+_\ &J/^'97P$_Z'#QO_
M .% O_QJ@#\U**_2O_AV5\!/^AP\;_\ A0+_ /&J/^'97P$_Z'#QO_X4"_\
MQJ@#\U**_2O_ (=E? 3_ *'#QO\ ^% O_P :H_X=E? 3_H</&_\ X4"__&J
M/.?^"/7_ " O'O\ U]Z=_P"@W%?9]?.W_#LKX"?]#AXW_P#"@7_XU1_P[*^
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M 3_H</&__A0+_P#&J (*ZCX._P#(_P!I_P!<Y?\ T6U<]_P[*^ G_0X>-_\
MPH%_^-4?\.RO@)_T.'C?_P *!?\ XU0!]$T5\[?\.RO@)_T.'C?_ ,*!?_C5
M'_#LKX"?]#AXW_\ "@7_ .-4 ?1-%?.W_#LKX"?]#AXW_P#"@7_XU1_P[*^
MG_0X>-__  H%_P#C5 'T317SM_P[*^ G_0X>-_\ PH%_^-4?\.RO@)_T.'C?
M_P *!?\ XU0!]$T5Y?\  G]DOX;_ +/6O7OB'P5KGB"ZGO[06TR:OJ@G0)N#
M950BX.0.>>,^M>H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"SU\-=5^,7QQ^(FD>%/"VAV_G:MKNN7J6]M;(2%&YV(&YF*JJC+,S!5!)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9ZM_:%O'_9S:CIEI!9CRGD66;S)(G7]TC[=N7V@@D ^FZ*** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cah-20200930_g2.jpg
<TEXT>
begin 644 cah-20200930_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^,_AO;_%F4:OJ$'A3Q-<6,LD%Q86=PMK.\#)YOE-*ZX/&0V.M?*?[=W[8_\
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M5-2N+2[O9-1B(0/#*MW:Y0AB=LA+%F4,?T#_ ."O_P"S9I/_  4J_P"":OP
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M/R9D:9]T<Z;@" N/SM\?_%3]@W_@J)_P6S^.WCC_ (+"?M77W@WX8?#^_O\
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M[;BSO;=98I1G.&1@0PR >1VH _EJ_P""GW[=W[)G[47[17[+OQA_8J_9 O\
MX6?L_P#PP\>0VJ>)Y_!EKHEEJ6I/>V%S>1QQVQ,;>1!;1$L7+9=B0!M+?9__
M  4(2*?_ (/$?V;-ZJZ_\(AI3#(R,A-9(/YX-?N/I&CZ1X?TR'1=!TNVL;.V
M39;VEI L442_W550 H]@*LT ?CC_ ,'K_P#RC<^&G_9<+3_TSZK7/_\ !T;_
M ,J_7P,_['#P?_ZCVH5^UU% 'X@_\'#?_*LM^S[_ -R!_P"H_/7SS_P7FT#Q
MWI'[$O\ P3A^-7Q$\!:KXI^!_AOX8>'5\::-82R1PRW+6&DR/;S2*0(GN+2.
M6*)S@C9+@C)S_2)5;6-&TCQ#IDVBZ_I5M?6=RFRXM+R!98I5]&5@0P]B* /Y
M8?\ @K'^WC^R)^U5\1_V:_B?^PS^QOJ/PN^ GPH\;&WF\42^"K71;/4=5N9]
M/N+FW1+4M&[06]@C,Q<N3(Q( VL_V)_P7W\/_&3_ ()E_P#!9SX._P#!<?P!
M\,+WQ7X#6PMK#Q9)8DA(;E+>XL)X))5!6#[1I]PHA=_E:2.0<[<']VM&T71O
M#NF0Z)X?TFVL+*W7;;VEG L442YSA44 *,GL*?J.G:?J]C-I>K6$-U;7$92>
MWN(@\<BGJK*V00?0T ?B9^R]_P %SOV[_P#@L#_P5N^'O@C_ ()T^'?$?@;X
M!^'K.WG^+<7B?P]I]V;BU25YKB2:;9+]D>50EK D4V\L3(<C<$^6OB)IO[.7
M_!#[_@M3\:[[_@IK^P58?%CX,?%J^O\ 6O .L:CX#T[6OLHN;QKR-[-=1 A9
MHO.DM;A Z2 JC\KL#_TG>&O"7A7P9IW]C^#_  SI^DVAD+FUTVRC@CW'JVU
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M60NU_9C_ &G? ?CZ6P3?J%MX3\56M]-:H3@-+%$Y>-2> 6 ![5Z=7X%_&/\
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M]JWXP>+?$_CWX^^,-)@^'-S?6;SQ+:62ZM((&((2SB2.:/9&JA1DX YK]_J
M/$[K_@I9_P $Y;&YDLKW]O[X)PS0R%)8I?BKI"LC X*D&YR"#P0:[GX2_M'?
ML\_'V*XF^!/QY\&>-4M5#73^$O%%IJ0A!Z%S;R/M!]Z_F5_X(+?\$5/V6/\
M@L'\5/VB_P#AI?Q]\0-#_P"%=^(-*_L3_A!=5L;;S_M\^K>=Y_VJSN=V/L46
MW;LQN?.[(V[W[;W[ FF_\&\O_!7S]F_7_P!B+XZ>+-;3Q3J=G<2:9K\]NVH-
M"VHI:7-G,UM'$DUO<Q2-& 8U.0_)*@@ _I_HKYO_ ."CW_!5O]C3_@EA\/\
M3/'/[5OCJ[M[G7II(O#GAG0K'[7JFJF,*93##N50B!EW22.B NJ[MS*#R_\
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MW'X2BNU)MPOED&[VSLI&&?=D'<:[C3_ASX%^!'_!ZYX8\*?"+PCIOAW2=?\
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MLW_P_P!'U+X>1:KJ&COX.U;38KK3I[&VU^\@A@E@E4QR(L1*[64C!/%?3?\
MP:\?\$U_VU?^"=>@?'6R_;'^"_\ PATOC+Q)I-UX;7_A(]-U#[9#"EZ)&S8W
M$PCP9H^'VD[N <'!_P $3/\ @FO^VK^R+_P57_:W_:3_ &AO@O\ \(]X*^)W
MB35+KP/K7_"1Z;=_VE#-KES=1MY-M<22PYAD1\2HA&<$!@10!\V_\&A_P ^
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M7<G$$$EU&]S-(V."_P#:NG2>ZI=_[7./_P &^]WX\^+$_P"W/_P7=UW29?\
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MOX5>/-5DO?"OB._-O/)ILK)Y4=UY37=NT%XL0A202I);NT"%=R@Y^R/V6/\
M@G5_P4R\$_\ !#KXX?L]?M=_&[Q+\4OC9\3_  !KUKH/AK7_ !M_:*Z*9]-D
MM[33$O;N;R][2,6DD\P0J750Q6/>P!\V_P#!N'^P;^R=\2O^"%7Q0^)7Q/\
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MK27JW$<<EQ!;"S2[@N;;,D#-:JL,D9C=9%!R1N8-^K-% 'Y4?\$Q_P#@WO\
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M )19> ?^S@-*_P#3'KE>O_\ !I__ ,H2OAS_ -C!XB_].US7D'_!ZM_RBR\
M_P#9P&E?^F/7* /!--_X.4_^"C/[.7[.?PU^-WA+_@EO/)^S3HVAZ1X>3QQX
MDBO8;K6FM[>.U>>*ZC8P6J22Q.L>Z*520%WLQ('UY_P66_X*:_LUZE_P1J\
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M$$A(]/J* /VPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH J:__ ,@*]_Z])/\ T$U^*U?M3K__ " KW_KTD_\
M037XK4 %%%% !1110 4444 %%%% 'W+_ ,$>O^0%X]_Z^]._]!N*^SZ^,/\
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M_7WIW_H-Q7V?7QA_P1Z_Y 7CW_K[T[_T&XK[/H **** "BBB@ HHHH ****
M"BBB@ HHHH \0^*G_(_ZC_UT3_T6M<]70_%3_D?]1_ZZ)_Z+6N>H **** "B
MBB@ HHHH *ZCX._\C_:?]<Y?_1;5R]=1\'?^1_M/^N<O_HMJ /:**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH J:_\ \@*]_P"O23_T$U^*U?M3K_\ R KW_KTD_P#037XK4 9O
MC'Q9H7@+PCJOCGQ1>?9M,T739[_4;@J3Y4$,;22-@=<*I/X5\F_LZ?\ !5M/
MC%\>K?X;>-O@GJOAG0/%-Y%!X%UJY0EI7:W$J)<\[09E(>,IP ZCYAF2OJ/X
MN>$O#'C_ .%?B3P'XUU!;32-;T*[L-2NGE5!#!-$T;ON;A2 Q()Z$5^?O[+'
MQ)^//[!_[0T?P4^(RZ1XV\#>(/$NA>&H/&NEOA[:2>R3^S G/*?9MNY=K<1M
MMD;:-P![O\7?^"K'@3X7?$[7O"]E\$O%NO>%O!VKQ:7XT\<Z9 #9Z5=.X0QX
MP=^USL.60E@0H.5+=G^UM^WEX2_9:MO!CV?P\UCQG<>.5N9-%M/#K*TDD4*1
M.9 N"6!692,#H">U>=?\%3OA_P"-]:_9RUB^^#UQX<M_!MC=OJ7Q:TC3S';Z
MAK*QS6LBK',L+JDJA&=F?YB-G# ;6J?$W]FOXE?M>>*_@S^T#^S9\:[#X>>'
MM(^'Y;1)9+1KK4[(74&TK' V(VQ"4B9S("I!(S@&@#W[]E7]HFY_:;^&]Q\0
M;KX5:]X/:WU>6Q_LOQ%"4G<)'$_F@%1\A\S XZH:P_VU?VV_AI^Q7\/(O%?B
MR%=5UB_G2+1_#5O>+%<7@W#S),D-LC1<DN5(SM7JPKF?^"<'QY^*_P 6?!'C
M+X>?''6(=5\4?#CQK=^'K_7((51=02)L+(0H W;E=<@#*A2>22?)?^"RG[.7
MPHL_@3XJ_:6DT%KCQ?>3Z1IT>H7,Q9;2W2< I"G1"V?F;ECR 0"00#[CL[@7
M=I%=A-OFQJ^W/3(SBI*K:-_R![3_ *]H_P#T$59H ^Y?^"/7_("\>_\ 7WIW
M_H-Q7V?7QA_P1Z_Y 7CW_K[T[_T&XK[/H **** "BBB@ HHHH **** "BBB@
M HHHH \0^*G_ "/^H_\ 71/_ $6M<W<7$%I ]U=3I%%$A>221@JHH&223P !
MWKI/BI_R/^H_]=$_]%K7CO[6GPN\4?'#]E?XE?!?P1K"Z?K/B[P#K&C:3?,^
MU8+FZLI8(G)'( =U)(Y SC!P: /+_P!G'_@K7^P9^U=^T%KW[,_P2^.=AJGB
M;17VV:DA+?70L7F3-I\A.+D188/@ _(S*'0;ZZ3XG_\ !2+]A3X+_'.T_9K^
M*?[4/A31/&][)#&F@WM\0\,DN#$DT@!CMV<,I5960D,I PP)_(O_ ()$>(OV
M0/AA^VEX?_9;_P""@'[)]_\ #7XW>%]9T6T^&EZ\4UI;KJEOIL5JQEE@DC,D
MEZRI.JNLMO*\V0Q\Q=WKW_!=_P#9 ^ 7[-/[/_CC4/A]^RWJGB/6_COXY77/
M'/QNUZREU"W^'(CO[)C*T\5M)-;V\OG2QI#&?NF4?-A(R ?IC^U!^VS^RE^Q
M=HNG:_\ M0_''1/!T&L3O%I2:E([37C)C>8X8E:1U7<NY@I5=RY(W#/;_#?X
ME?#_ .,/@72_B=\*_&6G>(/#VM6HN=*UG2;I9K>ZB.1N1U)!P001U!!!P017
MQQ^U1^RI^SDGP@\+_P#!0"[^ &L_M.>*/ WPCT_P_P"#/"EJBZA9^);6Y:)1
M?+:M%,ID9+AYVG 8B+<<,53&9_P;;Z/X=T+_ ()=>']/T/XC6FNW!\4:K+J^
MG6BS*/#MV\P=]+=9E5UDC5D=AC:6F)4NI5V /M'XO_%_X:? +X9ZS\8_C%XP
MM- \,^'[,W6L:O?%O+MX@0N2%!9B6*J%4%F9@ "2!5GX:_$;P5\7_A[HGQ5^
M&^O1ZIX?\1Z5!J6B:E%&Z+=6LT8DBE"N P#(P.& //(%?E7_ ,' _P 5_''[
M7$'CO]C#X-Z[+;^$/@AX"E\>_&K5K4Y22_\ +/\ 9&C$CC<S-]I=3D%0K##0
MXK[T_P""5_\ RC2^ 7_9'_#O_IN@H ][KJ/@[_R/]I_USE_]%M7+UU'P=_Y'
M^T_ZYR_^BVH ]HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"IK_P#R KW_ *])/_037XK5^U.O
M_P#("O?^O23_ -!-?BM0!B_$?P#X<^*G@#6OAIXOMFFTO7M+GL+^.-MK&*5"
MC%3_  L <@]B :^-_P!FK_@EWX[\!_',W/Q<^,^KZ]X,\#:]I^I>#M.FLTC3
M4[F"V"VTTA$C,HM1^Z"8P=O&U25/W%10!\=_%/\ X):>+_%/C7Q=8_#']J+5
M/"GP]^(>L?VGXS\&PZ4LQEG+[Y?)E+C8';MC & 0ZJ%'7?'3_@GWJ&O^(?!/
MQ&_9>^,5Q\-_%'@;PTGAW3KU=/6]BN-+12J0R(Y )7<YW$-G=R,A6'TM10!\
MR^'?^">?B'P'^S(_P2^&/[3'B#P]XGU/Q2-?\3?$"QAE6[U.Y;/FH5BN(V5&
M&T8,C?=).XL:]#_;0_9B_P"&O?@/??!+_A-_^$>^VWUM<?VG_9OVO9Y,@?;Y
M?F1YSC&=PQ[UZO10!'96_P!DLXK3?N\J)4W8QG QFI*** /N7_@CU_R O'O_
M %]Z=_Z#<5]GU\8?\$>O^0%X]_Z^]._]!N*^SZ "BBB@ HHHH **** "BBB@
M HHHH **** /$/BI_P C_J/_ %T3_P!%K7E_[0/@SX@_$3X&^+O OPE\?R^%
M?%.K>'+RU\-^)(1DZ9?/"P@N,8.0LFTD 9(!QS7J'Q4_Y'_4?^NB?^BUKGJ
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M** *FO\ _("O?^O23_T$U^*U?M3K_P#R KW_ *])/_037XK4 %%%% !1110
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MO=1P3O''<Q7-MMF4,0'&6Z$#(^M0?\-8?&S_ *,?\=_^!5M_\57NE% 'A?\
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M_P#";MO_ )-H_P"&)/C9_P!$J\=_^$W;?_)M?J=10!^6/_#$GQL_Z)5X[_\
M";MO_DVC_AB3XV?]$J\=_P#A-VW_ ,FU^IU% 'Q'^QY:?&S]D^QUZR_X9A\=
MZ_\ VY-;ON^QVUKY/E"08QY\F[/F>V,=\U[1_P -8?&S_HQ_QW_X%6W_ ,57
MNE% 'A?_  UA\;/^C'_'?_@5;?\ Q5'_  UA\;/^C'_'?_@5;?\ Q5>Z44 >
M%_\ #6'QL_Z,?\=_^!5M_P#%4?\ #6'QL_Z,?\=_^!5M_P#%5[I10!X7_P -
M8?&S_HQ_QW_X%6W_ ,51_P -8?&S_HQ_QW_X%6W_ ,57NE% 'A?_  UA\;/^
MC'_'?_@5;?\ Q5'_  UA\;/^C'_'?_@5;?\ Q5>Z44 >%_\ #6'QL_Z,?\=_
M^!5M_P#%4?\ #6'QL_Z,?\=_^!5M_P#%5[I10!X7_P -8?&S_HQ_QW_X%6W_
M ,51_P -8?&S_HQ_QW_X%6W_ ,57NE% 'RGXJ^)?QL\3:_<ZY_PR'X[@^T,I
M\K;;-MPH'7S1GIZ5G_\ "7?&S_HTWQW_ -^K;_X[7UY10!\A_P#"7?&S_HTW
MQW_WZMO_ ([1_P )=\;/^C3?'?\ WZMO_CM?7E% 'R'_ ,)=\;/^C3?'?_?J
MV_\ CM'_  EWQL_Z--\=_P#?JV_^.U]>44 ?(?\ PEWQL_Z--\=_]^K;_P".
MT?\ "7?&S_HTWQW_ -^K;_X[7UY10!\A_P#"7?&S_HTWQW_WZMO_ ([6GX.^
M*7QL\)Z_#KG_  R!X[N/*5AY6+9,[E(Z^8?7TKZIHH \+_X:P^-G_1C_ ([_
M / JV_\ BJ/^&L/C9_T8_P"._P#P*MO_ (JO=** /"_^&L/C9_T8_P"._P#P
M*MO_ (JC_AK#XV?]&/\ CO\ \"K;_P"*KW2B@#PO_AK#XV?]&/\ CO\ \"K;
M_P"*H_X:P^-G_1C_ ([_ / JV_\ BJ]THH \^^#/QC\>_$W4[VQ\7_ 'Q#X.
MCM8%DAN=:FB9;ABV"B[">0.>:]!HHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HK%^(_Q"\'?"3X>Z[\5?B'KD6F:!X9
MT:ZU77-2GSLM;.WB:::5L<X5$9CCTK\\_A9^T=_P7M_;O^':?MA_LG^%_@3\
M+_AQK<)O_AAX%^*.GZE>:UXCTPG=!=7\]K(([,7*!7C6+E5D&21B1@#])J*^
M9/V"/^"DOA+]JS]EOQ5\:OC;X7C^%OB;X4:MJ>B?&WPSKNH)Y7A74=-C\R\=
MISA6M?*Q,LWW=A(R2A->??\ !,W_ (*SR_\ !2C]KGXW>#_AYX)N-.^%G@30
M?#5Q\/=:U729K6\\2)>R:FL^IA9<$6LAM46 ;02D9<G,FQ #[<HKRW]N/XT>
M+/V;_P!BGXP?M#^ K6QGUWP%\+?$'B/18-3A:2VDN['3;BYA65$9&:,O$H8*
MRDKD!@>:^+?@OXO_ .#F?XX?!WPG\:O#/CC]BJUTWQAX:L-;T^VO]&\4B>*"
M[MTGC20([*'"R $!B,@X)'- 'Z245\<?#W]N3]HWX5_\%/(OV!OVSM.\(PZ3
M\1/A_!K_ ,%/%GAFQN+:/4=1M(@-:TF8SS/YLT;$SQ%5CQ;A=P+. +5__P %
M ?B1XS_X*/\ BW]GGX2V&ACX1? CP!+K/Q[\87FGS7%R-7N(6FLM'L'25422
M.!&N9F9)?E_=XC?!(!]>T5^6U_\ \%1O^"N'AG]DRS_X*T^+?@+\'(?V?+@V
M^M77PRAFU+_A-;7PI/<)''?_ &QI!9/=^6ZW!A\L(8SC(?@?0_\ P5A_X*X?
M"G_@G3^S=<^+/"\+>+?B7XC\*7VJ?#?P/IUI)<37D4%LT\NI7*1C,-A;1*T\
MTK%1LB95.[H ?85%<7^S=X_UWXK_ +._@+XI>*$@74_$O@O2M5U%;6,I$)[B
MTBFD"*22J[G. 2<#')KM* "BBB@ HHHH **** "BBB@ HHHH **** "BO@/X
M@_MI_P#!1G]M/]J/X@?L\?\ !*_3/AKX;\%_!_6_[ ^('QA^)]G=WT5]XA1%
M>?2=,M+9EW-;[E6>24X#-@;<*9.P_80_;N_:CU']J'Q)_P $Y?\ @H]\._"V
MA?%_0_#2^)_"OBCP')/_ &!XWT S"![JV2X)E@N(92$EA8Y)+,H"KR ?9E%?
M"'Q)_P""S?A?6_\ @JI\*O\ @G/^S-I<?B2QO/&6L:+\8?&OV&5[#2+ZTT>^
MNDT6WG!"-?++;AYAEO*6/RR"[-Y?W?0 45^9/PH_:?\ ^"^7[8GQ&^,^J?LG
MZY^RII'@CX=_'?Q5X"TB#Q_HWB'^TY8]*O3"DLIM)7B8M$T>6&W+!OD48%=E
M\?/VU?\ @IG_ ,$Z_ /P?^.O[>D7P;UOP/??$-_#WQUU3X;:3J:1>';"]98M
M+U6"6[F!2**8[;D/&^=T8CP7R #]!**^4_\ @HO^V[\6O@MXR^$?[*G['>E^
M']:^,/QH\5I;Z(NOVLMWI^B:!:A9M4UJZC@EB=HHH<*BB1=[R#:6*E3YUX[_
M &N_^"I'[37[2WQ8^$__  3;\(?!K2?"GP3U.#0=;\2?&&#5)Y/%'B!K6.ZF
ML[1+&2,6T$*2QQO+)O)=P5!&=H!]XT5^?C_\%D/BC\4OV"OA!\4OV?/@;I ^
M.OQK\>R^ =!\">)=0D;3-$UZSFNH]4NKN6#]Y)8VJV4\Q,9WNCQ#@DX]'_8G
M_:__ &NG_:U\7?\ !/K_ (*#>&? <?Q#TGP7;>-?!OBOX9I=Q:3XCT"2Y-G,
M3;W;R2V]Q;W.R-P7(82JP"@!G /KRBBB@ HHHH **** "BBB@ HHHH ****
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M_:7_  BOA?3]'_M'[/Y/VK[-;1P>;Y>YMF[9NV[FQG&3C-=10 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cah-20200930_g3.jpg
<TEXT>
begin 644 cah-20200930_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _E)^#/_  5[_P""@/PN_P""SMG+\1?VR_B?
MJGPQTG]I!M%\0>']6\;7LVE1Z7/JTUNT+0/*8]J6XE9$(P/)&,8K]*O^#NW]
MO3]HK]EWX8_!/X)?LI_&?Q5X,\5^-?%.HZE>7W@O7)["]EM+.".!('D@96,4
MDM\&VD[2UN#U08_'_P")/P-E^)WP,_;X^*6G6Y%W\,OV@_#6N&YCX>."?5_$
M>FN 1T!DO86/O&#VKZV_:\^/\/\ P5N_X*;^ /&,=TE[I7PU_8=O/%?B*"/#
M+;:K+X5O=4=CV5UNK_3XV]/*'>@#]*?^#4S]H?X\?M-?\$P[_P"(_P"T5\9/
M$WCGQ GQ2U:S36O%FMSW]TMNEM8LD0EF9FV*7<A<X!8^M?=]E^U;^RYJ7Q3?
MX%Z=^TGX!N/&T4S0R>#H?&-B^JI(OWD-H)?.##N-N17X"_\ !/?]L/XA?L1_
M\&E_Q;^*_P (M;N-+\5ZI\7KWP]H.K6KE9;"2^3389;B-ARDB6YG9'&"L@0@
MY%?*E]^RY_P1GT?_ (),67QW\+_M_7R_M<6VG0>)/[&BOKE(UO3<*[:8L8MQ
MLE2(\3"7=YZ;MVP[  ?UP7-S;65M)>7EPD4,2%Y997"JB@9+$G@ #G-?GK_P
M7:_;M\*1_P#!&[XY_%7]AS]K[29?%?A*7P[$VO\ PO\ '<,M]H[S>(M-@D4S
M64Q>!GC>6,@D$JSKT)%?G%_P5F_X*V?'OXU_\&W/[-U_)XTO+;Q'\:KV\T7X
MBZM!,4GU6VT22:TNED*X_P"/J=+>:3;@,"R$;79:J_\ !7O_ (-P_@K_ ,$V
MO^"1ES^TM\%/BMXR_P"$X\/VNBV7Q;%SJX;3?$EO=WUI')&+=$7RTBU VDL2
MEF 6$;M[A9  ?5U]%_P4._;(_P"#<S]GKQ1^SW^W--X%^*FJ:O;7_B'XC^,?
MBA=:+/J5HIU6.2WDU %I)G9C;L(V)R(<_P  K]2OV=+?Q/X-_9B\"6GQ:\<6
MVKZSI7@/2T\3>)3JOVF&]NHK*(7%W]I?'FH[J\GFM]X-N/6OY_?^"D'_ "I^
M_LK_ /90--_]%:_7=?\ !>O]HKXOW_\ P3W_ &%?^"<'PF\83Z):?&GP-X?/
MBN>&1D%U%'9Z7;6EO(5(+P&:YDE=,X)@B]* /W&^%G[5?[+WQSUZ[\*_!+]I
M'P#XQU33U+7^F^%?&-EJ%Q;*#@F2.WE=D /'('-;OQ,^+7PJ^"OA>3QQ\9/B
M;X>\):+%($EUCQ-K4%A:HQR0IEG=4!.#QGL:_'+XG_\ !I9J?[/7Q.^$'QT_
MX)._M07G@WQOX(U9+GQ1KGQ$U669+LQA66X@CM+;[SL)(Y;=B(GBDVY&&$G>
M?\%]OV!_V2_CS^U9\,?VD_\ @IQ_P4PTCX??!SP[HDMFGPC\MH+^_E42R3W-
MC(DDDDSR2M;)*4M2RQ0HH8,5( /U%^$?Q^^!'Q_TFXU[X#_&OPCXVL;201W5
M[X1\26NI10N<X5WMY'"DX/!/8U^3_P"P]^UC^T_XR_X.I?C[^S1XM_:$\9ZG
M\.]#\+:C-HW@>^\1W,NDV,B)I15XK5G,4;#S9,%5&/,;U-?$7_!&7QC^R#\*
M_P#@YB\(_#__ ()9?%#Q;J/P5\8:#K&G71\2+-%)?+%H%Y>O$5E2.1X5N[2&
M2,RH'&,'ID_3G_!/G_E<4_:2_P"Q/U3_ - T:@#]SJ_FZ^#GB;_@L]_P<O?M
M!?%3XI?LZ?MT77P=^&'@?68K?0_#EGXKU#3((()VF-I$8=/ >ZF\N$O+/.>'
M<B/"_(G](M?SN?M>_P#!O_\ \%>/^";O[4WBS]J3_@BO\2=7N?"6O:A+>Q:!
MX2\11V6J:=;M(TOV&XL[AE@U&WB9BL0'FL0!NB!!) /8_P#@AQ^VE_P4]_99
M_P""J/B?_@C/_P %'/B'K/Q%BCL[DZ#XKU2]N-2>RO(;+^T(GBU"=1+-:7%D
M'8),=R.L841GS$/[)_%WX_? G]G[1[?Q#\>?C5X2\$:?=S&&TOO%_B2UTV&:
M0#)1'N)$5FP1P#GFOR!_X(=?\'"?[8GQ>_;)A_X)C_\ !5#X:-I/Q"ODG@T'
MQ#=>'&T;45OX8&N#9ZC9[4C4R0H[1R1I$,A5V-Y@9?B[XD?%?]A'_@J+_P %
MNOCIXS_X+ _M77O@SX6?#N^U#P[\-="@U":%;E+2]:TACC:.*7RD*Q37<H4
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M8!  #^C/1OB5\.?$?BB^\$>'O'^B7^M:8"=2TBRU6&6ZM "%/FQ*Q>/!('S
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M?\%4Y?BU\"/VM_B_XYN/A?\ !?4HG\-^$- U\VMM_;>J&XAEOU5E=598M-'
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MGQ=_X.;/VU_^"F?Q$^#W[,?_  1U^$7B?P'\1=5UE)?&UUJ^FV&JVNUD$;1
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M$MO183O RM?K%0!^&/\ P9B?\C5^UW_V.'A__P!#UJO)_P#@@5^SI-^UT?\
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MCP_;E$2+3H[F5F,I0*SNP)7?(RJ65%9OS)N?^#;+]I:3_@X1_P"%])\(K?\
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M\'76E>++G0;:3PUHD-FS6!LO,6%VB4&0*T"E=Y)!9R#EVS]'_P#!P-_P2_\
MVU_VR_CW^R/XC_97^%MYXYTCX4ZO=-XUUK4?%.FVMQ;Q&ZTADGE^V7$+7#NE
MK.[&)6.5.0"R@]+_ ,'2G_!.O]L?_@HU^S%\-/AY^QI\'O\ A,M8\/\ CR74
M=7L_^$@T_3O(MFLI8A)OOKB%&^=@-JDMSG&.: /EC_@YHU.ZU/\ ;?\ ^"?>
MLZK=&2:XU6&:YGD/+,VI:,S,3]237<?\'N5S G[&_P &;-I ))/B;<NB8ZJN
MG2@G\"R_G7HW_!QU_P $G?VO_P!M7X#_  )^,_['/AU-4^(OP3:07'AJ.^@B
MN;F*=+)_-@>9A$\EO-9*?++#>LKE=Q4*WR'_ ,%)_P#@GY_P<I_\%C/@+X/^
M)G[2'[.'A'2M1\':W]A\.?"GPSJVGZ;/-#/;N;S6[N2\U%HU;S+>UA2$2[L2
MNRQ1J&:0 7_@Y;^*&IZW_P %DOV6?A#XQ^!NO?%3PCX6\":+KD7PKT*V>>X\
M2SW6J70N;6*)$<R&>/3[:%E"L2J,*Y?]K?Q1^U)^TG_P45_9R_;#_9)_X(-_
M'?X%ZM\./%=G_P )==V_PFU"*WU:R2]M6B$BVUA$BA(?MD4C/G=%,JD[4 K[
M[_X+Y?\ !)/]K7]IKQ+\&?V_O^">\EL?C?\ !/[*D6B7%Y! ^I6T$XNK<PR3
ML(6D@N/-)BD8)+'<2#.5"2><_LK?#O\ X.2_V_\ _@H)\//CS^VU]M_9S^%O
MP]2$^(?#G@GQ"]C;>*ECE\Y[9[)+VX>X>=PD;R3%8XH=WE_/D. ?LS1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !12.Z1H9)&"JHRS$X %?&OP4_X+<_LR?'/]EGXX_MK>$O /C)_AE\#]=O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>"/'7BG1Y-*\)?$>UW6UM)-;WA9Y$7>%N8'BEA8 D!O, )')=^W1XM^!M_\
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MR#[,LEO<B)=Q8EV#[% /K'_@C?\ \%M?CY^V_P#M'>/OV%?VY/V2W^%?Q?\
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M .$X_P"$?U#4;K_A(_[ _LSS_M5W+<;?L_GS[-OF;<^8<XS@9Q7'_P#!:O\
MX)2?\/@_V6- _9H_X7U_PKO^P_B!:^)_[;_X1;^U_/\ )L;ZU^S^3]JMMN?M
MN_?O./*QM.[*_7]% 'XD_%?_ (- ?$_C#Q'IOPF\#_\ !3/QGI?P#M]675&^
M%]_9W-U'IMTV3<-91M=_9E9RS[)7C+QB3#F8J6?[8_X**?\ !$WX9_MH?\$W
M/!W_  35^#7Q/7X5>%O ^JZ7<:)?KX<_M<K!96\\(B>,W-N7>0SEWE+DE@Q(
M)8D?;U% 'YT?\%(O^" W_#P?]AKX"_L7_P##6/\ PB/_  I'1[&Q_P"$D_X0
M3[?_ &U]GTR&QW_9_MT/V;=Y7F8\R3&[;DXW'J/^"K?_  1._P"'G7Q4^ OQ
M,_X:8_X0C_A2.H3W7V+_ (0S^TO[:\R>PEV[_MD'V;'V'&=LF?-SCY<-]WT4
M ?#'[;/_  1<_P"&Q?\ @J5\$_\ @I7_ ,-)_P#".?\ "G;?2XO^$+_X0[[9
M_:_V/4KF]S]L^V1_9]_VC9_J9-NS=SG:.8_X++?\&_?PQ_X*E>-_#_[1OPX^
M,U_\*?C#X8MHK>R\8:;8F>*^@AD,L"SHDD4B2Q.28[B-PZ!L%7"H$_0ZB@#\
MM/\ @EY_P;6Z=^R#^U4O[=?[:/[5^L?'3XHZ?N;P[>:M;3"#3YC&8A=RR7,\
MTUW.L?RQEBBQ9)"LP1T]D\3?\$7/^$B_X+>^'O\ @LG_ ,-)^3_8.CO8?\*X
M_P"$.W>?NT2YTO?_ &A]L&W_ (^?-Q]G/W-F>=P^YZ* /AC]O#_@BY_PVU_P
M4L^!?_!1#_AI/_A&?^%+7&ER_P#"'_\ "'?;?[9^QZH]_C[7]LB^S[]_E_ZJ
M3;C=S]VO*/\ @I%_P;IZO^TI^V.W_!0K]A+]LW7O@)\5M0C5?$5[I%O,T&H2
M"(0FXCDMYX9;:1XE"2K^\CEQDJK%V?\ 3ZB@#\YO^"4?_! M_P!AC]I77?V[
M?VKOVK]=^.7QKURPDLH?$^M02I'IT4BK'(X:>::6>8Q(L0D9E5(BT:I@YKPK
MX$^&Y/VW_P#@[>^)GQVTV+[7X7_9F^'T6APZB!NC75)K,VAMCZ,);W5B/>T8
M]<5^QU>%?L/_ /!/#]G[]@.V\>R_!B37=0U7XF>-;GQ3XT\1>*-02ZO]1OYB
M2VZ1(XP(U9I&5 O#2R')W4 >ZT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 5-?_Y 5[_UZ2?^@FOQ6K]J
M=?\ ^0%>_P#7I)_Z":_%:@ HHHH **** "BBB@ HHHH ^Y?^"/7_ " O'O\
MU]Z=_P"@W%?9]?&'_!'K_D!>/?\ K[T[_P!!N*^SZ "BBB@ HHHH **** "B
MBB@ HHHH **** /$/BI_R/\ J/\ UT3_ -%K7/5T/Q4_Y'_4?^NB?^BUKGJ
M"BBB@ HHHH **** "NH^#O\ R/\ :?\ 7.7_ -%M7+UU'P=_Y'^T_P"N<O\
MZ+:@#VBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@;6-1T,:UX8B\0(-FLZ<3Q/$VU>H^8 !E(5B&.TT ?1E%%% 'W+_P $>O\
MD!>/?^OO3O\ T&XK[/KXP_X(]?\ ("\>_P#7WIW_ *#<5]GT %%%% !1110
M4444 %%%% !1110 4444 >(?%3_D?]1_ZZ)_Z+6N>KH?BI_R/^H_]=$_]%K7
M/4 %%8OQ)^(7A3X2?#K7_BMX\U(66A^&-%NM6UF\*%O(M+:%III,#D[41C@>
ME?GG^Q=_P<$Q?M)_M;V?P1^*/[+OB#P/X1\?:C;VGPH\3WT9+SR26:W$<=\,
ME5:Y5EDA,7 65 =XS+0!^DU%?GY^T7_P<"?";X"_'7Q=X#TO]ESXA^+? /PU
M\1P:#\3OBMH5J&TW0-0DD$30[=I\PI(?+.YXR74JH;*EOO;1?$>A>(O#MIXN
MT758+C3+ZRCO+2^C?]W+ Z!TD!_NE2#GT- %VBOSR\%_\'$OP$\6_&O1]"N?
MV=/'^F?"3Q+XR;PKX9^.E_9;-%O]4#;0N"OR1,1D/O+A<LT:!7V?H;0 5U'P
M=_Y'^T_ZYR_^BVKEZZCX._\ (_VG_7.7_P!%M0![11110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"&L/C9_P!&/^.__ JV_P#BJ]THH \+_P"&L/C9_P!&/^.__ JV_P#BJ/\
MAK#XV?\ 1C_CO_P*MO\ XJO=** /"_\ AK#XV?\ 1C_CO_P*MO\ XJC_ (:P
M^-G_ $8_X[_\"K;_ .*KW2B@#S[X,_&/Q[\3=3O;'Q?\ ?$/@Z.U@62&YUJ:
M)EN&+8*+L)Y YYKT&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BL7XC_$+P=\)/A[KOQ5^(>N1:9H'AG1KK5=<U*?.
MRUL[>)III6QSA41F./2OSS^%G[1W_!>W]N_X=I^V'^R?X7^!/PO^'&MPF_\
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MWAGP''\0])\%VWC7P;XK^&:7<6D^(] DN39S$V]V\DMO<6]SLC<%R&$JL H
M9P#Z\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#Y4_X+D:1XGUS_@D)^T18>$8)I+P?"[4I72#
M[QMXX_,N.G4>2LF1Z9KU?]D;QO\ #2Z_8^^$?B3PMKNGV_A_6/ 6@)X;D-RB
M1S1RV,/V>*/)PS%<!5&2<8%>EZQH^D^(=(NM U[38+VQOK9[>]L[J(213Q.I
M5XW5N&5E)!!X()%?EO\ &W_@WN_:7UOX2ZI^Q5\ /^"B=KI'[.FHZR=1T/X?
M^//AI!K^H>"9#*TN-)U%IXYD".[^5DJT08X9F9V8 ]*_X)R^'/!_Q3_X*8_\
M%$87\/6&L_#_ %WQKX3T"]TZ\MTN+&^O8?#IM]8MY(F!23+R!)48$'=AA79_
MLHV5GIO_  6P_:JT[3K2*WM[?X5?#..""",(D:*FM!551P    !P *U_^"1?
M[ _QN_X)M> ?&_[-?C;QMX8\7^#9/%4FO^$/'%M;W,7B/7+B^>22^?7!(SQR
M7*,L")/&Y\V/&Y4*8KU;X7?LA_\ "MOVWOBQ^V3_ ,+"^V_\+0\+^&M'_P"$
M<_LGR_[,_LD7H\W[1YK>=YOVS[OEIL\OJ^[@ Q_^"L7_ "BR_:6_[-_\9?\
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MVUG3TBSQP/.[^OZ[?Q._X)I?M&_'?]DKPG\.OCS^WU>>(_CC\.O'*^+OA_\
M'>P^'%AI+Z=J,32"&.72K=S!-;^1+)!+$7 E5LMR!70_L1?L&?&?X._';QA^
MV3^V5^T=9_%+XN>+O#]EX<M]2T?PPND:7X>T*VE>==/L[?S)&(DN)&GED=LL
M^W &TE@#ZEHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cah-20200930_g4.jpg
<TEXT>
begin 644 cah-20200930_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT3VOQ0^&E]XP;X>67Q$T*;7U@$S:'%J\+7@B*!PYA#;]I1E;.,88'H:^$?\
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M<1_9O[.6Y,&/M/VY8<#[/Y9!F&[> =E?TDUE'P)X'/B<>-CX-TK^V@NT:O\
MV=%]JVXVX\W;OQCCKTH _&K]G7X!?\%*O^"(/_!O+#XA_9Y_9Z\.>+?B=KOB
MVX\5_%;P+XJT2YU)M+TJ]MEMF"6]M-&TTT,%M9&:([E0/<9!$1S^;'_!0+]J
M3_@CY_P4!_9Y\+Z+^Q3_ ,$W_%7@[]JGQ+J.GPZC9^!](6VT9KD\7<,%G;7#
MI<B5\^4$MHY/F!9EVE'_ *T:QM+^'7P^T37YO%>B^!=&L]4N2WVC4K73(H[B
M7<<MND50S9/7)YH _('_ (*!_M%_\%#/^"3G_!,S]F#P#\1?V2_ _P 7_A78
M>!=$T/\ :(LO%7A^76)]/DMTMM]DS><;:.)X1);I<2Q2HLL()/SQAOS,_:CT
MC_@GM_P4L_;*^#G@'_@@=^QS\0? ?CG4=>%UXPNKB)H+*P/FV[0W20)=7*6B
M6VV6225#%$H"X#DY']9$T,-S"]O<1+)'(I5T=<A@>""#U%9?A?P%X%\#K,G@
MKP7I.CBY8-<#2].BMQ*1T+>6HW$9/7UH UJ_$'QE_P KM/A/_LG\G_J)7M?M
M]10!_*U_P2F_86G\._\ !T"O[-$^ER+H7PB^*OB;68XL96&TT_[0]A,%/ #R
M"PY]&7T%?7G_  1@TSXA:U_P6"_X*<Z-\([_ .R^*[O5?&4/ABZWA?)U%O$&
MHK;/DD 8E*'.1C%?O310!_*O_P $;OVTOV1/V'?A-\5/V>OC=_P3M\1_$#]K
MK6_%5YIWP_\ /\&0W]_]HEM4MXM/)N3YUB\5TL\LICC+N)1G<4 'L'_!$_5[
M2P_X-UOV^OA=J!,&NZ':ZO<:IITHQ+;I-HJPIN7J,O:3KSWC/I7]&T?@SP?%
MXE?QG%X4TU=8DB\J35EL8Q<LF -IEQO(P ,9QQ6E0!^;W_!IY#%%_P $3?AX
M\<2J9/$7B)I"!C<?[5N!D^IP /P%?F=\'_VF/CE_P:Y_\%3/CE\.OB9^R_KG
MC/X;_%_4Q<>$)M*D-N^IP1W5S-IDMK*R/'*Z)>36\T(^99&R#\H#_P!*5?B-
M\>/B)_P<P_\ !-3]OOX@^*/A1\,/$W[3'P:\3ZGJ%QX)TJ[CDU2WTVUN;D7$
M$>+9A=6LULO^CX?]RR[BH.5* '@W_!'3XK?M"_'3_@Z=\7_&;]J7X6S>"/&O
MBGP;J&IWW@^Y<M+HUI-I-E)86LA8!O,2R:U5MRJVX'<B-E1[)_P0?_Y66/VZ
M?^PAXI_]2B&O0O\ @A=^P+_P4,^(?_!2[XJ?\%F/^"D_PCA^'NO^,M%DTWPY
MX0,0AF+RBVB,OD&222WAAMK1(%$Q\R0R%CPN6_8R@#\,?^#.C_DOW[;?_8X>
M'/\ TJ\1T?\ !!__ )66/VZ?^PAXI_\ 4HAK]SJ* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGP]^U_^RMXKL_&^I^'_
M -HGP9<V?PTOY+'X@WR^(K<6_ARYC+"2*]E+A+=E*,&#D;=ISBN(_P""I7[6
M[_L*?\$]OBS^U592QIJ/A3PC,V@&504_M2X9;6Q# ]5^U3P9'<9K\\?^"97[
M,'P5^$__  :\^,/$?[6OBCQ!I>C?&#PYKOC/XG^(]$@6YU46UW)Y4<\7F!O-
MD-I;VSX8'YI'ZYR0#];/AE\5_A;\:_!]O\0O@U\2M \6Z!=R2):ZYX9UF"_L
MYF1BCJDT#,C%6!4@'@@@\BM^OS<_X)L_M3_\$W?^";G_  0XTG]H[X2?$[Q]
MKWP,\,ZY>I'KWB+0$_MB2>ZUIK=E:WA5 5%S-M! 'R#)S4'QC_X.O_\ @D3\
M'KWPS8-XV\9>)9/$>BV>J3_\(MX96<:-#<QK+&EX99HPLH1U9HHO-=,X8!OE
MH _2JN5^+OQT^"7[/OAN#QG\>OC%X5\$:/<WRV5MJOB_Q#;:;;2W+([K LMP
MZ*TA2.1@@.XK&QQA3@^"'QL^%O[2'PC\/?';X)^,;;7_  IXJTR/4-"U>TW!
M+B!QP=K ,C Y5D8!E965@""!^5?_  >K?\HLO /_ &<!I7_ICUR@#]=='UC2
M/$.D6OB#P_JEM?6%];)<65[9SK+#<0NH9)$=25=64@A@2"""*POBQ\:O@W\!
M?"Z^./CG\6O#/@O17NDM4UCQ9KUOIUJT[ABL0EN'1"Y"L0N<D*<#@U^8WP8_
MX.AO^"3/[/GA'X7_ ++/C/XD>)KV]T?P+H6F:_XLT/PX;K1=+NDL($ECDF60
M2R>6P*LT,4J@@@$X./5/^#AD?\$^_C-_P31T'7_VS_C;XKT?X6ZMXVT?4=%\
M4?#"T@U&>]GDM+I[5H]RNCP21/(^\=?DP<&@#[.\?_M4_LP?"?P;HGQ&^*?[
M1_@+PUX>\2Q)+X<U[Q!XPLK.RU5'C$J-;3S2JDX:-E<%"05((X.:L_$S]I']
MG;X+:EHFC?&/X]^"_"5YXED*>'+3Q-XIM+"756#(I6V6>13.098P0@/,B#^(
M9_"7_@Z;LOAQIO\ P2&_8QT[X.:SJ.H^$+?3["/PKJ&L0K'=W6FKH%N+:6=%
M "RM"$9E  #$@ 5V'_!UM_R=/^P7_P!C!>_^EV@4 ?M9XO\ VC/V>_A[\2-'
M^#?C[X[^#-#\7^(5C;0/"NL>*+2VU+4Q)(T<9M[:202S!I$=%V*<LI Y!%=E
M7Y9_\%./!/\ P38UG_@NU^S)XF_:+^,_Q(T?XTV5GH8^'7AKP[HT$VBZ@BZS
M>M;F[F>,O&6N#,K;6&$53U.:^MO^"C?_  5L_8D_X)9^$M-\0_M6_$:XM]1U
MP2'P_P"%-!L3>:KJ2H0'>.$%52-20#)*\:9^4,6XH ^EJ*^,O^";W_!>C_@G
MC_P5%\97?PN_9]\;ZUI'C*VM7NH_!_C72EL;Z[MT^_+;F.26&<*.61)"ZJ"Q
M4*":U?VB/^"WW_!//]D_]JC6/V0_V@_BG?>&?$V@>&&U[5;Z^T>0Z?#:"U-R
M )ER7E= %2)%9WD944%F (!]<45\'_L#?\'&O_!-C_@HK^T$/V8_@OXB\5Z-
MXLO$G?P_;>,M!2SBUSR4:21;5XYI07$:-)LD\MRJM@$@@;W_  4B_P""^7_!
M//\ X)=>/+3X2?M ^+?$&L>,;FRCO)O"G@G1TO;NRMY,^7).TLL4,6X E4:3
M>5PVW:RD@'VE7&? []HKX$?M,>%KOQM^S[\7/#_C+2=/U6;3+_4/#NIQW45M
M>Q!3);R%"=DBAT)0X(# XY%>$_\ !-7_ (+*?L-_\%6+#6H_V6_&FJ)KGAV&
M.?6_"?B?3/L6I6UN[;5G"*[QRQ[OE+1R.%8J&V[EW?#W_!._Q=<_L"?\'+/[
M1_\ P3\\XV_@OXZ6?_">^$++.(TU5H!?S").B*4EU)&V]19Q#&%& #]BJ***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!1\3^&= \:>&M1\'>*])AO]+U:QFLM2L;E=T=S;RH4DC8=U96((]#7R1_
MP1@_X)T?&#_@ES\#/&O[+OC/XG:/XI\&+\1=0UCX87%FTWVRQTFYVXM+M9(U
M02!D\PF-G!>:3G %?8M% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M\6_\$M/^"8GQ"_8Z^.?Q_P#VN?VD/'&@>)OB;\<_'TNIRW?A_P ]K;2=&5WD
MMK"-IT1\JTK!L* 5A@')3-?:5% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%17]U]AL9
MKWR]WDPL^W.,X!.,U\5?\/B_^K=/_+N_^Y* /MJBOB7_ (?%_P#5NG_EW?\
MW)1_P^+_ .K=/_+N_P#N2@#[:HKXE_X?%_\ 5NG_ )=W_P!R4?\ #XO_ *MT
M_P#+N_\ N2@#[:HKXE_X?%_]6Z?^7=_]R4?\/B_^K=/_ "[O_N2@#[:HKXE_
MX?%_]6Z?^7=_]R4?\/B_^K=/_+N_^Y* /MJBO&/V//VO/^&L+'7KW_A7O]@?
MV'-;IM_M;[5YWFB0YSY4>W'E^^<]L5[/0 4444 %%%% !1110 4444 %%%%
M!1110 45AZK\2/!>B:A)I>IZSY4\) DC^SR-C(!ZA2.A%5_^%N?#S_H8/_)2
M;_XB@#I**YO_ (6Y\//^A@_\E)O_ (BC_A;GP\_Z&#_R4F_^(H Z2BN;_P"%
MN?#S_H8/_)2;_P"(H_X6Y\//^A@_\E)O_B* .DHKF_\ A;GP\_Z&#_R4F_\
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M1110 4444 %%%% !1110!XA\5/\ D?\ 4?\ KHG_ *+6N>KH?BI_R/\ J/\
MUT3_ -%K7/4 %%%% !1110 4444 %=1\'?\ D?[3_KG+_P"BVKEZZCX._P#(
M_P!I_P!<Y?\ T6U 'M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 5-?_Y 5[_UZ2?^@FOQ6K]J
M=?\ ^0%>_P#7I)_Z":_%:@ HHHH **** "BBB@ HHHH ^Y?^"/7_ " O'O\
MU]Z=_P"@W%?9]?&'_!'K_D!>/?\ K[T[_P!!N*^SZ "BBB@ HHHH **** "B
MBB@ HHHH **** /$/BI_R/\ J/\ UT3_ -%K7/5T/Q4_Y'_4?^NB?^BUKGJ
M"BBB@ HHHH **** "NH^#O\ R/\ :?\ 7.7_ -%M7+UU'P=_Y'^T_P"N<O\
MZ+:@#VBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)'MIQAXBR@E&'J,X/N* +%=1\'?^1_M/^N<O_HMJY>NH^#O_ "/]I_USE_\
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M5X[_ /";MO\ Y-H_X8D^-G_1*O'?_A-VW_R;7ZG44 ?EC_PQ)\;/^B5>._\
MPF[;_P"3:/\ AB3XV?\ 1*O'?_A-VW_R;7ZG44 ?EC_PQ)\;/^B5>.__  F[
M;_Y-H_X8D^-G_1*O'?\ X3=M_P#)M?J=10!^6/\ PQ)\;/\ HE7CO_PF[;_Y
M-H_X8D^-G_1*O'?_ (3=M_\ )M?J=10!\1_L>6GQL_9/L=>LO^&8?'>O_P!N
M36[[OL=M:^3Y0D&,>?)NSYGMC'?->T?\-8?&S_HQ_P =_P#@5;?_ !5>Z44
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MX?\ CSX:0:_J'@F0RM+C2=1:>.9 CN_E9*M$&.&9F=F /2O^"<OASP?\4_\
M@IC_ ,%$87\/6&L_#_7?&OA/0+W3KRW2XL;Z]A\.FWUBWDB8%),O($E1@0=V
M&%=G^RC96>F_\%L/VJM.TZTBM[>W^%7PSC@@@C")&BIK0554<     < "M?_
M ()%_L#_ !N_X)M> ?&_[-?C;QMX8\7^#9/%4FO^$/'%M;W,7B/7+B^>22^?
M7!(SQR7*,L")/&Y\V/&Y4*8KU;X7?LA_\*V_;>^+'[9/_"POMO\ PM#POX:T
M?_A'/[)\O^S/[)%Z/-^T>:WG>;]L^[Y:;/+ZONX ,?\ X*Q?\HLOVEO^S?\
MQE_Z8[RODO\ 8!_97_X+7R?L\?!/Q=:?\%6/!4?@5O!?AN\B\('X&61G72?L
MENXL?M7F[BX@_=>=C.?FQFOO/]K'X%_\-0?LL?$O]FC_ (2G^P_^%B?#_6?#
M']M_8?M/]G_;[&:U^T>3OC\WR_-W[-Z;MN-RYR-#]GKX4?\ "A_@%X'^!W]O
M?VK_ ,(9X/TS0O[4^R^1]L^R6L=OYWE[G\O?Y>[9N;;G&XXS0!\L?\%\/@W#
MXH_8"UO]J#PGK']B_$/]GJZC^)'PX\21P[WL[_3CYLD##(+PSPB2)XR=K$HS
M!M@%=S_P2 _9KTS]G3]A7PEJ5[KKZ[XO^)< \??$CQ5<QA9];U[5T2[N9WQV
M7>D*#M'"G?->G?MK_LW?\-A?LC_$?]EC_A,_^$=_X6!X/OM"_MW^SOM?V#[1
M$T?G>1YD?F[=V=F],XQN%6-)^"/B_P (?LB6W[-_P^^*ATC7]+^&Z>&M#\;K
MI'F&RO([ 6L.HBU\T;MDBK-Y/FC.W;O'WJ /BW]MOXCZW_P6"^.&J_\ !*+]
MF2XF;X5>%M=M#^U-\4;8XMHHX)DG'A73Y1_K;Z9XE%PZY6W0%6W,6CKZ#_X*
ML?#_ ,!V7_!-?]H_QI:>"]*CUBU_9J\8Z7:ZLFGQBYAL1HUV_P!F67;O6'<
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MI:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cah-20200930_g5.jpg
<TEXT>
begin 644 cah-20200930_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-YGP]\'P/"VDQZ?IFH-<F&99(VD(DOWN9-L;H@)8LKF1L<G_ ,$QOV&O ?\
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M3F@!W_!9+]GWX>_M3?\ !UG\ ?@1\6="CU7PUKGA;P^=<TJ;/EWMM!<:G<O
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M9[F%[/[1<?94O+1W:W8/</.T:I;RS.\8+#:J5\$_"[XA?&'XB?\ !T!^SO\
M%'XL?L 6G[,^IZ_:0S6G@&T"+/<V1M=3@6^N0D4.)I CPL&BC;; N5[GZ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_('_ (/5O^467@'_ +.
MTK_TQZY7Z_5^0/\ P>K?\HLO /\ V<!I7_ICUR@"#XO?LW?\$&D_X(D6GC/X
MM_#?]G_0O%"_L^65S_;_ (>L-(L_$3:Z=&C>-DDM0MS-=M=!?D;<7<L'!#,#
MYE_P:M_M6:'^QM_P17^._P"TU^T/JUY;?#KP'\1[N_M&5-TDLIT[3U>UM@Q
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M%O# \.7WB+5KC1UAME2VFTR,7ATD*DI6.),*YW?,N2#0!]\?\%J_^"W^H?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M82RH01W H ]SHK\:_P#@AW:_L;^)/CAX3^(FB_\ !0GXF^(?B7H'@Z74M?\
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MW_7[IG_H%S7W;0 4444 %%%% !1110 4444 %%%% !1110!\P_'?_DK.L?\
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M444 %%%% !1110 4444 %%%% !1110!3\1_\B]?_ /7E+_Z :_!>OWH\1_\
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M_P"*H_X:P^-G_1C_ ([_ / JV_\ BJ]THH \+_X:P^-G_1C_ ([_ / JV_\
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MT>[<A7[WFG&,YZ5]?44 >%_\-8?&S_HQ_P =_P#@5;?_ !5'_#6'QL_Z,?\
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MOH!F$#W5LEP3+!<0RD)+"QR2690%7D ^S**^$/B3_P %F_"^M_\ !53X5?\
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MUU'JEU=RP?O)+&U6RGF)C.]T>(<$G'H_[$_[7_[73_M:^+O^"?7_  4&\,^
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MS)<3-\*O"VNVA_:F^*-L<6T4<$R3CPKI\H_UM],\2BX=<K;H"K;F+1U]!_\
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M!Z=^W1X*\'>!O^"BG[$5AX*\)Z;I$%_\8_&NI7T.EV,<"W%Y<^&-2FN+EP@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cah-20200930_g6.jpg
<TEXT>
begin 644 cah-20200930_g6.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
MD 'T P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^,_AO;_%F4:OJ$'A3Q-<6,LD%Q86=PMK.\#)YOE-*ZX/&0V.M?*?[=W[8_\
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M5-2N+2[O9-1B(0/#*MW:Y0AB=LA+%F4,?T#_ ."O_P"S9I/_  4J_P"":OP
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M/R9D:9]T<Z;@" N/SM\?_%3]@W_@J)_P6S^.WCC_ (+"?M77W@WX8?#^_O\
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M[;BSO;=98I1G.&1@0PR >1VH _EJ_P""GW[=W[)G[47[17[+OQA_8J_9 O\
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MHO.DM;A Z2 JC\KL#_TG>&O"7A7P9IW]C^#_  SI^DVAD+FUTVRC@CW'JVU
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M(O?MH_"3]H/_ (*D_M7_  8\#?L,_#?X;ZOX(\1:G!K'CGPE:E-2\4-'K=Q
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MU,GRIK_Q&]BI&,0_V]?C_P!#$A_&OT.H **** "BBB@ HHHH **** "BBB@
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M<_;/MDGVC9]GV?ZF/=OW<8VG[GHH ^&/V7?^"+G_  S9_P %>?BM_P %5?\
MAI/^VO\ A9VCWUA_P@?_  AWV;^S?M,]C+O^V_;'\[;]CQCR$SYF<C;@G[/G
M_!%S_A1'_!8KXD_\%9?^&D_[5_X6%H]U8?\ " ?\(=Y'V#SELAO^W?;'\W'V
M3IY"9\SJ-O/W/10!\,?\$W?^"+G_  [X_;E^/7[9_P#PTG_PEW_"[M8O;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-OCGP#X0_9&^(OCWP=\*-4M].^*GQ&\.PH+'0+F1]C1A64B0HV4.]XLNK 9
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MX8>VMM0"R(TL3[;X@>8J;"Q5N#T.,4 ?:-%%% 'W+_P1Z_Y 7CW_ *^]._\
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M"W_[4WQLOK&:R_X8C\=KYT+)N^TVQQD$9QNKXK_X8D^-G_1*O'?_ (3=M_\
M)M?J=10!^6/_  Q)\;/^B5>._P#PF[;_ .3:/^&)/C9_T2KQW_X3=M_\FU^I
MU% 'Y8_\,2?&S_HE7CO_ ,)NV_\ DVC_ (8D^-G_ $2KQW_X3=M_\FU^IU%
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M_P#@5;?_ !5>Z44 >%_\-8?&S_HQ_P =_P#@5;?_ !5'_#6'QL_Z,?\ '?\
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MD8B2XD:>61VRS[< ;26 /J6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cah-20200930_g7.jpg
<TEXT>
begin 644 cah-20200930_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _E)^#/_  5[_P""@/PN_P""SMG+\1?VR_B?
MJGPQTG]I!M%\0>']6\;7LVE1Z7/JTUNT+0/*8]J6XE9$(P/)&,8K]*O^#NW]
MO3]HK]EWX8_!/X)?LI_&?Q5X,\5^-?%.HZE>7W@O7)["]EM+.".!('D@96,4
MDM\&VD[2UN#U08_'_P")/P-E^)WP,_;X^*6G6Y%W\,OV@_#6N&YCX>."?5_$
M>FN 1T!DO86/O&#VKZV_:\^/\/\ P5N_X*;^ /&,=TE[I7PU_8=O/%?B*"/#
M+;:K+X5O=4=CV5UNK_3XV]/*'>@#]*?^#4S]H?X\?M-?\$P[_P"(_P"T5\9/
M$WCGQ GQ2U:S36O%FMSW]TMNEM8LD0EF9FV*7<A<X!8^M?=]E^U;^RYJ7Q3?
MX%Z=^TGX!N/&T4S0R>#H?&-B^JI(OWD-H)?.##N-N17X"_\ !/?]L/XA?L1_
M\&E_Q;^*_P (M;N-+\5ZI\7KWP]H.K6KE9;"2^3389;B-ARDB6YG9'&"L@0@
MY%?*E]^RY_P1GT?_ (),67QW\+_M_7R_M<6VG0>)/[&BOKE(UO3<*[:8L8MQ
MLE2(\3"7=YZ;MVP[  ?UP7-S;65M)>7EPD4,2%Y997"JB@9+$G@ #G-?GK_P
M7:_;M\*1_P#!&[XY_%7]AS]K[29?%?A*7P[$VO\ PO\ '<,M]H[S>(M-@D4S
M64Q>!GC>6,@D$JSKT)%?G%_P5F_X*V?'OXU_\&W/[-U_)XTO+;Q'\:KV\T7X
MBZM!,4GU6VT22:TNED*X_P"/J=+>:3;@,"R$;79:J_\ !7O_ (-P_@K_ ,$V
MO^"1ES^TM\%/BMXR_P"$X\/VNBV7Q;%SJX;3?$EO=WUI')&+=$7RTBU VDL2
MEF 6$;M[A9  ?5U]%_P4._;(_P"#<S]GKQ1^SW^W--X%^*FJ:O;7_B'XC^,?
MBA=:+/J5HIU6.2WDU %I)G9C;L(V)R(<_P  K]2OV=+?Q/X-_9B\"6GQ:\<6
MVKZSI7@/2T\3>)3JOVF&]NHK*(7%W]I?'FH[J\GFM]X-N/6OY_?^"D'_ "I^
M_LK_ /90--_]%:_7=?\ !>O]HKXOW_\ P3W_ &%?^"<'PF\83Z):?&GP-X?/
MBN>&1D%U%'9Z7;6EO(5(+P&:YDE=,X)@B]* /W&^%G[5?[+WQSUZ[\*_!+]I
M'P#XQU33U+7^F^%?&-EJ%Q;*#@F2.WE=D /'('-;OQ,^+7PJ^"OA>3QQ\9/B
M;X>\):+%($EUCQ-K4%A:HQR0IEG=4!.#QGL:_'+XG_\ !I9J?[/7Q.^$'QT_
MX)._M07G@WQOX(U9+GQ1KGQ$U669+LQA66X@CM+;[SL)(Y;=B(GBDVY&&$G>
M?\%]OV!_V2_CS^U9\,?VD_\ @IQ_P4PTCX??!SP[HDMFGPC\MH+^_E42R3W-
MC(DDDDSR2M;)*4M2RQ0HH8,5( /U%^$?Q^^!'Q_TFXU[X#_&OPCXVL;201W5
M[X1\26NI10N<X5WMY'"DX/!/8U^3_P"P]^UC^T_XR_X.I?C[^S1XM_:$\9ZG
M\.]#\+:C-HW@>^\1W,NDV,B)I15XK5G,4;#S9,%5&/,;U-?$7_!&7QC^R#\*
M_P#@YB\(_#__ ()9?%#Q;J/P5\8:#K&G71\2+-%)?+%H%Y>O$5E2.1X5N[2&
M2,RH'&,'ID_3G_!/G_E<4_:2_P"Q/U3_ - T:@#]SJ_FZ^#GB;_@L]_P<O?M
M!?%3XI?LZ?MT77P=^&'@?68K?0_#EGXKU#3((()VF-I$8=/ >ZF\N$O+/.>'
M<B/"_(G](M?SN?M>_P#!O_\ \%>/^";O[4WBS]J3_@BO\2=7N?"6O:A+>Q:!
MX2\11V6J:=;M(TOV&XL[AE@U&WB9BL0'FL0!NB!!) /8_P#@AQ^VE_P4]_99
M_P""J/B?_@C/_P %'/B'K/Q%BCL[DZ#XKU2]N-2>RO(;+^T(GBU"=1+-:7%D
M'8),=R.L841GS$/[)_%WX_? G]G[1[?Q#\>?C5X2\$:?=S&&TOO%_B2UTV&:
M0#)1'N)$5FP1P#GFOR!_X(=?\'"?[8GQ>_;)A_X)C_\ !5#X:-I/Q"ODG@T'
MQ#=>'&T;45OX8&N#9ZC9[4C4R0H[1R1I$,A5V-Y@9?B[XD?%?]A'_@J+_P %
MNOCIXS_X+ _M77O@SX6?#N^U#P[\-="@U":%;E+2]:TACC:.*7RD*Q37<H4
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M8!  #^C/1OB5\.?$?BB^\$>'O'^B7^M:8"=2TBRU6&6ZM "%/FQ*Q>/!('S
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M?\%4Y?BU\"/VM_B_XYN/A?\ !?4HG\-^$- U\VMM_;>J&XAEOU5E=598M-'
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MGQ=_X.;/VU_^"F?Q$^#W[,?_  1U^$7B?P'\1=5UE)?&UUJ^FV&JVNUD$;1
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M$MO183O RM?K%0!^&/\ P9B?\C5^UW_V.'A__P!#UJO)_P#@@5^SI-^UT?\
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M;?\ ^#MSX._LYZO,UQX7_9R\''7[C3R=RQZJUD=26X']UC+/I /M;CN:]/\
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M?7WA'Q"FZQU>*/P_IC-:S@ YC<#:PQT-?<?_  2F_P""E?[,_@__ ((B7?\
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M!F@#WK_@DA^T]J?[9/\ P34^#'[1WB#4&N]7U_P-:QZ_=LV3<:E:[K.\D/\
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MR/R-_P!MV8\F3;Y6<G=A?N>B@ KX8_8F_P""+G_#'7_!4KXV?\%*_P#AI/\
MX2/_ (7%;ZI%_P (7_PAWV/^R/MFI6U[G[9]LD^T;/L^S_4Q[M^[C&T_<]%
M'PQ^R[_P1<_X9L_X*\_%;_@JK_PTG_;7_"SM'OK#_A _^$.^S?V;]IGL9=_V
MW[8_G;?L>,>0F?,SD;<$_9\_X(N?\*(_X+%?$G_@K+_PTG_:O_"PM'NK#_A
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM_&_Q.U2'X.VVMJ6FL='D12EV5?.0JQR$ Y#2.K'<K'/8_\ !-']HO\ 9_\
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M10 4444 ?<O_  1Z_P"0%X]_Z^]._P#0;BOL^OC#_@CU_P @+Q[_ -?>G?\
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M_P#':/\ A+OC9_T:;X[_ ._5M_\ ':^O** /D/\ X2[XV?\ 1IOCO_OU;?\
MQVC_ (2[XV?]&F^._P#OU;?_ !VOKRB@#Y#_ .$N^-G_ $:;X[_[]6W_ ,=H
M_P"$N^-G_1IOCO\ []6W_P =KZ\HH ^0_P#A+OC9_P!&F^._^_5M_P#':T_!
MWQ2^-GA/7X=<_P"&0/'=QY2L/*Q;)G<I'7S#Z^E?5-% 'A?_  UA\;/^C'_'
M?_@5;?\ Q5'_  UA\;/^C'_'?_@5;?\ Q5>Z44 >%_\ #6'QL_Z,?\=_^!5M
M_P#%4?\ #6'QL_Z,?\=_^!5M_P#%5[I10!X7_P -8?&S_HQ_QW_X%6W_ ,51
M_P -8?&S_HQ_QW_X%6W_ ,57NE% 'GWP9^,?CWXFZG>V/B_X ^(?!T=K LD-
MSK4T3+<,6P4783R!SS7H-%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%8OQ'^(7@[X2?#W7?BK\0]<BTS0/#.C76JZY
MJ4^=EK9V\3332MCG"HC,<>E?GG\+/VCO^"]O[=_P[3]L/]D_PO\  GX7_#C6
MX3?_  P\"_%'3]2O-:\1Z83N@NK^>UD$=F+E KQK%RJR#)(Q(P!^DU%?,G[!
M'_!27PE^U9^RWXJ^-7QM\+Q_"WQ-\*-6U/1/C;X9UW4$\KPKJ.FQ^9>.TYPK
M6OE8F6;[NPD9)0FO/O\ @F;_ ,%9Y?\ @I1^US\;O!_P\\$W&G?"SP)H/AJX
M^'NM:KI,UK>>)$O9-36?4PLN"+60VJ+ -H)2,N3F38@!]N45Y;^W'\:/%G[-
M_P"Q3\8/VA_ 5K8SZ[X"^%OB#Q'HL&IPM);27=CIMQ<PK*B,C-&7B4,%925R
M P/-?%OP7\7_ /!S/\</@[X3^-7AGQQ^Q5:Z;XP\-6&MZ?;7^C>*1/%!=VZ3
MQI($=E#A9 " Q&0<$CF@#])**^./A[^W)^T;\*_^"GD7[ W[9VG>$8=)^(GP
M_@U_X*>+/#-C<6T>HZC:1 :UI,QGF?S9HV)GB*K'BW"[@6< 6K__ (* _$CQ
MG_P4?\6_L\_"6PT,?"+X$> )=9^/?C"\T^:XN1J]Q"TUEH]@Z2JB21P(US,S
M)+\O[O$;X) /KVBORVO_ /@J-_P5P\,_LF6?_!6GQ;\!?@Y#^SY<&WUJZ^&4
M,VI?\)K:^%)[A(X[_P"V-(+)[ORW6X,/EA#&<9#\#Z'_ ."L/_!7#X4_\$Z?
MV;KGQ9X7A;Q;\2_$?A2^U3X;^!].M)+B:\B@MFGEU*Y2,9AL+:)6GFE8J-D3
M*IW= #["HKB_V;O'^N_%?]G?P%\4O%"0+J?B7P7I6JZBMK&4B$]Q:132!%))
M5=SG ).!CDUVE !1110 4444 %%%% !1110 4444 %%%% !17P'\0?VT_P#@
MHS^VG^U'\0/V>/\ @E?IGPU\-^"_@_K?]@?$#XP_$^SN[Z*^\0HBO/I.F6EL
MR[FM]RK/)*<!FP-N%,G8?L(?MW?M1ZC^U#XD_P""<O\ P4>^'?A;0OB_H?AI
M?$_A7Q1X#DG_ + \;Z 9A ]U;)<$RP7$,I"2PL<DEF4!5Y /LRBOA#XD_P#!
M9OPOK?\ P54^%7_!.?\ 9FTN/Q)8WGC+6-%^,/C7[#*]AI%]::/?72:+;S@A
M&OEEMP\PRWE+'Y9!=F\O[OH **_,GX4?M/\ _!?+]L3XC?&?5/V3]<_94TCP
M1\._COXJ\!:1!X_T;Q#_ &G+'I5Z84EE-I*\3%HFCRPVY8-\BC KLOCY^VK_
M ,%,_P#@G7X!^#_QU_;TB^#>M^![[XAOX>^.NJ?#;2=32+P[87K+%I>JP2W<
MP*113';<AXWSNC$>"^0 ?H)17RG_ ,%%_P!MWXM?!;QE\(_V5/V.]+\/ZU\8
M?C1XK2WT1=?M9;O3]$T"U"S:IK5U'!+$[110X5%$B[WD&TL5*GSKQW^UW_P5
M(_::_:6^+'PG_P"";?A#X-:3X4^">IP:#K?B3XPP:I/)XH\0-:QW4UG:)8R1
MBV@A26.-Y9-Y+N"H(SM /O&BOS\?_@LA\4?BE^P5\(/BE^SY\#=('QU^-?CV
M7P#H/@3Q+J$C:9HFO6<UU'JEU=RP?O)+&U6RGF)C.]T>(<$G'H_[$_[7_P"U
MT_[6OB[_ ()]?\%!O#/@./XAZ3X+MO&O@WQ7\,TNXM)\1Z!)<FSF)M[MY);>
MXM[G9&X+D,)58!0 S@'UY1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RI_P7(TCQ/KG_!(3]HB
MP\(P327@^%VI2ND'WC;QQ^9<=.H\E9,CTS7J_P"R-XW^&EU^Q]\(_$GA;7=/
MM_#^L> M 3PW(;E$CFCEL8?L\4>3AF*X"J,DXP*]+UC1])\0Z1=:!KVFP7MC
M?6SV][9W40DBGB=2KQNK<,K*2"#P02*_+?XV_P#!O=^TOK?PEU3]BKX ?\%$
M[72/V=-1UDZCH?P_\>?#2#7]0\$R&5I<:3J+3QS($=W\K)5H@QPS,SLP!Z5_
MP3E\.>#_ (I_\%,?^"B,+^'K#6?A_KOC7PGH%[IUY;I<6-]>P^'3;ZQ;R1,"
MDF7D"2HP(.[#"NS_ &4;*STW_@MA^U5IVG6D5O;V_P *OAG'!!!&$2-%36@J
MJHX     X %:_P#P2+_8'^-W_!-KP#XW_9K\;>-O#'B_P;)XJDU_PAXXMK>Y
MB\1ZY<7SR27SZX)&>.2Y1E@1)XW/FQXW*A3%>K?"[]D/_A6W[;WQ8_;)_P"%
MA?;?^%H>%_#6C_\ ".?V3Y?]F?V2+T>;]H\UO.\W[9]WRTV>7U?=P 8__!6+
M_E%E^TM_V;_XR_\ 3'>5\E_L _LK_P#!:^3]GCX)^+K3_@JQX*C\"MX+\-WD
M7A _ RR,ZZ3]DMW%C]J\W<7$'[KSL9S\V,U]Y_M8_ O_ (:@_98^)?[-'_"4
M_P!A_P#"Q/A_K/AC^V_L/VG^S_M]C-:_:/)WQ^;Y?F[]F]-VW&Y<Y&A^SU\*
M/^%#_ +P/\#O[>_M7_A#/!^F:%_:GV7R/MGV2UCM_.\O<_E[_+W;-S;<XW'&
M: /EC_@OA\&X?%'[ 6M_M0>$]8_L7XA_L]74?Q(^''B2.'>]G?Z<?-D@89!>
M&>$21/&3M8E&8-L KN?^"0'[->F?LZ?L*^$M2O==?7?%_P 2X!X^^)'BJYC"
MSZWKVKHEW<SOCLN](4':.%.^:]._;7_9N_X;"_9'^(_[+'_"9_\ "._\+ \'
MWVA?V[_9WVO[!]HB:/SO(\R/S=N[.S>F<8W"K&D_!'Q?X0_9$MOV;_A]\5#I
M&OZ7\-T\-:'XW72/,-E>1V M8=1%KYHW;)%6;R?-&=NW>/O4 ?%O[;?Q'UO_
M (+!?'#5?^"47[,EQ,WPJ\+:[:']J;XHVQQ;11P3)./"NGRC_6WTSQ*+AURM
MN@*MN8M'7T'_ ,%6/A_X#LO^":_[1_C2T\%Z5'K%K^S5XQTNUU9-/C%S#8C1
MKM_LRR[=ZP[@&\L';D XR*^6/V9?^")O_!5W]CGX0V'P(_9L_P""\UOX8\+:
M=///!I\/[*'A^X>2::1I)9II[B[DFGE=V),DKNQX&<  ?>7[2'[/^K?M'_L<
M^/?V5]>^(7V6^\>_#/5/"E[XK_LE7\F:]T^6S>]^RK(@;#2F3R0Z@XVAEZ@
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M9?%[P3XE\$V_B#PSXOVQ&%;J6TF9?L]SY1*/(F?-7@@%I#)YK_P2U_X(A_M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>cah-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20200930"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cah-20200930.xsd" xlink:type="simple"/>
    <context id="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib65a26413b874508a85f6777e242d835_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie14ef2e16a4341de83a616bd95c70060_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i46f40891839a4ff8ad0be8029fc7bfd7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0a0d931ce9114013b82c3979d4b5e05b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i294271bac59b4238aea6794f938ecb5e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia89288edcb8b47c297dde696b64571bb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i80f34ae0045b4d819eb72fa537be56f1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia1773a34a7364c23ad4929d51cd3e157_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i15805896000345a2aa639595943a623a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id41cee2cbbf94186823098ff6df8ac9d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6ab12b17254a47d586a4f825f9c57c99_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia6a8677c7cb741318b51781ad9f6c93d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idb0b0cb8b19e49fc80606766f904aa26_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iff2fb339e24f483a8549de70efe24187_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i86a90808957b4495abd9dc6d75d56f79_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f7801ce08874014aa040090ccd71767_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i653c52bdb74a4a2a96fa0272a365cd9e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7475a55c7a2b497c85c0ca7944fc4f26_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8309f66561364b29839c307a5e8335a3_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5e60c9a0ea354d95a50f7ca4fbb9cd93_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i56ca687f7a1242d7bd026d4ff5c1e5ed_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6b7f5e8f3b874a2eabbb08714f01af4c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if49a22a27bb14af798584b89e48847e9_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7600f4c2e92b4932bd31018892472063_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8bd66c2d5fb84642b32933030ebed96e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i09053d52c644470daa05bd64b11874a3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4663ceccbd74405690acfa2d2fb25056_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0cf2f42b91f3400680f775825de130a9_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie0e3bba2014545cda514af0b95f5bc4d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0ac2341eaa1242f1aaba8d054128bda5_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id34905e19a1f4553a93dc88294b01178_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8807b0cd3a1a4aeca6c16a4e6b2aa3f7_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie2cde32b3af84d33b1714302c8341607_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4cb6b2dd88864d668c5919feb00ee76c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i56c6be751ee64c558fe3494c112900ab_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1a2579521f524f83869e7f228bd84ff9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief7037b2735b4e7f8e6c6f2d9b8d7038_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i425faefcb193459095f9eb5f9e4acf2c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia0c1f80baf7644c585599ba8c1f2323c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8480697f2bdf44918df39a9f5e84e330_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i48091522a54b466aaad728773c54a0a8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9da27597353943d181889c1d5456c85f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib649dc8198854be78403495cec1847cd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib9929e41c0c24b0bba4c253330973f70_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0491c5bcabd34939b8a41c8f69eccb12_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i438081d1a6924fc1a9b6b1dd950a9fcd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i021a5d537d2842cb817b9d054f4ff9b5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0adfa8f5d5214083a20b748280dfcefc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d951315c1c544ba967df1be4c66d58d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1dd2a95f5f2b4b88bbcc6c6297bc95d0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie926bbb0cbef440c994d8834ad4a9199_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iccf269ca481e4302b7d6164d95f0269a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia572b6f1eebf44cfbaeb9d8411357eca_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ied58b175619b4bfebfb6b5b530246f5e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i91fcd765710a4070b7c3c4036717d1cf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6ea560c27996450ea297ecbb41e9bf97_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3bfc5884ee88416c9abb63244dab609c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i741ef9d887c94534a8eda6eccfbe2ad3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i119b91cee7ad43a3a902d392163cea9e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i771e1aea6b7f427a9df601aaf7660e54_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6561ef3f208042318b204d099ad1b0e0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i939be74b35cc40a8969fcbc5e8654858_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i39e37f424f344ed4861a30e0289b675e_I20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="ie1ec20ee64f4429a823a5f846ef8b554_I20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac21abb30a6046b1aaef99f6b707cbd5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0dd1e60e6ffd4307b7bf4207ea74288c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaf9406084961493d9d4b3eb6d8055a86_I20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="if5b6097a61c849798a37a8304de056d5_I20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="ie47435aa0ab74b408fd91dfc770477cc_D20201102-20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <context id="if790e73672e840e5b0d954ff370e0e96_D20201102-20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <context id="iab0a211a496049da89686dc5fe319089_D20201102-20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <context id="iefc77509e5de47719bffc603ae04f45c_D20201102-20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <context id="i7f21d49611034f3fa4a6fb00669c782b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibf6467237c464a1aa045646e1b87276b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia09951da05f64bf3a7732138bd69fdfc_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib3306233e5db4b188aa16b734cd988cf_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0f2e67b10f4d497fa601aa7acf5cafd5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia819620c77c04e44820e9270d0163402_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icee8303e1efb47e5b605a6d6693baa6d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i198d88ecb6cb419a8da8c55f4bdd2385_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i90891cc2a4a8436bb9f99a47f2669996_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icf6d9f7208624a0aa1b66fad4bab9571_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i72e11ec7b02f4f62aa657fb2116b44ad_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4fb4c3b745404fd9b199d24994707757_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i821519601f81436faf796e3e48f6e226_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6e14eef936ce478e977bd2365ab2dcc9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i07b43a414d2b4f6fa40be7cadc0a1262_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i91e3c7cc8bf8416a8084c477ef5ff7e1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4f47cfe18fe54226a1df09ddb6efef0c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i996aed144ffb4a48a0ee5fbb315c6670_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id645783b71294f05bb6047acb455691b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i269f7fc0ae604642a4a6a3d792040971_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if6ccfc94660444b69cd33d2b61edc9e1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifbaf94dcf17e4c03b40d6ee4e6a38630_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if3ee5fbf2771456f9b16564e61ebe4f5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i70de2fa7134c4f26a5575c7874c7dbc1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id9465d58bd9c4791a0eb659e86c94043_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id083a10b766c4345a49d14f0632816a6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i24179129a5974fea826c6897ed376db7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iba45d8ce890d432cbb652a278df25802_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia0d69c82422d48839b20ba8699842249_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i76bcd37a41304f9a80edf0b488038276_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5672d212637f41acb8eb88dd1e16d3ab_I20191204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2019-12-04</instant>
        </period>
    </context>
    <context id="i67e8522d8b5645e79d6b9af6f3933166_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i30acee2f999d4666aa8a690497305ee1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i364789c943c04565b9bde52a3752220d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i78e7580ef4ee445389920d8d3c96ab6c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0d125daceaeb49239b6bf716b1f7b342_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia53329ae895148609299a5ce40e3c592_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1cabdcfb164044c48c31dcddf5873c35_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i453407ee376d4fe78c2176a18171602c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic66e4cdcd5a046cfae01e323cbb8b418_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id8f75c382c1c4df691a419c0e178c753_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0defeec516474249b8995ba49880c24a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i62af4253c8a346ccbeeba7311323f9a6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e3b1bc368924c059f7e70628540e193_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2de354d09bc44a9fa3785d5625393d00_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib3917f66b8f644838a6208b4c579c8bf_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i09f112593ed04de0a5bb4ca0a2030c04_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i38b597f3573d47b49abc5302f1695a37_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iecb54beca65c45029506df58645bad06_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i06a632d5955e4aa3866f348c953d8d08_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2f6e1c05bec24505be4e45733f808646_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i781f2efb9025488d94dcbfda31c5bd48_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibcebc361e52048eaba97198b6a5faba9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d88dbb2b05d4b1b89fa61aa66aedbad_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iee2cbf3fb2124481bec0997184cebcb1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d0e8c9c681b47eeb9760d46de31a6d1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i52baa5c5a9654848bd9121d59999a39b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f4974c67c114c848433b0dfc9102fde_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id5632dcd9d2a4e40a78e375c76a736e3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c3a5767abd1403ab78e9bf2adee431c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2dab659e59834b43b34ab0f7563c0c82_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie7066c54e7dd4fceb8588adf471ba835_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i098156347d904aa088fa3e1e5127a1d4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i75fa3de7c8a54b8b83706d76e4c35b76_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i857ee1bbc77f4af191655dfc896df4c3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie2aeccd462de4b89be3251b77c14116a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7566b8915269491e8cf903384ee23182_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc62178c06b346f2a9d5381f46838f85_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibad9b2879e704eba834be054682ed6c5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie19d22156ae648a3a872b2507b4de145_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7cc829ddfa7546fe9e92c22e0ea07a60_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia5ae4550dbfd4e139f3bcceb77e3e045_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6e44ccff288b4a86886c5aab9864e13b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5efd6d972b064462a3d6638360713a1e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie4631166cbef49ac95cee271f9ff8821_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i72080d3b192041d29bdb612c6d87d607_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f40a80a6e5847bfa13e893d637f65d2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if7b231115e4c4896aea559547eb04df6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5cdf4ef85d164520b43ff6d702fd42c4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="reportable_segments">
        <measure>cah:Reportable_Segments</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N18yLTEtMS0xLTA_65d228f3-1a86-4cff-accc-57dc5a687309">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N18zLTEtMS0xLTA_304e67de-87d6-4872-8ad8-d43bf7444c66">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N180LTEtMS0xLTA_3fa356af-f83d-4cac-89b7-f819897de1b1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N181LTEtMS0xLTA_d6b42868-1fb5-404e-9047-72fd57576d95">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY180L2ZyYWc6OWI3OTIyYjBjMTA0NDA3ZTljZDlmZjY0NmI0YjcxYTMvdGFibGU6MTFjNjRjMDdhM2EzNDczMmFmMjVhOWZhMjlkZWEzOTcvdGFibGVyYW5nZToxMWM2NGMwN2EzYTM0NzMyYWYyNWE5ZmEyOWRlYTM5N182LTEtMS0xLTA_c1782548-25b4-43c0-a363-d914ae4466c4">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF84NQ_2392e9e6-3f40-4967-b4f9-bfec65cb5cf7">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6NWQ5MzFmYjU2NmE5NDIyMGFkMjgwMzllMWNiNjFjNzcvdGFibGVyYW5nZTo1ZDkzMWZiNTY2YTk0MjIwYWQyODAzOWUxY2I2MWM3N18wLTAtMS0xLTA_c9a5e9fe-9ee2-428c-baaf-89b23565eb0a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xMjI_546696f8-b79e-4788-9e68-93f653829630">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6OGI0MzI0OTBkNWY4NDU4MjljZDM2ODc4NzliNmM5MDgvdGFibGVyYW5nZTo4YjQzMjQ5MGQ1Zjg0NTgyOWNkMzY4Nzg3OWI2YzkwOF8wLTAtMS0xLTA_a85b49aa-1fd4-4d81-bb2f-4b81674d7a79">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTA0_3d796855-157d-4575-96d9-0916d7dcd333">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTA1_7e15130d-e899-4588-9d99-a83671531a7a">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8wLTAtMS0xLTA_c3df32ce-e458-4e21-aa78-7f333e6ff205">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8wLTYtMS0xLTA_b1d2ad4a-30be-4121-808f-fb3e32bffc29">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8zLTAtMS0xLTA_d79b74f1-777b-4d5d-8bf0-5a8fe274d0d8">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8zLTItMS0xLTA_2398fc82-e68f-4b68-b1ac-3a3b43c6b7b3">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8zLTQtMS0xLTA_8b1490d4-5f9a-4677-b8db-4c868c62d537">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6YzQzMDgzODJlMzEwNDkyNWE1MzczYWRmYmNkNjU1MGEvdGFibGVyYW5nZTpjNDMwODM4MmUzMTA0OTI1YTUzNzNhZGZiY2Q2NTUwYV8zLTYtMS0xLTA_688f33d1-665c-46a9-be08-9bbb38b4f45b">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTA2_b6858634-8381-4159-b4de-3e7862582e7d">614</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTAw_39e27a64-525c-45c2-88fd-7ac0608a18c9">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6NGQwYmJhMmYwODQ1NGU1M2EwN2FmZTJkN2YyNzVkZWQvdGFibGVyYW5nZTo0ZDBiYmEyZjA4NDU0ZTUzYTA3YWZlMmQ3ZjI3NWRlZF8yLTAtMS0xLTA_964b5075-6324-424d-bc79-26394d2d7600">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6NGQwYmJhMmYwODQ1NGU1M2EwN2FmZTJkN2YyNzVkZWQvdGFibGVyYW5nZTo0ZDBiYmEyZjA4NDU0ZTUzYTA3YWZlMmQ3ZjI3NWRlZF8yLTEtMS0xLTA_6db00b44-db52-4574-b20d-7ab0d40daa1f">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6NGQwYmJhMmYwODQ1NGU1M2EwN2FmZTJkN2YyNzVkZWQvdGFibGVyYW5nZTo0ZDBiYmEyZjA4NDU0ZTUzYTA3YWZlMmQ3ZjI3NWRlZF8yLTItMS0xLTA_b38e02b7-29c9-4099-8a41-4de8c23f3645">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTAx_9168ad7f-61a3-46db-898f-967220bec7ce">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTAy_580a66ea-1b8d-4379-87c8-89d651cd6dec">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6MmVmMjM3MjRkOWNkNGM4YjliZjE5YTZkMWJkNWJhMDAvdGFibGVyYW5nZToyZWYyMzcyNGQ5Y2Q0YzhiOWJmMTlhNmQxYmQ1YmEwMF8wLTAtMS0xLTA_b765719a-f28c-47d8-9f71-060449f92b3c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6MmVmMjM3MjRkOWNkNGM4YjliZjE5YTZkMWJkNWJhMDAvdGFibGVyYW5nZToyZWYyMzcyNGQ5Y2Q0YzhiOWJmMTlhNmQxYmQ1YmEwMF8xLTQtMS0xLTA_1e684231-b369-4f54-a684-9237c3e38b89">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGFibGU6MmVmMjM3MjRkOWNkNGM4YjliZjE5YTZkMWJkNWJhMDAvdGFibGVyYW5nZToyZWYyMzcyNGQ5Y2Q0YzhiOWJmMTlhNmQxYmQ1YmEwMF8yLTQtMS0xLTA_8edf2660-0c99-4db1-912a-aa875f75c755">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xOTAz_72cbf7ca-7bc6-4930-bc3a-69c350ea562b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib65a26413b874508a85f6777e242d835_I20201031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xL2ZyYWc6NWIyYzAyNTdmZDQ5NGViN2FhMmQ3MTNmZTY5ODAyN2QvdGV4dHJlZ2lvbjo1YjJjMDI1N2ZkNDk0ZWI3YWEyZDcxM2ZlNjk4MDI3ZF8xODk4_4af88f43-20bb-4d67-843c-7f597b54e4d3"
      unitRef="shares">293420561</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMi0xLTEtMS0w_afa53e97-0136-4996-b5ef-c1e56b19df1a"
      unitRef="usd">39065000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMi0zLTEtMS0w_a9358593-699a-4bdf-918a-88fbc5876b12"
      unitRef="usd">37341000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMy0xLTEtMS0w_ab9efb76-192e-476e-94c8-d44d11818a61"
      unitRef="usd">37350000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMy0zLTEtMS0w_500a27b4-4278-4df8-b972-1e257ee90f2d"
      unitRef="usd">35662000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfNC0xLTEtMS0w_d23b5a57-8f02-4893-80ed-f4a17942e8e4"
      unitRef="usd">1715000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfNC0zLTEtMS0w_b3843f64-6b36-4fb3-af8f-03b8155ac044"
      unitRef="usd">1679000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfNy0xLTEtMS0w_61bae5b7-0642-4cfd-bee8-bd9ab7bd5aca"
      unitRef="usd">1137000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfNy0zLTEtMS0w_3e17e3e0-4176-499b-bb06-ce0158bf3682"
      unitRef="usd">1107000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfOC0xLTEtMS0w_d77a4a0b-44d6-4690-b565-e942ccdb870f"
      unitRef="usd">37000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfOC0zLTEtMS0w_af0fbfc6-3037-41cf-b465-69896fb17fec"
      unitRef="usd">30000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfOS0xLTEtMS0w_10f6f738-bc34-40c4-b289-e9d8972fbeb0"
      unitRef="usd">118000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfOS0zLTEtMS0w_b54140ad-831a-427a-9597-8eff77645560"
      unitRef="usd">132000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTAtMS0xLTEtMA_f0a7715e-1911-4b84-8fda-51816f1e0c6c"
      unitRef="usd">-9000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTAtMy0xLTEtMA_00e9d090-8963-4470-b568-8349778d14b4"
      unitRef="usd">-1000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTEtMS0xLTEtMA_05f35b6f-0918-4127-9d24-cafb7e2c137d"
      unitRef="usd">-1038000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTEtMy0xLTEtMA_cc86dda5-8d6b-407c-8455-c4e65e3a6459"
      unitRef="usd">-5673000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTItMS0xLTEtMA_acb98e8d-3839-4494-aa86-63ff78a2dbd2"
      unitRef="usd">-624000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTItMy0xLTEtMA_2efd8bbd-a76d-41c3-9dd6-83b3b639f6d1"
      unitRef="usd">-5264000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTQtMS0xLTEtMA_e3edd258-a125-4296-a971-9ca5db196a65"
      unitRef="usd">7000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTQtMy0xLTEtMA_557f8e4a-f012-4fd0-8e44-bcf858f23fea"
      unitRef="usd">-14000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTUtMS0xLTEtMA_64eb7b90-3b5f-497e-b247-d4278a7e3607"
      unitRef="usd">45000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTUtMy0xLTEtMA_f79722e2-4baf-4a7f-9416-f163d2831132"
      unitRef="usd">66000000</us-gaap:InterestExpense>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTYtMS0xLTEtMA_89215112-1ccc-417c-9d94-eafb08a5b9d8"
      unitRef="usd">1000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTYtMy0xLTEtMA_cc37e363-c607-4a61-8d90-0e1e111ecc0a"
      unitRef="usd">0</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTctMS0xLTEtMA_bef17080-43c1-47f2-bbf0-1fb42eaf0e3d"
      unitRef="usd">-663000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTctMy0xLTEtMA_9d872721-d626-4716-912e-6814f1c2ec67"
      unitRef="usd">-5344000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTktMS0xLTEtMA_e8e5b488-1c27-4d13-baa5-e82e6acda9ad"
      unitRef="usd">-410000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMTktMy0xLTEtMA_ae300862-41c4-4157-85a8-2aa5e604a81e"
      unitRef="usd">-423000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjAtMS0xLTEtMA_b2490442-0a29-4a99-a0fd-204faf270df3"
      unitRef="usd">-253000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjAtMy0xLTEtMA_2d8ad3d5-6657-45b7-83ae-8d18adac12ff"
      unitRef="usd">-4921000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjUtMS0xLTEtMA_bbe5a379-45b4-43f2-b118-574fd8965b56"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjUtMy0xLTEtMA_d3ef08b9-471b-4246-b1d3-a4f96a493e49"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjYtMS0xLTEtMA_d247fec4-c37d-422e-b9e7-f11f8b28de6f"
      unitRef="usd">-253000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjYtMy0xLTEtMA_838367ee-74ca-466b-a32a-86a26862eee0"
      unitRef="usd">-4922000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjktMS0xLTEtMA_0c20577a-dcf0-451b-be54-1641e0f3917f"
      unitRef="usdPerShare">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMjktMy0xLTEtMA_d57726b0-c9f7-4fa8-a171-9fc39de4f75a"
      unitRef="usdPerShare">-16.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzAtMS0xLTEtMA_6db0d192-7215-4b35-b0e1-353f49d7e9f5"
      unitRef="usdPerShare">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzAtMy0xLTEtMA_67e3e28e-183f-4a16-8b90-b651f9a116b4"
      unitRef="usdPerShare">-16.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzMtMS0xLTEtMA_434ed15b-fbf8-4d46-aa5c-4c33a66b4037"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzMtMy0xLTEtMA_fad8d6f8-c33e-421d-ab7e-bb46c41c9243"
      unitRef="shares">296000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzQtMS0xLTEtMA_2585ed94-b7b1-4dd7-acaf-eaab431c2877"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzQtMy0xLTEtMA_7f22aeb3-2c4e-4462-aa3a-e7c20a345b48"
      unitRef="shares">296000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzYtMS0xLTEtMA_2935d489-21f4-45ab-8dfa-b90b2995e1f1"
      unitRef="usdPerShare">0.4859</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY181OC9mcmFnOmJkYjBlZTk3ZjY4OTQ4Yzk5N2YxNTM4MjZhZmM4MmRiL3RhYmxlOjE0ZTJkYjIwNmM4MjQ5OTZiODgxMTMzNTc1NWQ1MmU3L3RhYmxlcmFuZ2U6MTRlMmRiMjA2YzgyNDk5NmI4ODExMzM1NzU1ZDUyZTdfMzYtMy0xLTEtMA_e948f0e8-378f-4f0e-9574-5557855c679b"
      unitRef="usdPerShare">0.4811</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMi0xLTEtMS0w_b2490442-0a29-4a99-a0fd-204faf270df3"
      unitRef="usd">-253000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMi0zLTEtMS0w_2d8ad3d5-6657-45b7-83ae-8d18adac12ff"
      unitRef="usd">-4921000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNS0xLTEtMS0w_43ff63d6-8b09-4a0f-ac2d-b051f5a3d7b6"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNS0zLTEtMS0w_44297ab7-113f-4d89-b59d-3efbd93860be"
      unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNi0xLTEtMS0w_29326c80-ddc0-43c9-bcb3-bef6c3ddc855"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNi0zLTEtMS0w_d793785f-7a65-4daa-af4f-5ef7bd967b08"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNy0xLTEtMS0w_0aa6b9d0-0a95-4cd8-a051-cb64f43e62a2"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfNy0zLTEtMS0w_59fd98b5-230b-48f9-bd01-40b7711716c7"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfOS0xLTEtMS0w_13b37bc0-9f53-4398-b428-c18028a19b2b"
      unitRef="usd">-236000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfOS0zLTEtMS0w_e5467240-ee58-48e8-bfc9-dbffe27fab0d"
      unitRef="usd">-4943000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMTEtMS0xLTEtMA_0742bf18-4cab-4d3e-aab5-7a1b6e9dd6a9"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMTEtMy0xLTEtMA_a2a74775-ff99-48fa-9ae1-2255d52108ef"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMTMtMS0xLTEtMA_4f01ee9f-efaa-4cf2-a794-684ee3fdbc1a"
      unitRef="usd">-236000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182MS9mcmFnOjI1ZGI0NWIyMjFiMzQzMDQ5MWJhYmVhYThjYjc3ODgyL3RhYmxlOmE2YzliOWI1NDg5NzQzMmQ4N2M3NDM1Mjg2ZmE0MGNhL3RhYmxlcmFuZ2U6YTZjOWI5YjU0ODk3NDMyZDg3Yzc0MzUyODZmYTQwY2FfMTMtMy0xLTEtMA_93eb34b3-a87e-484b-a73c-114eb53e12a2"
      unitRef="usd">-4944000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMy0xLTEtMS0w_2b244cf3-6228-4709-815d-fd58cd4e8a61"
      unitRef="usd">2746000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMy0zLTEtMS0w_b8cb326a-86e2-410f-8863-1de26bad1ed6"
      unitRef="usd">2771000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNC0xLTEtMS0w_c4592acc-0877-42bb-8d1b-9a5858ceadc6"
      unitRef="usd">8637000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNC0zLTEtMS0w_a1a9a023-7dbb-4c93-851b-7cc40e8eff5a"
      unitRef="usd">8264000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNS0xLTEtMS0w_e934cf45-5d74-470c-bbe0-99c2b2775ee1"
      unitRef="usd">13439000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNS0zLTEtMS0w_277031c4-aa59-4662-9536-cd622f5c5dd4"
      unitRef="usd">13198000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNi0xLTEtMS0w_3e99c390-a024-4316-9176-0e8d16ce66eb"
      unitRef="usd">2208000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfNi0zLTEtMS0w_0347ac32-4077-414c-aada-265924904da8"
      unitRef="usd">1707000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfOC0xLTEtMS0w_d4464e85-cc74-47dc-8d41-4f731a1d49fc"
      unitRef="usd">27030000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfOC0zLTEtMS0w_7c793fcc-6293-4191-a6d9-eb8904df29cb"
      unitRef="usd">25940000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTAtMS0xLTEtMA_a8131361-4404-4063-9fa7-3e1a1a2c9f8a"
      unitRef="usd">2369000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTAtMy0xLTEtMA_29345203-b642-4ad0-97a5-b562033decb2"
      unitRef="usd">2366000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTEtMS0xLTEtMA_b0f1bd37-d3e1-4bfe-99a8-fb0c64932427"
      unitRef="usd">11186000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTEtMy0xLTEtMA_143ff88b-fced-4d40-b7f0-c46a080026e9"
      unitRef="usd">11275000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTMtMS0xLTEtMA_62227f2a-fe5b-427b-bf14-9f983f5868e6"
      unitRef="usd">1142000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTMtMy0xLTEtMA_afe877aa-547d-4972-b1ed-90f2286c537b"
      unitRef="usd">1185000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTQtMS0xLTEtMA_efe14f33-a52b-48c7-b352-067bd9689f4c"
      unitRef="usd">41727000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTQtMy0xLTEtMA_84b682e4-0736-4f00-8f5f-82d277003fce"
      unitRef="usd">40766000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTgtMS0xLTEtMA_171360c8-b90e-4ad8-a838-de8c0d5575a6"
      unitRef="usd">21688000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTgtMy0xLTEtMA_74edffcb-f7b8-4459-80e6-aac1133c7fce"
      unitRef="usd">21374000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTktMS0xLTEtMA_381244a6-0e54-47ec-85bd-88c8e5ac98e8"
      unitRef="usd">12000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMTktMy0xLTEtMA_ee6c8603-e4eb-4102-b193-f8e58ac19d55"
      unitRef="usd">10000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjAtMS0xLTEtMA_a7b0aaa5-5dbf-4e59-bc78-3fbb34761507"
      unitRef="usd">2316000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjAtMy0xLTEtMA_f8f78c91-c525-43f2-8268-66ba9896f689"
      unitRef="usd">2231000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjItMS0xLTEtMA_3c1e6148-aaf5-4187-9de5-b5b582f79946"
      unitRef="usd">24016000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjItMy0xLTEtMA_03e4c5e1-538e-43f9-b198-ca14b59dcdc0"
      unitRef="usd">23615000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjQtMS0xLTEtMA_d1920119-b6f4-474e-a97c-4e8c4ab4dbd6"
      unitRef="usd">6728000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjQtMy0xLTEtMA_6e986a12-ba0b-48cd-8a38-9247eedd42ae"
      unitRef="usd">6765000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjUtMS0xLTEtMA_042ee7b3-19ec-4eab-a1f1-86f44e0a6be5"
      unitRef="usd">9558000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjUtMy0xLTEtMA_b96b3f01-e9af-4cad-a23e-633240983b74"
      unitRef="usd">8594000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmVjZWI1ZDBkNDgyMDQ0YzU4MzU4YmZhODM5MTViODhlXzgyNDYzMzcyMDgzODA_32a85c2b-cc05-44e9-9aba-7e72d86e1643"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmVjZWI1ZDBkNDgyMDQ0YzU4MzU4YmZhODM5MTViODhlXzgyNDYzMzcyMDgzODA_7602f5dd-0fc2-42cc-ada6-1eba9dd139fe"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmVjZWI1ZDBkNDgyMDQ0YzU4MzU4YmZhODM5MTViODhlXzc2OTY1ODEzOTQ2OTY_80967284-98ae-493d-92e0-a15ee26e0cda"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmVjZWI1ZDBkNDgyMDQ0YzU4MzU4YmZhODM5MTViODhlXzc2OTY1ODEzOTQ2OTY_a794d2d7-7822-4026-a211-df623f175e4e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMS0xLTEtMA_05c4daf8-c65c-44da-82a0-e6b910eccee4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMjktMy0xLTEtMA_8d621111-a8b3-4481-b1c7-054ab18ba1d4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjhlOTBiNDdkYTZlZDRjYmY4MDBkNDcyMjkyMTg0ZDU1XzgyNDYzMzcyMDg0ODY_588edacd-672b-4aa3-85c7-e33a891bda26"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjhlOTBiNDdkYTZlZDRjYmY4MDBkNDcyMjkyMTg0ZDU1XzgyNDYzMzcyMDg0ODY_5e339fbf-8763-4b55-8c5b-9f9fcc87483d"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjhlOTBiNDdkYTZlZDRjYmY4MDBkNDcyMjkyMTg0ZDU1XzgyNDYzMzcyMDg1MDE_43606707-242a-4df4-a77c-76840360c634"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjhlOTBiNDdkYTZlZDRjYmY4MDBkNDcyMjkyMTg0ZDU1XzgyNDYzMzcyMDg1MDE_89b43bfa-5f1b-4591-a3b1-8871e34e3e9a"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMS0xLTEtMA_3db15bf0-4d33-4929-8334-eb87165ac0ce"
      unitRef="usd">2760000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzEtMy0xLTEtMA_90c93230-8767-4308-a635-73e0ada6edc1"
      unitRef="usd">2789000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzItMS0xLTEtMA_e4575651-3e24-4750-ba90-31cebf1b0871"
      unitRef="usd">771000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzItMy0xLTEtMA_f294c95a-86fb-4d8f-9b05-0d13625df95b"
      unitRef="usd">1170000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE0MjI4NjRiYjIxODRhYTRiNDFjNDgzNmQ0ODQ4NWU3Xzc2OTY1ODEzOTQ2MjA_2edc19de-1790-437c-a349-2e572b5dc730"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE0MjI4NjRiYjIxODRhYTRiNDFjNDgzNmQ0ODQ4NWU3Xzc2OTY1ODEzOTQ2MzQ_a8d10c2d-38eb-4887-b27b-9710e2f4824a"
      unitRef="shares">34000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzMtMS0xLTEtMA_f8e3e04e-2e6d-4aeb-b0b5-cb8ed4fc674d"
      unitRef="usd">2022000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzMtMy0xLTEtMA_6b05184a-c42b-4196-a561-46253c504e2b"
      unitRef="usd">2066000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzQtMS0xLTEtMA_16484406-f141-4012-afd7-6d5aad89878c"
      unitRef="usd">-87000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzQtMy0xLTEtMA_bd6ed05f-9bb8-4d8f-9a35-3966d4e9e86f"
      unitRef="usd">-104000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzUtMS0xLTEtMA_ae5991e2-17c7-42ee-a821-9f5ad077fe7f"
      unitRef="usd">1422000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzUtMy0xLTEtMA_b859cdcd-466b-47ad-9d1e-5f1918432bec"
      unitRef="usd">1789000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzYtMS0xLTEtMA_75df4781-351a-4ad7-ba96-592588a478f7"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzYtMy0xLTEtMA_78e3e400-7430-4b74-8739-0aafc68b81ae"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzctMS0xLTEtMA_c83fe184-803c-47e5-aa06-1bf207ac8828"
      unitRef="usd">1425000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzctMy0xLTEtMA_aa88c7e3-3c76-44c6-8ae5-2181cb531c8c"
      unitRef="usd">1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzgtMS0xLTEtMA_fd02b521-a0b5-4ac3-a5ff-69f948310053"
      unitRef="usd">41727000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY182NC9mcmFnOmM1MWZiNzYyNTIyZDRmZDlhNTc1NjY1ZGE5MzVhYzA2L3RhYmxlOmE1ZWUzZTM4NjZhZDQ5OTVhYjY3Mjc5ZjQwZjkzODFmL3RhYmxlcmFuZ2U6YTVlZTNlMzg2NmFkNDk5NWFiNjcyNzlmNDBmOTM4MWZfMzgtMy0xLTEtMA_cc41e1cd-123f-45f2-891b-59ef0951fb33"
      unitRef="usd">40766000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i46f40891839a4ff8ad0be8029fc7bfd7_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0xLTEtMS0w_ebc840b4-3b64-4862-92b8-89775e42eee6"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46f40891839a4ff8ad0be8029fc7bfd7_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0zLTEtMS0w_ca76e8cc-41e3-46b5-8849-82ff85a42513"
      unitRef="usd">2789000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a0d931ce9114013b82c3979d4b5e05b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy01LTEtMS0w_a8aca732-202d-4f0f-9282-60c54bf0ea29"
      unitRef="usd">1170000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i294271bac59b4238aea6794f938ecb5e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy03LTEtMS0w_493d25c1-1458-48a1-bb3a-c937c85923a2"
      unitRef="shares">35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i294271bac59b4238aea6794f938ecb5e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy05LTEtMS0w_eaa450e2-9e77-4390-9af1-8c46e5840375"
      unitRef="usd">2066000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia89288edcb8b47c297dde696b64571bb_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0xMS0xLTEtMA_2fc1d1c3-4c4b-4ec9-bfee-05bd87ae0946"
      unitRef="usd">-104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i80f34ae0045b4d819eb72fa537be56f1_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0xMy0xLTEtMA_39e66775-7ad8-4855-b55c-d9df12acb353"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMy0xNS0xLTEtMA_a158e0ac-b7fe-4bcb-89dd-7d75faa923c2"
      unitRef="usd">1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNC01LTEtMS0w_d247fec4-c37d-422e-b9e7-f11f8b28de6f"
      unitRef="usd">-253000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ia1773a34a7364c23ad4929d51cd3e157_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNC0xMy0xLTEtMA_a78ed7b5-1292-4e12-ba3f-d5c9c634c7a5"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNC0xNS0xLTEtMA_1bc1880b-c546-4982-9333-216d3ea79bd5"
      unitRef="usd">-253000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i15805896000345a2aa639595943a623a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNS0xMS0xLTEtMA_e073974a-808c-4410-a011-c4d72207b635"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNS0xNS0xLTEtMA_9e24c08b-0068-4555-b869-4ed93bcb7ca7"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id41cee2cbbf94186823098ff6df8ac9d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNy0zLTEtMS0w_e9351c46-7c88-498b-9226-0b4ab13aeb63"
      unitRef="usd">29000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6ab12b17254a47d586a4f825f9c57c99_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNy03LTEtMS0w_fa51cb3d-4b8a-4f6f-82ce-779dcd76a44f"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6ab12b17254a47d586a4f825f9c57c99_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNy05LTEtMS0w_e00e4793-f2c9-4202-82e8-df3f2d8dca32"
      unitRef="usd">44000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfNy0xNS0xLTEtMA_46ccc304-c1ae-40ae-bf1c-8b169bc23da2"
      unitRef="usd">15000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:Dividends
      contextRef="ia6a8677c7cb741318b51781ad9f6c93d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfOS01LTEtMS0w_91f5de83-9107-430a-8a62-8c966dbf30bb"
      unitRef="usd">146000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfOS0xNS0xLTEtMA_f858a288-bf8b-4b18-a45e-4c20fff966ea"
      unitRef="usd">146000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesIssued
      contextRef="idb0b0cb8b19e49fc80606766f904aa26_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMS0xLTEtMA_bf37653e-1c05-4cf9-9b50-f7e67c95f776"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb0b0cb8b19e49fc80606766f904aa26_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMy0xLTEtMA_2c67ebff-e31f-4aad-af52-a87a7aba4542"
      unitRef="usd">2760000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff2fb339e24f483a8549de70efe24187_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItNS0xLTEtMA_3d19461a-464c-46f0-8d7c-d30d3a6b0a20"
      unitRef="usd">771000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i86a90808957b4495abd9dc6d75d56f79_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItNy0xLTEtMA_cc2a7625-9223-45ee-9f7c-c269ad4a85d9"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i86a90808957b4495abd9dc6d75d56f79_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItOS0xLTEtMA_c3f79926-4ecc-42e3-8128-6e85116e3a3d"
      unitRef="usd">2022000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f7801ce08874014aa040090ccd71767_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMTEtMS0xLTA_fb67db12-d498-4895-8034-046714354cfc"
      unitRef="usd">-87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i653c52bdb74a4a2a96fa0272a365cd9e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMTMtMS0xLTA_7080de58-91ef-4bb7-af12-941f52528cc7"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOjRkZmI1MjJlMDdmOTQ0YzFhMmM0Y2E5MmZiZDU5OWVmL3RhYmxlcmFuZ2U6NGRmYjUyMmUwN2Y5NDRjMWEyYzRjYTkyZmJkNTk5ZWZfMTItMTUtMS0xLTA_a23446f2-da14-4028-bdd5-dceca41d82a4"
      unitRef="usd">1425000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7475a55c7a2b497c85c0ca7944fc4f26_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0xLTEtMS0yOA_0ac39e6f-fd8a-444c-80d8-bf11a072e773"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7475a55c7a2b497c85c0ca7944fc4f26_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0zLTEtMS0xMjY_d4407d4c-2960-4015-a69e-f69350be5080"
      unitRef="usd">2763000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8309f66561364b29839c307a5e8335a3_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS01LTEtMS0xMjk_dddd321d-621c-4819-a605-c4369ee7379e"
      unitRef="usd">5434000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i5e60c9a0ea354d95a50f7ca4fbb9cd93_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS03LTEtMS0xMzI_f79abcb2-e75a-4413-aca0-c1186eb9b930"
      unitRef="shares">28000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i5e60c9a0ea354d95a50f7ca4fbb9cd93_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS05LTEtMS0xMzU_f0e60a8d-072a-4e05-af06-b1f2b43e0552"
      unitRef="usd">1790000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56ca687f7a1242d7bd026d4ff5c1e5ed_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0xMS0xLTEtMTM4_eb793af5-8f82-42f5-87ef-35321c1fc1b9"
      unitRef="usd">-79000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b7f5e8f3b874a2eabbb08714f01af4c_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0xMy0xLTEtMTQx_d1cfc774-591f-4c90-9a97-402232cb2fb0"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if49a22a27bb14af798584b89e48847e9_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMS0xNS0xLTEtMTQ0_c43273e1-5e4f-4b0d-b691-4cd8b2f33c60"
      unitRef="usd">6330000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMi01LTEtMS0xODc_70ab3979-f283-49af-8fca-e64d8740ccd2"
      unitRef="usd">-4922000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i7600f4c2e92b4932bd31018892472063_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMi0xMy0xLTEtMTQxOA_f59498e9-8d8b-4d73-89b9-a38938f15503"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMi0xNS0xLTEtMTkx_b37fa2ba-cc56-4ce4-a73c-ff19e32fbaf7"
      unitRef="usd">-4921000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8bd66c2d5fb84642b32933030ebed96e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMy0xMS0xLTEtMTM2Mg_0095157c-7ae3-45ba-aff5-eb4ff966ecbe"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMy0xNS0xLTEtMTk0_b2bcdfbd-cbbc-4abe-8f0c-e0144c29602b"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i09053d52c644470daa05bd64b11874a3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNS0zLTEtMS00Njk_01659686-b953-4e3b-bea3-b1ef88b1a6cc"
      unitRef="usd">24000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNS05LTEtMS00NzI_43a7d6c9-dce9-4e54-b70f-fe88e57222b7"
      unitRef="usd">31000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNS0xNS0xLTEtMjAx_ff3c38e8-7db5-4069-b460-ff39eb126f92"
      unitRef="usd">7000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i09053d52c644470daa05bd64b11874a3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNi0zLTEtMS0xMzcx_54893a3d-402f-47af-9eeb-e690b2fe654c"
      unitRef="usd">70000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNi03LTEtMS0xMzc0_7fb7fe57-38a5-4a1a-b0aa-146f6dec274c"
      unitRef="shares">6000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNi05LTEtMS0xMzc3_27c49e65-3cf6-4448-a5dd-18e3271fe034"
      unitRef="usd">280000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNi0xNS0xLTEtMjA0_c37b62a3-78ef-4486-a125-901ce341304d"
      unitRef="usd">350000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:Dividends
      contextRef="i4663ceccbd74405690acfa2d2fb25056_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNy01LTEtMS0xMzgw_8c6f7e61-786f-4b5c-9468-785d7c04004a"
      unitRef="usd">141000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfNy0xNS0xLTEtMjA3_a521f01b-40c8-4f66-badd-b31fc266451c"
      unitRef="usd">141000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0cf2f42b91f3400680f775825de130a9_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMS0xLTEtMTM5NA_4f975191-8a3a-401b-9684-b16d453dd754"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cf2f42b91f3400680f775825de130a9_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMy0xLTEtMTM5Nw_587001b2-2492-4ed6-9c96-009286504eb7"
      unitRef="usd">2669000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0e3bba2014545cda514af0b95f5bc4d_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtNS0xLTEtMTQwMA_f2265a3e-a748-4edf-97bf-3413116a555a"
      unitRef="usd">371000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i0ac2341eaa1242f1aaba8d054128bda5_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtNy0xLTEtMTQwMw_9d6aa5f9-6235-4a1d-9b29-d9851cd11a11"
      unitRef="shares">34000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i0ac2341eaa1242f1aaba8d054128bda5_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtOS0xLTEtMTQwNg_a5b55915-b101-4f51-b0ca-4a6c810bd005"
      unitRef="usd">2039000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id34905e19a1f4553a93dc88294b01178_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMTEtMS0xLTE0MDk_7b95b0c4-6fc0-4ad3-abc9-26e4d054f274"
      unitRef="usd">-101000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8807b0cd3a1a4aeca6c16a4e6b2aa3f7_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMTMtMS0xLTE0MTI_12b6da7d-9dc7-4b81-97c9-a8668b6ecdcc"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2cde32b3af84d33b1714302c8341607_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183MC9mcmFnOjc3ZjVjOTdjMWI3MTQ5YmZiYTUxMThhNDM2OTYzZDViL3RhYmxlOmY2MzA1ZWZhNzQ1OTRjYzM5ZWRhZmFlNDVhNGQzM2EzL3RhYmxlcmFuZ2U6ZjYzMDVlZmE3NDU5NGNjMzllZGFmYWU0NWE0ZDMzYTNfMTAtMTUtMS0xLTE0MTU_89a9f614-8bb9-4942-96bc-781c95b374d0"
      unitRef="usd">903000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMy0xLTEtMS0w_b2490442-0a29-4a99-a0fd-204faf270df3"
      unitRef="usd">-253000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMy0zLTEtMS0w_2d8ad3d5-6657-45b7-83ae-8d18adac12ff"
      unitRef="usd">-4921000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNi0xLTEtMS0w_85476d04-a067-4ab0-a314-e4719c4f6c20"
      unitRef="usd">205000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNi0zLTEtMS0w_501a8ca1-0671-4cf4-b480-12fb205c806e"
      unitRef="usd">234000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfOC0xLTEtMS0w_a10b325f-a0e4-4f70-b70f-874a51cdf775"
      unitRef="usd">-9000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfOC0zLTEtMS0w_466c2cef-c903-4584-8410-2ef8bcc85563"
      unitRef="usd">-1000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfOS0xLTEtMS0w_cdfbddcf-e704-4ee9-881e-240d7aa31385"
      unitRef="usd">28000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfOS0zLTEtMS0w_5eaec63c-1767-4c4d-96b6-61fb53764dd4"
      unitRef="usd">20000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTAtMS0xLTEtMA_fa6f51bf-b19d-40a9-8f0b-4a80e20af9e0"
      unitRef="usd">16000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTAtMy0xLTEtMA_2621561e-0e0e-478f-9d37-6a332d4cb004"
      unitRef="usd">29000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTMtMS0xLTEtMA_cc08aeb7-c9fa-4662-9096-8c079adc7576"
      unitRef="usd">388000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTMtMy0xLTEtMA_ead6ee3f-93cd-4f9a-b4ad-6789965f973b"
      unitRef="usd">-229000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTQtMS0xLTEtMA_be2aaf81-81aa-4bdd-9785-3a48c3c9b455"
      unitRef="usd">245000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTQtMy0xLTEtMA_56fe2c78-1602-4c1c-80fe-577f37c248b1"
      unitRef="usd">-356000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTUtMS0xLTEtMA_1a95ed02-24be-4450-951f-19667b2a085d"
      unitRef="usd">313000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTUtMy0xLTEtMA_c96dd8a7-8f18-4284-8c59-f7aababb9a61"
      unitRef="usd">-1812000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTYtMS0xLTEtMA_0ada9aa7-aedc-44e6-9730-b5aec3fe4fec"
      unitRef="usd">-585000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTYtMy0xLTEtMA_0084b2f3-4cbf-4603-86ac-5b77dd27c2da"
      unitRef="usd">-5211000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTctMS0xLTEtMA_fd2bc096-b069-412a-8294-750cdd7b1876"
      unitRef="usd">270000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMTctMy0xLTEtMA_4d7dbece-c6d6-4cb4-8c45-9a995749d9bf"
      unitRef="usd">-653000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjEtMS0xLTEtMA_7fdfb87e-f696-423d-aaac-4ea0cef6d0fe"
      unitRef="usd">78000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjEtMy0xLTEtMA_01929fce-9583-497d-9582-3006532fd7ea"
      unitRef="usd">72000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjItMS0xLTEtMA_8ed720e7-768c-4807-a272-554ec63394d7"
      unitRef="usd">17000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjItMy0xLTEtMA_b43ede6b-1ba3-4ea4-af16-664e32d146b4"
      unitRef="usd">3000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjMtMS0xLTEtMA_7dc9181e-f6cf-4825-846f-0fc8ae906a90"
      unitRef="usd">1000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjMtMy0xLTEtMA_e0cac445-5f98-4693-b533-d687831d1bcb"
      unitRef="usd">2000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjYtMS0xLTEtMA_59aa2b1e-a225-4770-b187-86d56c455858"
      unitRef="usd">-94000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMjYtMy0xLTEtMA_56df8c52-1edd-4996-ac4d-fd4761102db2"
      unitRef="usd">-73000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzAtMS0xLTEtMA_36e47ba1-5140-437e-a566-d1af399ec487"
      unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzAtMy0xLTEtMA_e4b2cece-4738-497e-a919-16248f1e98b9"
      unitRef="usd">-2000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzEtMS0xLTEtMA_8cf98a99-b9da-429e-88c6-2b3e59e75ad3"
      unitRef="usd">40000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzEtMy0xLTEtMA_6913d0b7-a20d-454f-8f48-aba2456f636c"
      unitRef="usd">74000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzMtMS0xLTEtMA_61058849-fb9d-4e6d-b9c1-fc262af3f881"
      unitRef="usd">-12000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzMtMy0xLTEtMA_65a81ade-5734-4df3-a0b3-b9d449f1a688"
      unitRef="usd">-13000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzQtMS0xLTEtMA_550ebd7f-f945-4591-979b-ec6b2cdee35a"
      unitRef="usd">146000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzQtMy0xLTEtMA_1fb8d48a-84b8-47e5-b510-0210064089ee"
      unitRef="usd">146000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzUtMS0xLTEtMA_c3e89ae9-234a-4daa-ab68-84c346a698cd"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzUtMy0xLTEtMA_503c3675-10d4-4925-a9f6-575001d590f4"
      unitRef="usd">350000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzYtMS0xLTEtMA_030bfcdb-7884-4db6-9243-31be4e9437c7"
      unitRef="usd">-198000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzYtMy0xLTEtMA_b1f3bcf2-fce2-4d6d-8428-388bbd5ad037"
      unitRef="usd">-585000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzgtMS0xLTEtMA_b0c339b8-56f9-4bfd-9db8-cdaaa485eb82"
      unitRef="usd">-3000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfMzgtMy0xLTEtMA_403623ed-3b17-49cb-bfaa-f2320e620b5c"
      unitRef="usd">-8000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDAtMS0xLTEtMA_b05e792a-3cff-460f-b9cd-b0dc7fbe8452"
      unitRef="usd">-25000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDAtMy0xLTEtMA_e24ec8e9-e746-4b93-882a-73e02b6138f3"
      unitRef="usd">-1319000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDEtMS0xLTEtMA_876e7b26-5d3a-4463-9ffb-91a724d8685d"
      unitRef="usd">2771000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if49a22a27bb14af798584b89e48847e9_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDEtMy0xLTEtMA_14ee07a0-5d05-448c-91ba-99656a218f7b"
      unitRef="usd">2531000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDItMS0xLTEtMA_536c6b62-cd48-4a9d-b0eb-234c7df11103"
      unitRef="usd">2746000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie2cde32b3af84d33b1714302c8341607_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183My9mcmFnOjFjN2VlMWQ1ZGI1YzQyYzdhMjQ3OGI0OTQ5MzQ5ZTNjL3RhYmxlOjhhZTc4Y2MxMTg2ODQwNjc5YzBhMzQyYzQ2ZDE3OTE2L3RhYmxlcmFuZ2U6OGFlNzhjYzExODY4NDA2NzljMGEzNDJjNDZkMTc5MTZfNDItMy0xLTEtMA_f9c36ff9-bc1f-4236-8fb8-2f55dffee995"
      unitRef="usd">1212000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183OS9mcmFnOmFiNzA5ZjAzM2IwYzQ2YTI5ZDg5N2NlNTFhZmI5YWRiL3RleHRyZWdpb246YWI3MDlmMDMzYjBjNDZhMjlkODk3Y2U1MWFmYjlhZGJfNDc3Mw_72e77671-1925-4cce-8a9b-349066a02a51">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2021 and June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K"). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183OS9mcmFnOmFiNzA5ZjAzM2IwYzQ2YTI5ZDg5N2NlNTFhZmI5YWRiL3RleHRyZWdpb246YWI3MDlmMDMzYjBjNDZhMjlkODk3Y2U1MWFmYjlhZGJfNDc2OQ_043893d3-344f-4e4d-8384-44451ff8fceb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2021 and June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual &lt;/span&gt;&lt;/div&gt;Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY183OS9mcmFnOmFiNzA5ZjAzM2IwYzQ2YTI5ZDg5N2NlNTFhZmI5YWRiL3RleHRyZWdpb246YWI3MDlmMDMzYjBjNDZhMjlkODk3Y2U1MWFmYjlhZGJfODI0NjMzNzIyOTg3NA_9120f6c1-5045-4750-9b64-b70ae82e1f3f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RleHRyZWdpb246ZGFlMGY1ZjJiNDNmNGNiY2I4M2I3M2ZiYWFjYWM2MmRfMTI3Nw_d61977eb-238c-4daf-be6d-12049a7b9b65">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Restructuring and Employee Severance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance costs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of lease costs associated with vacant facilities, accelerated depreciation, vendor transition fees, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2020 and 2019, restructuring costs were primarily related to implementation of certain enterprise-wide cost-savings initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RleHRyZWdpb246ZGFlMGY1ZjJiNDNmNGNiY2I4M2I3M2ZiYWFjYWM2MmRfMTI3NA_9caa071c-c950-4fd7-b185-31065dcfa8ca">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance costs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfMi0xLTEtMS0w_06ef23ba-4495-421c-bfd3-164416376260"
      unitRef="usd">24000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfMi0zLTEtMS0w_84746d1e-38d3-4d17-909b-74ae173bf48e"
      unitRef="usd">20000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfMy0xLTEtMS0w_492a4a37-887b-4120-9eb1-6a515ba188b6"
      unitRef="usd">13000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfMy0zLTEtMS0w_cc6213f7-3f03-4599-97a3-0b17855f14c9"
      unitRef="usd">10000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfNC0xLTEtMS0w_d77a4a0b-44d6-4690-b565-e942ccdb870f"
      unitRef="usd">37000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOmEyM2QwYTk5MTM0ZDRmMTJhNjY1ZGM4MTJiYzhhODY1L3RhYmxlcmFuZ2U6YTIzZDBhOTkxMzRkNGYxMmE2NjVkYzgxMmJjOGE4NjVfNC0zLTEtMS0w_af0fbfc6-3037-41cf-b465-69896fb17fec"
      unitRef="usd">30000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RleHRyZWdpb246ZGFlMGY1ZjJiNDNmNGNiY2I4M2I3M2ZiYWFjYWM2MmRfMTI1Mw_90247b90-c5cc-4126-8d24-a36191a937af">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i4cb6b2dd88864d668c5919feb00ee76c_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMS0xLTEtMS0w_0362da77-0b3c-4ed3-b636-7c762a6e681a"
      unitRef="usd">68000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i56c6be751ee64c558fe3494c112900ab_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMS0zLTEtMS0w_7ce51a87-080c-4806-a58c-bb49723bc437"
      unitRef="usd">28000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMS01LTEtMS0w_8a8d3f2b-efd7-4644-bf5b-2d1f4ad90fb1"
      unitRef="usd">96000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="i1a2579521f524f83869e7f228bd84ff9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMi0xLTEtMS0w_f375b81d-6755-4440-b13b-4fd122a985e1"
      unitRef="usd">17000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="ief7037b2735b4e7f8e6c6f2d9b8d7038_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMi0zLTEtMS0w_ebbd418f-3af7-435f-9e6d-3a2c1a7e627e"
      unitRef="usd">10000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMi01LTEtMS0w_26e9a0c1-cddb-438d-a896-2dbda92d4f39"
      unitRef="usd">27000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="i1a2579521f524f83869e7f228bd84ff9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMy0xLTEtMS0w_d7b09cc1-01b5-4ba2-988a-a698dd10b878"
      unitRef="usd">13000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ief7037b2735b4e7f8e6c6f2d9b8d7038_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMy0zLTEtMS0w_fe8e4c94-4cd0-4716-9840-6180ba297f0a"
      unitRef="usd">11000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfMy01LTEtMS0w_6a73125c-8549-4ac1-a2a6-ef6abefba304"
      unitRef="usd">24000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i425faefcb193459095f9eb5f9e4acf2c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfNC0xLTEtMS0w_b0747882-0c8d-4e30-b9a4-73db4248209f"
      unitRef="usd">72000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia0c1f80baf7644c585599ba8c1f2323c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfNC0zLTEtMS0w_5c1303f6-6530-44af-b128-09e73183343c"
      unitRef="usd">27000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184Mi9mcmFnOmRhZTBmNWYyYjQzZjRjYmNiODNiNzNmYmFhY2FjNjJkL3RhYmxlOjcwOTQ4YzI1ZjI3MjRhNDg5ZGUyZWVmYjUzZjM4Y2U1L3RhYmxlcmFuZ2U6NzA5NDhjMjVmMjcyNGE0ODlkZTJlZWZiNTNmMzhjZTVfNC01LTEtMS0w_c129602b-9ad4-48ad-bdc6-fbce5026d8a6"
      unitRef="usd">99000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNzY5NjU4MTM5NDk1NA_a856f25f-8fd9-41e4-85ca-347570317bce">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Goodwill and Other Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,357&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,907&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,658&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;798&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;807&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,844&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,788&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets was $115 million and $129 million for the three months ended September&#160;30, 2020 and 2019, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2021 through 2025 is as follows: $333 million, $398 million, $358 million, $329 million, and $278 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDcx_09d8a113-7464-4ac5-bd0c-0c38a7e3556f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,357&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i8480697f2bdf44918df39a9f5e84e330_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMS0xLTEtMS0w_9aa6cfba-ff1d-49ca-bfa1-c20a725dc01f"
      unitRef="usd">2657000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i48091522a54b466aaad728773c54a0a8_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMS0zLTEtMS0w_a5b372e7-71c4-4ac5-9d1b-8ff031408335"
      unitRef="usd">5700000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMS01LTEtMS0w_342cbdb0-db51-4f70-ab28-920d35b4a534"
      unitRef="usd">8357000000</us-gaap:Goodwill>
    <us-gaap:GoodwillTransfers
      contextRef="i9da27597353943d181889c1d5456c85f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMi0xLTEtMS0w_5543568d-b683-4e2d-92cc-2c9135a1f8b8"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="ib649dc8198854be78403495cec1847cd_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMi0zLTEtMS0w_5a1ea32f-655f-4eaa-81be-112470345a70"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMi01LTEtMS0w_60e779ad-8a7b-49a4-a8be-d56cb83043ac"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i9da27597353943d181889c1d5456c85f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMy0xLTEtMS0w_e96bf660-f397-40e7-bcc3-3d4e10084521"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib649dc8198854be78403495cec1847cd_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMy0zLTEtMS0w_a5e72a0d-9ce7-45f3-bcc0-a0362bd7070f"
      unitRef="usd">18000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfMy01LTEtMS0w_1545f533-c69a-46dd-bd45-02959e5246ab"
      unitRef="usd">18000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ib9929e41c0c24b0bba4c253330973f70_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfNC0xLTEtMS0w_6c92ed62-112b-48ea-b3e9-89b85ae9458f"
      unitRef="usd">2657000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0491c5bcabd34939b8a41c8f69eccb12_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfNC0zLTEtMS0w_3a74af75-c31b-4745-af7a-cdaab5e1a233"
      unitRef="usd">5718000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmJiMjg2YzYyODIwMTRhNzZiYjhhZjUwZTZmMGQ0YzZjL3RhYmxlcmFuZ2U6YmIyODZjNjI4MjAxNGE3NmJiOGFmNTBlNmYwZDRjNmNfNC01LTEtMS0w_76b9e163-bad1-4675-b27c-89ea6ed86446"
      unitRef="usd">8375000000</us-gaap:Goodwill>
    <cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDYw_594de549-60d6-46c4-aa7a-55cc000e915b">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,907&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,658&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;798&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;807&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,844&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,788&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i438081d1a6924fc1a9b6b1dd950a9fcd_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMy0xLTEtMS0w_0339a03f-0fa2-44bb-a305-394b4099fcef"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i438081d1a6924fc1a9b6b1dd950a9fcd_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMy01LTEtMS0w_3c3234c2-35d3-45ad-8f2c-ebebadcf10e8"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNC0xLTEtMS0w_79166f84-f50e-4e6a-9af8-541d6ea8079b"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNC01LTEtMS0w_dcdbe54b-f2fe-4ab9-849e-49295b49e5b9"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i021a5d537d2842cb817b9d054f4ff9b5_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNy0xLTEtMS0w_3a9d09eb-8047-42db-b222-dfcd90433295"
      unitRef="usd">3565000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i021a5d537d2842cb817b9d054f4ff9b5_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNy0zLTEtMS0w_1ae982a7-1f5b-4762-b378-92825a98820c"
      unitRef="usd">1907000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i021a5d537d2842cb817b9d054f4ff9b5_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNy01LTEtMS0w_45661cb7-72bd-4d93-9c56-e5015780e9c8"
      unitRef="usd">1658000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i0adfa8f5d5214083a20b748280dfcefc_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfNy03LTEtMS0w_c4917cab-2897-494b-af29-fdc898a9b274">P13Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6d951315c1c544ba967df1be4c66d58d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOC0xLTEtMS0w_fa82b88b-0227-4d4f-9686-332a4bbf96fa"
      unitRef="usd">674000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6d951315c1c544ba967df1be4c66d58d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOC0zLTEtMS0w_b95adbd6-7f0e-4024-8fae-4b3a8caad5ab"
      unitRef="usd">351000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6d951315c1c544ba967df1be4c66d58d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOC01LTEtMS0w_95e2a626-9127-4abc-84de-b5d3d4265498"
      unitRef="usd">323000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i1dd2a95f5f2b4b88bbcc6c6297bc95d0_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOC03LTEtMS0w_d136b1e0-949e-4fcb-ab9f-4ba125353815">P13Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie926bbb0cbef440c994d8834ad4a9199_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOS0xLTEtMS0w_7f33238f-c133-4a58-a10e-4f63b59f5092"
      unitRef="usd">1605000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie926bbb0cbef440c994d8834ad4a9199_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOS0zLTEtMS0w_ed717271-5ac4-4637-ac97-24cca14ccfdb"
      unitRef="usd">798000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie926bbb0cbef440c994d8834ad4a9199_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOS01LTEtMS0w_476694a8-cc18-45e9-9228-1a8d6ef6fe35"
      unitRef="usd">807000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="iccf269ca481e4302b7d6164d95f0269a_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfOS03LTEtMS0w_51dc59b2-34de-497b-8d7b-c92f192baea0">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTAtMS0xLTEtMA_7a5521eb-e54c-4fbb-bfac-4ab2cec5428c"
      unitRef="usd">5844000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTAtMy0xLTEtMA_097bba5a-a326-4b57-9897-b9ca0bcf5fe3"
      unitRef="usd">3056000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTAtNS0xLTEtMA_dbec31ea-e2cf-4986-977b-3c947a3e9ac9"
      unitRef="usd">2788000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTAtNy0xLTEtMA_aa0c8daa-b553-4c98-938a-eb53df3bf6ff">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTEtMS0xLTEtMA_48d1c55a-1ace-405a-a88a-dd71dd82457b"
      unitRef="usd">5867000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTEtMy0xLTEtMA_9afb7e77-24d8-4b88-9848-6109bd53a025"
      unitRef="usd">3056000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOjQ3OTZkNjkyMmIzZDQyY2ViZWViY2MyMzJjYmY2YjM1L3RhYmxlcmFuZ2U6NDc5NmQ2OTIyYjNkNDJjZWJlZWJjYzIzMmNiZjZiMzVfMTEtNS0xLTEtMA_8e80ac9b-2e1b-4c6b-8920-427c7f5bf2a3"
      unitRef="usd">2811000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia572b6f1eebf44cfbaeb9d8411357eca_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMy0xLTEtMS0w_ae583957-a536-4eeb-b40a-1aa646dfa6b4"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia572b6f1eebf44cfbaeb9d8411357eca_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMy01LTEtMS0w_ef4fab37-78f7-4e7b-a889-d70d2d7db9af"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNC0xLTEtMS0w_d976b71d-0942-4499-a6e5-439da6c3b09b"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNC01LTEtMS0w_7b0aa5e7-6da1-4d1d-867d-c6b6b1dacd7c"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ied58b175619b4bfebfb6b5b530246f5e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNy0xLTEtMS0w_363c8448-8116-4ad9-a3eb-ef235c58f978"
      unitRef="usd">3554000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ied58b175619b4bfebfb6b5b530246f5e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNy0zLTEtMS0w_673797eb-da37-409c-91af-4ea2b2db19f8"
      unitRef="usd">1828000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ied58b175619b4bfebfb6b5b530246f5e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfNy01LTEtMS0w_e4781366-3b4d-40ec-855b-84632159bad7"
      unitRef="usd">1726000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i91fcd765710a4070b7c3c4036717d1cf_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOC0xLTEtMS0w_32b35ece-1d90-45db-920c-6aa7689b0b6f"
      unitRef="usd">673000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i91fcd765710a4070b7c3c4036717d1cf_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOC0zLTEtMS0w_3112ca40-af2c-42dd-8e4e-5aec4be4b7fd"
      unitRef="usd">341000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i91fcd765710a4070b7c3c4036717d1cf_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOC01LTEtMS0w_3c5311f4-2079-40b2-b405-b2e8be4fd300"
      unitRef="usd">332000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6ea560c27996450ea297ecbb41e9bf97_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOS0xLTEtMS0w_5f84e260-89cb-4bc8-9bba-66cb32b68225"
      unitRef="usd">1604000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6ea560c27996450ea297ecbb41e9bf97_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOS0zLTEtMS0w_0541ec0e-1983-4ffc-98df-ae0b41a8aab1"
      unitRef="usd">767000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6ea560c27996450ea297ecbb41e9bf97_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfOS01LTEtMS0w_55b4b4b1-3326-4090-ad36-475080069a8c"
      unitRef="usd">837000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTAtMS0xLTEtMA_40a6ebf4-caa7-4b38-9fa7-52c7eb6218e9"
      unitRef="usd">5831000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTAtMy0xLTEtMA_222a1dd1-23e3-4ca1-b7f7-6f55a32cc437"
      unitRef="usd">2936000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTAtNS0xLTEtMA_7e6a106b-7194-4a60-b753-9d4b0a345de0"
      unitRef="usd">2895000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTEtMS0xLTEtMA_a930d491-5759-435b-b9fe-0d7e4ea18932"
      unitRef="usd">5854000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTEtMy0xLTEtMA_73fc57e5-ff9e-40e2-ab43-9027c988ddf0"
      unitRef="usd">2936000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RhYmxlOmY4OWNhNWJlYjhkZDQ0OTFiM2U1YTZiNmUzZDFiNzUyL3RhYmxlcmFuZ2U6Zjg5Y2E1YmViOGRkNDQ5MWIzZTVhNmI2ZTNkMWI3NTJfMTEtNS0xLTEtMA_0a178cc0-7054-4c86-ab83-e14348794579"
      unitRef="usd">2918000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfMjY0_d025b4b9-f99c-451a-9e22-4f676c6a70b5"
      unitRef="usd">115000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfMjcx_cec47a63-3fda-42a4-8282-4b92c9fbb113"
      unitRef="usd">129000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDMz_40cb4f37-6247-4cbb-9655-9745744cdb88"
      unitRef="usd">333000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDM3_aa9aaa93-c999-45e5-9b9a-0fe8024e45ab"
      unitRef="usd">398000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDQx_3a7745c1-d3ea-4c64-9039-e683bdcc524a"
      unitRef="usd">358000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDQ1_5d98f187-257f-4595-8d8f-f93df6754ab7"
      unitRef="usd">329000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY184NS9mcmFnOmIwZGNhMDAzNTk5YjQ3NTdiNzBjMjBkOGU5MmU4OGM5L3RleHRyZWdpb246YjBkY2EwMDM1OTliNDc1N2I3MGMyMGQ4ZTkyZTg4YzlfNDUz_3343420c-6873-426f-91e9-107f36a61719"
      unitRef="usd">278000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNzY5NjU4MTM5NzIzMQ_b7fa1a6b-bfb0-40eb-8c34-e1ba35d242d5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;4. Long-Term Obligations and Other Short-Term Borrowings &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had total long-term obligations, including the current portion and other short-term borrowings, of $6.7 billion and $6.8 billion at September 30, 2020 and June 30, 2020, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $21.7&#160;billion and $21.4&#160;billion at September 30, 2020 and June 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2020, we repurchased a total of $37 million of notes due in 2022 with available cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion committed receivables sales facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#x201c;CHF&#x201d;) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose-bankruptcy remote entity whose assets are available solely to satisfy the claims of its creditors. &lt;/span&gt;&lt;/div&gt;Our revolving credit facility and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of&#160;no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every fiscal quarter thereafter. At September 30, 2020, we were in compliance with our financial covenants.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfMTI2_4a3c7517-4882-424d-b09a-e063939f4464"
      unitRef="usd">6700000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfOTg5NTYwNDY1MTk4NQ_2706e1c4-856a-411f-a513-3899730a8ed8"
      unitRef="usd">6800000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNzY5NjU4MTM5NzQ5NA_eaef3f4b-5386-4437-81f1-d3f879e54f68"
      unitRef="usd">21700000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNzY5NjU4MTM5NzUyNw_57d36fa6-aec0-4b5f-acd6-dfd59d082ce9"
      unitRef="usd">21400000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNjAy_35aa1069-b40b-4d17-b747-b4e54ff123f3"
      unitRef="usd">37000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3bfc5884ee88416c9abb63244dab609c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfNzgz_ed784e17-7a81-4ae3-b6af-f838184a1d74"
      unitRef="usd">2000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i741ef9d887c94534a8eda6eccfbe2ad3_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfODIz_180eacd5-7b9d-4fde-86c9-7537342be2b9"
      unitRef="usd">2000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i119b91cee7ad43a3a902d392163cea9e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY185NC9mcmFnOjgzZmJjZWQzMDZmZDRkZGNiOTUxMjZkZjg5ZGIzODIwL3RleHRyZWdpb246ODNmYmNlZDMwNmZkNGRkY2I5NTEyNmRmODlkYjM4MjBfODY4_2860b0af-9b43-492e-b630-5e3b6ad801b9"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2Xzc2OTY1ODE0MzE4Njg_94682b5f-8f75-46eb-b477-8776946ccaa4">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health Corporation ("CVS Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the U.S. District Court for the Southern District of New York ruled that the OSA was unconstitutional and enjoined its enforcement (the "Ruling"). In April 2019, the State, among other things, amended the OSA so that the assessment would only cover opioid sales in 2017 and 2018, subject to the State's appeal of the Ruling. In September 2020, the U.S. Court of Appeals for the Second Circuit reversed the Ruling and, as a result, New York will likely seek to collect amounts due from distributors and manufacturers for 2017 and 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, at September 30, 2020, we recorded an aggregate accrual of $41 million for calendar year 2017 and 2018 based on the estimated payment amount. This is our best estimate of the OSA payments probable at September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 2,800 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#x201c;MDL&#x201d;). In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial in West Virginia in the Cabell County and City of Huntington cases is scheduled for January 2021, and a trial is scheduled to begin in Madison County, Ohio, in March 2021 in the case brought by the Ohio Attorney General. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is the basis for the ongoing negotiation of definitive terms and documentation. Negotiations under the Settlement Framework continue and have centered on the amount and timing for payment of the cash component as well as standards for settling distributors&#x2019; controlled substance anti-diversion programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of these discussions, we have recorded total pre-tax charges of $1.02 billion and $5.63 billion in litigation charges/(recoveries), net in the three months ended September 30, 2020 and 2019, respectively. In total, we have $6.59 billion accrued at September 30, 2020, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately 411 lawsuits as of November 2, 2020. Of these, 116 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Affirmative Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#x201c;National Union Fire Insurance&#x201d;), seeking a declaration that defense costs are recoverable under our insurance for certain of the lawsuits described above. We have not recorded a receivable for any recoveries related to the litigation against National Union Fire Insurance at September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). The subpoenas seek documents relating to our anti-diversion policies, procedures and program, and our distribution of certain controlled substances. We are cooperating with these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis Product Liability Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of November 2, 2020, we are named as a defendant in 354 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,526 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another 31 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and are engaged in resolution discussions with certain plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2020, we had a total of $494 million, net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;end of the range to be approximately $961 million, net of estimated insurance recoveries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Louisiana Sheriffs' Pension &amp;amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Specialty Solutions DOJ Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, we received a civil subpoena from the United States Attorney&#x2019;s Office for the District of Massachusetts seeking documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with this request and are engaged in preliminary resolution discussions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Active Pharmaceutical Ingredient Impurity Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#x201c;Sartan MDL&#x201d;) &lt;/span&gt;&lt;/div&gt;alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We were also named as a defendant in a Multidistrict Litigation alleging API impurities in Zantac and its generic form, ranitidine. We intend to vigorously defend ourselves in these matters.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="i771e1aea6b7f427a9df601aaf7660e54_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzI1NA_e7dd65b8-c214-46c5-9ad5-3e689a16693f">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:MaximumQuarterlyPayment
      contextRef="i771e1aea6b7f427a9df601aaf7660e54_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzQ1NQ_ec386b93-f155-4df1-b625-09f7671e58ad"
      unitRef="usd">45600000</cah:MaximumQuarterlyPayment>
    <cah:AggregateAnnualAssessment
      contextRef="i6561ef3f208042318b204d099ad1b0e0_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzM5MTA3_025c0fed-5002-4125-bce6-bbbb42514ac9"
      unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct
      contextRef="i939be74b35cc40a8969fcbc5e8654858_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzM5MTI2_36badba9-d99a-4290-8971-5f412cb4684f"
      unitRef="usd">41000000</cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i39e37f424f344ed4861a30e0289b675e_I20201102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTg2_61698846-f23f-4339-ab24-7ba4b3b79978"
      unitRef="reportable_segments">3300</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="ie1ec20ee64f4429a823a5f846ef8b554_I20201102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTA3_edafa46f-c4ad-4487-96bf-3e121ecd2a04"
      unitRef="reportable_segments">2800</cah:LossContingencyLawsuitsNumber>
    <cah:NumberofStateAttorneysGeneralfilinglawsuits
      contextRef="i39e37f424f344ed4861a30e0289b675e_I20201102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQzMDAz_9e3daf13-211b-4fe9-aef2-6426b2772eb3"
      unitRef="reportable_segments">25</cah:NumberofStateAttorneysGeneralfilinglawsuits>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2ODkxMDc_a024248d-a20b-4a3e-8564-bf099edfdcee"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="iac21abb30a6046b1aaef99f6b707cbd5_D20190701-20190930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzM5MTc0_f08d9a18-6ca2-42fc-9fdc-b242c2cec640"
      unitRef="usd">5630000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LitigationReserve
      contextRef="i0dd1e60e6ffd4307b7bf4207ea74288c_I20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEzNzQzODk1NDEwMTM2_6437ba59-5b15-4383-9c7a-e86dffa06a3b"
      unitRef="usd">6590000000</us-gaap:LitigationReserve>
    <cah:LossContingencyLawsuitsNumber
      contextRef="iaf9406084961493d9d4b3eb6d8055a86_I20201102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTky_e36a980d-2b1c-42a5-8e8d-5d5734f9260f"
      unitRef="reportable_segments">411</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="if5b6097a61c849798a37a8304de056d5_I20201102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTk4_17cbe7b0-92f3-48b6-ace6-a37f76e726c3"
      unitRef="reportable_segments">116</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ie47435aa0ab74b408fd91dfc770477cc_D20201102-20201102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTI0_1ec90024-1637-4d55-8e1c-468c1c386430"
      unitRef="reportable_segments">354</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="if790e73672e840e5b0d954ff370e0e96_D20201102-20201102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTI4_311c9600-08f4-45d0-9cb7-b46e111031b5"
      unitRef="reportable_segments">4526</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="iab0a211a496049da89686dc5fe319089_D20201102-20201102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTMy_d5724c96-b31e-477a-8a83-69d43789ae4c"
      unitRef="reportable_segments">31</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="iefc77509e5de47719bffc603ae04f45c_D20201102-20201102"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzQyOTM2_0448104b-779a-4061-8915-0876c806683a"
      unitRef="reportable_segments">36</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i7f21d49611034f3fa4a6fb00669c782b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzE1MTAz_0b54ffcf-d3ae-4684-a517-a9f0aa07df05"
      unitRef="usd">494000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ibf6467237c464a1aa045646e1b87276b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDAvZnJhZzo2ODJiZGY4MGY4ZWM0ZTg2YTcwZmEzNDRmYzZjNDFlNi90ZXh0cmVnaW9uOjY4MmJkZjgwZjhlYzRlODZhNzBmYTM0NGZjNmM0MWU2XzEwOTk1MTE2MzE1MTEx_9382d124-fc16-4cd0-b321-6c039e9eb24f"
      unitRef="usd">961000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzc2OTY1ODE0MjI0OTM_341d2608-371b-4d95-9f9a-247a7e3e843d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our provision for/(benefit from) income taxes as a percentage of pre-tax loss (&#x201c;effective tax rate&#x201d;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Settlement Framework&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the $1.02 billion and $5.63&#160;billion pre-tax charges for the opioid litigation during the three months ended September 30, 2020 and 2019, respectively, the net tax benefits are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision/(benefit) for income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the initial opioid accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent.  Including the relatively lower tax benefit of the current quarter charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax benefit in the current quarter increased by approximately $450 million over the tax expense that would have been recognized without the impact of the opioid litigation charge and is expected to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significantly increase our provision for income taxes during the remainder of fiscal 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2020 and 2019, the effective tax rate was 61.8 percent and 7.9 percent, respectively. The increase in the effective tax rate for the three months ended September 30, 2020 compared to the prior year period was primarily due to the treatment of the tax impacts of the opioid litigation accrual, partially offset by the prior-year benefit of discrete tax items.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $994 million and $998 million of unrecognized tax benefits at September 30, 2020 and June&#160;30, 2020, respectively. The September 30, 2020 and June&#160;30, 2020 balances include $750 million and $753 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2020 and June&#160;30, 2020, we had $147 million and $146 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of loss. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $370 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $179 million and $176 million at September&#160;30, 2020 and June&#160;30, 2020, respectively, and is included in other assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition. The indemnification receivable was&#160;$19 million at both September&#160;30, 2020 and June&#160;30, 2020, and is included in other assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzI4OQ_a024248d-a20b-4a3e-8564-bf099edfdcee"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iac21abb30a6046b1aaef99f6b707cbd5_D20190701-20190930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzc2OTY1ODE0MDYxMDQ_2ddd8891-47bf-4a20-8bfa-c53ccc82e321"
      unitRef="usd">5630000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia09951da05f64bf3a7732138bd69fdfc_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2MzA0MDc2_a3e09a73-aa87-4ad3-922c-66120a1aecaa"
      unitRef="usd">35000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3306233e5db4b188aa16b734cd988cf_D20190701-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2NDczMjc_e6c244d1-8fe1-4e73-89fe-25242809bb06"
      unitRef="usd">488000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0f2e67b10f4d497fa601aa7acf5cafd5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2NDczOTk_70a40d0a-8dac-454f-b9e1-0e7a139d7ac0"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia819620c77c04e44820e9270d0163402_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2NDc0MTM_676948d1-7814-4c31-8ad5-efa5d5ceb0d5"
      unitRef="usd">469000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEwOTk1MTE2MzA0MDU4_732d852b-ac9b-4177-a0a5-be15a7d79736"
      unitRef="usd">-450000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzEzOTA_6b8508c6-0364-4015-9d4f-586048e1d4d7"
      unitRef="number">0.618</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE0MDU_3d69f33e-86c9-49f5-843b-1105e4e57e3d"
      unitRef="number">0.079</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYxNzY_cba7bc2a-9d37-4ff3-9099-f4957945f18f"
      unitRef="usd">994000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYxNjg_ad35c2f3-ea47-4629-a1a1-eb28e8afbd77"
      unitRef="usd">998000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYxODQ_9b2bb905-d574-4910-bf92-8bddfe94e41d"
      unitRef="usd">750000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYxOTY_ce9ec387-93c2-4451-9837-56d7fa79de70"
      unitRef="usd">753000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMTI_9eb42a5f-00c1-41db-8b69-2cc24ceb8a79"
      unitRef="usd">147000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMDQ_903f4138-a5a2-4e96-abf2-f31ba63126af"
      unitRef="usd">146000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="icee8303e1efb47e5b605a6d6693baa6d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzI3NzU_27c8120c-f939-4666-ac82-357b2736ab27"
      unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i198d88ecb6cb419a8da8c55f4bdd2385_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzI4MDA_0a57123e-6a99-4be1-9189-8eb94eac5ef3"
      unitRef="usd">370000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:OpenTaxYear
      contextRef="i90891cc2a4a8436bb9f99a47f2669996_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzMwNzI_cac8a916-1f73-4db2-bada-d844722acc8f">2008</us-gaap:OpenTaxYear>
    <cah:IndemnificationReceivable
      contextRef="icf6d9f7208624a0aa1b66fad4bab9571_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMzA_958841f0-eddf-4a49-8c7f-8ee4ce26b5de"
      unitRef="usd">179000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i72e11ec7b02f4f62aa657fb2116b44ad_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMjI_20f85c44-c335-4f02-a235-d4175b98cff8"
      unitRef="usd">176000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i4fb4c3b745404fd9b199d24994707757_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMzg_6d069194-8474-4eda-aa65-db6b7a29d62b"
      unitRef="usd">19000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i821519601f81436faf796e3e48f6e226_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDMvZnJhZzo4MDM3OGM0OGVkYjE0Mzg1ODJhMmJlYTEyMTc3ZTQ0Yy90ZXh0cmVnaW9uOjgwMzc4YzQ4ZWRiMTQzODU4MmEyYmVhMTIxNzdlNDRjXzE2NDkyNjc0NDYyMzg_81cb6e18-878d-45b3-acf4-d101f9472b03"
      unitRef="usd">19000000</cah:IndemnificationReceivable>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90ZXh0cmVnaW9uOjdhYTViNzE4Njg3ZDQ2ZjA4NjAyZDZiZTY1YmQwNDllXzEyNjk_0804567d-22f0-41c2-8367-e5d9b278b74d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;(2)    The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90ZXh0cmVnaW9uOjdhYTViNzE4Njg3ZDQ2ZjA4NjAyZDZiZTY1YmQwNDllXzEyNTY_be1a186c-4c9f-4605-862a-5876df869d60">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;(2)    The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6e14eef936ce478e977bd2365ab2dcc9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzMtMS0xLTEtMA_de764bfd-4c0e-4f87-bde6-412339f43849"
      unitRef="usd">1070000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i07b43a414d2b4f6fa40be7cadc0a1262_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzMtMy0xLTEtMA_20687f76-1345-42dc-ad37-9f219b515e3f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i91e3c7cc8bf8416a8084c477ef5ff7e1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzMtNS0xLTEtMA_dde1990a-62a9-4edd-ba45-68bf0ae036d5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4f47cfe18fe54226a1df09ddb6efef0c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzMtNy0xLTEtMA_02a6f765-63ff-4b79-a2c4-cc2a38d0fb8b"
      unitRef="usd">1070000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6e14eef936ce478e977bd2365ab2dcc9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzQtMS0xLTEtMA_be03715a-1eef-4d11-abf6-51071948e5ef"
      unitRef="usd">111000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i07b43a414d2b4f6fa40be7cadc0a1262_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzQtMy0xLTEtMA_5670bb0b-519a-42e9-9599-508f3ad1c6c5"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i91e3c7cc8bf8416a8084c477ef5ff7e1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzQtNS0xLTEtMA_c782f7c4-cb7b-4fad-861a-3bf86c4e64a4"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i996aed144ffb4a48a0ee5fbb315c6670_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzQtNy0xLTEtMA_5cca1e42-4c2f-48f2-ae7b-aacf5628c3c9"
      unitRef="usd">111000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i6e14eef936ce478e977bd2365ab2dcc9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzYtMS0xLTEtMA_d0699fb4-40c4-428d-aa83-0c842ce238ae"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i07b43a414d2b4f6fa40be7cadc0a1262_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzYtMy0xLTEtMA_9e39cc17-3499-442c-a98b-117844b0ec83"
      unitRef="usd">24000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i91e3c7cc8bf8416a8084c477ef5ff7e1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzYtNS0xLTEtMA_c8207bb2-2a12-4738-addb-77d0124dab55"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i996aed144ffb4a48a0ee5fbb315c6670_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTpkNTQ5YzNjZTc4MTc0OTk1ODc3YzlhMzNlZTdkYjdjNC90YWJsZXJhbmdlOmQ1NDljM2NlNzgxNzQ5OTU4NzdjOWEzM2VlN2RiN2M0XzYtNy0xLTEtMA_ee367fea-2347-4898-a181-38ddf3fcd140"
      unitRef="usd">24000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id645783b71294f05bb6047acb455691b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzMtMS0xLTEtMA_37cb4dd9-b442-4289-8966-f216d3553371"
      unitRef="usd">721000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i269f7fc0ae604642a4a6a3d792040971_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzMtMy0xLTEtMA_43604637-72c1-48c5-900b-95512fd5ae0a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if6ccfc94660444b69cd33d2b61edc9e1_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzMtNS0xLTEtMA_5984d30f-30d7-4649-b00e-a93e31ad79dc"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifbaf94dcf17e4c03b40d6ee4e6a38630_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzMtNy0xLTEtMA_ec7b83d7-3066-4533-9e2e-a8d90abcbd88"
      unitRef="usd">721000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id645783b71294f05bb6047acb455691b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzQtMS0xLTEtMA_e0ea6394-91d8-4ce7-ac9c-204b0df6124a"
      unitRef="usd">114000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i269f7fc0ae604642a4a6a3d792040971_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzQtMy0xLTEtMA_76661b96-1fb8-44de-a015-c3588522d178"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if6ccfc94660444b69cd33d2b61edc9e1_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzQtNS0xLTEtMA_994e1e12-fbc4-4376-ad37-6163d2dc029d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if3ee5fbf2771456f9b16564e61ebe4f5_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzQtNy0xLTEtMA_2f4b00dc-05e3-43d0-9c1d-9c000a3df66a"
      unitRef="usd">114000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="id645783b71294f05bb6047acb455691b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzYtMS0xLTEtMA_6dad959c-4b72-4ad4-90b2-31cfe2ca910c"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i269f7fc0ae604642a4a6a3d792040971_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzYtMy0xLTEtMA_4b6e1e60-1791-48af-9e1d-556fbd3c6599"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="if6ccfc94660444b69cd33d2b61edc9e1_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzYtNS0xLTEtMA_9ef2833c-4dc7-4547-9421-bf018d561498"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="if3ee5fbf2771456f9b16564e61ebe4f5_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDYvZnJhZzo3YWE1YjcxODY4N2Q0NmYwODYwMmQ2YmU2NWJkMDQ5ZS90YWJsZTozMmMwZTJmZWI2OGU0OWYzOWRmZDAzNzA4NDU2Y2NlZC90YWJsZXJhbmdlOjMyYzBlMmZlYjY4ZTQ5ZjM5ZGZkMDM3MDg0NTZjY2VkXzYtNy0xLTEtMA_03d286be-3112-455d-9150-6de07b8a2213"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzc2OTY1ODE0MTM4MjY_801284e4-383e-4cf0-8a32-869488a022f9">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of loss. For the three months ended September&#160;30, 2020 and 2019, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2019, we entered into a forward interest rate swap with a total notional amount of&#160;$50 million&#160;to hedge probable, but not firmly committed, future transactions associated with our debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains and losses recognized in other comprehensive loss were immaterial during the three months ended September&#160;30, 2020 and 2019. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September&#160;30, 2020 and 2019. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During three months ended September 30, 2019, we entered into a &#xa5;64.0 billion ($600 million) cross-currency swap maturing in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $25&#160;million loss and a $16&#160;million gain &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the three months ended September&#160;30, 2020 and 2019, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of loss for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were immaterial during the three months ended September&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The gain and losses recognized in the three months ended September 30, 2020 and 2019 were immaterial. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, Brazilian real and Japanese yen.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2020 and June 30, 2020 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzMyNjM_f3517237-1b5d-45a0-961b-3d486f625784"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i70de2fa7134c4f26a5575c7874c7dbc1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzQxMzY_cd61ff4a-be42-4e2b-a67c-2d87bde3ce32"
      unitRef="usd">50000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="id9465d58bd9c4791a0eb659e86c94043_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzQ5NzU_412c4f2c-1c14-4665-aa07-1e0769b4ba54"
      unitRef="eur">64000000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="id083a10b766c4345a49d14f0632816a6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzk4OTU2MDQ2NjkwNDU_580903e7-061c-4154-848d-e28bce358f68"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i24179129a5974fea826c6897ed376db7_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzk4OTU2MDQ2NjkwNTg_bccb6ee5-8f8c-40ea-8aa3-edae928dcc2f"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90ZXh0cmVnaW9uOmZlYjY0NTk3MDU3ZjQxNzI4NjVmMTYyYjg4NzczODhhXzcyOTc_41cb7222-7aa8-4950-bbd9-4f5cc408a3cf">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iba45d8ce890d432cbb652a278df25802_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90YWJsZTplZmY2YWQzNGVhNGM0YzQ2OGU3MzQ5OWM1MDg0YmU0My90YWJsZXJhbmdlOmVmZjZhZDM0ZWE0YzRjNDY4ZTczNDk5YzUwODRiZTQzXzEtMS0xLTEtMA_310b57c4-d11f-47ea-81c2-3d12fc13ece0"
      unitRef="usd">7245000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ia0d69c82422d48839b20ba8699842249_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90YWJsZTplZmY2YWQzNGVhNGM0YzQ2OGU3MzQ5OWM1MDg0YmU0My90YWJsZXJhbmdlOmVmZjZhZDM0ZWE0YzRjNDY4ZTczNDk5YzUwODRiZTQzXzEtMy0xLTEtMA_721f7f80-077f-40c8-9396-f3062948648e"
      unitRef="usd">7273000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90YWJsZTplZmY2YWQzNGVhNGM0YzQ2OGU3MzQ5OWM1MDg0YmU0My90YWJsZXJhbmdlOmVmZjZhZDM0ZWE0YzRjNDY4ZTczNDk5YzUwODRiZTQzXzItMS0xLTEtMA_8ea830c7-37de-4f20-b263-dabd236c6845"
      unitRef="usd">6740000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMDkvZnJhZzpmZWI2NDU5NzA1N2Y0MTcyODY1ZjE2MmI4ODc3Mzg4YS90YWJsZTplZmY2YWQzNGVhNGM0YzQ2OGU3MzQ5OWM1MDg0YmU0My90YWJsZXJhbmdlOmVmZjZhZDM0ZWE0YzRjNDY4ZTczNDk5YzUwODRiZTQzXzItMy0xLTEtMA_f6028062-e49a-42a0-b494-dc5fcdbb0342"
      unitRef="usd">6775000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzEyNjA_4f014aaa-8527-4706-a721-4b346424f3a7">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Shareholders' Equity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2019, we entered in an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $350 million and received an initial delivery of 6.4 million common shares having an aggregate cost of $280 million. The average price paid per common share was $43.76. The ASR program began on August 20, 2019 and was completed on December 4, 2019 when we received the final 0.9&#160;million common shares. We funded the repurchases with available cash and short-term borrowings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income attributable to Cardinal Health, Inc., net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i76bcd37a41304f9a80edf0b488038276_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzU5NA_0f64b863-7cb2-4f81-a59d-2b3a9f17ee4f"
      unitRef="usd">350000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <cah:TreasuryStockAcquiredShares
      contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzYzMw_a9d92216-fe29-41e3-bb73-002afa751078"
      unitRef="shares">6400000</cah:TreasuryStockAcquiredShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzY3OA_a615c606-a1dd-4412-81a5-10b026f4b461"
      unitRef="usd">280000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ibb67e071ad32419f9b387dbd380aa8cd_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzcyNg_de8e9135-0b56-41ae-b45b-caf283c21136"
      unitRef="usdPerShare">43.76</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <cah:FinalSharesReceivedfromASRProgram
      contextRef="i5672d212637f41acb8eb88dd1e16d3ab_I20191204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1Xzc2OTY1ODEzOTY4MjU_91fb9ce3-6398-45dc-ae88-379e718bf888"
      unitRef="shares">900000</cah:FinalSharesReceivedfromASRProgram>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90ZXh0cmVnaW9uOmRlYzc0OTMwNDU3ZjQxOTQ5NjUxMmQ3MjFiZmQwNjU1XzEyNjc_f53eeb74-7a5c-440b-b9f8-b60084339013">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income attributable to Cardinal Health, Inc., net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67e8522d8b5645e79d6b9af6f3933166_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzEtMS0xLTEtMA_cf0e9a34-d56b-4963-9a80-8e1347fc2078"
      unitRef="usd">-92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30acee2f999d4666aa8a690497305ee1_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzEtMy0xLTEtMA_596dc188-da50-4304-bf65-947dde31fe3c"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i364789c943c04565b9bde52a3752220d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzEtNS0xLTEtMA_1d8151c4-c81b-4f9c-86cf-4334894121ab"
      unitRef="usd">-104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i78e7580ef4ee445389920d8d3c96ab6c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzItMS0xLTEtMA_9a2d8a34-d37d-43a6-85a5-b23ac5e03ba9"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0d125daceaeb49239b6bf716b1f7b342_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzItMy0xLTEtMA_a6764f1e-ebd5-4fb5-a5aa-f647f1f49467"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i15805896000345a2aa639595943a623a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzItNS0xLTEtMA_460e4ad8-72cd-4e58-a73b-2964481284b5"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i78e7580ef4ee445389920d8d3c96ab6c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzMtMS0xLTEtMA_d9e0099e-74d6-4ffa-af63-958650f1de87"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0d125daceaeb49239b6bf716b1f7b342_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzMtMy0xLTEtMA_24457c62-4077-4302-afa4-d67ae1810de5"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i15805896000345a2aa639595943a623a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzMtNS0xLTEtMA_ce176e94-d58a-4c99-988b-c0141793bf20"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i78e7580ef4ee445389920d8d3c96ab6c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzQtMS0xLTEtMA_55c48161-087f-45cd-acad-2811dc3d397b"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0d125daceaeb49239b6bf716b1f7b342_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzQtMy0xLTEtMA_bdff1251-33f3-4c31-a658-0e96628316c7"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia53329ae895148609299a5ce40e3c592_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzQtNS0xLTEtMA_842f8e74-703a-4cf4-9f98-e00a9de03e2e"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cabdcfb164044c48c31dcddf5873c35_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzUtMS0xLTEtMA_4a446d20-e280-40d7-914c-5680fe1458e8"
      unitRef="usd">-80000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i453407ee376d4fe78c2176a18171602c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzUtMy0xLTEtMA_9e207ae5-76fd-4381-b6bc-06e99a524650"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic66e4cdcd5a046cfae01e323cbb8b418_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTIvZnJhZzpkZWM3NDkzMDQ1N2Y0MTk0OTY1MTJkNzIxYmZkMDY1NS90YWJsZTo4YTkyYzBhZmM3ZTg0MjI3OGQxYTg0ZmVlNzZlMmM2MS90YWJsZXJhbmdlOjhhOTJjMGFmYzdlODQyMjc4ZDFhODRmZWU3NmUyYzYxXzUtNS0xLTEtMA_5b1ebb62-8642-44b7-ae5d-6cebceef5997"
      unitRef="usd">-87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzU5OA_87e081e2-142a-48fa-8f2f-56bf0b69a4d0">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Loss Per Share Attributable to Cardinal Health, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units, and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for September 30, 2020 and 2019 were 7 million and 6 million, respectively. For the three months ended September 30, 2020, and 2019, there were 2 million and 1 million potentially dilutive employee stock options, restricted share units and performance share units, respectively, not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been anti-dilutive as a result of the net loss during that period.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzU5NA_df4d7988-8f2b-46c2-8dd3-9984db5da5af">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units, and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzItMS0xLTEtMA_6ea12baa-63bf-44fb-b367-ffec31502b78"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzItMy0xLTEtMA_c80efc9c-36e9-4cfe-9538-17d6fdf982de"
      unitRef="shares">296000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzQtMS0xLTEtMA_6fd08cbb-c713-44bf-8a46-fa6bb5f95b13"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzQtMy0xLTEtMA_f3561939-a3c1-483a-9bc1-1a8bdfd27e2c"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzUtMS0xLTEtMA_b7f0a47b-3dbd-48ac-a980-a1d6c43c3af3"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90YWJsZTo5ZDQ1YWIxN2M4ZDA0MDUwOWM4ZjQxZDU0NGE5ZjM3ZS90YWJsZXJhbmdlOjlkNDVhYjE3YzhkMDQwNTA5YzhmNDFkNTQ0YTlmMzdlXzUtMy0xLTEtMA_63c0a157-f104-407b-8bab-c64873c4c93e"
      unitRef="shares">296000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <cah:Numberofsharesexcludedfromcalculationofdilutedshares
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzEwOTk1MTE2MzA2ODg_3ac7b51e-9418-49d4-a609-3bfff3be079c"
      unitRef="shares">7000000</cah:Numberofsharesexcludedfromcalculationofdilutedshares>
    <cah:Numberofsharesexcludedfromcalculationofdilutedshares
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzEwOTk1MTE2MzA3MDc_4cba8e4a-41bd-4a33-83e4-7f5e1d0e2eb5"
      unitRef="shares">6000000</cah:Numberofsharesexcludedfromcalculationofdilutedshares>
    <cah:Sharesthatwouldbeantidilutiveasaresultofnetloss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzEwOTk1MTE2MjgyMTE4_6d92e7fa-5a7e-4443-be1e-63aa91248f57"
      unitRef="shares">2000000</cah:Sharesthatwouldbeantidilutiveasaresultofnetloss>
    <cah:Sharesthatwouldbeantidilutiveasaresultofnetloss
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTUvZnJhZzozZWIwYTE0MzZkM2U0M2NkYTc1ZmYwMzkzMzE5ZGQyZS90ZXh0cmVnaW9uOjNlYjBhMTQzNmQzZTQzY2RhNzVmZjAzOTMzMTlkZDJlXzEwOTk1MTE2MzA3MTQ_34ef5ba9-fbd0-44ce-b80a-570450274b35"
      unitRef="shares">1000000</cah:Sharesthatwouldbeantidilutiveasaresultofnetloss>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3NDQ_bc6ee068-26d7-458a-8b54-2c68c5e1b1cf">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,916&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,069&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,093&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,069&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: last-in &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $5 million and $3 million for the three months ended September 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the opioid litigation as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i84d08fd1ffc74d6494b61b46546492fc_100" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized pre-tax charges of $1.02&#160;billion and $5.63&#160;billion during the three months ended September 30, 2020 and 2019, respectively, which was retained at Corporate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,809&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzEwMg_501b2ce6-09e1-4c3f-beee-cff22bd03a01"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzEwMg_d2903e3f-3f2d-4225-90c1-79d7b6d354cb"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3NDg_30f9bc0e-5884-4888-b7f2-00345b1690a2">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,916&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,069&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="id8f75c382c1c4df691a419c0e178c753_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzItMS0xLTEtMA_955c2bce-8219-409a-8482-3b5c1052abbc"
      unitRef="usd">34916000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0defeec516474249b8995ba49880c24a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzItMy0xLTEtMA_039bc1fd-621a-454a-a446-641246e345af"
      unitRef="usd">33212000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62af4253c8a346ccbeeba7311323f9a6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzMtMS0xLTEtMA_116acb22-41dc-43de-8536-4446d01976bb"
      unitRef="usd">196000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e3b1bc368924c059f7e70628540e193_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzMtMy0xLTEtMA_643e917d-7524-42ba-b7ec-6625c5abd586"
      unitRef="usd">216000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2de354d09bc44a9fa3785d5625393d00_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzQtMS0xLTEtMA_c7688e98-28a7-48d9-82ea-9c364b8572ba"
      unitRef="usd">35112000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3917f66b8f644838a6208b4c579c8bf_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzQtMy0xLTEtMA_883a953d-6905-484d-94ec-ee59744c11a3"
      unitRef="usd">33428000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09f112593ed04de0a5bb4ca0a2030c04_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzUtMS0xLTEtMA_71657f2c-8693-48f7-a25f-a8848f96a4a8"
      unitRef="usd">3438000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38b597f3573d47b49abc5302f1695a37_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzUtMy0xLTEtMA_f3154622-b4d9-4943-a42d-85860478f1b6"
      unitRef="usd">3446000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iecb54beca65c45029506df58645bad06_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzYtMS0xLTEtMA_477244c9-73e0-4e68-bdb1-4948ccca5cfa"
      unitRef="usd">519000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06a632d5955e4aa3866f348c953d8d08_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzYtMy0xLTEtMA_7fc6ca3b-da18-4860-a478-138447658fcb"
      unitRef="usd">471000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f6e1c05bec24505be4e45733f808646_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzctMS0xLTEtMA_c32abd56-18a1-441a-b9ef-2c0c3157db2b"
      unitRef="usd">3957000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i781f2efb9025488d94dcbfda31c5bd48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzctMy0xLTEtMA_72a5f112-316a-414c-90da-e79129c8445e"
      unitRef="usd">3917000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcebc361e52048eaba97198b6a5faba9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzgtMS0xLTEtMA_ffd2ff64-a0bf-4770-928b-089294ae0491"
      unitRef="usd">39069000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d88dbb2b05d4b1b89fa61aa66aedbad_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzgtMy0xLTEtMA_8bfda17e-1a47-41b6-9a8f-aebed6c7f834"
      unitRef="usd">37345000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee2cbf3fb2124481bec0997184cebcb1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzktMS0xLTEtMA_9ed9a87e-ba96-4de5-9606-5340851913e5"
      unitRef="usd">-4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d0e8c9c681b47eeb9760d46de31a6d1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzktMy0xLTEtMA_4c21fe5e-575f-443b-bb74-1dae59219add"
      unitRef="usd">-4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzEwLTEtMS0xLTA_afa53e97-0136-4996-b5ef-c1e56b19df1a"
      unitRef="usd">39065000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTphMDgwNmVhMmQ1ZjI0ZGIzYjIzZjM3NTA1MmU2MTNhMS90YWJsZXJhbmdlOmEwODA2ZWEyZDVmMjRkYjNiMjNmMzc1MDUyZTYxM2ExXzEwLTMtMS0xLTA_f25a3b79-02da-4ea8-a545-0fd8f4977842"
      unitRef="usd">37341000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3Mzk_b0d95ffa-ae6b-49e9-b36b-02df37beab30">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,093&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,069&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i52baa5c5a9654848bd9121d59999a39b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzItMS0xLTEtMA_aa490186-0742-439d-8a32-2bfc2e32eb72"
      unitRef="usd">37976000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f4974c67c114c848433b0dfc9102fde_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzItMy0xLTEtMA_c9e509e4-4246-4796-84ab-544d549f8d63"
      unitRef="usd">36310000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5632dcd9d2a4e40a78e375c76a736e3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzMtMS0xLTEtMA_80972585-26b0-4187-be7f-84df5f04fef7"
      unitRef="usd">1093000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c3a5767abd1403ab78e9bf2adee431c_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzMtMy0xLTEtMA_7336aaf1-008b-4a41-a416-aa1dd794c606"
      unitRef="usd">1035000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcebc361e52048eaba97198b6a5faba9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzQtMS0xLTEtMA_ffd2ff64-a0bf-4770-928b-089294ae0491"
      unitRef="usd">39069000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d88dbb2b05d4b1b89fa61aa66aedbad_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzQtMy0xLTEtMA_569a7aea-9d19-4db7-b8a0-a97bd3cf29c5"
      unitRef="usd">37345000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee2cbf3fb2124481bec0997184cebcb1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzUtMS0xLTEtMA_9ed9a87e-ba96-4de5-9606-5340851913e5"
      unitRef="usd">-4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d0e8c9c681b47eeb9760d46de31a6d1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzUtMy0xLTEtMA_ca4ece9d-18e1-474a-a64b-effe7a6ee557"
      unitRef="usd">-4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzYtMS0xLTEtMA_afa53e97-0136-4996-b5ef-c1e56b19df1a"
      unitRef="usd">39065000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTo2OTBhZDc3MmVlMTk0ZGQwYmY1NzVkMzA3OTNlY2ZhNS90YWJsZXJhbmdlOjY5MGFkNzcyZWUxOTRkZDBiZjU3NWQzMDc5M2VjZmE1XzYtMy0xLTEtMA_c9d7089f-29aa-401b-90fc-d9d392cd61d1"
      unitRef="usd">37341000000</us-gaap:Revenues>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQxNjg_436302ae-b6ac-4257-b84b-388e17db3540"
      unitRef="usd">5000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQxNzU_0302902b-97db-4904-a006-006a4dfa37de"
      unitRef="usd">3000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i7747b0cf61884365a645dcaa8a508d0d_D20200701-20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzk4OTU2MDQ2NTUzMTc_6cd5e1d0-c187-465b-bd9d-bbb9667aeb85"
      unitRef="usd">1020000000.00</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="iac21abb30a6046b1aaef99f6b707cbd5_D20190701-20190930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzk4OTU2MDQ2NTUzMjY_1bfcc83a-2153-45a1-b81f-773387d3c1ba"
      unitRef="usd">5630000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3NDk_ce944219-e6b4-4ed8-95e0-f11c48d9a2b9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2de354d09bc44a9fa3785d5625393d00_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzItMS0xLTEtMA_a4889358-7d4b-41cd-87ca-1705589deebc"
      unitRef="usd">402000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib3917f66b8f644838a6208b4c579c8bf_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzItMy0xLTEtMA_663e8f28-5278-477f-a213-99b213b9e766"
      unitRef="usd">398000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2f6e1c05bec24505be4e45733f808646_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzMtMS0xLTEtMA_c0d1d208-ad96-4fe4-ab03-dec8d3119cfa"
      unitRef="usd">230000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i781f2efb9025488d94dcbfda31c5bd48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzMtMy0xLTEtMA_2b59a5c8-7442-4f52-8134-26c11d0a6b61"
      unitRef="usd">170000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibcebc361e52048eaba97198b6a5faba9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzQtMS0xLTEtMA_b4dac84e-00ff-4773-81b9-f61672df1ee5"
      unitRef="usd">632000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5d88dbb2b05d4b1b89fa61aa66aedbad_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzQtMy0xLTEtMA_1a671ada-87cc-4ea6-8ea3-fb0b5f18ece3"
      unitRef="usd">568000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iee2cbf3fb2124481bec0997184cebcb1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzUtMS0xLTEtMA_c818c16d-5629-4d6f-a317-a72baeb08166"
      unitRef="usd">-1256000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6d0e8c9c681b47eeb9760d46de31a6d1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzUtMy0xLTEtMA_736907c9-8a03-425b-9b75-c36bbd3af158"
      unitRef="usd">-5832000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzYtMS0xLTEtMA_acb98e8d-3839-4494-aa86-63ff78a2dbd2"
      unitRef="usd">-624000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmMzE4OTllNDE0YmI0YTQ0ODg4OTUxYjMxZjNiYTkzNS90YWJsZXJhbmdlOmYzMTg5OWU0MTRiYjRhNDQ4ODg5NTFiMzFmM2JhOTM1XzYtMy0xLTEtMA_33b21a32-839d-42fe-a2b2-d739cd272fac"
      unitRef="usd">-5264000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90ZXh0cmVnaW9uOmFhN2Q4M2QxOWFmZDQyMWI4NDZlNjVlZWY3MDRmOTJjXzQ3NTE_d60a146c-63e9-4fe2-ae41-397212d6f850">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,809&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="i2dab659e59834b43b34ab0f7563c0c82_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzEtMS0xLTEtMA_ed92c6ae-7be9-4b88-818c-75007a219aa9"
      unitRef="usd">22809000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie7066c54e7dd4fceb8588adf471ba835_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzEtMy0xLTEtMA_94dbe5b3-0e13-4e80-8cf2-b13a8f8cd042"
      unitRef="usd">22398000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i098156347d904aa088fa3e1e5127a1d4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzItMS0xLTEtMA_8d5dd251-9363-48ab-b49c-560dc80f4438"
      unitRef="usd">14985000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i75fa3de7c8a54b8b83706d76e4c35b76_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzItMy0xLTEtMA_1bfe7103-6d56-4a41-9b09-a357a1f48e69"
      unitRef="usd">14691000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i857ee1bbc77f4af191655dfc896df4c3_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzMtMS0xLTEtMA_0b083e2d-82cd-4588-8e84-8015ab534a49"
      unitRef="usd">3933000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie2aeccd462de4b89be3251b77c14116a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzMtMy0xLTEtMA_6d323ca2-aad3-49c1-b85c-d453feaf3adf"
      unitRef="usd">3677000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzQtMS0xLTEtMA_efe14f33-a52b-48c7-b352-067bd9689f4c"
      unitRef="usd">41727000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMTgvZnJhZzphYTdkODNkMTlhZmQ0MjFiODQ2ZTY1ZWVmNzA0ZjkyYy90YWJsZTpmNzVlZjU5OTJmNjU0MTRkOWFmMGEzZWUzZmJhZWFkYS90YWJsZXJhbmdlOmY3NWVmNTk5MmY2NTQxNGQ5YWYwYTNlZTNmYmFlYWRhXzQtMy0xLTEtMA_644853ba-d11d-4116-9bc3-54c3f15e4b33"
      unitRef="usd">40766000000</us-gaap:Assets>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzNDM_c8706d10-9f38-4f67-bee8-fa6e4adb0b2b">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $4 million for both the three months ended September&#160;30, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48.34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $124 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66.36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized was $0.3 million, which is expected to be recognized over a weighted-average period of two years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49.07&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $39 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzNDg_e8c06f1b-d2c6-42ed-bc9e-131734444303">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzItMS0xLTEtMA_da3e26a5-639b-41be-869e-15dbf4eee4c9"
      unitRef="usd">19000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc62178c06b346f2a9d5381f46838f85_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzItMy0xLTEtMA_829fa2de-5bb5-4ab7-a1e6-b346ec4be54d"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzMtMS0xLTEtMA_b2287a00-252b-4303-b37d-523ae30c8199"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibad9b2879e704eba834be054682ed6c5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzMtMy0xLTEtMA_9e8d5fbf-ddbf-4ba9-9e88-ba4627044047"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzQtMS0xLTEtMA_10fbc1f5-59b4-450b-8a89-629b97cfcafc"
      unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie19d22156ae648a3a872b2507b4de145_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzQtMy0xLTEtMA_6c610239-f851-4045-8b20-74d21e7dde2a"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzUtMS0xLTEtMA_1cfbe175-e44a-4a74-ae5c-8ceaabfaf8f2"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4acdb1d2541c4343b39ad272a6b7b3bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTozNmZhMjFiM2EzNjU0MzcxYTNjMjI3YzI5OWE2ZWZlYy90YWJsZXJhbmdlOjM2ZmEyMWIzYTM2NTQzNzFhM2MyMjdjMjk5YTZlZmVjXzUtMy0xLTEtMA_ef497ecd-1f43-476a-9c17-0645dec70b8a"
      unitRef="usd">20000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzI5MQ_b271b6b3-24ce-4b29-93c4-59d9fd67449d"
      unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzQ3Mw_fe12ef4d-4d55-473a-9c97-8c24a6ea11df">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzMzk_2681ecd7-05f3-4365-8c0e-a429e57bee4c">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48.34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7cc829ddfa7546fe9e92c22e0ea07a60_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzEtMS0xLTEtMA_38559bb8-e0dd-43f7-a285-b22d063cdac4"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7cc829ddfa7546fe9e92c22e0ea07a60_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzEtMy0xLTEtMA_7f9bbeb5-9f00-4d3d-971c-7b69244f3c9c"
      unitRef="usdPerShare">45.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzItMS0xLTEtMA_df1c2835-1f18-40d5-a855-cfcb5b42c9e4"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzItMy0xLTEtMA_4dfe5503-e8a7-4136-8081-4afd7d1bac76"
      unitRef="usdPerShare">53.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzMtMS0xLTEtMA_eba5f094-b827-45ac-bded-1a0c6fd28468"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzMtMy0xLTEtMA_6a75503c-5002-41a5-94ef-c59080cf8668"
      unitRef="usdPerShare">48.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzQtMS0xLTEtMA_727a629d-3b3a-4573-91df-7ff5f73d4180"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzQtMy0xLTEtMA_bb57b984-fb07-4838-b4c9-38acb13128c6"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia5ae4550dbfd4e139f3bcceb77e3e045_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzUtMS0xLTEtMA_644607ff-8c9f-4381-bbdc-9487124a988e"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia5ae4550dbfd4e139f3bcceb77e3e045_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0N2E3ZDA0MDZhZmM0ODVjYjY0Y2Y0MzI2ZmIyZDlhYy90YWJsZXJhbmdlOjQ3YTdkMDQwNmFmYzQ4NWNiNjRjZjQzMjZmYjJkOWFjXzUtMy0xLTEtMA_486ee695-8ce0-4109-a27f-8303da5f8566"
      unitRef="usdPerShare">48.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia5ae4550dbfd4e139f3bcceb77e3e045_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzgyMA_39843774-9280-4751-9ed7-7e67e9282ab2"
      unitRef="usd">124000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7566b8915269491e8cf903384ee23182_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2Xzg5Mw_9b5c445d-16df-4a65-88b3-7ef9ecb84302">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzEwMDc_ee73260a-4050-406a-bae2-5bbd358ef437">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cah:ExercisablePeriodOfPlansInYears
      contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzEwMzQ_d5b57c69-4a6d-4e4c-a0f5-b30e96512772">P10Y</cah:ExercisablePeriodOfPlansInYears>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzNzA_cce3e0af-deec-4cdf-b219-aa766bbd4b1e">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66.36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzEtMS0xLTEtMA_deeb1c6d-aa6f-47d3-9a44-510a07838314"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie14ef2e16a4341de83a616bd95c70060_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzEtMy0xLTEtMA_d7897ba9-3020-4241-a1c3-83e3dc170f59"
      unitRef="usdPerShare">65.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzItMS0xLTEtMA_183343bb-b642-4c4f-af88-007ac92e2bfc"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzItMy0xLTEtMA_3f8f48ef-5188-4649-a60a-0876715ac8c3"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzMtMS0xLTEtMA_802681f1-26ff-4469-b27b-44b638633050"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzMtMy0xLTEtMA_5645edb6-35ee-4507-8267-c1569d5e1b4b"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzQtMS0xLTEtMA_dbae5500-680e-496b-9bba-c4f1d90d62e0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzQtMy0xLTEtMA_13413019-6f02-4aea-a8f2-3de839cccb87"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzUtMS0xLTEtMA_5881b37f-88f6-47af-ad96-c0a03e8e49c5"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzUtMy0xLTEtMA_76b38402-67d9-4e3c-9231-ccb6557dfcd3"
      unitRef="usdPerShare">66.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzYtMS0xLTEtMA_f694d174-89f1-484f-885b-06eb9bfd787c"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib2050e0c2b244293b0d9307ba6e58fa8_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTo0NjBhNGRjY2I4ZDE0NmYzYjdkYzE1ZTRlMGMyY2JjNS90YWJsZXJhbmdlOjQ2MGE0ZGNjYjhkMTQ2ZjNiN2RjMTVlNGUwYzJjYmM1XzYtMy0xLTEtMA_5932f263-137f-4ee4-8463-717c2f42885c"
      unitRef="usdPerShare">66.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i6e44ccff288b4a86886c5aab9864e13b_I20200930"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE0MDM_c97d6af6-73f7-4dfd-bfdf-face6177b313"
      unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE0NzY_15b27358-e8c0-47b9-bc8f-ebb44791261e">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:AdditionalStockOptionPlanDataTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzMjU_0fe75f4d-ca9b-423f-8a01-e6e250718fd9">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cah:AdditionalStockOptionPlanDataTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6e44ccff288b4a86886c5aab9864e13b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpkOWFjZWFkZjBkMDc0MTVhYTM5MjUzMmIyYmI1Zjg2YS90YWJsZXJhbmdlOmQ5YWNlYWRmMGQwNzQxNWFhMzkyNTMyYjJiYjVmODZhXzEtMS0xLTEtMA_906af400-1bb3-4a16-9854-a0903d07dcdb"
      unitRef="usd">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5efd6d972b064462a3d6638360713a1e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpkOWFjZWFkZjBkMDc0MTVhYTM5MjUzMmIyYmI1Zjg2YS90YWJsZXJhbmdlOmQ5YWNlYWRmMGQwNzQxNWFhMzkyNTMyYjJiYjVmODZhXzEtMy0xLTEtMA_d21f36ff-8b05-4e5f-b9fb-d0145c73482a"
      unitRef="usd">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i6e44ccff288b4a86886c5aab9864e13b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpkOWFjZWFkZjBkMDc0MTVhYTM5MjUzMmIyYmI1Zjg2YS90YWJsZXJhbmdlOmQ5YWNlYWRmMGQwNzQxNWFhMzkyNTMyYjJiYjVmODZhXzItMS0xLTEtMA_8c65ddf2-d834-4b34-95d2-224f127e1f51"
      unitRef="usd">5000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i5efd6d972b064462a3d6638360713a1e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpkOWFjZWFkZjBkMDc0MTVhYTM5MjUzMmIyYmI1Zjg2YS90YWJsZXJhbmdlOmQ5YWNlYWRmMGQwNzQxNWFhMzkyNTMyYjJiYjVmODZhXzItMy0xLTEtMA_997fbbf6-584a-4343-acac-3db46ee0442f"
      unitRef="usd">12000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZToxYTRkNzczYjQ5NzY0NmQxYWUxOGFmZmQ1NDIyNWNkMC90YWJsZXJhbmdlOjFhNGQ3NzNiNDk3NjQ2ZDFhZTE4YWZmZDU0MjI1Y2QwXzEtMS0xLTEtMA_86bb5bd9-5cda-4163-b059-8ed69e16e1f9">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie4631166cbef49ac95cee271f9ff8821_D20190701-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZToxYTRkNzczYjQ5NzY0NmQxYWUxOGFmZmQ1NDIyNWNkMC90YWJsZXJhbmdlOjFhNGQ3NzNiNDk3NjQ2ZDFhZTE4YWZmZDU0MjI1Y2QwXzEtMy0xLTEtMA_1aa0cfb4-8d62-4377-b400-9ebde18a339e">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZToxYTRkNzczYjQ5NzY0NmQxYWUxOGFmZmQ1NDIyNWNkMC90YWJsZXJhbmdlOjFhNGQ3NzNiNDk3NjQ2ZDFhZTE4YWZmZDU0MjI1Y2QwXzItMS0xLTEtMA_c705c046-d938-49fc-a52f-020f36eda0ef">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie4631166cbef49ac95cee271f9ff8821_D20190701-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZToxYTRkNzczYjQ5NzY0NmQxYWUxOGFmZmQ1NDIyNWNkMC90YWJsZXJhbmdlOjFhNGQ3NzNiNDk3NjQ2ZDFhZTE4YWZmZDU0MjI1Y2QwXzItMy0xLTEtMA_1681fc04-a1d4-41ca-a919-032374c8c375">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <cah:VestingPeriodinyearsforShares
      contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE2MTk_ec08373d-2e48-4446-abb3-2e637c89aa95"
      unitRef="number">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i72080d3b192041d29bdb612c6d87d607_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE3ODI_9d27f5ef-9226-4324-9913-ce99a145015e"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4f40a80a6e5847bfa13e893d637f65d2_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzE3ODg_9df5b4d8-7a76-42b3-9d09-f204962a2f86"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIzNTA_b88179c7-cdea-4deb-9931-3f42e85b549e">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49.07&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if7b231115e4c4896aea559547eb04df6_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzEtMS0xLTEtMA_bb33daa5-b87d-4607-87e1-602170f54a62"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if7b231115e4c4896aea559547eb04df6_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzEtMy0xLTEtMA_cf1a207b-fb16-4c19-ba07-f0a2d5eca2ae"
      unitRef="usdPerShare">54.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzItMS0xLTEtMA_4c387bec-cad1-4ac7-aad3-a18180749261"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzItMy0xLTEtMA_0fd8dad6-5643-4775-930a-371cb835311d"
      unitRef="usdPerShare">55.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzMtMS0xLTEtMA_00d6560c-8f12-4c44-ade0-2b095ee22272"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzMtMy0xLTEtMA_762f815c-7c5e-4cc5-801c-cd79df2ecf9c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzQtMS0xLTEtMA_54f3bd1f-6835-4981-993f-8a6883d4fbf3"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzQtMy0xLTEtMA_f24600ce-ca8f-45a8-8622-537ee9cc59a2"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5cdf4ef85d164520b43ff6d702fd42c4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzUtMS0xLTEtMA_82bc2dae-5fa6-43ce-9277-a8035bbe980c"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5cdf4ef85d164520b43ff6d702fd42c4_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90YWJsZTpjYWYwZGI1ODVhMzY0YTBjYTUxMGZkMDliNWIxZWJlYy90YWJsZXJhbmdlOmNhZjBkYjU4NWEzNjRhMGNhNTEwZmQwOWI1YjFlYmVjXzUtMy0xLTEtMA_ed800a1e-440a-47c6-86ad-a643650bab80"
      unitRef="usdPerShare">49.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5cdf4ef85d164520b43ff6d702fd42c4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIxOTc_ad24f0f9-8aa9-4a8b-a791-f88e703df798"
      unitRef="usd">39000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i34fd88ed9d7c425c836f26fc70bf9156_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0ZDA4ZmQxZmZjNzRkNjQ5NGI2MWI0NjU0NjQ5MmZjL3NlYzo4NGQwOGZkMWZmYzc0ZDY0OTRiNjFiNDY1NDY0OTJmY18xMjQvZnJhZzpjNDBiY2ZiZjUxNDM0YzhlOTczNTIyZTc5NzFmNjdjNi90ZXh0cmVnaW9uOmM0MGJjZmJmNTE0MzRjOGU5NzM1MjJlNzk3MWY2N2M2XzIyNzA_ca9ec556-e5e9-4c3c-9108-d7b3efc0ae94">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815410328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,420,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815482904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 39,065<span></span>
</td>
<td class="nump">$ 37,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold</a></td>
<td class="nump">37,350<span></span>
</td>
<td class="nump">35,662<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">5,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(624)<span></span>
</td>
<td class="num">(5,264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(663)<span></span>
</td>
<td class="num">(5,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for/(benefit from) income taxes</a></td>
<td class="num">(410)<span></span>
</td>
<td class="num">(423)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(4,921)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Cardinal Health, Inc.</a></td>
<td class="num">$ (253)<span></span>
</td>
<td class="num">$ (4,922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in shares)</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (16.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in shares)</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (16.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.4859<span></span>
</td>
<td class="nump">$ 0.4811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999892979688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="num">$ (253)<span></span>
</td>
<td class="num">$ (4,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Net unrealized gain/(loss) on derivative instruments, net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive loss</a></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(4,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: comprehensive income attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="num">$ (236)<span></span>
</td>
<td class="num">$ (4,944)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816910472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 2,746<span></span>
</td>
<td class="nump">$ 2,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">8,637<span></span>
</td>
<td class="nump">8,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">13,439<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,208<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">27,030<span></span>
</td>
<td class="nump">25,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,369<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">11,186<span></span>
</td>
<td class="nump">11,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">41,727<span></span>
</td>
<td class="nump">40,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="nump">21,688<span></span>
</td>
<td class="nump">21,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,316<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,016<span></span>
</td>
<td class="nump">23,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">6,728<span></span>
</td>
<td class="nump">6,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">$ 9,558<span></span>
</td>
<td class="nump">$ 8,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value, Issued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">$ 2,760<span></span>
</td>
<td class="nump">$ 2,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">771<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value</a></td>
<td class="num">$ (2,022)<span></span>
</td>
<td class="num">$ (2,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (87)<span></span>
</td>
<td class="num">$ (104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' equity</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 41,727<span></span>
</td>
<td class="nump">$ 40,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999817725416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>AOCI Attributable to Parent</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2019</a></td>
<td class="num">$ (6,330)<span></span>
</td>
<td class="num">$ (2,763)<span></span>
</td>
<td class="num">$ (5,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Statement of Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Earnings/(Loss)</a></td>
<td class="num">(4,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(4,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2019</a></td>
<td class="num">$ (903)<span></span>
</td>
<td class="num">$ (2,669)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2020</a></td>
<td class="num">$ (1,792)<span></span>
</td>
<td class="num">$ (2,789)<span></span>
</td>
<td class="num">(1,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="num">(34,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2020</a></td>
<td class="num">$ (2,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Statement of Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Earnings/(Loss)</a></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2020</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2020</a></td>
<td class="num">$ (1,425)<span></span>
</td>
<td class="num">$ (2,760)<span></span>
</td>
<td class="num">$ (771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2020</a></td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2020</a></td>
<td class="num">$ (2,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815889592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="num">$ (253)<span></span>
</td>
<td class="num">$ (4,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by/(used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">(Increase)/decrease in trade receivables</a></td>
<td class="num">(388)<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase)/decrease in inventories</a></td>
<td class="num">(245)<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase/(decrease) in accounts payable</a></td>
<td class="nump">313<span></span>
</td>
<td class="num">(1,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">5,211<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="nump">270<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments', window );">Purchase of investments</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments', window );">Proceeds from investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net tax withholdings from share-based compensation</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(585)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and equivalents</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(1,319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at beginning of period</a></td>
<td class="nump">2,771<span></span>
</td>
<td class="nump">2,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 2,746<span></span>
</td>
<td class="nump">$ 1,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Purchaseofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999810488408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999814741784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2021 and June 30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K"). </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815336408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Restructuring and Employee Severance </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of lease costs associated with vacant facilities, accelerated depreciation, vendor transition fees, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020 and 2019, restructuring costs were primarily related to implementation of certain enterprise-wide cost-savings initiatives.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999810204792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Goodwill and Other Intangible Assets </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,657</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,718</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,375</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,565</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,907</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,658</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,605</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">798</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">807</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,844</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,056</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,788</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,867</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,056</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,811</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,831&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $115 million and $129 million for the three months ended September&#160;30, 2020 and 2019, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2021 through 2025 is as follows: $333 million, $398 million, $358 million, $329 million, and $278 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999814514872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Long-Term Obligations and Other Short-Term Borrowings </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $6.7 billion and $6.8 billion at September 30, 2020 and June 30, 2020, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $21.7&#160;billion and $21.4&#160;billion at September 30, 2020 and June 30, 2020, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, we repurchased a total of $37 million of notes due in 2022 with available cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose-bankruptcy remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div>Our revolving credit facility and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of&#160;no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every fiscal quarter thereafter. At September 30, 2020, we were in compliance with our financial covenants.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999810535208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Commitments, Contingent Liabilities and Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the U.S. District Court for the Southern District of New York ruled that the OSA was unconstitutional and enjoined its enforcement (the "Ruling"). In April 2019, the State, among other things, amended the OSA so that the assessment would only cover opioid sales in 2017 and 2018, subject to the State's appeal of the Ruling. In September 2020, the U.S. Court of Appeals for the Second Circuit reversed the Ruling and, as a result, New York will likely seek to collect amounts due from distributors and manufacturers for 2017 and 2018. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, at September 30, 2020, we recorded an aggregate accrual of $41 million for calendar year 2017 and 2018 based on the estimated payment amount. This is our best estimate of the OSA payments probable at September 30, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of loss.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 2,800 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;). In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in West Virginia in the Cabell County and City of Huntington cases is scheduled for January 2021, and a trial is scheduled to begin in Madison County, Ohio, in March 2021 in the case brought by the Ohio Attorney General. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is the basis for the ongoing negotiation of definitive terms and documentation. Negotiations under the Settlement Framework continue and have centered on the amount and timing for payment of the cash component as well as standards for settling distributors&#8217; controlled substance anti-diversion programs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these discussions, we have recorded total pre-tax charges of $1.02 billion and $5.63 billion in litigation charges/(recoveries), net in the three months ended September 30, 2020 and 2019, respectively. In total, we have $6.59 billion accrued at September 30, 2020, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately 411 lawsuits as of November 2, 2020. Of these, 116 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affirmative Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union Fire Insurance&#8221;), seeking a declaration that defense costs are recoverable under our insurance for certain of the lawsuits described above. We have not recorded a receivable for any recoveries related to the litigation against National Union Fire Insurance at September 30, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). The subpoenas seek documents relating to our anti-diversion policies, procedures and program, and our distribution of certain controlled substances. We are cooperating with these requests.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 2, 2020, we are named as a defendant in 354 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,526 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another 31 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and are engaged in resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, we had a total of $494 million, net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">end of the range to be approximately $961 million, net of estimated insurance recoveries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we received a civil subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with this request and are engaged in preliminary resolution discussions.  </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) </span></div>alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We were also named as a defendant in a Multidistrict Litigation alleging API impurities in Zantac and its generic form, ranitidine. We intend to vigorously defend ourselves in these matters.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999814655560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Income Taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pre-tax loss (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Settlement Framework</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02 billion and $5.63&#160;billion pre-tax charges for the opioid litigation during the three months ended September 30, 2020 and 2019, respectively, the net tax benefits are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision/(benefit) for income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent.  Including the relatively lower tax benefit of the current quarter charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax benefit in the current quarter increased by approximately $450 million over the tax expense that would have been recognized without the impact of the opioid litigation charge and is expected to </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly increase our provision for income taxes during the remainder of fiscal 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020 and 2019, the effective tax rate was 61.8 percent and 7.9 percent, respectively. The increase in the effective tax rate for the three months ended September 30, 2020 compared to the prior year period was primarily due to the treatment of the tax impacts of the opioid litigation accrual, partially offset by the prior-year benefit of discrete tax items.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $994 million and $998 million of unrecognized tax benefits at September 30, 2020 and June&#160;30, 2020, respectively. The September 30, 2020 and June&#160;30, 2020 balances include $750 million and $753 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020 and June&#160;30, 2020, we had $147 million and $146 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of loss. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $370 million, exclusive of penalties and interest.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $179 million and $176 million at September&#160;30, 2020 and June&#160;30, 2020, respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition. The indemnification receivable was&#160;$19 million at both September&#160;30, 2020 and June&#160;30, 2020, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999810255272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Fair Value Measurements </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,070</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,070</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2)    The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999814599416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments Disclosure</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of loss. For the three months ended September&#160;30, 2020 and 2019, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2019, we entered into a forward interest rate swap with a total notional amount of&#160;$50 million&#160;to hedge probable, but not firmly committed, future transactions associated with our debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses recognized in other comprehensive loss were immaterial during the three months ended September&#160;30, 2020 and 2019. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September&#160;30, 2020 and 2019. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended September 30, 2019, we entered into a &#165;64.0 billion ($600 million) cross-currency swap maturing in 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $25&#160;million loss and a $16&#160;million gain </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended September&#160;30, 2020 and 2019, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of loss for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were immaterial during the three months ended September&#160;30, 2020 and 2019.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The gain and losses recognized in the three months ended September 30, 2020 and 2019 were immaterial. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, Brazilian real and Japanese yen.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2020 and June 30, 2020 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,740</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,775&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999810268392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Shareholders' Equity </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2019, we entered in an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $350 million and received an initial delivery of 6.4 million common shares having an aggregate cost of $280 million. The average price paid per common share was $43.76. The ASR program began on August 20, 2019 and was completed on December 4, 2019 when we received the final 0.9&#160;million common shares. We funded the repurchases with available cash and short-term borrowings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(104)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(87)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999814766664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share Attributable to Cardinal Health, Inc.</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Loss Per Share Attributable to Cardinal Health, Inc. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for September 30, 2020 and 2019 were 7 million and 6 million, respectively. For the three months ended September 30, 2020, and 2019, there were 2 million and 1 million potentially dilutive employee stock options, restricted share units and performance share units, respectively, not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been anti-dilutive as a result of the net loss during that period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999810202104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Segment Information </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,916</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,212&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,112</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,428&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,438</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">519</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,957</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,917&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,069</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,345&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,065</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,341&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37,976</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,093</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,069</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,345&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,065</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,341&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: last-in </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $5 million and $3 million for the three months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i84d08fd1ffc74d6494b61b46546492fc_100" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized pre-tax charges of $1.02&#160;billion and $5.63&#160;billion during the three months ended September 30, 2020 and 2019, respectively, which was retained at Corporate. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">632</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,832)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,264)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,809</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,398&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,985</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,933</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,727</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815229592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $4 million for both the three months ended September&#160;30, 2020 and 2019. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.92&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.94&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48.34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $124 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"/><td style="width:51.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.15&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66.19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66.36</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized was $0.3 million, which is expected to be recognized over a weighted-average period of two years. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49.07</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $39 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999909694792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2021 and June 30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual </span></div>Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815385832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,657</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,718</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,375</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Definite and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,565</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,907</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,658</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,605</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">798</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">807</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,844</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,056</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,788</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,867</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,056</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,811</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,831&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815387672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,070</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,070</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2)    The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815229592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,740</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,775&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999810474216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(104)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(87)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999898507544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted loss per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999893638968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37,976</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,093</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,069</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,345&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,065</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,341&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,916</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,212&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,112</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,428&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,438</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">519</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,957</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,917&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,069</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,345&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,065</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,341&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">230</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">632</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,832)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,264)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,809</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,398&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,985</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,933</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,727</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999808462232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"/><td style="width:51.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.15&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66.19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66.36</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AdditionalStockOptionPlanDataTableTextBlock', window );">Schedule of Additional Data Related to Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.92&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.94&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48.34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49.07</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AdditionalStockOptionPlanDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A disclosure of additional data related to all stock option activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AdditionalStockOptionPlanDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815409400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999972598552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999808273272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816440856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Goodwill, Transfers</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">8,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">8,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Goodwill, Transfers</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Goodwill, Transfers</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 5,718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816623048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">5,844<span></span>
</td>
<td class="nump">5,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,056<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 2,788<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 5,867<span></span>
</td>
<td class="nump">5,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">2,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">IPR&amp;D, trademarks and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,565<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,907<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,658<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,605<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 807<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999814529976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</a></td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Asset, Expected Amortization, Year One</a></td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Two</a></td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Three</a></td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="nump">$ 278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816059384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, Long-term and Short-term, Combined Amount</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="nump">21,688<span></span>
</td>
<td class="nump">21,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">21,700<span></span>
</td>
<td class="nump">$ 21,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member | Committed Receivables Sales Facility Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816218056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 02, 2020 </div>
<div>Reportable_Segments</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,038.0)<span></span>
</td>
<td class="num">$ (5,673.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(410.0)<span></span>
</td>
<td class="num">(423.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | Reportable_Segments</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NumberofStateAttorneysGeneralfilinglawsuits', window );">Lawsuits Against Distributors | Reportable_Segments</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | Reportable_Segments</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain', window );">Opioid Lawsuits State [Domain] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | Reportable_Segments</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_MaximumQuarterlyPayment', window );">Maximum quarterly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | Reportable_Segments</a></td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product Liability Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember', window );">Alameda County [Member] | Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | Reportable_Segments</a></td>
<td class="nump">4,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember', window );">Other Jurisdictions [Member] | Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | Reportable_Segments</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">litigation settlement liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,590.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020.0<span></span>
</td>
<td class="nump">5,630.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020.0<span></span>
</td>
<td class="nump">$ 5,630.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(450.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 488.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember', window );">Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | Reportable_Segments</a></td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember', window );">Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | Reportable_Segments</a></td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaximumQuarterlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaximumQuarterlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NumberofStateAttorneysGeneralfilinglawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of State Attorneys General filing lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NumberofStateAttorneysGeneralfilinglawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_AlamedaCountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999894960696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 410<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">61.80%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="num">(1,038)<span></span>
</td>
<td class="num">$ (5,673)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="nump">$ 6,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Charges</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">$ 5,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_CareFusionMember', window );">CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification receivable</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember', window );">Patient Recovery Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification receivable</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IndemnificationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IndemnificationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816655080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Narrative (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative Assets (Liabilities), at Fair Value, Net</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative Assets (Liabilities), at Fair Value, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative Assets (Liabilities), at Fair Value, Net</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative Assets (Liabilities), at Fair Value, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=117331979&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999893638584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Narrative (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Currency Swap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Foreign Currency Contract, Asset, Fair Value Disclosure | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 64,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="num">$ (25)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999810297128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 6,740<span></span>
</td>
<td class="nump">$ 6,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 7,245<span></span>
</td>
<td class="nump">$ 7,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999892939528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 04, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FinalSharesReceivedfromASRProgram', window );">Final Shares Received from ASR Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (using cost method), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TreasuryStockAcquiredShares', window );">Treasury Stock Acquired Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FinalSharesReceivedfromASRProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final Shares Received from ASR Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FinalSharesReceivedfromASRProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TreasuryStockAcquiredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Acquired Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TreasuryStockAcquiredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999815459144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="nump">$ 6,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income, before reclassifications</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income, before reclassifications</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income, before reclassifications</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (87)<span></span>
</td>
<td class="num">$ (101)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999808743352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999817034712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Numberofsharesexcludedfromcalculationofdilutedshares', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss', window );">shares that would be antidilutive as a result of net loss</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Numberofsharesexcludedfromcalculationofdilutedshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares excluded from calculation of diluted shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Numberofsharesexcludedfromcalculationofdilutedshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares that would be antidilutive as a result of net loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Sharesthatwouldbeantidilutiveasaresultofnetloss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999909334056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="num">$ (1,038)<span></span>
</td>
<td class="num">$ (5,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project Costs On Investment And Other Spending</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="nump">6,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="nump">$ 5,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816690024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 39,065<span></span>
</td>
<td class="nump">$ 37,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">39,069<span></span>
</td>
<td class="nump">37,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">35,112<span></span>
</td>
<td class="nump">33,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,957<span></span>
</td>
<td class="nump">3,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember', window );">Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember', window );">Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">34,916<span></span>
</td>
<td class="nump">33,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember', window );">Medical distribution and products [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,438<span></span>
</td>
<td class="nump">3,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember', window );">Cardinal Health At Home Solutions [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 519<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816985752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (624)<span></span>
</td>
<td class="num">$ (5,264)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (1,256)<span></span>
</td>
<td class="num">$ (5,832)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999893096312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 41,727<span></span>
</td>
<td class="nump">$ 40,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">22,809<span></span>
</td>
<td class="nump">22,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">14,985<span></span>
</td>
<td class="nump">14,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 3,933<span></span>
</td>
<td class="nump">$ 3,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816468280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Disaggregated Revenue Within Reportable Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 39,065<span></span>
</td>
<td class="nump">$ 37,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">39,069<span></span>
</td>
<td class="nump">37,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">35,112<span></span>
</td>
<td class="nump">33,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical | Nuclear Precision Health Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical | Pharmaceutical Distribution and Specialty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">34,916<span></span>
</td>
<td class="nump">33,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,957<span></span>
</td>
<td class="nump">3,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical | Medical distribution and products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,438<span></span>
</td>
<td class="nump">3,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999893655896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue by Geographical Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 39,065<span></span>
</td>
<td class="nump">$ 37,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">37,976<span></span>
</td>
<td class="nump">36,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,093<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">39,069<span></span>
</td>
<td class="nump">37,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuebyGeographicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue by Geographic [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuebyGeographicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816506616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ExercisablePeriodOfPlansInYears', window );">Exercisable period of plans (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 124,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 39,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="nump">240.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ExercisablePeriodOfPlansInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The instrument's contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ExercisablePeriodOfPlansInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999817682040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999893773144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 65.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">66.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 66.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999810539592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options at period end</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable options at period end</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999808679672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 45.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">53.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">48.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 48.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139999816255128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">55.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 49.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MF3O%+;G(=9@[4H%+<6-8)V2A(:&(5&0F4Y@$,!>D6Y]@N/KC+099^3W%;;J
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M>H*[0ID/X/U*2KV_,3]0'J9._@502P,$%     @ 8H)E45\ P'2I!0  SA0
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MMU>#Z8"DL&;[3'\33Y_AZ-#8V$M$ILJ_Y.DHZP](LE=:Y$=E1)#SHOIES\=
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M@N&4U>%9=:/%KCQ_6@FM15Y>;H&E((T _G\MA'ZY,2^HCS 7_P-02P,$%
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M_@;XY[ =W!#"86#[O'^$,6#4'7;S,,HT^=F_DXLXWX&UMT%Y&4<T8KY!/I?
M4#.E:5VAT=2IU8JL$ Q8#+?LY 1N<D0H8-(YTQK2@^LH_=^RGZ$SY:80BJS?
M4*5@>>6ZZ7602QKH=2?Y"5E1@KI'C.*#N[8"L_)/$$N(-PKK*ZI=;9\Y=_YR
M/UJ_=\\??X?_#%._G1ZX65%I,PE+"IE<#TAB4S]'Z@GJM;_1YQKI?>"')3WA
MP#@#^K[4&O<3MT'[*)S\ %!+ P04    " !B@F51LR'5"]0%  "8&   &
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MJ-]/XAZH]F[8"D;6[CZVD(;:URT+NDZCL@KT?2FEV0C6P?:"/OT;4$L#!!0
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M_HD:=;+7]X^4IF+F",]#L,4:ZW/%*DGUU24I7:3T"3%"S4FCR( L9NXF "R
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M.T(L E_5H4:0IF#P%)VKMD._Y0[];?!(2L@':I&Q^@TQ:7J^_B7!QT+Z&Q0
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M-5ARQ8Q19EE=UH$$&:90]+%5*[I6@B"63^K!R@(^ .WFI(=+VZX1@^]DB?6
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MY7504"$=?,0A[AEG<)^U>8UF\, J_!K#=NP%R;I1T'7*-]*F.@?96^;;.&G
MA#RRM*O& S.Y,#";L;OF\&[F<"9+C_I<A'-RF<I(_%!:F#X2KYR604&&##W#
M1T6:O$-22U,=C&%:4<GBS\G:BN*?>'975PD*(\FW\A4'=\Y&I["V;)YN+FU#
MHBP*9-UDC2:HM3NG6Y.5(47O>X'<+,HLH$3H*?Q/%!D/SQ)4!H:S@;+V^!=\
MYQBD3!-0/1;17;TK6[;Z47 'CW9_A^#DT$>/\&MKRM6:J\ A^-*?OP6E>&A
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M*$L;\'QI$%K5#1W0?#.[^Q]02P,$%     @ 8H)E4<,V+%X=!@  ,1,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULS5AM;]LV$/XK!R\8$L"1;=G.
M6Y, 3M:] 5V#IFT^#/M 2V>;B"2J)!7'_?6[(R5'<J4L+=9A0&*]D0_OGGON
M>-+Y6NE[LT*T\)@FF;GHK:S-SP8#$ZTP%290.6;T9*%T*BQ=ZN7 Y!I%[":E
MR2 <#H\&J9!9[_+<W;O1E^>JL(G,\$:#*=)4Z,T5)FI]T1OUJAOOY')E^<;@
M\CP72[Q%^R&_T70UV*+$,L7,2)6!QL5%;S8ZNYKP>#?@H\2UJ9T#>S)7ZIXO
M?HLO>D,V"!.,+",(.CS@-28) Y$9GTK,WG9)GE@_K]!_=KZ3+W-A\%HE=S*V
MJXO>20]B7(@BL>_4^E<L_9DR7J02XWYA[<=.QCV("F-56DXF"U*9^:-X+'FH
M33@9=DP(RPFAL]LOY*S\25AQ>:[5&C2/)C0^<:ZZV62<S#@HMU;34TGS[.7M
M2F@\O"*_8KA6*<7:"*;K?& )G<<,HA+IRB.%'4AC>*,RNS+P.HLQ;LX?D%5;
MT\+*M*OP6<!;S ,8#_L0#L/A,WCCK:MCAS=^UM6Y<_5&;$A9%F9:BVR)[OS/
MV=Q833+YZYG%)MO%)FZQR;_ Z_-(HS" +C2X0^#,L_0/I)7H'F06D3.D=,@3
MD1G8)X6X%'C 9-,'NT+X\8>3,!R^NN'G[GSTZ@ HO]W#.6:XD!;4 B+4#IA.
M5:'IL)!TR_0AEIH0E38@LA@PS1.U030!O"> !:VGUC);@A7SA,S0ZD'&:, J
M*Q(PM2A$=5?PD<_)@ W838Z\JE@+'9\1JD9LJ M(&Q;3.6HGD'TR,I5)0C#F
MP,F%?D:G\ XIH#*R-,$M"T5&GE4+[0$-H9]C>%UZ4%*H\H9!3-$H? 4CN$'M
MRB!1W 9X"B&\?][)/0A/^&?HJ/*,6/&X95UC(MA<J[HQUL+ WJ1RV 5NKNS*
M1<\ZJE)/%;90Y<CAJ#%!09TAIS'X0 Z9=N(,+"E9^%Y!P%XM3D.P).NU2)(-
M/-!$DB#@IX(\$UG&!YD9\C/A)#.@'MQ4-G.#0IN@:S$11;I B(19D>!80JRU
M3X5\$(E#LBMA@<?G8N.45N1$!UO XB/YL(%.0AW*]!N1_$S:)/. <I\H=IN%
MJ0="M]NW0\)90X5]$D5$Q$-.8_PLD:J"S#[HXOS.;2 8'\Z((=H/X0^5L3,T
MC/S\O<CP*8!CTM!D&IR&\$L9DA"FX^!H#!_]C/W1 4Q.@M,)7+-:$P8A^D@K
M"Y0\H!)U=6PLUB*9":]X$HPG,&M[[@N+US,U!X>LZ89H(V5L'S)TA85#E#IZ
M2X,*XKA?YSS;FM/!?J8LZ8<3)E++C&(8^[P8A=O,Z,-Z):,52.,R-"JAYUB?
MY.0H8%V1+TKR*6Y2Q4Y%:U4I]=:5A[>YETAKU?@^2>*"Q\[C(^I(&B=?5[$Q
M*T<LM$K=:FY]B(G) &8DZZ9UNR"<0A0Q*NRE.<00HU!BW!.]E&L%5KE$ :7*
MXL-0ZC_9N'2BAV71I+]=(UZ0>HVZV\C#;\XR'ZLODNIM88GG+&93ODBK*8G\
M:!J,IMNTVDV3UYZZEB<OS+.=]5LRS1EQ%-#>]+H9I^ZQXZ/_.BN;HNI*QF$P
M_G[)V"(K4S4;(.)8LFWD>(S4Q"2-G;5N_-E.]]#"<E,DL^52XY*P*&6I,M'K
M2?24)JH6WFW*V<H!WL'V7-!&X?,X]11MQYDR!IONZ'B!W7>[K&KDUI$MC:A?
MX,:7\S^1BTY/)K3J5\*T.<(P]5:JO@NVMUC&U\Q2'^-#]IG)V XMB?'=DGO9
M6TE\\'T]66%(<9*ZU\:<I1()Z>BJFL.Y@H^6IY!(O%Q=_@B]1.M+9XD;]Z%*
M!%\,4[$!]R;AZ_!GU(I!PLF0EXQ*,Y[0?%]25JN@T^O_30^4=QBXN\GM;R/0
MXJ<Y>'GYKC/R-9W1*.#>:#H)J ^HBO@P(,5-@\FTZHZ^L7;_4X\T"HZY2SH-
MAL?_=3WNBD]791Z??J_"#-*+[HM,:^1/T/:*/:A]QDB1Y,,?:PR10I+P7S2V
M=[??@V;^,\C3</\QZ0VICTHJ)+B@J</@>-H#[3_0^ NK<O=1A-Z<K$K=Z0H%
MB9D'T/.%4K:ZX 6V7\DN_P902P,$%     @ 8H)E42-@:'#O!P  X1,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C N>&ULG5A=<]NV$OTK&#ZE,[(DVTE[
MF[$]8[M)Z_9VZD8W[<.=/D#D2D(" @P 2E9_?<\N2(KVV)ZX+Q(_@/TXNWMV
MB;.=#Y_CABBIN]JZ>%YL4FK>SF:QW%"MX]0WY/!FY4.M$V[#>A:;0+J23;6=
MG<SGW\YJ;5QQ<2;/;L/%F6^3-8YN@XIM7>NPOR+K=^?%<=$_^&#6F\0/9A=G
MC5[3@M+'YC;@;C9(J4Q-+AKO5*#5>7%Y_/;J#:^7!7\8VL71M6)/EMY_YIN;
MZKR8LT%DJ4PL0>-O2]=D+0N"&5\ZF<6@DC>.KWOI[\5W^++4D:Z]_=-4:7->
M_*=0%:UT:],'O_N).G_$P-+;*+]JUZV=%ZIL8_)UMQD6U,;E?WW7X? U&TZZ
M#2=B=U8D5OZ@D[XX"WZG J^&-+X05V4WC#..@[)( 6\-]J6+*QU-5'ZE;@-%
M<DEGK%RE%CE,_&YAULZL3*E=4I=EZ5N7C%NK6V]-:2BJ5_W5-V>S!*-8]*SL
M#+C*!IP\8<"I^M6[M(GJG:NHNK]_!F<&CTYZCZY.GA6XH&:J3N<3=3(_F3\C
M[W1 Z%3DG3XA[S&'_W^YC"D@H_YZ1L'K0<%K4?#Z)2%X#,AGQ7#UOHV-+NF\
M:%A0V%+Q1'A_:X,J/?!VD2J^BG"LT@DW*^.T*XVV*F(QH?Q25,:5MJU(I0VA
MC 0.$:JM12Y^\L&D_9'?.>SW(CD%;RWN8KN,IC(Z +2)9!5OB:-T,BY1*'W=
M:+=7@-1%+>4:\^HZZ]KH+:DED5-D#:J 39VJ#[2B0*Y$0))7Q8XFA2I\&_#'
MFR-66AU4$[R#&'8#'@".WUL=H-7N(:'Q(2E PB6NCN='ORL0G3CZ):]2Q'FI
MD%5 8XG[/K74*Q%6##N+;YBEL +&7.M0P4RK?B)MTV:B;EPY%:L,W/EJS%3K
M+,4H]O 2NDO0\:4UB*;R>!IV)M)4 KHRL83"/6FQ.;)7/[>.8/!#J+JE\.)8
M;!)W!!TDR8LR0P=B@6S?2']D [A@? ]?9\CDH'/\!+]PJ"%A:+N?OCA!#_F!
MU&]@5,7N<*J&"JL)I)HV8N7'Z6**8)8M\&> V91W=^5&NS6I:U_7)DJ_>54L
MWETCHL:AT-LN)>'IP]R)]Y-'(CRJ%N-RW^Q)M0)(UL>6X]<%LE++?5]5C%D3
M(, TB+M:DZ. BI'WG(!5%R7UT1F^6S $X-_BQ\O+6UC+N2L59>H14$$LA>RI
M^A_V9HBR32CB)RJ>46?;D:89/59Q2+Y6T*CU9U(4DZG%#BG9B/[>='AM=%)Z
MM4)@AU+.QAP\>5&VL?RR8PO&RGFHG:(GI18K>Q6UW@/H%9?B*OBZ2^O>S(%5
M,AK7O_UQ\\/1\?<*,BNJ30DT^V= E*O.N#;73>?*D$=LS]KZ)703%OKZ0'.1
M8=X:WT:[[Z.>G09!J?=# <Z'Y/EE(H(',[2-O4;F".Q:MA&<'R-)?+3:,D<D
MZ= [O8\H@+5QCG'IL 5!A6H@,HGU02^;V7F7M]PGAJGZ$\'1#A /T(E02VZ-
M=$"F1=H2TQA+3H]"V5%I("O /P%:*:%'9F6"\NZ>M[(!0VC.6.";ZXMMWFV(
M.5!6X-HI$'("LY8'R:/-V,#)9G)N[HSERD"R4F\FV!5IQH'>;4R9^0*A"ZVD
MLZ250>HA \;V34:YVO@HXH7/,!=*ESS8+DROXT:M, MGEAN*9Z(^M=5ZE.>C
M.NKQX\;28PR^L)6"#MENAXSW6^Y F)NGZ#EBJ&^,$YNX]^KJ$X;*K,81X(X\
MXS%O:+72AKOE:%#H OOOJ+CC031J$"S8BXOB4 ED(R%F@8:V/+!HMC2V",'8
M7.XU/'2@ZD&I5E *S.1!J$ GL*HXK:NJB\*8 W,\.O?8>HDZ](Z[84^>")GQ
ME:CD NB1,L#9((5*S9VJAZ>7+73'6;+D7&IRX?;CQ*J%3P]Z--M]KS,*)?V+
M%MPZC8H0;G/5I&M\D&[W$Q4WDBE+ME-7';-_:EW^*AH:8R_@ZUBXST@A8*$1
M?/\=^.W2.2;D9X;C-\-P_.;9X?@#D$=-OA\,&8WCZ'ZNPJ 5'QN6OT8LHGE9
M>>FKSRL8O;Z1@2 C<:2NT;]-4O_UPLHWW<1U,C_^-K/Y^\O%E<)(T4K;R;/0
MJ->O6Y/G$TF=CI*DPR(]4IY0N,V2YI%!E5F;S=H0/0S,&#2$XX0(40YDMGII
MF4\V9*NCY(]JK@RFZ8J6":3=SSX3"-+=H)VWFY%OS&YKO%/%D,HC]?@&]179
M;#>GC*D(8U_/O\SM=UQ#S.@3Q37*41S1;TXB';UC:U'L#8\%<HV*(;!D;M"H
MSP$DZ8C#!))5/T1$;S6&?H@Y@IBCJ"'O@=LYY5L'[=;\#;>ZS5(@I<>G"3\$
M5X&$_$Y+2P)_,SY0Z83%J.I'PJ[38J3 A/6WU$],/3$<E.9NVN'T%$Q"M1U4
M0P,CMS7X@.&@3+H# 4CH_,YM3?K*4KO/W*G*8089P2N?0X]!S-E5H8U;WTCA
M#CX+;]U#5US@F89VW42U0BOTB/J78286:;C$)QIX'5R-C[J'%.Z(JMS+!+A>
MX<-@[X SR?1CI*'THTW^U @ ^=&YYK@;LX6:<C/2BCMDX.+MVW=FJ1>P[/0Q
M*IN-CET0E+4<+C$;HKKS"<SP=#B_NLS'-H?E^?#K5QW@8,1PM<+6^?0[T%?(
M!TKY)OE&#G&6/B$#Y'(#.J? "_!^Y<'$W0TK&$[U+OX!4$L#!!0    ( &*"
M95'DD?3]/P0  /X*   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*U6
M;6_;-A#^*P>M*%+ C63)LA77-N D:Y=AZ8PD6S$,^T!+9XNK1*HD%3?]]3M2
MLN*@MN$- PR1)]_+<W?/49QLI/JL<T0#7\M"Z*F7&U.-?5^G.99,G\L*!?VS
MDJIDAD2U]G6ED&7.J"S\, B&?LFX\&83]VZA9A-9FX(+7"C0=5DR]72)A=Q,
MO;ZW?7''U[FQ+_S9I&)KO$?S6[50)/F=EXR7*#27 A2NIMZ\/[Z,K;Y3^)WC
M1N_LP6:RE/*S%6ZRJ1=80%A@:JP'1LLC7F%16$<$XTOKT^M"6L/=_=;[>Y<[
MY;)D&J]D\8EG)I]ZB0<9KEA=F#NY^0G;?!S 5!;:/6'3Z X##]):&UFVQH2@
MY*)9V=>V#CL&R2&#L#4('>XFD$-YS0R;393<@++:Y,UN7*K.FL!Q89MR;Q3]
MR\G.S#Y(F6UX40 3&?QJ<E1P(PP3:[XL$.9:H]%P]L!(TF\FOJ&0UM!/6_>7
MC?OP@/L(;J4PN88?18;92WN?H'9XPRW>R_"HPWNLSB$*>A &87#$7]3E'SE_
MT2GY?Y_Y-==I(76M$/Z<+[51Q**_CH0==&$'+NS@4!HT7%E-<>0*.@C+)[C#
M2BICJPWWN";RFWTU/^K;CO%85RS%J4=SJE$]HC=[R!%6LJ 9Y&(-381F$/DW
MU$"-AS2GY&G/12,RI9ZL,BME+8Q%NMY!JAMXKF[60AI6C.&,MB5IT,#I-[#(
M&0U.BK7A*2O@%C.W/EA=N&0%$RD",_!S+;!K*KR"L#>,1[3&O5%@Y:07D?S<
MJO1+S15F/1#H<%6U(O :H5+<>LS^IL&QZ#2\_B$)^^&[[U8::1I802.F%(KT
M":BU0A>L.2IV'-C\I)N+K6D_L;\=^,1)@^625/;G0-HNAU$,1Z@3=]2)3Z;.
M-:ZXX 9;]F:M^/87.NGVT'D?EXX&.YE+^IE,;;7X<W#6S!*1)BUH3R4;[ZO9
M2^Y\4))4YVE:ES6UA=+Y2,W^Y$Y9S-["_!$5?35H8NRGQP*9ES0Z_%O3P@4J
M+C,X^P.9(F\[M2GX"G?0Z3'<+.Y>L[)Z=]VS+,C((7T1=QI/S8SHL>V_$S_Z
M\Y;'_+!KJ[BU:FVN#\.X<J<]Q5/8\%#GO-(0]>)A#/W>13"BYS F]D7PT.%L
M,8-@)3:@*ZJ69>YP-( H[D-$H<GD&A_I$UQ1(0VFN9"%7#_M)$FN@QA&%PDD
M-E"_S>YP;G$O&5" 7A /B>RCA'"%K=$A!MAI2(9V*AHS.R4)A;*%>7D&G,*%
M_[VG_[:?_ZF7\8!*G814K=XH')[8R BB 34R"D_IX@!&5.,D&IW2PJA//;B(
M; N3B_B4_E$"KUH;M]+IMN]4\W?N)%2(M;MY:4CMMZ2YGG1ON\O=O+G3/*LW
M-\-;IM9<:"AP1:;!^8C.+-7<MAK!R,K=<);24-7=-J<+*BJK0/^OI#1;P0;H
MKKRS?P!02P,$%     @ 8H)E49VO>"!Q P   P@  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&ULK55M3]PX$/XKHUQ5@83(RRX%<;LKL;35]51T"+C>
MAZH?G&2RL7#LQ78(O5]_,TXV!)67+_<EL3TSSSS/>&PO.F-O78WHX:%1VBVC
MVOOM:1R[HL9&N$.S14V6RMA&>)K:3>RV%D49@AH59TGR(6Z$U-%J$=8N[6IA
M6J^DQDL+KFT:87^N49EN&:71;N%*;FK/"_%JL14;O$;_]_;2TBP>44K9H';2
M:+!8+:.S]'0]9__@\$UBYR9C8"6Y,;<\^5(NHX0)H<+",X*@WSV>HU(,1#3N
M!LQH3,F!T_$._7/03EIRX?#<J']DZ>ME=!)!B95HE;\RW1\XZ#EBO,(H%[[0
M];X?9A$4K?.F&8*)02-U_Q</0QTF 2?)"P'9$) %WGVBP/*C\&*UL*8#R]Z$
MQH,@-403.:EY4ZZ]):ND.+_Z+*2%;T*U"!<H7&N1*NX=[-V(7*';7\2>LK!O
M7 R(ZQXQ>P%Q!A=&^]K!)UUB^30^)G8CQ6Q'<9V]"GB-VT.8)0>0)5GR"MYL
ME#P+>+.W)7^4KE"&53OX?I8[;ZE+?KR28S[FF(<<\S=S',"9<T@5%;J$KU+D
M4DDO*=]0[A*H-Z^P:*V5>@-KX:1[KNBOY[NI$2JCZ(@QB ][!W1*'6TF>#8R
MH7LFY,C1@G@DM:<>6>U#,Z$EZ-CMB.5,#(0_!=H/CTV.=MP4V).:FE,I.F<$
M\17O44$Z_+/A/X,;XX4:RG$*Y\+5@'>M)%:AY=Y!>I <)_1__]M)EF:_/QGU
MMK](BP6I[]'YH5'3?4C3=/3<_7F-SFTG; D%-23O+'EG^Z-'-I\._VPU_N^"
MCK/T!3EL>4G,_!DQ\S?$',VF0\;AEC"_9,B%$KI 6BM46U(S3(TLNO4M::I:
M7;H#Z&I9U&"JBA1"I=J"C'R9!E>Z^]!RIQ2FH3?"!0M,FNF0.3A\@CGDXWAN
M2RZ7_PF.VZP_%J8*>$+SI).^AIQ4@!)V@Z%=72.4HBO0WA*G0FPE[8'\MT_.
M]IKN8;BCA Q<R0<B2&)-@T0X]Y-4@=[D8'!J'P@_J8FC.(^6[EY":AV?A;O6
M>)H,'+96%H3VW*T13R[F!DD!/S^.!+;:]W?TN#J^<&?]Q?[HWC^/%U0 2857
M6%%H<GA\%('MGYQ^XLTV7/-4+GHTPK"F5QHM.Y"],D1ZF'""\=U?_0=02P,$
M%     @ 8H)E4?:3IZK' @  $ 8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&ULC5513]LP$/XKIV@/(#$2TD*GJJW4%A";AD"4L8=I#TYR22P<.[.=
M%O;K=W;2%!!4>XE]SMUWW^?<728;I1]-B6CAJ1+23(/2VGH<AB8ML6+F6-4H
MZ4VN=,4LF;H(3:V193ZH$F$<16=AQ;@,9A-_=JMG$]58P27>:C!-53']O$"A
M-M/@)-@>W/&BM.X@G$UJ5N *[8_Z5I,5]B@9KU :KB1HS*?!_&2\&#I_[_#
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MJC_NC@^EL^Y]\$3>O;*NF<PY]HL25LCJ'29X_,ONY=(MM&CL:V$I-%Y,[;3
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M'^9@YL4IV))$+Y4KCXKU;'W2/B_/E\WR\IA^S0WNE2429A@:'?>0LBE/ON7
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M=KV$H_8:5PL%.T(]#(<,^2(W^>[3=:A+L3AH#S^;T+!GVT2&B)&;B)_NN=K
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MY [E_N49SFH*SX\D&C=UBTOP^ #X!#5?5R7Z_(&^P=1B;OX\@MQMD+LE<O<
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M#4S>9'$:5-QHL<H/5.9":Y'EERG!"9%V@/E](81^N[$!JC.YR7]02P,$%
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M6)S3N%!2WV7:3TT6L-:D*/04%TLBA_;J&;809X"6+^@9$B$577) I>DUNGH
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M_6A$?4[6$\4K>]3,N=('EQWF^ML"A G0]Y><J\>).;W:KY7T#U!+ P04
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M,M8#.HC20-_?<:Z>-V6 9N1?_ M02P,$%     @ 8H)E4:@3<I/^ @  A@H
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MY#[#\/D LW[-K.]E-C<R>2*_%M:M]JQT4.,-3B/T5S6A*^\"2]!GT(:+%2E
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MWF5?OR:BZ%B*B>*9O?277.D6P@X3W>6!, 'Z^8ISM9N8#:J^<?P?4$L#!!0
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M*8^J0S;N_->"NQ6Q<W7Q52=U?,-1?5I\MQ)V3U.MWTK_'<.P]D;+4:_]2]3
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ML7?O08)KMN?Z11Q_PY-#?:-O);BR3SB>]@8>K/9*B^PD3 19FKM?]O,4B(I
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M4Q^G82HI]39HQATHW9@>F4PZU'TH3:L:WJD7?<&5V.3IGT@OIIG8DS1Y4NN
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M/K:74I<S)]J/W=/ O&C7\)>-UN>Q[=;<6%GM7^39OX3TZ2=02P,$%     @
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ME<+D$U!+ 0(4 Q0    ( &*"95$'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 8H)E454X$)+O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ 8H)E49E<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !B@F51RY=63RP%  !8%0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ 8H)E45\ P'2I!0  SA0  !@              ("!< T  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( &*"95$4@+V390,  " *
M   8              " @4\3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " !B@F51LR'5"]0%  "8&   &               @('J%@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 8H)E43)>SEDJ
M!@  RQT  !@              ("!]!P  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( &*"95%8$[\G*@8  *\7   8              "
M@50C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !B@F51
M#W&J[P0#  "H!P  &               @(&T*0  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ 8H)E4:$!'ASI!P  \A,  !@
M     ("![BP  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M &*"95'H5;+Z#P0  +()   8              " @0TU  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " !B@F51_UP>&7X$  "L"P  &0
M            @(%2.0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( &*"95&9EKOZ]00  &L+   9              " @0<^  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 8H)E40/M\<98%@
MYST  !D              ("!,T,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " !B@F51G4K"<=\*  "+'P  &0              @('"
M60  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( &*"95&Z
MBNH+7 ,  .X'   9              " @=AD  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ 8H)E42N!87!."P  XB,  !D
M     ("!:V@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &*"95$C8&AP[P<  .$3   9              "
M@5>,  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 8H)E
M4>21]/T_!   _@H  !D              ("!?90  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " !B@F51G:]X('$#   #"   &0
M        @('SF   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( &*"95'VDZ>JQP(  ! &   9              " @9N<  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 8H)E40XO9QGV @  C08
M !D              ("!F9\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " !B@F51.EEJS>4"  !W!@  &0              @('&H@
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( &*"95$F)H3W
M @4  $H.   9              " @>*E  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ 8H)E4?8_E4&>!   P X  !D
M ("!&ZL  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !B
M@F51?PUGHYH"  "S!@  &0              @('PKP  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( &*"95&"WY4@.0,  (,+   9
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M970S,RYX;6Q02P$"% ,4    " !B@F514.]E]GP#  !<"P  &0
M    @(%DQ   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M &*"95&G5^%Z P8  #8?   9              " @1?(  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ 8H)E407PRN\R!0  .18  !D
M             ("!4<X  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " !B@F51L5*HJX@#  #K#P  &0              @(&ZTP  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( &*"95%?F;U\8P,
M !4*   9              " @7G7  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ 8H)E4?*SOYZH @  M@8  !D              ("!
M$]L  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !B@F51
M)LF+,5H#  "\"@  &0              @('RW0  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( &*"95$@HW/_A00  )\3   9
M      " @8/A  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ 8H)E4>020YKF @  @ <  !D              ("!/^8  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !B@F51&-_92)8"   =!@
M&0              @(%<Z0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( &*"95&*^NJ?]@(  $0(   9              " @2GL  !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 8H)E4:W76GCO
M P  1A$  !D              ("!5N\  'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " !B@F51TI%NMBX#   Z#   &0
M@(%\\P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( &*"
M95$?Q4+EJ0(  +D(   9              " @>'V  !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ 8H)E4>>53 _# P  _@\  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( &*"95'6& +&4 ,  *P*   9
M  " @:<+ 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M8H)E49I3VWB= P  #PP  !D              ("!+@\! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " !B@F51IEGZW*8#  !K#   &0
M            @($"$P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( &*"95'J0#NG90(  %P-   -              "  =\6 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ 8H)E49>*NQS     $P(   L
M     ( !;QD! %]R96QS+RYR96QS4$L! A0#%     @ 8H)E46'56P-^!
M""4   \              ( !6!H! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( &*"95&\ =;!X $  .P@   :              "  0,? 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &*"95$4U''DT $  *T@
M   3              "  1LA 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   _ #\ ,!$  !PC 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>158</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statement of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1306301 - Statement - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122108 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126109 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134111 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142112 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2320303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2343308 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Restructuring and Employee Severance Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Income Taxes Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Fair Value Measurements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Financial Instruments Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Shareholders' Equity Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Segment Information Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails</Role>
      <ShortName>Segment Information Disaggregated Revenue Within Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Segment Information Revenue by Geographical Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails</Role>
      <ShortName>Segment Information Revenue by Geographical Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Share-Based Compensation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cah-20200930.htm">cah-20200930.htm</File>
    <File>a21q110q093020ex311.htm</File>
    <File>a21q110q093020ex312.htm</File>
    <File>a21q110q093020ex321.htm</File>
    <File>a21q110q093020ex991.htm</File>
    <File>cah-20200930.xsd</File>
    <File>cah-20200930_cal.xml</File>
    <File>cah-20200930_def.xml</File>
    <File>cah-20200930_lab.xml</File>
    <File>cah-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20200930_g1.jpg</File>
    <File>cah-20200930_g2.jpg</File>
    <File>cah-20200930_g3.jpg</File>
    <File>cah-20200930_g4.jpg</File>
    <File>cah-20200930_g5.jpg</File>
    <File>cah-20200930_g6.jpg</File>
    <File>cah-20200930_g7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cah-20200930.htm": {
   "axisCustom": 4,
   "axisStandard": 21,
   "contextCount": 158,
   "dts": {
    "calculationLink": {
     "local": [
      "cah-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cah-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 442,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 21,
   "keyStandard": 278,
   "memberCustom": 22,
   "memberStandard": 34,
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cardinal.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Goodwill and Other Intangible Assets",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Income Taxes",
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119107 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122108 - Disclosure - Financial Instruments",
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126109 - Disclosure - Shareholders' Equity",
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134111 - Disclosure - Segment Information",
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142112 - Disclosure - Share-Based Compensation",
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Segment Information (Tables)",
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343308 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ie14ef2e16a4341de83a616bd95c70060_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ie14ef2e16a4341de83a616bd95c70060_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Restructuring and Employee Severance Narrative (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails",
     "shortName": "Restructuring and Employee Severance Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillTransfers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillTransfers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ib2050e0c2b244293b0d9307ba6e58fa8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ib2050e0c2b244293b0d9307ba6e58fa8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ib2050e0c2b244293b0d9307ba6e58fa8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ib2050e0c2b244293b0d9307ba6e58fa8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
     "shortName": "Commitments, Contingent Liabilities and Litigation Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i39e37f424f344ed4861a30e0289b675e_I20201102",
      "decimals": "0",
      "lang": "en-US",
      "name": "cah:LossContingencyLawsuitsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reportable_segments",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Income Taxes Narrative (Details)",
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i996aed144ffb4a48a0ee5fbb315c6670_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Fair Value Measurements Narrative (Details)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i996aed144ffb4a48a0ee5fbb315c6670_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Financial Instruments Narrative (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ib2050e0c2b244293b0d9307ba6e58fa8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "shortName": "Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ib2050e0c2b244293b0d9307ba6e58fa8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ib2050e0c2b244293b0d9307ba6e58fa8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ib2050e0c2b244293b0d9307ba6e58fa8_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Shareholders' Equity Narrative (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i76bcd37a41304f9a80edf0b488038276_D20190701-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ie14ef2e16a4341de83a616bd95c70060_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i67e8522d8b5645e79d6b9af6f3933166_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Segment Information Narrative (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "iecb54beca65c45029506df58645bad06_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ibcebc361e52048eaba97198b6a5faba9_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ib2050e0c2b244293b0d9307ba6e58fa8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i2dab659e59834b43b34ab0f7563c0c82_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
     "shortName": "Segment Information Disaggregated Revenue Within Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Segment Information Revenue by Geographical Segments (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
     "shortName": "Segment Information Revenue by Geographical Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i52baa5c5a9654848bd9121d59999a39b_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i7475a55c7a2b497c85c0ca7944fc4f26_I20190630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statement of Shareholders' Equity",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
     "shortName": "Condensed Consolidated Statement of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i7475a55c7a2b497c85c0ca7944fc4f26_I20190630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Share-Based Compensation Narrative (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ie14ef2e16a4341de83a616bd95c70060_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "ie14ef2e16a4341de83a616bd95c70060_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i8fd04dbd12954a0ead3b8eaf784ef15a_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
     "shortName": "Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:AdditionalStockOptionPlanDataTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i6e44ccff288b4a86886c5aab9864e13b_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i7566b8915269491e8cf903384ee23182_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i7cc829ddfa7546fe9e92c22e0ea07a60_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "if7b231115e4c4896aea559547eb04df6_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "if7b231115e4c4896aea559547eb04df6_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1306301 - Statement - Restructuring and Employee Severance",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Restructuring and Employee Severance",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20200930.htm",
      "contextRef": "i5a242ad400534f76ae512f09cf4a0734_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 58,
   "tag": {
    "cah_AdditionalStockOptionPlanDataTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A disclosure of additional data related to all stock option activity",
        "label": "Additional Stock Option Plan Data [Table Text Block]",
        "terseLabel": "Schedule of Additional Data Related to Stock Option Activity"
       }
      }
     },
     "localname": "AdditionalStockOptionPlanDataTableTextBlock",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cah_AggregateAnnualAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "terseLabel": "Aggregate Annual Assessment"
       }
      }
     },
     "localname": "AggregateAnnualAssessment",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_AlamedaCountyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alameda County [Member]",
        "label": "Alameda County [Member]",
        "terseLabel": "Alameda County [Member]"
       }
      }
     },
     "localname": "AlamedaCountyMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Amortization and other acquisition-related costs",
        "terseLabel": "Amortization and other acquisition-related costs"
       }
      }
     },
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CVSHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CVS Health [Member]",
        "label": "CVS Health [Member]",
        "terseLabel": "CVS Health"
       }
      }
     },
     "localname": "CVSHealthMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CardinalHealthAtHomeSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cardinal Health At Home Solutions [Member]",
        "label": "Cardinal Health At Home Solutions [Member]",
        "terseLabel": "Cardinal Health At Home Solutions [Member]"
       }
      }
     },
     "localname": "CardinalHealthAtHomeSolutionsMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CareFusionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CareFusion [Member]",
        "label": "CareFusion [Member]",
        "terseLabel": "CareFusion [Member]"
       }
      }
     },
     "localname": "CareFusionMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ClassActionLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "terseLabel": "Class Action Lawsuits [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "terseLabel": "Committed Receivables Sales Facility Program [Member]"
       }
      }
     },
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated Liability for New York Opioid Stewardship Act",
        "label": "Estimated Liability for New York Opioid Stewardship Act",
        "terseLabel": "Estimated Liability for New York Opioid Stewardship Act"
       }
      }
     },
     "localname": "EstimatedLiabilityForNewYorkOpioidStewardshipAct",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ExercisablePeriodOfPlansInYears": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The instrument's contractual term.",
        "label": "Exercisable period of plans, in years",
        "terseLabel": "Exercisable period of plans (in years)"
       }
      }
     },
     "localname": "ExercisablePeriodOfPlansInYears",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cah_FacilityExitAndOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.",
        "label": "Facility Exit and Other Costs",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityExitAndOtherCosts",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_FinalSharesReceivedfromASRProgram": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Final Shares Received from ASR Program",
        "label": "Final Shares Received from ASR Program",
        "terseLabel": "Final Shares Received from ASR Program"
       }
      }
     },
     "localname": "FinalSharesReceivedfromASRProgram",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_IPRDTrademarksandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "terseLabel": "IPR&amp;D, trademarks and other"
       }
      }
     },
     "localname": "IPRDTrademarksandOtherMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IndemnificationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.",
        "label": "Indemnification Receivable",
        "terseLabel": "Indemnification receivable"
       }
      }
     },
     "localname": "IndemnificationReceivable",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_LawsuitTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "terseLabel": "Lawsuit Type [Axis]"
       }
      }
     },
     "localname": "LawsuitTypeAxis",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_LitigationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Litigation Type [Axis]",
        "label": "Litigation Type [Domain]",
        "terseLabel": "Litigation Type [Domain]"
       }
      }
     },
     "localname": "LitigationTypeDomain",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LossContingencyLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "terseLabel": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "localname": "LossContingencyLawsuitsNumber",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_MaximumQuarterlyPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.",
        "label": "Maximum Quarterly Payment",
        "terseLabel": "Maximum quarterly payment"
       }
      }
     },
     "localname": "MaximumQuarterlyPayment",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_MedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical [Member]",
        "label": "Medical Member",
        "terseLabel": "Medical"
       }
      }
     },
     "localname": "MedicalMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical Segment [Axis]",
        "label": "Medical Segment [Axis]",
        "terseLabel": "Medical Segment [Axis]"
       }
      }
     },
     "localname": "MedicalSegmentAxis",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_MedicalSegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Medical Segment [Axis]",
        "label": "Medical Segment [Domain]",
        "terseLabel": "Medical Segment [Domain]"
       }
      }
     },
     "localname": "MedicalSegmentDomain",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicaldistributionandproductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical distribution and products [Member]",
        "label": "Medical distribution and products [Member]",
        "terseLabel": "Medical distribution and products [Member]"
       }
      }
     },
     "localname": "MedicaldistributionandproductsMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "terseLabel": "Net tax withholdings from share-based compensation"
       }
      }
     },
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New York Opioid Stewardship Act",
        "label": "New York Opioid Stewardship Act [Member]",
        "terseLabel": "New York Opioid Stewardship Act [Member]"
       }
      }
     },
     "localname": "NewYorkOpioidStewardshipActMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NuclearPrecisionHealthServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nuclear Precision Health Services [Member]",
        "label": "Nuclear Precision Health Services [Member]",
        "terseLabel": "Nuclear Precision Health Services [Member]"
       }
      }
     },
     "localname": "NuclearPrecisionHealthServicesMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NumberofStateAttorneysGeneralfilinglawsuits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of State Attorneys General filing lawsuits",
        "label": "Number of State Attorneys General filing lawsuits",
        "terseLabel": "Lawsuits Against Distributors"
       }
      }
     },
     "localname": "NumberofStateAttorneysGeneralfilinglawsuits",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_Numberofsharesexcludedfromcalculationofdilutedshares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares excluded from calculation of diluted shares",
        "label": "Number of shares excluded from calculation of diluted shares",
        "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment"
       }
      }
     },
     "localname": "Numberofsharesexcludedfromcalculationofdilutedshares",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_OpioidLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "terseLabel": "Opioid Lawsuits [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLawsuitsStateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Opioid Lawsuits State",
        "label": "Opioid Lawsuits State [Domain]",
        "terseLabel": "Opioid Lawsuits State [Domain]"
       }
      }
     },
     "localname": "OpioidLawsuitsStateDomain",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "terseLabel": "Tax Matters Agreement [Axis]"
       }
      }
     },
     "localname": "OpioidLitigationAxis",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_OtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Jurisdictions [Member]",
        "label": "Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "OtherJurisdictionsMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PatientRecoveryBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patient Recovery Business [Member]",
        "label": "Patient Recovery Business [Member]",
        "terseLabel": "Patient Recovery Business [Member]"
       }
      }
     },
     "localname": "PatientRecoveryBusinessMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalDistributionandSpecialtyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmaceutical Distribution and Specialty [Member]",
        "label": "Pharmaceutical Distribution and Specialty [Member]",
        "terseLabel": "Pharmaceutical Distribution and Specialty [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDistributionandSpecialtyMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical Member",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmaceutical Segment [Axis]",
        "label": "Pharmaceutical Segment [Axis]",
        "terseLabel": "Pharmaceutical Segment [Axis]"
       }
      }
     },
     "localname": "PharmaceuticalSegmentAxis",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PharmaceuticalSegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Pharmaceutical Segment [Axis]",
        "label": "Pharmaceutical Segment [Domain]",
        "terseLabel": "Pharmaceutical Segment [Domain]"
       }
      }
     },
     "localname": "PharmaceuticalSegmentDomain",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PlaintiffTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "terseLabel": "Plaintiff Type [Axis]"
       }
      }
     },
     "localname": "PlaintiffTypeAxis",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PlaintiffTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Domain]",
        "terseLabel": "Plaintiff Type [Domain]"
       }
      }
     },
     "localname": "PlaintiffTypeDomain",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PrivatePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "terseLabel": "Private Parties [Member]"
       }
      }
     },
     "localname": "PrivatePartiesMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales of available-for-sale securities and other investments.",
        "label": "Proceeds from sale of available-for-sale securities and other investments",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "terseLabel": "Product Liability Lawsuits [Member]"
       }
      }
     },
     "localname": "ProductLiabilityLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.",
        "label": "Project Costs On Investment And Other Spending",
        "terseLabel": "Project Costs On Investment And Other Spending"
       }
      }
     },
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.",
        "label": "Purchase of available-for-sale securities and other investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]",
        "label": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Definite and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cah_SegmentRevenuebyGeographicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Segment Revenue by Geographic [Table]",
        "label": "Segment Revenue by Geographic [Line Items]",
        "terseLabel": "Segment Revenue by Geographic [Line Items]"
       }
      }
     },
     "localname": "SegmentRevenuebyGeographicLineItems",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SegmentRevenuebyGeographicTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Segment Revenue by Geographic [Table]",
        "label": "Segment Revenue by Geographic [Table]",
        "terseLabel": "Segment Revenue by Geographic [Table]"
       }
      }
     },
     "localname": "SegmentRevenuebyGeographicTable",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_Sharesthatwouldbeantidilutiveasaresultofnetloss": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "shares that would be antidilutive as a result of net loss",
        "label": "shares that would be antidilutive as a result of net loss",
        "terseLabel": "shares that would be antidilutive as a result of net loss"
       }
      }
     },
     "localname": "Sharesthatwouldbeantidilutiveasaresultofnetloss",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other short-term credit facilities and an unsecured line of credit",
        "label": "Short Term Credit Facilities Member",
        "terseLabel": "Short Term Credit Facilities Member"
       }
      }
     },
     "localname": "ShortTermCreditFacilitiesMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMatterAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "terseLabel": "Tax Matter [Axis]"
       }
      }
     },
     "localname": "TaxMatterAxis",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMatterDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Tax Matter [Axis]",
        "label": "Tax Matter [Domain]",
        "terseLabel": "Tax Matter [Domain]"
       }
      }
     },
     "localname": "TaxMatterDomain",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMattersAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Domain]",
        "terseLabel": "Tax Matters Agreement [Domain]"
       }
      }
     },
     "localname": "TaxMattersAgreementDomain",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TotalOpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Opioid Litigation",
        "label": "Total Opioid Litigation [Member]",
        "terseLabel": "Total Opioid Litigation [Member]"
       }
      }
     },
     "localname": "TotalOpioidLitigationMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TrademarksAndPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Trademarks And Patents Member",
        "terseLabel": "Trademarks, trade names and patents"
       }
      }
     },
     "localname": "TrademarksAndPatentsMember",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TreasuryStockAcquiredShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Treasury Stock Acquired Shares",
        "label": "Treasury Stock Acquired Shares",
        "terseLabel": "Treasury Stock Acquired Shares"
       }
      }
     },
     "localname": "TreasuryStockAcquiredShares",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_VestingPeriodinyearsforShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "terseLabel": "Vesting Period in years for Shares"
       }
      }
     },
     "localname": "VestingPeriodinyearsforShares",
     "nsuri": "http://www.cardinal.com/20200930",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Statement of Stockholders' Equity"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r119",
      "r132",
      "r133",
      "r134",
      "r135",
      "r137",
      "r139",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r119",
      "r132",
      "r133",
      "r134",
      "r135",
      "r137",
      "r139",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r151",
      "r223",
      "r225",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r236",
      "r239",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r409",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r236",
      "r239",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r409",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r151",
      "r223",
      "r225",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r226",
      "r236",
      "r239",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r409",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r226",
      "r236",
      "r239",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r409",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r82",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "terseLabel": "Condensed Consolidated Statement of Shareholders' Equity"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r147",
      "r148",
      "r223",
      "r224",
      "r410",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r223",
      "r224",
      "r410",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r196",
      "r237",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts Payable, Current",
        "verboseLabel": "Accounts Payable, Current"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r382",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r39",
      "r44",
      "r45",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r40",
      "r44",
      "r45",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r42",
      "r43",
      "r44",
      "r395",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r84",
      "r85",
      "r86",
      "r309",
      "r413",
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by/(used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r241",
      "r264",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r73",
      "r164",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r78",
      "r127",
      "r134",
      "r141",
      "r154",
      "r303",
      "r310",
      "r346",
      "r377",
      "r394"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r37",
      "r78",
      "r154",
      "r303",
      "r310",
      "r346"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r243",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r235",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r235",
      "r238",
      "r294",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r23",
      "r75"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and equivalents at end of period",
        "periodStartLabel": "Cash and equivalents at beginning of period",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r347"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingent Liabilities and Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common shares, without par value:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, Value, Issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r58",
      "r386",
      "r405"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r57",
      "r301",
      "r314",
      "r385",
      "r404"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate",
        "verboseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r62",
      "r373"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of Goods and Services Sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap [Member]"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r378",
      "r379",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r29",
      "r80",
      "r213",
      "r216",
      "r217",
      "r218",
      "r357",
      "r358",
      "r360",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "terseLabel": "Debt, Long-term and Short-term, Combined Amount"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r73",
      "r122"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Derivative Assets (Liabilities), at Fair Value, Net"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r324",
      "r325",
      "r327",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r322",
      "r324",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r317",
      "r318",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Foreign Currency Contract, Asset, Fair Value Disclosure"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r316",
      "r319",
      "r320",
      "r322",
      "r323",
      "r326",
      "r327",
      "r332",
      "r333",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r219",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r59",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r97",
      "r99",
      "r101",
      "r102",
      "r103",
      "r108",
      "r109",
      "r387",
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Loss per common share attributable to Cardinal Health, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r59",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r99",
      "r101",
      "r102",
      "r103",
      "r108",
      "r109",
      "r387",
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r104",
      "r106",
      "r107",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share Attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee- Related Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r111",
      "r155",
      "r212",
      "r219",
      "r267",
      "r268",
      "r269",
      "r285",
      "r286",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r337",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r339",
      "r340",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).",
        "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1, 2 and 3"
       }
      }
     },
     "localname": "FairValueInputsLevel12And3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r227",
      "r228",
      "r233",
      "r234",
      "r337",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r227",
      "r228",
      "r233",
      "r234",
      "r337",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r337",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r341",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments Disclosure"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r165",
      "r167",
      "r170",
      "r174",
      "r374",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r170",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r165",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r170",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r227",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation (recoveries)/charges, net",
        "terseLabel": "Gain (Loss) Related to Litigation Settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r157",
      "r158",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillTransfers": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Transfers",
        "terseLabel": "Goodwill, Transfers"
       }
      }
     },
     "localname": "GoodwillTransfers",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r61",
      "r78",
      "r127",
      "r133",
      "r137",
      "r140",
      "r143",
      "r154",
      "r346"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r322",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r81",
      "r127",
      "r133",
      "r137",
      "r140",
      "r143"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r282",
      "r283",
      "r287",
      "r289",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Tax Disclosure"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r79",
      "r95",
      "r96",
      "r125",
      "r274",
      "r288",
      "r290",
      "r407"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for/(benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase/(decrease) in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "(Increase)/decrease in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other accrued liabilities and operating items, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "(Increase)/decrease in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r166",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r166",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r163",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Net Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r53",
      "r121",
      "r356",
      "r359",
      "r388"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r35"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r78",
      "r154",
      "r346",
      "r381",
      "r398"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r78",
      "r154",
      "r304",
      "r310",
      "r311",
      "r346"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r30",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated Litigation Liability",
        "verboseLabel": "litigation settlement liability recorded"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation Charges"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r29",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Purchase Commitment, Period",
        "terseLabel": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss Contingency, New Claims Filed, Number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r34",
      "r78",
      "r154",
      "r346",
      "r380",
      "r397"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r71",
      "r74"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by/(used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r46",
      "r49",
      "r55",
      "r74",
      "r78",
      "r87",
      "r89",
      "r90",
      "r91",
      "r92",
      "r95",
      "r96",
      "r100",
      "r127",
      "r133",
      "r137",
      "r140",
      "r143",
      "r154",
      "r346",
      "r383",
      "r402"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Earnings/(Loss)",
        "totalLabel": "Net loss attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r46",
      "r49",
      "r95",
      "r96",
      "r306",
      "r313"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: comprehensive income attributable to noncontrolling interests",
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r219",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of Reportable Segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r127",
      "r133",
      "r137",
      "r140",
      "r143"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating earnings",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r27"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r44",
      "r52",
      "r348",
      "r350",
      "r354"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other comprehensive income, before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r47",
      "r50",
      "r52",
      "r56",
      "r212",
      "r348",
      "r353",
      "r354",
      "r384",
      "r403"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive income/(loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r47",
      "r50",
      "r301",
      "r302",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Payments for Repurchase of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r68",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends on common shares"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred shares, without par value:"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, Value, Issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r46",
      "r49",
      "r69",
      "r78",
      "r87",
      "r95",
      "r96",
      "r127",
      "r133",
      "r137",
      "r140",
      "r143",
      "r154",
      "r301",
      "r305",
      "r307",
      "r313",
      "r314",
      "r346",
      "r389"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings/(loss)",
        "totalLabel": "Net earnings/(loss)",
        "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r177",
      "r400"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r60",
      "r156"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r16",
      "r22",
      "r399",
      "r419"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r44",
      "r45",
      "r52",
      "r348",
      "r352",
      "r354"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Amounts reclassified to earnings"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r134",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Assets by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r133",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r133",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Segment Profit by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r132",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "verboseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Reduction of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of Notes Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Employee Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r73",
      "r180",
      "r185",
      "r189"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "totalLabel": "Total restructuring and employee severance",
        "verboseLabel": "Restructuring and employee severance"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Additions",
        "verboseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r181",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r219",
      "r270",
      "r396",
      "r416",
      "r418"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r155",
      "r267",
      "r268",
      "r269",
      "r285",
      "r286",
      "r413",
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r54",
      "r78",
      "r118",
      "r119",
      "r132",
      "r138",
      "r139",
      "r146",
      "r147",
      "r151",
      "r154",
      "r346",
      "r389"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r44",
      "r353",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r336",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r165",
      "r169",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r161",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r161",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r173",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r183",
      "r184",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r181",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance_1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r127",
      "r130",
      "r136",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r243",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r246",
      "r258",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r31",
      "r76",
      "r112",
      "r113",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r114",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r132",
      "r133",
      "r134",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r143",
      "r151",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r116",
      "r117",
      "r127",
      "r131",
      "r137",
      "r141",
      "r142",
      "r143",
      "r144",
      "r146",
      "r150",
      "r151",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Distribution, selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r73",
      "r180",
      "r185",
      "r189"
     ],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "negatedLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of outstanding options at period end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r248",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Common Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r240",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of exercisable options at period end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r114",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r132",
      "r133",
      "r134",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r143",
      "r151",
      "r161",
      "r179",
      "r182",
      "r190",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r33",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r111",
      "r155",
      "r212",
      "r219",
      "r267",
      "r268",
      "r269",
      "r285",
      "r286",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r111",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r212",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r212",
      "r219",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r219",
      "r242",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "negatedTerseLabel": "Employee stock plans activity, net of shares withheld for employee taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r78",
      "r153",
      "r154",
      "r346"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Cardinal Health, Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r78",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r154",
      "r155",
      "r219",
      "r267",
      "r268",
      "r269",
      "r285",
      "r286",
      "r299",
      "r300",
      "r312",
      "r346",
      "r348",
      "r349",
      "r354",
      "r414",
      "r415"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedPeriodEndLabel": "Balance at end of period",
        "negatedPeriodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r219",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Axis]",
        "terseLabel": "Subsegments Consolidation Items [Axis]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Domain]",
        "terseLabel": "Subsegments Consolidation Items [Domain]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r355",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r355",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r355",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r32",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r32",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "terseLabel": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r15",
      "r212",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Treasury shares acquired (using cost method), shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r32",
      "r220",
      "r221"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period",
        "negatedTerseLabel": "Treasury Stock, Value"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r212",
      "r219",
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Payments for Repurchase of Common Stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r273",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r98",
      "r103"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r97",
      "r103"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r430": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r431": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r432": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r433": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r434": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r435": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0000721371-20-000131-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-20-000131-xbrl.zip
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M_AEQVQ*6 [8HEK4;2E<:2M$0]?,FPF%!F?]92FNOO<&HW>%O-P*VOONGPF*
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MK>LJ? BDENYVE4?NTU2_X=J:OT!W]%]02P,$%     @ 8H)E49T>XO?V!
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M\XSGS#*3!M=,*AZ3K%9IM$^$4F):[Z#?MSM>J#>A)/[39IEZ?[;9GZ/H_;'
ML_N]WL9AU_8VCGU2K6_[/?];J.T$FX>7U3K&$Y4WT+ME0?(7K:#53"@(I8A8
MY()7J"5]#R/J%S=:>+#$@0%W-9)5$%%G(A#^6@GJ%3+:<LW?0(]8"9GR;!$]
M'TE.,C@E4HKY\W:)^6>53/*DDBKY7PQAQ'7-X[QBM8M*#$LUNQ6MAS<IGW %
MZ%%OZ&CY9;\YAKNE'*AVB(FD!VMI\_I>EJQ#_P&M\SYGG:^M&VLW)^AH79U
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M(7OH&#,@7Y\3E\AE2&X9>8W$<"(E/P1YC \.JX"H!4N+WKH0L_90#;'"\-R
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MDH"IZ1[U@2W9L$R;0(TLL4-/R"JFUD#4TF5/E6O/C0SN#.P(J@ 5@ H^"70
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MD*@@\ A7A(<HK,$Y[4=)W%U]J3M)7ZL3+<][22<YNSDR+8CJPII21IB%DI,
M:;-[+WS%$#/GYB(7+M2I^%/5\;=^'N74QX)%2&L!/"HCP358M %!R*.^EKSZ
MX<T:>2%+BG]J,&<$\BE#(>C."# 'GB,5%'B5L*@.]4:K;,FN)F2-P*/W&?61
MRPF(3N%+3Q+78S[R%9+1AJ%L7<;ILLZW:DZ9*[$?AHQ05W,P2[44@B =BBBL
M02WLJBN^E:#-$Y&D04"TAG\0DR$7@GF8$,4%<\,:['*_3;6*!^46]MU#"CJ5
M,>]\XOW:1,Q\X)D(#(K ER&A8/L'6G&FP<84&G/EU1LG1_HRZ5R:C(2IFVJ"
M&P3V0VCJ?_K@D7G<XZ&+E1=B9 YS\3K4_=G58K#?,YDAYL&Q[C&\$@\&6AUI
MJ>-+#L(O.^;P3XFA3VEREO+N3Q#U)!HQ\S@^3]+!B4Z[4S?$NBZNH.\CC4PY
M>^%'!/L\5!%S$3=I1,S5=!W-D1Y**EDZ>)TKO,)\G#!1WOYU_&_-.X/S3?3L
M3#DB'7D1=@.78%,V%+M$N6'(%1*NKO!FK$'9!V"3,VOFO^69'J/L4%^=)NGW
MC_TXB=7Q0%_Q5!E'8$?6I8Z7V7W5/A$>E> !\"!D822%I#I@E 2T#EFPE4'0
M6KALU# JU7T0[T:Y_%U,^FY/- .2H_%]Y:9U.?3"#;V\4'M&!I/((T0K$C#$
M/>!B'(2"^:7/CY"+ZT0L.95\X%?9,/ZIF[&P-CX>BDS_9PC3V[N$?TP[Z6FS
M[=8-*Q8<"+5<O(RP#](2N^;42F2Z=/$ >YQ& 6$Z"@0%9;P!)&"S/':3+H][
M#1W,-<J(.0L9,01NKL<H9X0JR7G J1LHMP[I<A.('Y'%1.0H&?#.[<L;HCRF
M@^\2(RZ$YW+F$B; L 9?.8S VG9]*12M0=F,RF%R3:4RE$(:7"(61>!*N[[P
M!2AKU]?<)S@(*AQZJ@0"5W/H)0J)R]R A R1T%.F7YZG!5.!2RD/V";HRZ>:
M3#:AM0/:%J8:C16D_3F-+X$;/@'[_#Q@\:OKY(B:"+//&9) ;WX8<,_G@0<.
MMW8I4[2ZM&9075#3-/[S#0)I*'!9U-;0==WH6A.?>)1SEPN?".(&D0J1BJ3O
MN\3W99$]:>BZ554"+Q'P(<FRM["VN'>F>Q)0_Z^;0SX Y_MC-/[Y9I).$C64
M@P\Q%S:JNWE>ZBT#>(IF[C> IVY]@MD4^:&K?8_Y6 ?$U=0TGJ8DBCS?U:X.
M60W(R\BTT=F$]]IL*_3/S3&$,27M='A7*_XV&?9^NC?4D'.-R9D+EV.$.%B<
M+@F5B>T&3$D::0^\MR"L"3G/4]$-":V>A+31K=0--56@>WT4BBB2S/6X=DE$
M:!T4[@(2T6;;_3E,XTS%UL)<J6G9T.WJZ=:/,%+&TT:N1R(OXH2S2+@N8Z'T
M RRJ&P QE'/$05WF.+/[Q7$O[@Z?G!VP IJL2FQ%1(R U>;YDC#"D6GR1>$7
MC43@8Y_5#-W\>AGHGNM)UQS7W U#BA1W*2!=1![W?0_080KPAY&Z?8(.53$M
M<OE!SH=IP6.I>QP /J:Y\I=W2:HEKU(7<32=C_F4<@">YS+L>6#+"")0$'".
MF/ ](E48!#*:VMZH9CYM):+CC]S>N)U9^Y3MC0AKY@OD1@24O!]QFP7F<QE1
MR:,BO-EP?D4X?T(+H*4E5_, A0R[X)U(EVA" NSJ$/NN<A'SB(NKFQ-?"1Y>
M5L+[*/FH-S1SN9-O5(P!'\L!%DXQDEH'GNMII"-!?&UV-"AG"BQX3W#X4"^;
M;B$3OBHF%@H#%01:"B8%02$/% \DI1$12F$OJ'!=B4>;TU4!O8G+(2DQ.*PF
MFT:(, I#3L"?!<(/RQ!TI;-I5N?!CL]8FEKQ)_QZ9S@X3]([YR!LG?(>[QSI
M2]T;ZF.=7H(XV3\ZKHY9N[RL'1DQ%48^=@.&30E C@1C$5=$<!%2'U676:V^
MX]<'? #HFMCIY:E^-\SJD]GA8XV0EKYP<40BAD$[43\2&(%[00A7U;9%UHJ!
M957%!!-!>L(GE+@D4J% 8:@P"4/BN[Y/*WQ"<@X&/H'=!P,<:9E<ZO2F+#)6
M$W0$&%$PSUT4!0B46&2Z?3+M:1)$3&/,:B>2UH2.)<DGIA'1.@H])C7Q QWZ
MO@ [CE$NL)*R#H5/>)S^Q3M#_:^;T<=_PX@\E><W'\PYX=M5EXN;]GO]X2"S
M=Z!E61\3DSG(G1FSFG>IW5*1-W-F,G%K!G0T3-/ZE(-V?4$\3A!16(""BSAQ
MA?8E5]+E"+,:E&M\/IP]*TWCFA!0B+0G?2D#$9FC\#QP R*)[^N(1I&O*VRC
M;C@!>34A(!(17T8:!9&F!"P(CE3DADH)IB,=N15.:%^J"L,[/?4SE%60I*M"
M16'(N%:(D C\!4X"[FI-(R%,F4;&ZE 0^M?#F6*$^@'X=@B')'*I$,PE/I>"
M4,I"5(/^6(WQNE9G%+,P\B.P5+4YU49,9)5Q3_DA=HD;CN)C]2"@3;(]5FZ\
M+HF (B9E)$/"@'X($2R4RO/ $V)(*QGJAH VUGA=%@$)<_9/R0CYFDC7$\15
M3&NB00X%K [=E!KCM0)4Y%EC-<*^CPAE42@0HPR("&FA241K146_",Y\5VD<
M<1]Y1)((W%9*?2K]P"?25T+6(.ZQJ^WY1-N@NRQL=A1GWV\5 ^39^;M.<O5O
MK<XJ[5J,\E7T\&ZR2IPE!"/_]=Z7H_+QA;-5%-@'U!3"5:$D?HC M12,ACI@
M8#FXQ"MZ35>8.Q?$-/"?8=;C*]Y?)9I-8N&2F%"9-AO(%3YCDGB$<A(J!*XD
M\W" &*]#2L7#<&12^>*SWMZU/#=I&.;\7<HWIM[5M'-'$# ;#CD-?1)I'F F
M61#Z6GD^4\*O0<F2&N!V/45,!"=4!5('H:N(AZ4 @8HY]@,581JX]=IUJJZ7
MO+1C&0H\XP 3C!4) B\4V!4\8&$8P$\DK)5Y6EUL+<LP94*"B.0$>2Z)0AZX
M6D6N ,2Y7H!]=DMN(NRA5:-MI3()X9:'EB"3*/.QP@@S4_T0<2D"+8+ 5%M"
M3'E<Y&8>PBZI +BFK"F @$N60#G,UP$%'@\$.)]4^Z%B(N01B[S0\Q!CU>?S
MT6&(O?\,85YODVX_Z>E1Z\;RMATIA]UA!^Y5A=(M;=\==3',!F:$_9[L#!5X
M/)^2U.;Q#P9I+(:VN.9)<ICT#.C2I-.!6VQ2JE[Q 8LE5J]WN=3@O(9AJ @S
MG:8#SD*7A+[G4EV'J.?#\7RH!^]YW#.U+-ZE27?2J]79)N.:$3\(P5'UI#DX
M2T4HE 9;R_.!T[%;X036A^(ZD?$&X]$/M ^6L8Z(UH10+PA#P%Z@/!DR+EB=
MFDMNG)!>OZ_L*H2I JG.M2 A]DR#W\A'3*#(%Q[!&TT=-1#MZZ<03CT/AQP\
M;HI(P-P0AR&G4A-7>Y*&FT@AE5$(Z\<^,NW89200(RXAD@320THJ%=' ]Z17
MX5-_&ZLT5I-+23WB^EJ;""F)M!](C'S&48! &;BX!KF4&RG^5],\E3%-)' Q
MY2YA,N+:1=K#GA0B$ 0%FX/KR@CRI6]5%B^?V<NCN/;P[<H@\JGT BR1)"IB
M(>($A=+5",2!3[T::'ISKOAMTLN23JQLE81]H)-;5/$10,Q-\<FRT<FRTD]&
M5%D>!2M?,'%F[)RG7;"VAP-3;&YI+S:UV^Y_U6Z<Y70/#_*>.NYKTZ5O%6W@
MUF^SN$I'6DL*-HM/, D%N+Q4<!(&@2LQX378_VOHN%)TO)Z]3H9Y1##U9, ]
MT--2:"VX[R$$NCH*:Y&CT-#QN.G84'8T3S^E0+'F]KRK7U&&8B/[MKO:$TA(
MCP4A)M*E8>1KWV4XH 1LBM!KY'!#OU66OUAICYIVE$(2PL.(>WY %64@DD-/
MN6XC?Y^7?FLI!(47(C]B3 01(R3P LZP"VZVI'YHCCXW0K!61+2FUEUAA!"F
MH:>5;=?#J0 *XB['KN=*MRX]CM='1+,4VH%6AE[4M$?1SPLA/R?]%A/91.GG
M!8*&?N11WU/$%R3D0E+/Q1%B(05]VDB_AG K*7&U%)0(+3FCDE 7A]1E9M.+
M$2JX<AO?^S&$^Y:G*N[Q3NXZ[ S^G73U<=(9+J6[1M7H=DT^-^/,PXJ&E&K"
MS5%2%GDDD"'U5*#<H!&X#=U64=[BB&DD70HB%X.\A?^))F U>%'@@M!MY&U-
MJ&<]4L\/4(1U)$(74Q($RARL%Y'B'I)4*-)(O9I0SYK.E$EMHM1(4^R20'/!
M0Q^%@6"<1N;++RI[:BD)J +V%P(+ERHBD C"B#/$.3-%OL!R_T4E02WY4FL,
M4MPS1;,Q(0$"V\ -@34#8AA6H WAR[=)VD\ F_HPZ17HW$3.9,K5X(=(!H@D
MOM8B])FK"%/:0YPIM"&<^>S87 ]O4BPXIY+RD('%14R)"X01^)WPAWNAJ EO
M'M_3 ]2T0DYO7G\YWBP^#",2^D0R7R)$)*".>)YP521#Y.)(Z9KPX5HQMQZ>
M4]2$=J0*%>;@';O<#[1G2@<Q[GM,UR4_\Q[,E4(49.>7C31/0^EQZC.?"X6(
MZW%A*N^+"'.E-0%OM?[,]XPH7%=6"+=%G&@8>$003WB$"S?R@3FE*X,*5R"I
M>HAAU?OX*SE,83+:F*1$^TJ1"!R3@ 8!5Q'QD>"!5^$*? TYK."TM1L&""0!
M\57H$L[=((BX:5=($?8Y4J21#I4+0*ZF_1<%O"OMRX!3(@(1>" GE&\.7GE4
M^!6NB-+0P5*[7E%?:R2$]/V(\ B%B%$*SE80,M 1TJNW/'B68,=JU#;F6DI%
M&%8:^#,4VL,4"1^\8H(0X_7FSS7@95G52JA)E0T1Q2PD(=*!C$+7\P*B-?90
M4*=J SM7/%4G-WT]C9LC;=*VY$"KXT$BOW_IQ8/LZ/C+)GJ[0C)LSHZZ#)PD
M!EYNJ*@7H(BPP NB@-; VZTB,M?C]P:1R3T6"N&0$NYJKCP1:![YP)L1HKS^
MG+G7[7>2&ZTM*C_V5]-DO0)<R54H<."'X+H2;9Q4(K1+@2FQ5N#*UI\KGQV1
MZ^%(CT2F([L*E2\)IC+P0,:R2/JNB$"#UB%GZB>(_*33*$F[O"?U\3E/-_.8
MI$:APACPQ34C ?=XX&.!J>FOJ30B&\"/SXS&]7"CZ62)0Z4B[H,LC72H0RPQ
MUJ I79^S&C1T6;>-LQ*'@E.N":6N$I$B&GEAY DI-7AZVM,NJ4$!JVJA96GM
MIPF1,HIP$ C" Q8$8'EP+L* &2R)VJ+E66R/E:"$ZD@Q%8+R<1DA#'-/,>:!
M4>'ZR.-(UU: K0$E2Q)>FC /(<:DT!$)N0RI*;_LHRB,HB# TSE3#6Z6;!S<
M1N13C /L!BXXS,@TF$0*AT()AK!D*O 5,%@-3'43=SPR[45R!)JO!W$O[@Z[
MRPK^5\-Z7(\30"+B\L#E3-. ^"+BR--!"!+8\R-&51WBGK,(A%\W!+(< HE\
M@4$7(*I-%5;3LYI3&E+B:^&:8GVUU<[/@+V5Z&8J541T%%"%&*'8%<2+(J9\
MDT1)L*SP3G_5$/(8^_55?/T:II8,4ZFS_.NYYLK.1\67;_Z ?XJX-5%N$"D4
M1=(GBI&0@.85A(&33D(<R;]-$YOQ,]G@I@.8Z,:]UKF.S\X'KXG;IOW![U>Q
M&IR_1J[[O[>F[^3I&=PLDL$@Z;[V^J8FIZTN6MX@DA3FU9))I\/[F7Y=?OA=
MQ5F_PV]@S9VXIUOVH=\O=6KS75J\$Y_U7IO5%F./9]!V\UD,8+4#5;ZGN-RV
MEUX-U-UK'FYCSYM[V6VCN=?6-2Q9:-A7%A(Y- "\69\#F7M;Y0-]KDP%V->X
M?^T@0*4%:@[?CHX&MV&>@SO'\IL_S&#E0#!VDK[^AV''*/H] F)L1;P;=VY>
M__=.&O..<\C3-+GZ[^V,][)6!K1;W)7%/_3K %YMOUV5A.7^;C%?$)JAK7QN
M2DNS?0O<^GK8 ^(Q=\%\>"7FX9RG.OKGUC]^SEG^UIL3RPE)Y+PUG-L;9'^\
MXH O ]22ZTKLWH,XUZ!MZ^&W6KIX91EK]+8[G#[%OX;3BU\&2=]^G: 6J4V%
MX.4R>-)_.F.'03MTYU^>P2KE#07*"[$U$[+%\@H  70=FWO@6/(#TBFN&W#=
MO;@H6NX3J#,Q,(<MX94/90?$;O&#/X,?MMY\.=P_V=MUCD]V3O:.IRFX^I,_
MWGO[Y6C_9'_OV-DYW'7V_N_;?^\<OM]SWGX\.-@_/M[_>/B %4WP!UO] M%"
M"_S*LW.@LT'2V_ZO?R#F_K[;?MMVL$M)N.#*PNF5A15 '38K>P>VF/,'V#>]
MI'<X[,(@TBG,H",CAV/*,<%<@12G'HE\\ PHPI$;RHAPU_=F%@=S>MS8FTK'
MKW<3.32&FS$$MXJ#)MY?-V(WN?R CRY/O8.ANMB[_/8^O/AX<>9^V]TAW[J?
MK[]UOUT<_CCZ?GCQF1Z^W\<'7_?=PXLOKOE^ -<^>(>=TQ\).7S_^>KC^V_?
M#[Y^ZY[^D/#\J?OQY"@^O'@7'^Z>HD/[_<_N*0JN/^!O-Z=?)3O\NG]S^F/G
MYO!$=;_MFO'_B@_QN_.#[F?OX.2P^^WDE'[<A>OX\Z5Z_Q=1__ZS\PUW+L5%
M@DXO_KPXV-U'A_C;]\/=[^ZWK_O>Z=>]FV^[\OH ?^L<7GPG<-W[]BX@AY__
MQEZ(=:C!)P 'O$5"YK<$B<*6B+1D5 HJ(]!BR&U]MC;F& =OG 7IJIX:A;81
M8DLWZ4+<9L$Z3#J R4-Y]TLOEHG2SL'QHI)IEAT%;UTVZUKG; !/PXK!2P1S
M->D(WNDD Y%<S^+LST.> I%U;HYT/TD'M63R=[%X_P6>@??^>-<]O?B"#[M[
M]'!W_^;@_;OO!Q=G5P<_.IV#KX?FG3!G63SS%[R+]KZ=).C;[O<?,+_X\.04
MGYY\=P\N]J].OWZ^@7?\^/CUR_4I-NL[\ Y1</7A9&=P<.Q>P_]_RY!3'4:Z
M%6J-6P0'LB4XCUI!*+!'&=7"Y5MO_NL?H4_H[[>%Q$A&_-QP71TEWZ^%W(7T
MZ^<O.T<G>T<?3IVCO4\?CTZ<3U^.CK_L')XX)Q\=L"Y.P(1PD.=\/'(0?:%>
M.A_?.2?_WG,F#(^1T;'S]L1<1J%'IN#S$+/P&=3S;<#<8>]2/3N#<^W\IV0R
M)P]9.!H<)K5\Q3W!_:^529:'$<\5O[G1/-6]6>S_R<YG+P\]UI+Y'ZWAKX')
M_P9WE(4L"EK"#W6+^$$ K,S@'R]BU MP:&.FQ[H_L &MW'STW&W' /VQ6O\9
M+/_%Z#-)&SNEL5-J8:><I##]V$2;:F^H?'R_[Q[\V(>Q_O7]\.LI.=S]0@XN
M.A??=@_PQUU)#G]TXL/N 3W8/;MMJ)#3B\\_#LR\WW]&WV"-AR=G-Q^_'GX_
M^ 'C_#CS/G[=QZ<_OE]]?#=MJ/" F@*[O(4B15I$!:@E!(Y:1 2(^43YW \+
M0X5LKJ%R<K1S>+QOS9%J6"KLV2,F#S-<!B.N*RV7*$VZSM_%'V>0C#X_+D94
M&57X-NEVX\SL@3GO8E!B0/N@[U_G"G^%$98]NQ-F7IF_L99R[?$VV,>3'?=O
M3_DA"RAM(>JK%J$^;85,F>Q;Q)2OI/(\;^L-:B'D^5YUC2Y,%HK9K9R8CO29
MJ?[->X-#N/+K$13ZV]>((L]5+1V$(1"4L>H5?.*!QWQ$/<1]<,O+RKU.7KIW
MV]GOR79UR6NT,V='>QT/X$UR 7I[L7?-Y<!2B=EK2T?4X?#,R4R/M"@&9S3N
M.?$@<^2Y=55?+KAL1-;G&5#&VICFFU.S/8.I?<'IBX2"5W'/]7L?ON\B6=&X
M'FK[M$X3#E8'X=4  OO^XB//WBI%],Y>*:*+&,DYH]RF]6ZL5$>OPU)>N<.7
MF6(._32Y-')I.C:5:S$0QL5!=;#);.F'MWGIMK?@T-92J>7>W^D/\.!VSWY\
MW/VS<_!C[PH4VLWAUSUT\$/^./UZU#WM'L)<OZ"#]WNWO+_^Q>'NP=7'W0-R
MT/WRXP LIX\G^^CTY,N/PQ^'Y]_>?XM/\6=\>/+EZO2O6V%J3T4>EKJE01>V
MB,:HQ;D?M/P(+"O-H@B[=.O-Q_,X>8+K]X \C%^1 6[3]PF_WB_R]*2E\1K;
M_\]-V:<CRA9(&4SPEN<*W2((*#MP@Z@5"4][6$21Q.'6&P^!+T$#QMB]]#U;
MIN.[^2\5D^GAPRU#2^,OK%AUP-=/P-E/G8MA&F<JEM;?3Z(_1/KJ33PIANVM
MZ1GOQ3_L]Y>;)QX>#<O]HV.G.+"26LA-<[=SF+1?+D!M]R5;/37C;4-O7=@4
M6XC24O/T+Z2'=I1*=985_WV ":!&!_U,!_V8M*Z4'PJ?1*CE^[YH$455*Q"1
MVZ(\B#3VB7)5L/4&T.LZHY##IPZ7>O5Q]O71[?8F+>:YF/ M?/R8GB17O88%
M%V#!_1$+8B\,(AG@EF:!V=1B04L@+EL>]P3Q)!.^\+;>[ X%X+;ANIHL9OTQ
MB((MK9G\,?T$=X(YW 0?%N'-SR/># 0BH:M(BT8A;Q'F^RT1*%"4,F"!9%A1
MSV^"#VO1-Y\28('.M[C?Q-06).MQY($%0>1Y"K48HQ+(FH<MH=V@%0HAO$"0
MB%"Q]89X+O(?$70P^RH;&G0H:,_L1?53D*=Q'UZEK[4<#N)+LT4%+K/.FM#"
M&&+ H([AT!GQ@^H<E/JI9,LW(U<HVHSUO)-J7EMA]J1=;_PW6+TT8!YI!5Z
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MF#P*_= &$NV)^K-.(FP5\1A(Z"PO\G5NQY,\!5+2Z:5IH&L?Z*>)&LI!-CJ
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M3_A^PUV/YJZ'^-RKY;1JZ8J:[?BMDY:?&S7_^VZJY#(;**P8R:.2@-FP6_9
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M=[[UTHYOP&Y\];C;YX#)*$VZ]K<29:,Z<.,WSB8FF+4<YND0P\R*%R=?.OS
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MYSVI3;8I>/7@I(\N6IK9=G@WZ9TYB2UZW-4\&Z8Z6U_@!]^?WO)\@9_[)_*
MP \*BL /0NN*_.253U<9^9DFJJ64QEY*=&5.,0LVMY@%>W*A#'_NV/[2"F7<
M%>%UR#RE;>;3%61((O*XXAOKR.:LU5SI8O-I,D^;,AE-VFF30-FDG:Z2UI:8
M=EH/>7.[G<S*NDU7*?%LN3FC-4DLF[UHXM;S4'-ETM6>F-%9+\99;L9F31AG
M3NO(,-AL GY$/N5&Y$O>MPGYB\G#"N1#/L3P^GD_]TJ)S:+3VEPC_3Z^F['4
M&K 6]MR:,-=L4EJI.+[URD>)XZJ3Q9S##;[;H*<*Z)ES@(#]4DQ;,Z7W6#.
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M-8RI'V,_!%;4/Z?";XTUU46<$?RTJK^"$ZD]WM$DX_L$3\@RYUN)-[([WJ4
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M6OC/8C?*T,2IA?-P>3BQ;W' RDBU(L'HO@SBG@(4%8>\;BP.F ^$,?H&MF5
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M*C(*@[NJ>,9,VAI/?ZOS@>!:+9$426MF?FCP2LN$]LK$L]Q@4^]IKZXJ(DS
M0 $Y+R2RT-0"=W5MB'Z GYJ[$/+VZ,.[IFR![<WKWP+55-5R1MB1JVQ<A+D^
MA7S12!5,DZ*R!9=\0I[&/[ZKNJ&4:;(S3;[R*6*^ ?5S@*F!A2$05,2@KBY4
MZ94X?[[N54ZH5V8B8#[4LM-:R_$B[X<=W0]G<(!Q5G06@).Z1O,-5IG"DO98
M3"C.;]*<<M.'8/:]W1"B8-%RJ"[XA@O0BEA%63AHO+B_'"+FK+8QV[WHWNX/
M>.74F"20K5=ZH#GO4O&FN-[FWA*T? +L6LIP[<A?V'Z%UY;&/,KLA19D'3QQ
M]L(&,=E[B#\7&/L$$+\D\MO>4ZR[3/5X_;_[RWJ0J1X;IWJL%I$LDQ1DDH),
M4I!)"BLF*4AU>V>!:'7M)K3C?,-^MB(PIRR^BN5C6Q>5AE5MQKQ,U; HBEE$
M:U=E=*=]5Y6O#/[_$;;)PRZ\A=^LMZ&B/F5075LKE]:F5I!_855B/,(=GH,?
M3^)\4$;OA,P?[]7S/T?\,=IC62[JP-_=X)TUO*M)5T0;9R,Z;%#K%*4B<RQT
MC /IAN*1VE+32%.8-=$WBM1-F\ZY'1>#%NYNA,>CJ*PGYLR='OFXM ]A@_5U
M3>QX*+-GU?#.2$-N*UCK"D^D3"IJU!7;\XW2<'64U=;F2^$M8;S2OU5%!Y:A
M%8VZB%2!._1NJCR>\ <NK/P$&W>3BKK.9=4?GG 53JI*S\V12@[@X6[E=A;,
MG*_)S;PX\Y(SJB,KF]5-RV)N93FG7)3?5&B(?%('(HGT U+$]]10&C%^%_/2
M>(6;+@FKY@HQ+_=8+3L3->SJ4)@E^]8LL57.3?S^AHZS0FK&;^%_@#H;$4]E
MZ:RRE/9Z02KMR% I*VP7E5MQ]QD-!LTJYSGL,+>_4Q_$NU[A'^0=-<;WD@#\
MMH><4.4:ALJDRIB;VN]B2#S7<;&]N8C;"HH\LKKF>GD^S8)EQ_F+Z0"SLCI[
M60)34"LH?CF&25%14 QAI.8[OFSQAHPUTFMXWA:*:UQE&J=U)-I,#M>F>5?>
M$Q##:JE89<]M6$R+"7GQW'^#$>"@.$F5.7BPD+U=$Z^0VLH9Y;-)6MQY7K.%
MCY'DW^*J_G"9;1D@2H]OL0AIX1,C13AE,U*"*R:S7_AW"S]O<[[VXH.MK!5U
MW'8)N*_V6+JRF@SW*XO+'O\\UEY,Y:B\/"XR5%[TE&/]Q724_E0:!'QOO"A"
M<^>"B^^/+8:?FB_PB!^,SH,GK1?3,3$KQ%#!K^P739<O_]$QNM9?O%SN6!>.
MXV/G1;/"\W%M)GCQLFDD:'4=Y@=HLZ3(16TT7BV45><-D859\$GH%\]L?\RS
MJ->(Y*#%'+0J]Q2\YKZH EWN,TETF==0;*OXK9072S%QQOG8P\+^_3W>$PEK
M'_./E?VR_TIG)@'AT8"P*ACTA.Y3M'D#."ZPQ'NQ5+GK_H4]5RUY\37])!PQ
MU;^B:J#%K40OIF])82D1M@?)%W-\L77&>)@/CF'$%T)[$XH<[Z>V4,29.CQ1
M/2;+X2Y#2A"6EA<KL]1B._->62J,A]PL5MW-H"(I^8#'6;?]EMY<MF@>?;D#
MXF4L)!19X9J)7<BQPD/93J7UH:NR]+8,7CW@X%59>EN6WI;QF,^A]+;3D=+;
MIBR]+:-:952KC&I];.GM#:^S%4MOEU[P:KNG3V(=QW'#!VYM&U6J]L"/0!/=
MZSOJR@+\ DHH9PKJ)6O-DRLOW^Z;KK=UT+/[CKM]A-;4OJNN!J7K#.OV+4??
M^JA.WS*V?YLX?=7=_@Y8?=-T=C!7V[6V<?&UDL/DDWMY4I**?%*2BGQ2DHI\
MLHVDLD5=>T.3F;N"V?"^C(SC.%'@94-1FDITAN9>OB =C4 ++YQ]HO[+BQ6T
M[O:=X=I')^SZ>SB\Q7:2RRHN]6WAQGQYC#EJJYS&4L-%,>,N[X)2Q(=_H&/V
MK+9BA@R47T1@PID(3+C"P(1GM1_OIV)ME.-?IH)MGFY;VN%"7&W/+MAX&9QL
M;RI67U]A,@LB(M!^2/0^+F5V/VG.Q,VEK>SVDD?:E2/=@6-UM;U;=)5(LN);
M<UI$0+U]_[%KY-33Y6$>S&$N]4*U85]%2;K[461[84SMUK%T\X%8K\X)F%>#
MC#'E')X;Y,K;!$-#/X*>S$8^*,J&VN.=@*9DR[6=^P'_OW5A9A2'X9#M84?0
M3=Q58\!#9[ RT:I*VX_II]DSVM[:?YZ-!&O-HH]MW9RSC6QMX?CMFAMPG]BQ
M]GSN@XAVG<-%_[R_._J3O-?&,S^V;:.5O"<)[\ )S]1427B2\)Z>\'2KG8BW
M%6E#"AR2_=K-?FK?M27_M>(LYOA/!MK()[<3:+.TNLJFG+,GY%Z<U?=P'_46
MG-"&QN M'N'"*[A=$'BLK7X7;4#!.[V+'IK/PPE3\K!;==C/[#AX2TE]![6P
M5P/QZ:Y4DB#V3Q!MY\]MB3<2CR4 [)'B#L?7O40ZWZ2FVD$+[@L.L /P8-Y7
M,*9-R+"8/Y["#O6H&T5211>IXO!.5%/EB1[6B1K/G$<E<B\Z&[7_W#E]4[K8
MU-C>%8G]PPJEC ]:0%]P7AU@:,/I"#LO9H>GT,ZW8?*15-$IJCB\$_7D@1[6
M@>KN\SY1"=R+Y7/UF7/ZIG1QZ!;UDS4;B!RTK-Y-Y5O3NH+Y+=.])5D<-%D<
MWI'J7;G$Y8FN>*+N,S]1"=V+Q75#FM.E.7W!Z9RMV[GOH.7U;BKC78'\EFGB
MDB@.F"@.[T U6Y[H89WHL;-V#+O$SB<Y&+6OZIT]FZ>V,/,J>$^-2>]6Z!R]
M@XJC\V40%Q9EWZP,HK%R1<ON2MC=U)^UGFH\<^.G-*Q(PG@FW&XZ75&>Y)&N
M>*26]<R/5,+W0OCN>S+]0-K%%^D7A0&<T6QXI\ D8=*3.!_P[- T4D+FCZ4I
MO'4,W<DT\;88#@Z;-+H"]-)\*@_T>1ZH!&\)WI(TGMPAT&X953[YE$]NZCM:
MN:4%9P*[[UBMT/V6U+I-$_(LF^ \VZ+87:F(;7<M!'\]7-BQS?H1=-\N,NA*
MUO2NB>"I]_V_=P0X$FE;=]26V[& ^9TCK:3U0Z5US3 EK4M:?Q:T;IJ6I'4I
M04L]2HK0$FIW'5QC=<5%)[%VEW30L="[ \7:PK1?3J!\4N=^HB7F_GHG]/4[
M5+3<2K[#]1;C^.EXG(X6M%J0[Y'O:?=['O #'@SOZ^8BYI_?P7O"5@.6C%DV
ME]7%SV(/@:M7@XPQY1R>&^3*VR1DH?*1W8S9R&>98J@]15?K"WDO^8)/O2//
MTI7;9@5I\3$=>(OCQ8L^MGJZ;<H>QZTXC(O^^;-H,2[YK\E_AME._I.D=^"D
M9^J&)#Q)>'L@O)ZGKU'>1,H<NY4Y^E+H>&8,J-E]VY(,V(K#F&/ A\PA&ZZZ
M56SW[-O>=K(S]N*SM.[W<NT)-+;5VUP>U"X.ZC W6),;O-L--MNSP1)J[CLH
MM:^VB!D><U:'[IQZ]NU,%YQ7!QC,4+M=ODF>CJRCM\G.NG)C=[.QNMZ.G96
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MG8U/3&_1B<$RCE[_&F?Y6/E[0K,QJTI4Z:JN\00 ^(>JH*=%">/A!#,!>2[
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M2.Q!!GN =:^J'2H,X=R8G4XR(;^B+5/\J[Q8_Z^2PY/"%,NPM&9IY9[]P7@
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MQK;@M0%? 98)ECU+ .VY@-?)FU=< (6STR\7&#<6&-<+%&![2^\$V-VR(G2
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M9U.40#F*C>L;'J-%R@D48!+1>"@VG_% %IIS\DCXG1R/@40F0[@20Z"0G%7
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M@#ENSS8Z6_YKBV4495G4;@DL$BRV !:U@$(UZE%5-X@3 DZ8@6<0UP*P<(+
M5)G+HLBB"!:Z/1^!NC^F/72KUUGR#:@ZS>+'B"9M3ZOM@FA2'L0=8(T$F75
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M9P*!QD0"0I=0;BB'Q.1KK-HU5AFP2Y$2D %[*8 ]:3,&R:3&4D9+41I #9)
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MZZ&4@D)$M8;14E+06B>0X/<8W[E?79F MSJ(IHW@NWT4#!?.( P<5:E7DV)
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M*1D(.F"X0A$NG8P(28CE$23Y&T)N6\\E!<K'5GHN7W#8="&N^7ZEV>GU'M5
MZL:SEKY/Y6OO=;FXA4^U=08YS"B*PDZ)(4J[E+D9N:XAQJ9^)!'(!_U(XHO[
M$N=GAO:X1R.6=UK^/W&C9H2>!Z$;XQ/<O1U[)*".*R84"%@2$)5RB%:]U<!S
MZE(!!&M=ZMW[1BVC*$GNW)NO\7I1=9X00PYAH!9[E4(,"3:.((BD5)@*'$GQ
M#*!Z'3 _=SNAT<]H.3]:7C/Z][:/ E-42:^ =*G3DQ,$2&44T$0J(@-B#)*-
MK=L%/=>GU_GZ26;I^4X6WT>+[]@<_?G[R! 1-#8:6,MX-$(]!5H0"T) RA,<
MC YBP'9N"_"+L)WUR42:+GE[_;KOQB=KG79]W;=[C5^^,#[?5-K1#.V$2E__
MSIV,\S56^AJKW+!T<84IC>/<8L>"D913; A6A$ "O?%.<3^/PKRN%0OP>#^)
M'6.G0,WW]\*^_CW5T_M9=WT[>W;G4J47UX( </7X"$+%$!,6".U3C>BH5G4(
M#'A#!QU/K?$;6POY#:9KL]RE.H/+$[#Q#"XO"2X3/!T>&6RL"R9N9&,LH-IX
M( .TP$-$J4T9>=B4!UIRD]K\S97XYKH?77YHG38[%SY5L.K8GY7X_.U>)2'#
MKT;_XLJD'.0:5<X;_7K=-UWRPE3\Z)?1WO1W'WVNG^OK__Q_$B/\+GLGR[M$
M\_ AJ" CCF'+*:4".JTAB_87-0BEB,/Y#PZ*()I!(9*=LVX*G8G/T'%%7DF1
M2O>7[GF7>%(D23H-+S.?.9A/;5QU(#[KSR.(.%-<<F 4BS:5)P88KPDPR <I
M#=+<VDA\;F?3YK/8C"$9YE=YB>8IHFNX\% @[0BF2 5EB!3.."*AUM*ZC/*E
M0WEVA?*7NT>4:.&X5:D>KHHHSR@P @80O)2>"8RQ2272U_D0.5\CX]DRO7@9
MSYX7S\;^NI/MWT<A$$NDER!J(08HY H8RB&([RMO$.9!X8VMA:OLY8/UF:6O
MV.65KC\]Z]IZW.R5TV[GN*M;5^Z0TI^JO^Z#C:4;\I_U1<NW^[V/G>[7JUVQ
M%R:*CF8(G <"&Q/E B_M[R-&I4H='%/^7P!4Z "4]P9XKJ#!P7-&H^4NEE D
M(I^&9M"XLV;6TDW#*<6SMNU_SQK=7)EX7L"8**)EX9$(1H1H[0$B=>1,&FE@
MXAH!1'G@<46P2(#!UQ,O7I.</H/_)BOW9<OJ1 TH2XZPL%1%%0Z(#3S5$9=
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M8BL)C7*80;?LH/M] G2_'TFE5>"( FF, E11#!0W%@B);"3 1$2RN[&EX!K
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MCLJ&_XH(DDN"/C_U&ZS37O@P7*6O<9'VV@GYM]LN_>?#>'$RT,\%],>3Y,]
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M0:O6V-NI1>91:QVT/M8/\,>3VLG?/V\RC,-/'YO53P?H\.3O>/U:J_:IUCC
MNS0R%5+%AXV#'Q]/#GY4<;7U-53W=TGM_,AQI(0HTKJD37U: C"I"VQ$>:JT
M,)%BL)L'?,0+ :VFR@E$-<8&^50&)=+QE/$A[5RGU.^&[Z0H6SZ'>GO:<VR<
M?/T3>VC@,&Z=-CL7WE>^)8=2(;K/29F_V7H$XZ;?"W=L[_<1C\L2=?$R^SFR
M9*OC?"(+K(H$F08G@$&2 8(@9\X&+:V>?7^6AV\E%W#H) U2:(8ADTCQ%/$B
MR?-V<[/ZT6;M76W6I*][;V>DFNRZ:+([(J26&&]YY0I8(,Z2BDTE9LM/F"L@
MDFRR&0,BY[LEH<O/T2@&BY<1O?E@[*&:)01_L%=*D\:^7^]&J:C&[]5[E0^W
M3]&OQ6P^44+'\R9O#H;E(L\>^/??GL6G[J9O;6S]$5E]O%DS,?Q;Q<IFSHF9
MGH57XDV0=.RRGO;1F40EGK7I:0HI;7<>\5CY2G,CQ@=&WOA"A<Y;^68E4^,7
M+8PR][.7(?6]#+U+;Y#^$7LKR#TJ2TK[8^G](*6]]>&BBK^<'^S_9-7]:KS/
MUU9U_^]Z[212_4]5&E\W#B[K];UXSYLI[0?[NY>'.W_5]_9__JZF9_IT\+O:
M^H!K)__\/+@\CJ__/MG[]('&OT.U,4QG_P;/CR#W 1.32N4I!BB.)H()C@#$
M*46<"(XYC A'5[66R;SR]L*5]-82,Q<M)[*2F+EPN9"E-VO-F+D09EY>8::D
M@G*'/" R(B5U2( X_08(JCT2Q 0J?6*%2ZH0^%Q]R]:V!\1';1O-=/SE?S?Z
M$X==4UGK6A1_+P]AL[K^=C3_'^+T;[?=7IK\ H,R!,T#01<3M(TJK*DF D@I
M#* (0Z"\08!KAIC12$K#-[;0[79:*T+;<E.(-2<E&1>6B MC:F(MQX@$ 4B
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M'OWU$0CB,#PZ>3,^ZG[L'A]TOIY>MB@0DCZZ.0UASK1UT@J/L$/]AW,>:T;
M\G2YYAY&"KB;B("ZBG 6A!(V7H;V8L/Y*KD_- :L#Z:Q!YI%3"@GBB<L\:.8
M^ER!HNG[.XZ"&S: [1_F([5SBY\GFNYB':WA]E$*3&:ZOMLGN"LYQKA]Z)[S
M=[]WX9ZHO.L<<YB.Q1(U7/#8Y,Q\:@.'L3_XLX]OS'H7A3-]-QH+?VQWEK_2
MNB:+PANQ=+*;ZHW[HIPVD\[0..4ZN)8AKJ4_.:!=L)-+W[6QC<4HSU5OZ Q0
M')3.&IOS5)CS,\_S^OQVT83>,"F')X7GAE/=[TE#=_CWZWZ7PPYAT'34F^1!
MIK\84VN='/KGE 4B#@D8O@EZ<'PJ7>Z!N:.\*$B#5%.0.#NOHKWYPBZ'W].-
M]P21F>W)WWKRQR<7\/GI-<ZC=?*5'GTX]V,O4D10-PDC,'@(T2X+2> &"0BK
MP&.)D@G2P0+MIJ:#X<1WYTRY[:::ML_Z[_8['<-P>OVA*N"[ 7R-C&<$FB<P
M(26;7 JYS&N6 Y<"/O9OQ3K#]JYSV!-[YCTYZWUUU']'K-,9 SMS3+@%'QFP
M<1?'O,Z&;0>^Q<] H774MPQ8,G \?%J/AO"ZQGOQ0_C7"&,^\$)T,:+OC,,?
M/544>_!B("I5#-%%.&"9= :CO!@Q>-&P;]V;0'-FSOB/QC+VG),VK+)<,X.W
M*JVK+7&FWEB.U,D8[',VS%1131Y^5F0R8SE\-L6]#5H?+!EC2,4&\N5](?#Z
M%>_M%%];20/W]*C?*\7.+WLUIS5-6,?^N6)*!YIR-PR2R*4TB-V$:'1-Z"1.
M54AU!%?3)PMXM'6A;S"CWI+"JJ3P>7QT?1[&,H@TBURF!!@=/ 0N+63D2BW#
M%$Q&7V#E(I#"LL31[^35ST[O/1CEE4)[6ZBIL>!K# L!'Q=M5J ,*'7F-;GH
M4T:I/ZI2O!7'^@@%2GF9-L5=\_07YW)_?!Z$#$MT4@0AX]B.*'9Y3.$_%#FF
M)GZ@@YU7"P +ZA@E'+F5SW*$!?-('WZI05RQK(-;[ A6M/<VW'2U5O=;T"=Z
M B_#?@YZTH7J3D'X/I<+?0B\2\K,W#]0C7#_#=L"K2^[ FJ'-5E3=:!R9E0[
M\Q/=Z5_O5O8K*$_"*D:=#!Z#T<:E^J0<9OGD.G<]X%J$24*5@O^02*2,\R@
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MO*+T1F XCTT;VCTU!#,9G@?9X&" H \#6GVP!^_LYQ@GA(VG</:@'[O$9&K
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M\X6A"SSHHIY+.>2AGOVM5 ()KIB:XSP5C,W[07G&!760B53ZI9'<"&.D9A:
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MN%S%YE^@UY6$?5-)V)_@$F$H900DSS$BI@I#1(4R!U1R<'/B/69Y8Z5F9*5
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MT2SY#G5/L/;OU5'8LJJ^_KO?NSA1V$]+&G_5)W17X0=_ULZJ+<]:BV<=-M7
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MY0LE631Y$U9,&/$E'"!G7QF.VCH<D%"*(ZZ40C:+%.4E?2V1&ANZ*<J(ERD
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M,S 5OM=2(N@ E)AN9G/ORJDI%Z%3;?KT.+4TM"D#&Y[[JIZT6#K=Z9)_!9H
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M_TY^__6^9*H-C9"*737C?0UI^+5YU8(?L08OM;=+OM:"*S9;[:$RZ@\J@#]
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M5VH-'QJ=WW0.'B^3P/=8&-!(/.!K3OPH$ON6P2,74 &GV!V6OCL,%3 D+MI
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MCY0IG37'\?'+$E7."%^7HGBB3,E"TRI7VV,R:=;@=BG\<, :2Y>P(+I+Q%R
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M;/J1:25R;O8(,QSKG@V!9I3__!Q[%:ZS)*F+?,(_)XB-V4.6>/OQG"SMID,
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M7Z"]7SY>5*"]A[<??AQ^>5>MW'Z[.3RNW)R<_UD[.?_GXFCOM#HBE:LQF-4
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MR--.4S;H19Y1%_OF[_9@FEWCGMD_EG#7:'9*-W"Y.<I$S\AD95$G^F5S4W_
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M/1.#FZ28TD-BNBY/,YZ.'C8[)7-Y68>VP'2>*R!A\J3;!:383I.K6U2J+E2
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M/^=T\QT3=3O-G<HT>\&Y;55LK+$*B 8(I**4%G&_EW?>&KU1JORXG[U?<K7
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MH(ILX#\64&V30QEB .'ZX=6+V31*220!L8HA]M<X25E3Y()GQ$N,+2D2+J[
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MKAXD M]/P_):EL.S=!#@WPMGP=,J4BDY\JGP%H]2@^7W$L4@C8A,*%.&&>N
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MJ>DM)7=3U<L-AO0E79WX\W?_#U!+ P04    " !B@F51]]K6<X=A  !!; 0
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M6Z%5;N]7#%!OVZM1+@=G381D#0;NP&SP7"@5J"QM*2"J@^6U]6;^OIZ,/WZ
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MMAUXGGRGR1ZZ]C"0.)VBB@XD;L07BR%'9=&+8MGE9O !/WC< 28W.\"'>SO
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M">,=1$#7/!5)O'C_[NUT\G'JKRZ JB"]E81;48J84-D"#1CX4X:A%KC,M.I
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M)].%M.?SZ2A<STM$]F'RVV1<$L)(W^5B6MH<IC";7T!(F:<4,<".I=A$ +'
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M,G6\9,Z5(WPQF\%\UC@Y>/ E3;*"_9:VD0Y,1GL74N(Q,.EL=LS$@$Z[=-1
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MFIK:+.#NU_U'+PC]SW_[?U!+ P04    " !B@F5163HB-N P   [00  $P
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M\:B!K@3&GUX3IRO?.F/S;MG=O%<I/W>/=D.$N][Q*Q>,]J@Y$,_I?-G%PW9
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ME4?Y8W];]C,Q.]F*\K  R92Z[:61MW"@%F)1@WGB.T&X"8(]T0A')BV%3^\
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M RN(6([\D'YE0WF(KTN7SJQ-[9S58?&V8$?)WR7%BJ8!][[TN^ W>D8VH8S
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M+!>(C==+B:$>P54$/E[^78^8R-Z$(P\5G^! TV93/*U%M+O@L;8!7LKB^IO
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M)EFJK26%/"SZ.7MKVGWC\*X#7\/,$W/>V25L1(#]A(3I-&FR4/2IQ!A3,\]
M/U3 :Q^Q2?[1S7F2QW@C/BYIW8][+;PS^E808(_49%V#IN\D1+/V$#SQ<<XD
MHET"O#KFGBEB!B_AEF&+.M904[]_XA2P<TN>UCNBLO""ZSQ1%]Q%6K1B'EMP
M@]'6B,@)^+%1E/DV;^.'+\FOLN,@2%?[O=$(">FH\;YZFBKVN#9(""U:[T]*
M#S,KCYLU5\7V$03-I='+1+QHTW9PO=>6+M]F=B($)O"M),DZL,A.S"VH12WA
M O4A(O,S15+2Z9[E'8BG$!UQY.>E3!O8&!OARP4$:]H<AKE N55,ZN]$ULG
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MG37 MXX/.(/^ +SO@)3E><(Y'\ '0 \^WB1@!:SC^W/\>5WWYQ#@__,J*"#
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M=$-$[D#:XXI6477C8Y#\N2O]8@H:.^F:S#^J_4VS_S7%8OX?:?8_%/L_]9H
M)/CY4.?Q2P,X@,MYDJ@-_._QO\?_W:"TSL*[J7.*'+GC'5CH% ^(F7VQNFC)
M]H';Z?F<0S ^O]W/KPB><QZHIBPI_<KU50^Y5!N1<MA*IBIANK8K7W@=E5CR
M>XH'W'Q(VL.QY#ZDTNB.X]_F5MO(\1@&#Y"&[>E'8Y]^F=F0LLVS9MO<:.C
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M@=>.X7*#7ZH.Y_UE/H_LD&SHU-N*VWK>GWPUI(@F(I[Z'HW[$]R;(.TI&?+
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MJCF_#9VLX+\WK$-IDN[[6+"0>W-6S[AO6UR7]I/.>ZOKW^CR@+?[<U*&Y+^
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MEJR+4?%*DULCI^8^M4?-HLW4#O9%=+TBCEX!TI[A!?YD%@@-@% *V)9;-\!
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M./J8B>^2G@YH(,1M9@8EE]\'G]5-Q6:ZK1>I2HM_X,T>_H7ER'BP]K1PXWC
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M)^>HG*U+U-\FJ? YQV3RS\--83S@UG0=#]@ZNA JQ_<;I7L2=LPJY+9K"@^
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MJ@1U?-B"VV^E$?P85W.GU*!4S.%/X6 DICX,7D0<3JI&+ET!OFX,7BS1/FZ
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M]K A#Q",X0'QU]B[D,=/H]T,!68W3'Y*V-,/!FS\3#@XQ7'O'*X)</H1_G/
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MG4NR.1@I&W75HZZT*='.@*_@F[V'8?SYM/YKZ-!F>>(7L'JUR^+J8BM%@!*
M N"NTP.#==S"*:SB:*""_ <)D6RS*QXW^;NVAKM39"SU"3MAW:DKYJ&,'#HN
MN4GS8<=6^TB23-")LV[%6VX^<ITX(9/0&:/,#H/)/&!C7B!8,]R^>!VEBJ;E
M4.H$YQ((.%J&ZRZ"TW/"D2^^=W;U7' -V9K9/[YH)J*>-W$CA9X38J-H/PFV
MQ%+.@Z,&T[T+KE 7,P<IO;M@RS$C4C)5R-SLH<-%LC"[/I[+/2/]WN)C>HI&
M]K&EHT/O=1Q.=LON>) @MY5_16$*U;48AT(M%V;$T-"=%&%XK+/_H.J7Q>L$
M^Z GUF)WISP69BZ7T"",-Q8Y_8O5!6\6!N[F2I3"+)81OH%YG5%4!BT>ANJ+
M33)H,8M27[M+1MZEE,KA*UQ[G%[\\6DYH_A'97"X'0O98!6Y[]!(,=&^&0BS
MT8BMKH03C)!BR*536:*JS ,EK??9GE#EKY!?*>5Z<K^:7&-MDEW/XRW>0H\P
M V0(0_Y[[A0SFP=4H4_S@#ZC0(#SJ?+;+]I<"H560X7"5A<$&:?H^?,_6!$>
M!%7X BWVHFZL9%L>47?0Z-W6^*C;8T<N#+R->=+TTJ';?"XY3+V5G<+9/OSG
M%<L3J0@*#X!<2+#6XH(CO7<LARM<R=!V>07EO7GL$",?-V4@9>O[-&!H0=V!
MJ9)FEG366 5_)[5=J*"=[_76@QK\(XA3R:CZ?+;L*M,5<>PQ3.8*]R(5MP5.
M?L:V3C4SR[D/5YY^\W*PZ,.2BL&"<)'^H4CICP&A/JKQQZ+5GUTXXM=SF*7-
MB)Y>?4L>9=DV,"2[R!F>TI -.7I/4C^K@ZM1-W"AP&JODQK]B/,EJ;?[OU&V
M@K1D+'29O)#"B&&^3^:*D)#Y3L#^8YAVW9DB<:%V4\\MP2I.[O#YH 2_QZ,+
M=H/O1<UL-0(VOSLS,GG>%VZDVW: ([9<T33DN-?PCVDTK">YX!%#ZTTD2RS6
M24JPC?ON#VHEAISL7ZG8EFF2J4,HT94=#DL$F@8D"_VW7@,=B3(,\#H[=JH;
MK0@K="A'U94$;OY;K_P\)T;U8UW/E4YX-CTW\IUYO*W<1_@7\Q;GGJ4"?OP8
M', PG%Z,;S*C6_A7,DV35ZARKF-8[._@\ID6O32-5R$;O^PW=YG"L54*6>YL
M4\Y-"NT^6%LY;PRI3-=1V\%K;N#U%;0*V^R+9E;FMZHEU7C=[<%9"\^5]]]Q
M.OS>)UV6WS,4:>-(!XAW).Q#'CD3[/!U9 1;;"S5\90S7R+1RI9WRBJ35YP"
MO=[@I;\%-)B'$6YV&=>>.(2.NE$B=WXS(/F]UP;.A>;:B3N:(=OD)O A]I?;
M>>V3_7IU9WU?UP*)EI>.=DRW;"6\#;-Z)N["?,BY4VO /\$^/L0#_,D;1N$@
MS"L'I'UNGL"__F"F$G#;USL[ZI9-NNTVAPU!T !7/ GVF*Z,HT+G2&/%M/SV
MRBV3>+(;Y)=D;+'Q3_O5Z^D#@5Z]YVKK,V>[I=N;0HO#[.>R'0G32*\8 EM0
MEN)@RUFV(,-YF/D$CIM69$O1W%E[IGK%\3A7^1?WO-:4G(,/KJHG:%P>>YNZ
M)Z'I-^W\-?"8<MF"*LO\.RAZ 5ZL8.,A7W+<;R<W:F>TYXY:TM%<U]0G[O4W
M#[U]L77SUZS4"0A-(H@SS%KKB69PT+2C=OL!M6*%.V6_D%]R$Z7]/AF?/\KL
MW?=.?6M1+KL364&-%.@H6@!L.3T+UT'JS :8,EU(2D1J:V4'N8VXN<_X3U P
MI^&IR@U?RAG?2.>SM9_?>AY+R[;RQ?DBX!!&"5R\ ;ZHG/=E@=\SZ")U[M@X
M9YWG>%O'QF[WC!/6Y>.-P>]%J[N]?5]*?, 8\;&ZI[%C-4P/.(BQ87C*M!T[
MYO#V@%!J96IL6ML!:OJEBDBQ#!X0[MM4_8S46"\[5Q>EIL% )[%5'I[#%W9P
MMU7UUXY;BT<^#G0)$-@<?RA^:;_H_6PA[2<;*#F5(W]H*+:T)/,%)YVK2>RC
M0B=1\([,TE)B/W'WX$K01T&#RN<J\_FBB?<+?E@WQ<]\Q;QL/N>U_6F1^X8O
M*W/S?UF^!'O.,Z0E]&%(:BIP ]VL NL*>SP^..7N<73ME,:?'^6Q)5_'<.'=
MBD-3]\\M24\8%M7RL2JG<6/=3!?8K]1_;:X=',-.\8#D^:9#=GT&QA2ELV/6
M3VY&D6N:JA\7"I%N%N&?RW!%K5F7?J!?D.;-IBEC;8ZD(U_J)"7A,/?>33\.
M%#VOAWZN6MOF*K_X6Z)H]J&LYT.90.P4C&89@RVB7%'B  CAL#?0M%)0Q5(7
MW^L$9SQD&S+4ZFAV&ZN+C_?5OA%UH.IBW,,R7FF9Y#2JMFV<VZHKY/?=4I6M
M-@"&\ #8R U48D<P*"F:S9Q[;,<*+*STK)+>WLH_VQ8<=C'5)B8BDWODM(V-
MTY;SN\^,6Z&>@] A['AE)]@PQY9)>TM6;39EV_09XU*49SO?1-*#3>W\M\4H
MYGL.;JTCS7_.[NNL9[R]@=7[\+3G4\]93A8V"PWY][)E!FB4EMX1[/KR3H2]
MV[D[R)UDA>58!T?&KCM@S*4QCUIGY9656OU@9?=GCSOT;[ZZXB.8=G['5LGA
M0&#'P]3_)8-[&<EN#GD#>NH1P0 I<6]XFWC6J\9A_5TV.<)*$Z#XW V_VFEN
M\_8;7+EO9.A2Y=O1%>KH-'.*\]C83I7R O2S<&@=B^QI6F3YYD[TO"OA :$1
MK OSJM;@B>430G_*D/XUPDEMWLJ=I$"!DAVD>)1P1,.@.3: $<;RA#[=4:!2
M7E4YFERL/SAI?T'&)J$I,Y=.V4BA/4=PLO<Z&L)0-W%[Y!%,LT8E%>ERRIO,
M-,N2$KO2N4(_#B1FENNYB"D5+?(9BU3ZI!#JD_W#S4+VHEZ#3P+?(]1.\BT5
MN@6VXA#F>S&'4]> 8U*8$=C SHF7?Z(6._?]&D@%V,>1Z/\$6PY0_ U(%.@0
MF$"5;C)EJ<,8I&8SFN4]T"GF%Z"<*6QR8FE2FO?C+G7/BKH2U_:L_?5YD1XC
MVV=7-[]"[T>:ACT2QRF<+-+-U@.Z1IY_ \4PW1BQSRG>I0%N#5T4V:\WW&T&
M@O5^5TQX3AX)F\$0ZL>/E"MA7PI<_XWJO^>'!ULM9:""K]J)A#UE ?&_PRU&
M!N:+KSOJ_%Q\(=X3BW0*]@^PQ0X]BZ&.8KD?-A;R@(=U:RN2\*[%^61&6P>B
M)5 CC5Q1%,L2=IMV&20*POP'"]NCZJ,JS,9''<I^-.RF'C#04M2N;;_]O<$L
M4TXI>3%28,-N:P!$DQ5 VK?><2Q7U(\A0UN=1V200"1L30?YV-9?(F_E=PZ[
M-1=>>#JVX"-5:V5^\O&+M)B/FCUI8G'*YPWV3X.TZB(M&&3I@"WOU&0Y#]&T
M)RC!.EP*EG\&"KFG%B?8F:7ZY=Y@:,!%)27]$M_X"_*/!C":3R[Q[0Y[IB1'
M>< #Q/%";YLW%=#G6KBB_1%W=KTS#0MX?>F$T8STP;!4TTB+6$<'.DX(=NC,
MLW\$=[6.154$;WEX=F'%3''.^K+P)KD6@%9T]8\5ZA-JOI%U&J\R7<96U84D
MF<40:7[Z,5L3]J9/;/S9/>6<^\P_-"#9J7_\T)>([ICV)-3$]H\QWYY>U]M3
M&V*!0:A3BR4X&XH9<^"V<T[Q *O/Y:LF^_HUI([$G;$2?;H;6"Z]OXETPU*R
M#DZDZ>/>FHXE?BQ1_I857O8QTD_'_H']0__NSK;<RRI;,Z^+<B^!%]"P+F8!
M086-DX1@N(PE#;98$3?@R[N4/<OH)E^,/MJO)*?27;\(4IB))0T[WT<'A&\Z
ML25)<),5JO"JY(^\*K8OQ'J+EHI8[B=NA=5MAX.]8QGC00=\7)S*0;Q>ZEO4
M58 ;@Z;=XQIS[H.T-VCH,BX9I#TJL'VK0A9@[X$]<%*OFKTN9AK5UM_1U_?\
MY:79,3/0^R;+:FE*Z'&Z82A5NK9WE,H5!I&E7PX//$4"X(@^?\^,WM4"IC6L
M)370++ G(*U[%;$WSTT:SP1??'UC<_Z-;OUGC.3,@W4:LU%"W%O+L0JVT.\[
M$FE3'*VQSD\3)NYCKF^KK*77=N[@LWTA)Y1"T)["*OV@CG!W0T/DIV-7XKC=
M3UPU&+]558+B]UKX\R_I<H4U&0YM9,B)E$I1:M:!M;DB9I MC=HB]>BGLF0<
M0LQ02?)CIC=6=H242!4J[3K?<VJA7F)XXV8I#?]3WWYA)1&[]Z-QBV,DKG@%
M/,?PXXKT,L:9>QBH=EVR-'S+ Y:@'LI:*/VR>,:QR52^['W^@O.PD["$MR#=
MGYE[\6LYQ^#'6,B]XI'#I0'RF\?&QCO5&^KK;VB$;J7M?'I-5O(@]KJ;4.<B
M? #'%?%C-':2Q>HPUR8U.4_8JN%[TEJ:-;]4^'WI<^]2O_T\S]W4E1YML^%L
MR/Y-"0%OO]*V-+"5%Y\3 AEHMH(8LYQANK!M:KG?<FN@V\::Z&G'[7M%1P+#
M\/&COX.'!9/4L^X  M<4E"R"FA$J@0)GKK%C$9W09LT#^MU3F;VPJ0I7I('E
MSY:%NQA="&PB>=L(7;*4AY,9C6>R@W!B.NF.P;*KV5B/7CW_W_I#]D6:F=+C
MGR^8O?TP_$L.("HBD;I-7C(F#H/,?7@D[8>'RI%628O#UI10ZSXCS;" V.,<
MS1CS@'_VLE0PC7>SMBB<.H>/VYH%B8Q5W_+.?#N\[(CTC)V(6>#"7Y8$V+(7
M[0O>(%?YL65MN2(B4U@Y8E^1^)<5#2BO;!J5>-7DP5SOSF^*QCJ+P,O-'7OT
M*A4*JJT^R(3PFU+1BMO@E$JP!:D[9<O=!%=.$E&>S3=L'N0;\+CLNJ4\?JO_
M9H^S&9CCF9/,G\-Y]K.B\_R&*(UV_'M^IM]92"&NZ?"S,9B$A2[FQ#X>F9YW
M62V(./D1E_#R4M3)]PF] N%N@WQ_U9%F]I<'Y)H9\P"6"0](H:RI-6+-P!:]
M)A'Z8@H6\B=U483P"@=?#:[8_S8_I?\F\:Z-_<7-I26?I&P<ZM^-) +9-D):
ME-CO]R4[U]F"&5?4 ?HS+31_!T&[%F,C'K A<*A($W:X'_CZ([?1K(-I]BOF
M8]B5SUY\:8NGKLHU ):>A@6<F\]Z)?$&+9-2V3^QHGC,L0$U)M9DI?:7\)2I
M9&_/+#!YQ?QND6- 'Y^U[(G_U4/(@(&;!EMPURR52)T4U68#/+;%S6@X)4"B
MDD[=[!Y07WGY0\^+E!#5S:].1XE*V-GLHPW?&T.\.XK4QMV&89$ 7Q:1+5/@
M*B&]HWGGCTT]L8#"?N._+!X@5,0#/NPP1[B#;YL=#QBX6.&IRU(#6QY0(0QV
M#,=4AD^Q#@>A4):& 9XZ< )4?I"ANH:TL&,%L14KS$+!GK0M^F4BFW0U2G8J
M-00#"MK?[DM^I4C I+9)@\_Z38Y3%E>[3P_@O*1'?RI']F,$OE_=:W>]7/*R
M77D=;($TULL$)[B<UIN&JO6;-WV"9["M:94"U):8![VRZ4-YJVE7P@/,Z]]F
M2^URWC>C>Q>E(?7>B]C#*4?<^DZ%-4WG,UA6@>@:<BH;2U^4#5Q399V%DT]!
MF.3IIH'E[M+@ZL,:_1BEW.+]DC//'IS=.Q>6"Z >UKKT8%4HM$KR"Q[PE@>,
MI*U3N!M4/,N)@6H%I:CN8S^XZE >27/*]O:'I[XW%O!1W3*'IM[ZW+KN*[3U
MZC%T/3C/0<_[H'&WV9Y4J +3]F?:8,$[A/#YD1BF3F8V=M'4KWLV=H$':!EV
M %=+Y?Y(MB!(LCIOP6AD;ANFT!Y&>5H.$O9#Y+;\8?G7R3>:W(O?7_P$W?[2
M=#MIKC"B^MF.QV+F]Q\^V2?4"OI4P@>0?NK$PK)C!RA^2.E1.B;EAB*[5ZH@
M9(8,-EKU7M*3B(7Z?=X%^V>7)@]?0P#ZV\[B;^=+^)=/IOX=9B)",+Z4^PXA
M9-14]*9F:>* VL[!B'L.]$_EFLF)(><'CN6E;,<$B;WIZ8@?[ZR(%MGU5? K
M1C1H3C*9#$4LLJ4-Z=@%LP#67G^4C#E&+/! ZX^K?IF1DA)7E 6_=%/R%65J
MB\+47XEJ9LNF^QCNK?QHA2HV<OG( ^H;V'(N3'O.M69]MBFLS3K\2WFAOI'A
MS!Z%;2QTC\0\+KEU[B"?].N;ZBJ_O6:8&LQR+.2$AG56YY'\"KR&8^\3'#GE
M=<$AO4<9NZK'///6M-*'GP^+R1P]O#.K-OA4;P40*VZ-CUY YA*4Y]P":??0
M?-Z<AV @]H9D\?>&G-)ZDF^ _[#"6$7W@\CX2<%9JK^>_<X;&UUOA7MJ(U,@
M*C8A?OTHZ!0E)9P@"RO0*5+^EH;R_>=^<!48GTBJN9]*-P6Z.=?[/RK0.;I#
MS_N/0.'AW2>?M@.QC?\)R_Q?+?L9$EL-T>X[[D,43KXXT@D="^J(IXE#U!?1
M;'E^YOJEJ_-L'4Z=#)/)F$MI%H.[6PX(#%LJ]A%BGQTIDJT:U-L68^9:X8G5
MGF_1=#A_:L9YI- JLG+< -[?R)3E/ 5I#[ 0)D.(!L['035<:1X@.THX/5"7
M=L^ %=:%&?65RRR6S?Z;7].FU-:[>4RQ:N*FL #I =H/._*S"Z&L]J1DU O2
M@C?MS#DV?U^3ZO1'@8G#AN[GK(O'Q[YVYASI5<K6<4IU4-DMD?J]"^@3:D=#
M=IC$=>B9QR+QEX4K6 B[:CE \*B $]J5>ULY,>V6&@R#&]M2+9SU<0[]OXLL
M+.VV:YYW#XB^/;V)U32]-=I5KOS/*:YP,F.X%10#O=$HV*4=T1>'#%)1M?.4
MS>:V5X(KV=80-?[1(,T=4]V:<-PAL?INF\:EI9ZC!YI_7??^\ !U%9E4B$++
MHT G>V%M;!<N@UR%63"%C.NHH\5TQZ+2 *%T_2;W4J.]QU*9#$\QS4;3$Q6S
MA8HS6-VKK\=_MSZX0*<(H;T1--DOR16^:ZG%19#E!>KM@B2=W&:@$CBL4"3#
MN$L*6?I1XZ@\GC:25;G5)-_SJ)6&?;\=?^NSPEM[+HLC!V_'S/.S7 F!2!KU
MB%^HT''L6#(SC('\*>/:>(#<IFMPHUFVJ;_ \:@#UF1C\D*H[1OUIH$%5>8F
M?G4UL8*_-N-<T8R*PT@;?>W $HYMGN/*)##2N)N-!I*((T9:.2S_9NH;DEED
M7H]?P/A *H>*G%F;^YY23YG/8BFZX3%<47Z6+3Z-CFK/\#L5:_,W<E'F8SE)
M<OS6D;3CF=^<O76LGOU^FTM5WYEWVAG74TB&3;J9>3E<"2D>D+A,%J[@ 5,%
MA?3'C'%\ E=:'/V!6L,Z,A*;T,LZ3EW8A.#/T_%9U=%QJRT*["VN$ XI&,RZ
MUV7SL>N?;GR.=ANO&%PM,FRH]9)?=(W_K$7>Q_H9LJ);!LS=3'X:OP\+[Y3%
M;D9?HHRJO*74+,[7((Y^91-A>[I!\M728CBZ4YXLBNOA ><SA5+= SS%#^S7
MVKLGU>MW1WH63ENOG;LN"%K0T%',9N2)"P_P\N=N8>L.7KK$W08;GO.(;L$]
M<9AMN<H]U6&1GGW^;Y >+C=LMT:2?KN.ER5 :@&A*,K"9X,VR5%;.C$1_398
MX>W:77$Z+EU-E2$=L#J6'FISWG#B?0"XC8+3OWM#_[-7GJVXEJSN?2$Q!%A-
MS\)MT\_)B*<+ T3+[V-Y=RKA[C8#A8P(SJ&)A45]W*ZNY,29DS8T\Y//LNV>
M/>/7W2 LX.*!')E*?(>MT9Y'Z(XV081A\)825R0/10[ETKOO;1S#B/O?'*TY
MJV*PYT)4RL&;NE:ET=D'_;;.CJ-M$2<1Q>S  \:QS&YX%5'!)*8+['YE^I[Z
MU/'*B$GCH3J4[(_Z!GF&2L6V["O$T5"Q<V:ESWYW:GKG[@>J$_J1$_23H>.4
M<117U)BUAV $7V$I$]00*=Y]%N(!),W!R!@T;&?$,7M7'Z3C)8UK?IFH,G?>
MY(G^I]!,?_Y9$KR_^-3K01X0C*19>[+FZ822ULLO%PJ^79'4^_C$OZ<',YCC
MT<56FPW?0$06S,9+8U8:.?3@[H?>3Y_?VZ$-Z5'N735E;XE$8G:/4XF<!GL-
M(6=$0VZ7I:KC*;I!B\G-<_A L^_;7[U*C:@&383N7,=H-@T=)52W7?TP&RTG
M2MWVCU*>3(;"R&QY0YI! E>+V(^J2;X>46';,D8=06"WK.U /?E1KY'A^*NF
MH=\S38-NQKB]DT.RUQT:I1OUG!Y?O,D'TF8IJ<I%#0BP9'/RB)OA+EK(&\:I
M5DMY2"OMN354>:C^RF]S!XNA)Q&[@KU2I'J2\,LL?]=#53O3=?,Y%6PGUDEB
M/P@Y84>[F6V<;)"6 *IR!7]2)<Q=_'B 2.0$I37XD&ZLVWN#8+=MV\?/'DF5
M1M5;JUM&6^]]8G9"E+7(%9M%HI##J0 #*J792AP*A5:TY([*0%[D?LCRSU>X
M:;666RN35AZ^*>=%8DG\]$<M'46-JJ]VAKDBVG>Y'Z@22!1F*.,\@"LJ@K#=
MWH4Z)G6T=PK7-G@=3FXK$F&(C8SCGWCG?XKQJW883WYYY:L&3J/#.U5U$MM[
MDX:J,7*R!F3_,\=)LQ)_GZSXI^DU,M<$"4'0*:Y8.&LO(1P)]S[NV*0T))E.
MGLI_RXE"4*^)L2DJ[SG!@7G$59-\'&..(_G<K+YSS"?%Y8$ (%G]O5*1<XT2
M0DY ).CB:)H-YQF1/T"90TJ*'._N#C+#R8Q:X_"5P9>92PIVOKF @8I4\G[%
M3P=<:A"R+O>G@2W;RQ7%L2S!%AU+_A_H6O2"]GVXW*FOCJQP<*K;SGQ;V<'(
ML(9PMXESY7LQYCO51_UV:.PQ2\THD;82^FSDK- F>>. =D=E4I$J_&3J=HCW
M ,'Q@5O@&"$ZZVG/BW.'<FQ43[_8)-=II<%?A'%C+,(ZDFS9:!J:+3W-C$EF
MYG(>UF)D M50Y';GL9T'IRPLQ0HK:S%;^M5E"_Q=+FXCW!M]OT7MK1K'FH!C
M^8,MH2"".R,8IAOLQ/(@^$!D4@A[#X-TO.X-5-&0O!QDOW@A,T9Q\<2YD@:G
M$K\/N0>%%__X^&0&A3,1%17?2NP&$9Q1(VC#T0QJFZ=1<S/<=46_(1';=L"Q
MKOU$4]C8D<Z9[G"I])"F-!5^"-7GP__S@^XL>2R<*[K(VDU$U&8#K@T%:Y/;
M*>+PI[DNM/RVJIPVE]>6N<&["H4;WQ1\,J@]NJJS74I#POT2+G%K>K;56L$U
MT1T/_W%4WJ70R"CH)#6! IWHA'.G>  _;.L!-:02I>%OTZV3^R!2RA!?C&^X
MS $]ZJNLP3;UC@.Z/M)#2QLV\FU%V7RVE@6<_G,&'V.8K?"+>?\+Q0>$-7"=
M8*JGTJ#;L%LS1(=CK NTQ[=CGO2JIF0;CDYG7O$5JDJS*)^3'*EL*1+CQ"/+
M[<NX@0H^AS:9.!T4T"SA 5.Q4&7*MH]Y%$[)1T+5N6L2,[L=!6(MYX-<0!HD
M'"D"TC*'^UV?)>WC:GP/CCH!J??00IB3IQ@=D=0ZG]>7$%(3=&9^;<]&A-[Z
M>*A6F-PE[?A>WQ@*>UTS[Z*AV'*ONYG(XD@(+>2*.D%B3&-(,N&4#4,@;PBU
MR?S DKL_0XEPJ%[:KA3PO?C'S3NNFWP4ZDVA0A%=;%FR&^?>,C@NQ Q!:@+;
M@FX-UOKP 86">4![7L'UUS&!I-G209/LPQI>.]1?@C4IU(^"C)<ZVW0_+./^
MGE1P1AA<"[ABG-3< "5EE(PB3??NR9'Q@+X2;2:^^>4> 17"T,L\9P*(?^<P
MQ^HRXEM30OK6+TX=6P%IJ#*<=',1EA<L>9!L7\W(*]3+5[;HH;L,_*:]S!O[
M]O4E/]Y^*O<,\_F*Z+C-O.2G7MC"G>OD2T.Q]HGK\H!C5V<1]L96!A%:?!0.
MYP'>0C<HRPOAGHB($RH'/^@U\?, /[Y2\ ?IW'U)@0&DDZ/A';WSLZS];&-X
M8LH UFQ:(GX\8))<@K]B'DJWJ[SP>JA@<M+,I4CW\4A+8+:#S+.8A[GV?-$U
MTD+#9,@5!^M4S@\_ 5N4F_A95P/0-4()S29X]2Y/G<\S_4V:#+7AR+K:'/=)
M^2M2T8FOXNAY\L!-E1X@ZWWTPF<Z-0Z!$"@P\5.=7W092O0K]Y.:2D-?[M&_
M7K_>567V;S5L3XE0]WASIF_N9M ?E>G2_!0]I) ^8A.2/>WE19K-SMF7/+N6
M[JZR@,LJZG3261BVG.$?I=!^4)0"T%(4VDUJ%:E=G[]%.3KI4N2"99M3-329
MV1AL=-NO3W_6P4[(_Z&SU&/N3]%Y-.T7[N\!<,2 VRE&Y>SJT^U>AP?,WX-E
M\TAJO(@I/.#QQ]*KR6Q5!+JU,2Q!I,6T(,JC=$P0B-5$DK:/4TN48JLBU;)
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ME'YGV5/M_O5&?JB71\+\"<EG( TA/) [ED2NYP$+JM.+(R[,&4XV=0K;P0.
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M=OK7\?PKFV8G3\[D;;+33$'AG*Q0]Q#690!O-66;HYC*L!@+J?&VLTB4U7F
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MB^P??.Y-)$H(G &1AO$<69S?Z^]+^O\';H[?\(B".*1+75M& /J@,5R!K3N
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M0F [<>.0L>JF($_%M'9ADZ #H>88F6#/XF_ QI-R-[QK^X0^WW*R!F(132*
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MIZA=H!Q>S"ZA:\WT!E@[2SKZ9G=)=:&]IY:^C&V>2EA+L[6BW"B!P*D#:8]
MZ#@%8*/@7ZRKUA#.';)8;3>%5KL\3DW5YSPI\51]\<8WS>'+^;S?YT_N>&06
M<KCS[X0B27 )0!_<47D+L?\AH@P7.RKC)_?"MJR=Q*ZKV.25RG2TLKESWMKV
M7\SJB1]K6G&!\L&GW%YGBGA%I>ZX_/BA]>22>&EJKF7D-&5LD2N:Q7(D]E/E
M+676OV7.W@8%V4-E+1;'Q87<&=J=BL;V,PS;&\I#9D^>+4AWVG74;BZIZEQZ
MWY1_^;34O?LH_&<L>?U[KS?A8H8#4Q0^B#P28)42R4R*,CO&X%H$:@,^_T16
M[4<9SYJ"GQ8G?_X^B[ZBF?%T%+-GS[W?I,VT')(M)X4'!/& L1_(+RPB"BTI
MM/N32M 6</,R67 </]S2K M?S \-L%3OTWAE$BZ#BUIRP(7BPJM-!=]=V/E"
M%/ #UI;^(Q\<Y:)IKY1M4U9Z80WM!:D+4XI:V1!AUV!I1,*B"G[ZSZX#D6I'
MWV?]*%@!1U4Z>8#X+HKWXG6B!E3?6#8.@V<A^6M%*C>_/K0U"AMI8^*+W[?M
M.2?HE!T:YYG_S'\-<R,BK8+?<^#\FZKF^IB8<;/'U[,P,D]<,KZ\]/75V(S?
MFH7-XP$J(&UR<0SK#CL\)79@ 33M8=1KV_D?CW]I._5Q4?"?J1)E[@/:G4T5
MNXSN69=E^@C_YCH?K3V8J73GWFW^?J2$F[= 8 <:UB&Q96T4H)6D&H@'># J
MKR^+31Q8FMBEAZN\ /UH&-*?28FSW[LDD*NX.?I"8A18G9%;A " X O.T]J%
M _VZ,3%@(G;3=+RPNG#6PT>U<F=LU_^IRV6@ H0UL/.2C$:N2!T-I<+]2#1A
M-"298VFCYF>T*%.26]S=OW;0+<+H?V>R_ZZTJ)N'G2O6$\[IG/M(4LD5]7KC
M/A4]G\P#1,>9DW#5^N=SK:TL'%M?4@P.LD5X83A+NYO;PWVO4/R195LP&5W(
M[&V<?=1K4/Z;QH_BBG;P@!W5G%+*/)7MRP,>F7WX:\#DX^0B]5^W1.Q%"; ]
M$*TB>!8Z313$"<(A2P;"J+@\F\A^XOL0>M>"9PB=+CEQ9>03\=+%YC^<9T1!
MA!Z=(':CI'G 11)\%'R!D%@O GJ(L(?3P$0AI-^/T]P9A*V]8C;]AT Q)7[\
MT1ABNBO,".U7F8B"'G#Y\"A:-'.56<G>5B0Y8&2P@*G^B[K$TGP6Q8W.?\5^
MP_5<*"P,"7TY;<2WU,56:*-]M=S!N59'&4MHO=K%-&A'C_[\B4Y!29C;;S&;
M_,0#CEM>NKG[G<$F*&4[_OU8>_'NX&LNX8C@N<8I6.X='6#*07FE,<^;&Q$0
M2[DLB2+8,<[T7/ ;6EGPD/[]+;K+=_+F_84M.E3C']1ZROP$4J")+'6V+2</
M/66(Q#::*R^4L%AKL$"=7ZSC)"Q(&1&CL[[9?EN8N%<XL*]SRMF('&]I "7/
MIP2S3-F6\..(#- !#BE2[F.'O+:]?:E2_87\BY_;AS^JU-N5F^9\2U\8;XK]
M"< -S'&85($TC?/-^P(IT%&#T6SZ1?C,5'!4'W>0*AN<J?\P4R0[=,K#THE;
MO^:78MWVW'F"S_EK1W'E?21SY2A)MA"238%A3C$[((#V9J>%US SD)&9'U2N
M159\E=3N/XQC^N:'K"1?%I]-:-BZQ<>E&U5CP)8RY8HVLK:PM[V I5@F8,N5
M"O:>J> #5^82,,G,$Q"G[;U1OU'V1Z-5A3!'\^?S]MDN4>:;:(#E$J<$[<=Q
M9Y(XF808ENXOZN;F[MAI:M+5LD0#@@LGNW+F8TQ9]\55BJ_K9A/E4]K9J@<[
M^[H' 4/F=D1R&,"'>8 /Q8H'#$3(_5CI9DO!.*2><33*=<O-/  AI0%@J^Y4
M+-J6^YF%SF%6UKC;"A7._@XNK \9?U5UUV?:>/#?ON']+17"Y3TH^0Y6VW;<
MX\>^2AUN5U/AE)K'X*9[:]_)T08WEO37'+.G_944^1KZ%N66QJS[$H%=_U84
M >WUG:LVV7(EYA'!!$XNAPMBE+ZT^3>8R+\8^=!A/R'C(31R5=[<N6OA#!+K
M GB\G  R2 N(E!)8X3RO:);^A98UFJF&W]#(TK 6M5U-B4$<2=>-U"_IH?B]
M6DJQS3+\5BFPH5_)?)@K@G1I@</K7]G+0]59D#K($FP"E-S>*XFO:?WSO<BR
M\!PTVWGG,=Y+MH#.'*.V,;J,^CJ\5O?:5(^]LC)).<$#NHV!Y<7QXA9/"<B4
M+7N*N?T%Y')]>6([0J;3B<:#E0_ZY[WC0@QV$?8\<0P-FP(D]:H;[7Z'?>HY
MFWT\Z/=.!FE,FXGD(?$ORY8MQKE/F;H KO>2/(9-Q3/0!_3YBQ @='!_B-&B
M[L<_I^99YCS ,.J]Z:7QQ$]3\\M\\!\6/[$7"YW!IJKMYSQF.["4P)8CYKI0
M0ZL8RYMMG805#T*+Z$>^*F!$FK\/9:;X.(M^^'SM]ML1S%7.SC><.ROK=Z)6
M)?;./V$%X9]WT\6I*>:J6BG3'\.Z;1T/6)RT]];1[-F]:[;^O%W$^+W,IV]G
M1'LXR11O+.QM849_1.8!8BBN- 9V)6\Q=V1(@DST",(]P+K?\K@7TY_R/RW5
M+_QI=OS;FW=/=_P[_](B5[R70VZZ\/0P0X%9RGG8O./C-&4+C')[!:-H$YY+
MPQ?ZD=I_?_UHUDQ.\[?PN:/MV<<"/CGX?:?".ABVK%@GR%_G(<,TX&0T&2ND
MHP,,4I@G*^/8YI>'FE5KWML3#CZM%X[_('GGUNZ>?NV\^^SVJT)L&193"U$$
M\G#T-(X/;.U!.D@95P:5IK:543F&.-_<QL0L.)#1\X6$'X1>W=]_7WEPH@R.
M_O5>_P\C%'A'?3+K(OL<IQKTDX3U:M6 +Y9ZOW2,5TJH-4E9SS'>C\9G]2(&
M&RE-T4OWD[U0^EZN2J;5&SN!_1=8JO[8%T(+ZW=!#W(*(GIES@4Y>ZH.$37%
M8]I=*+H_QU86DW?M\FV\J?JU.U3_L[5&=9+UUZ@_\U2Y/ <*O"]H:M,!'<O8
MLGD*_<Y*11GWW+CK0+\>X^V?QC5N(RA#H15@:W%=X*AN*RC1;,ZENA2IP]/0
MKRY=^B("3*KSEEO.!AB4!>XQBE><[:_XVF),R=*[Z2!U6=.Y.TPP EVE,*_$
M(-,6NW"*Q%%TO<N"JA_#@3Z7UH3VG>J.=;"%6G\H8Y-K=0,\(P?F%]CO%5-V
M:03,9HWKL2YO[#_+_]/MW[C*^U_CO\;Z0/-&_QM02P,$%     @ 8H)E45M9
MT^+*-0  [T0  !,   !C86@M,C R,# Y,S!?9S0N:G!G[;L)5!-?MR=:B,Q@
ME'E0@H"B,OT=$%0D3H"(B",@"!$$F80X(2 AQ:"@#$9 05&(@H@*&&6*("2$
M444,@P@$@22@J( D**$@E<HK;[_W^GWWNU_W[;[W]NNU^A[6SLIPSJF]S]G#
M[U>GD/1+.,#2?0Y.#H#4(BG@)/H'2'X"2W;Z$_P"@   ;5*206 WL$CJ3_OS
MNNA/6RS]YU5F\6+IQ;(RLK+_)'(*\JC(R<K**\DK*/YIZ#ME)47E/Q_^3/)?
MABZ2D9:64923E5/\'VZ2!F"9O-1-J=_24H; HF52TLND),T %M51YI_4DP+^
M[R:U2'JQC*P<JH82VJ%J*:J^M#2JM RJ,?IK+/H[L'B9C.K*]3MEU0[YRAF>
M4]\0G_%0WFC72Z;&X2Z^\4:_\PD*BII:VCJZJU:;K%F[;I/59FN;+5MW[[%W
M<-SKM._(T6-N[A['/4_Y!YP.# H.N7 QXE)D5/3EQ"M7DY*O74_)S+IU.SOG
MSMW<@L)'18^+GSQ]5EY1655->U53V]C4W-+:]N;MN^Z>C[V?^OH'V%S>Z-B7
MK^/?OO\0S/SZ/2N<@^87_M@E!4A+_3_M7[1K&6K7HC][(/?'+JE%D7\Z+%LL
MLW*]K.K.0W*^Y]0,-\3+J^_*>/B2J6"T\3!?P^]\EZ*F\2;N*L$?T_[)LG^=
M80G_4Y;]OX;]5[O8@+*T%+IYTLL '""&"U+6 /\I_RG_'5F4G$)TY4J Q5&G
M#@LHJ58>9S:5&3:&#AU8X+Y<45^WUS_38?OM8TYVC8R\.[A@/&1.@Y>7B5R@
MX3ZA"C3^!-:"]#B#TQ7L$_8\YWK-(3^_X1VO<UL\><(9?]?U#_4>7@F3.[W[
MK6B]!) I_E@E-D$43$0./E'!]T](@$9*WRF_O#V88,/]X'2/$]X09-YG1UZ=
ME "<C$CK7.5SJ>V,E(7VB3-QX=:+E#9YMR&OS+;'Z (0A0M.6:$S/I( B42T
M]T.*B@0(I RVC^97"&*XCLVI$.?XZCZ"U3<+L_=OE>=TB;0@B["?8<I/C0;C
MEC4!.U6-4\6*$Q) E;X<.M*L"UZI.S(J5G/IC0A4* K.32I1MM8J]5BSS&%2
M=Y?'5:F=8SS&8J*W!)#+1;KR%;+[W 7CL&IFS]Y+JO8!$240?>;S_2F+)]W!
MH\_5;VZ7O:SX$.UZ? ":&-6"U=6$N&Z2WD1/%-B<;\D7US]/?>KYGOE[XG7'
M87E>QO*3">0U*^/ETM)T ?$4%"P8Y42VIN:YM7.F6PF*4>5ABM.3M9]]= 0:
M5:+@7V/D=>>D7UZ=*=U,Q[R+XKT<$S]G!,B33,@)&TD](QBUUJ31R=%&E5$O
MJ6<Z%\B6DW3"O=>V88.Y<*2XGG&*DCS"/T. 56-XC&L,/W(JR:)>D--&4 VR
M6XK7"NWQ*A-F5;.%P;D#4Z.I[>_7QKZ(IV^^K1>CW>1^\SN%'\)B#AU!Y%LI
MU:'$0$$@;*E'OBH!^"\*5_]4>_0K0/R@-CCYW2]K[7,ZE [6_4@Q*S,.5Q":
M>LW<(*;D:?>:@ETS3D8R1P]N<#)Y(%T?W18G <ZP^B4 CY+.X'K"Z\4E)%V(
MW.Q[US7Y-W9%\%Q.#;[.]MKCX U_76C3IC)=KS-H<U.IHA"0692#&)0+5E<\
M"Z7+0)0P#IB2"ZMM\QZ!+FD7YF]YOIPXB6%7?EMU'HQ2W34V382PD[-\$%'A
MB)_;Z<'K^?A&%KN09S+Y5-"VE]'SZ%-=\.B3+Q_/1.B]&GU/E6EV5R $#4<=
M-WP56*5 D]VPMT%N=B>/I06Y-O@L?RU(OE%WJ#BHUOZ*3YCP:8E/6UC8F3QK
M)[,KZY8X&L>?*&[$LN\)_<0/IBTJ)4 <I9(0!Y\[YW=O^B0_.76RRIIV(K[F
M$]M]S09'DQ7VI/4@<T2+H0&OY+<+CW62UH22C 6!S,'8$ +D:;VP./4T>Q9>
M>^KE4%R0;[X72*O347[&6BN5T'<;9&ZS6R0!F$H2(,AU<(XSWH:!5K5-#8ZZ
M#DRTTG4_&N7_X@:2?S\-MX"=_\I8'RPSUN?C.#VZL<E,8=/78Q$*NL3F.-"^
M%V:!S/<,_D$LM,:R 0^9.J8B6L@'L%JKQ5(>(AS@D]*C:N6NVH;&!@3+3FP*
M#EC:M.Z)<=[[';,F]>!^*_@;JH$'?3&634"6^ K&&Z+,FN=(J\1Y$>UA%ALV
M(O=MESW97G**;K+W'O\!IA.$UN)A]9(6.VTT9,^["[] @:/M'5JMV*5V>E%A
MF[9[[:6'QI2XN![9_/2\WVWYH"]7/;^7%Z]\:+-]8@P#;?(2OA-7X8(MV8FC
MK@FXD&EV($_KAB$?G6N2W;-?0$UY/BOSHD84ZKAR3[Z#/*3GI&WK1]<7:$TY
MEY#Z\7Q[RWX1HA#+[3C3SE-Q%J;W;E*Z-GKF_5/U3G'JY=E^Q^L:1]*P%9%K
M0J<ID+5U4[:^N@1(&".-D);Q;RT=\/Q._ZNO]/>;M(#"!!O8)2HC_4':L[@Z
M?_\E!7$X/]):4C^VW+UA6LV>0TT'J[!-5+F)C0[4)5D\BIY'\-P&T]A/'L6W
MER=F),A9#5BGVR[/5Y4 5^;AXX]5E"9W_1(%C;0)72MN?U[]JZ*B?? #/+K\
M*^,>E1V**(R@:=E)G%-%3M>EP1IZB.+KIT1O:)P::MVW]00%8UYD7>U>IK=>
M*[LS]MF:GZ3.CMHMXWN[EJG+&/>=0X>&0'='">AZ,TM'JK'QL"OUL\]W1#VQ
M^1."3?IZF/=N.$R3'9E@2\G&;?F2%82LO3_W #/L)0'8.4+_;BJ\O2B$4AD8
M;_Z\SMNTC>L<2M8:,,[M>92TV<M^P]>QZU*[C#[O5H[@E1*/B0L9@91XZ\N7
M* +&*"O15L_NI4G.(R:/JNX9S+H\W]KOQMNSX?[-OVHF\/$C_# ) "]E<".G
MROA:W#98_8CP&M3&:T\=26:H+H)M^1$5#0N'@]EHMT$?A6X/ML-QPN/:\R]K
MUWQN3MZP=(L$@$SD)K=PR)"-"%&\(')!/N)HN/0ZUV@N7N:'X#@$[NJ:-0IY
MJ]+1,7E)LWVEVPR'5EU.+)"Q-'XV&7V6@^W:3FW!).4,_T5(SL8OV[2V:C9N
M/WNY9YUYE.&:Y5NN;!87Z7C9M&KK)]&7H5YP$587T^LP:+'Q$C]$C$B=^.K6
MK%'R5?;0AQ=$*?[7'E[:0BFBY][;O5?394MK.];B\R9CR\\F)SE]XQA8U42(
M[\/Y4:&M62V4<A)5@'$3N-#B;9>!Q1#HWF?RR^+#C8LE6RJ_^9\!]KN='VR9
MB2ML;WSV1'$[ 9''20!3,](03KA4X(H4+>V4F^R5 %-8D6TP2;,7/O<4CN9[
M5U]_L/7QZU)7WKT]53W'KRM:K-IPYDJFO-2;M[)5=#WB$<A7D--X-FJ.*]<<
M*]=R6:-]PV"HC]XG WKEK:=-,KFR_G[;. )\AQ:\-!%1<.87(XHU(B>DVT=%
M7 2#O%?T%5%R+9TC[5R,R@3V%/EP[W1XQ)JRGX_#REZ_26*/60 &K+F$'/<%
M5T0EJ-/67F0",MTE0"@+,BE.K@M\$N*CQ+\Z_*#:*7;S_HK@W*X72=\>2+D%
M&]Q3U9!>I7Y>XZR4J,M>_:#4O[/(X02GN#E7Z%9$,X$EDX'UN%>FU$+'UG=%
ME)P\>[JR-IYS=^.'#9E_P:'S#>)L7"CJ:=:(RC9Q85VL: W2@Z^@%X\RKNA;
M]"UYR.T(>7>I(FEA#]YBNT,K-X,;F3GDYS1U(MDA!7?W$NG7 OZ9G2&_+0G&
M/WK[ *(U?=I:E-;_J[1*;T^^2=O^P@0,;XWT?!3J1RG(R$BU";Q"09#5P*A(
MGB2(EH9HZFHE1NB,5]\9WCZ6X7S^J=Y0B'6\474Y[5B:[X$#%Y+/OTN<P$$V
MUGMJ^7VPIA>B\)W;_MTHNE)\H2F[QW;/[=/D9K=]>]_(Z2SW5Q1W\UE78%-.
MV<I-&%DHU+7;S-"X+>#Q\55U:UQ/& *%,V6* .2,++$2QY.,T9RP&X5-=TA&
MD#??RR'V2"M)H\\,=N?FZ1I*_SCB6?K2.?SNA)'7B1-G\+R;AH+75O..*-9B
MLN@6/0S.;5,TN;03!JQ;I@0_L(O QLJ$^8-*Y[ #C(KL,2:Y4ESCVR#"9>^\
M$SXL-8#O=@G +HI:#MV/ZH>L]R%LI<H0"3#0%5L2OGFT8Y"A/4K=!\ AXCR2
M%,C<Q^!<P_$)9G8KQ?E@('5)%(UWZ35OD*P!N_$M4RJ=\YPJZ]<)!\+NK*JO
M[*KLV2U3E9%K5'-P>^O.9<N1,R!S!R/$%3(:A]7EA-%\>JH(3>-,:_@89YI=
MW%Q[@[*D,) 3NS*L\G2-K7>33%Y54]&;V[^^+*Z^X7I',X!]2 *4Z;9V(RN(
M=EU6\W7N!9"60T6OA7-LX>&J'L,;/.\V\UK[@QU9?2:Y !R/;FD\T@7R#[(@
MXW%8;:/P)!_3C!^P;)  6HA&?Y36GDZT/*=::D21O/UB[9PO5H_X=XSK!?&B
M]F1_/V=VN*!=WA@6),'OQ4]^DR$3&JQ>(7P';>%@(8/(R0L"N0;2EH\1W(A1
MI9)KN4JFTE\'*ZV=%GF?*"KP"LMV6K5;?=\BSI8MV$][.ILN* U^WE/N:'C[
M8L2;DU$&B1_=\%=A&0Y>NO0MARKS?:M-S<D^:>>> IIJ1B<MN_"<SO;8(&E/
MQE)B )I?*B%7Y"U,6;CNTS<UJRX%EX',M0S?8'@;BF!W4">[['(,O^'EZ>N@
M>\=OF 7X5O8@G4(U&5M@1FE)K$ZL3&PTZ@HG>^Q6AN+Y'I;0V@_I_!L28))N
M^KJ7&(!)LJ!=G8G0%,@65+,R=VC?>OC!83V^?M-!N1DJ.BQ<7,GP=^V/Y%JW
MH,!E-!)6HS6#2W&A9806]]S()@F 8]X<&1$7>!VEI;JN'IO_9*G1S3)[;-/^
MZE;@N1UR+T"FVFR,,P:R]A(N0-Y/U&1?/V3_F--]G+>FN?K[YI07C[_\V"#,
MHFX?M;LMUG/DL.1:>.Z"^S[J/>X>F9;K7(Z?.:5E=D<Z.$?O38.T3IM&T0[L
MO1%^\-AZ>U0W%RA*T/S,7Z!U+7>7K#5VRBL^Z\=9 )8A!1*QXL=V6T#F<Y!_
ME'4#OX2^FM2^,)Z&Z,'XCRUM5U9W/]H\_92YHO<]V[^ZO-SV?.VJL4^_=MD%
M9)1CWDE+@'W'H'3!*,\$7HX:N/BCF(X80(5<QR:,&JD'*UOG^O2'EKY"]_/1
MK*.TGK#P</OF9;R!J[VEG]H1<K*XW8+WX,L^(,H:7M;#HTTI"7J0)7D"L)7
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M3C6#J<Y5F58[#?Q_*:3?U\H]<%8F-M4>4#_TCT5#0(!5>Q"%ZP(EX5:454@
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M8>*Q%8&P5NY(D[YF3W%^U"8(#,!@/MMFN1@YF?6XGHLT[GGWL_GNJLA3#1\
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M&/UPFXOS:U$;N$[^TLJ93ZLRLF(,SIR4SL:^_'15!)#ZT(3@.E"\7V#56A7
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M^H<?(R@! PL'A'8-\C8]X=M(@L316XA_-/%P^ZI/ZL/^C7Y5]ZXN@=R,',2
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M>%5&AU(@D?[]M7QTWUS4(\%L#]\SM]X1(L[N/W%D)+FN!DU;(LZHL[[FL!9
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M)8$ZA9D/6$055;@!(2<<7O%9;"YY*?5>UK>(@WS,\! 6F*)@@3-UH"JU%X9
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M^; CMZ4]QQSJM%L&./]_^?_RUT5.UO=?4$L#!!0    ( &*"95%-Z,'L,DH
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M0@.,EY3N.T[DI_8,C/R94WV:2HJ*T9)A5J_>S/]VTZ^249'.KO]!8DYS_/A
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MOA"4_!(L'DI#<>7#YMP<95?X@-A'W+-^,]>2J(]9V\I=M"[VO=8KU<C%QM/
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M;C-,C@J?78R-@-QM5:O!$<7"VN W3TMZ:AJ80B;],>?'M)B/C%^63.HE?/1
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MH->JW)>T%O)&WBW\GL<A:##H:OF3]B"E6]I+C#G]L:/*0+]&J'O!VO+YA9'
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M43L;ADU0HE)I'Z'=WA+TUMMG.]\UNG;7%M"%3RB)F+R6_IPIA)2 ;!KHC$V
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M<I#QH=&HS?69C_?'9K@\N:F>=ZAJ8:_07U*7P^K^)]0-DIF5898B(JGPZOA
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M?XBBR.%]$X_?QRC@KE?Z-1>]'S3PS_2REW#=&F%P]TVTL+T*56 U:_-OA"N
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M>-IL!$,L:,*D'ZM=U.43&'TUI!B(H<498WRU%&P!]9K4BG3G*#Q/%:8^JUI
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MGF?^$D.$66:-J7J0#?*+2>G4<+FG<UQN[OL-=L&/DB(W.<KM,/[^)_@'.HW
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M%4@%*>[^1;J/;;DMLK*#B\+N;X0J6(8D@JKYYJ%MV(.T8'G[&:4KZNYE7QV
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M.=< W?UXV26[=Q[WL5+W\JX7+OI[[Z0^RRD!_.?L5A_X8"4(NG$Q0N#%M-'
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M_=_?[M?.H\CR)-W\VY_@3^Z?'+%A*4\VM__VI]]N?@'QG_[WO__3/_WK_P/
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M)>M$/BG_]CK_J^"W:F$ABH]2K3E6'.(@\KP !,(G .$0 \)H!*0OA8#,IU&
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M.6_G49:8CD=[A+UG*=^RH@DN>7I/ON;;I,CK6$@4($JAA !BI+S.F(: >$@
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MY)OM+E6/CC1T":?IEQD=O]RIU+]JZJ:?=//VL_650Z2:EIQ?TDR*I-AF8\8
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M%&5Q_LD>JW F-B1+4ETC0LVK11TJ*I@;09=!P%U) >(N X3Z(0@#S!$,J1?
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MKIA 7H!Y"&+&(C7'4@BPP!"(,/:B.) (<:ODDB=D+&T.;%0<5#[W%)9FT\9
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MI"CI$/LRB4DNXW V'8G!J_TXY[WBLBK7QI==??>WW_1U2K'R!6<Q\WQ  I\
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M6C'=8-LIZ9#"H>(VV92W0%-97V,M;YI5U](LKYC-]V%(2* K8P] 5R];$66
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M>O%#LG&V.=<_.KD&XL>94N58?AV1*P3F/@>A%R@GF*KABFG( (0N=D,*(QK
M^NMXN^'?^;?16##;ER$V_#O\)@SGR^7U\M0S\/"$2;N42"WKKYS&?J<&P&D0
M<$H(%I 4J5^?+2(;DJ7JWT<:I'[],5K^HY[B^]<03#=EG'R5,^QZ6]REF:[D
MO*)Q$$!&?4 B00 *60AB%B,0DH!+[/M1(*RBT3MD+6VEU+XP<]5D4]NK:U\+
M\!S&9M/!2,A-3.%]0>M5T^\"'&-7\#LG;O9Z?1?L/E6=[](K0\^#3C/=/K-I
M*;W,:%GR6QT%_51N1M^(;\5K9>,?*Q)%;NR['I"(Z_0#/ 24$E?O'4?,)Y[R
MI*VN\(VLW](8JGW"<J/FE%S?7-&7YS^+=9FCOKPJ<2JYK/HO+[-(*@](-6F;
M9G3D;K<]\9J],V?T>W?^[-Y)N'K6B>6=9FW<57.%Y:D^57.T;4YIW"0';*/"
M/LW!W#@JOM"!WJCXGC\('%=,_ZQS[]/-K2Y+?KWA98UL_6^E$4TVRLN]U\G1
M5X)XH8]C# )&8^5]!A+$$8U &+HPIIA2X5I%*)F)71K-:ZVO'*UW5<9=1P]_
MV55UUY>0*^V=2GW[M'4&/6%&T>/C.S'SC@5MK[QWYDB-G0O/0/+L^?',T3B5
M,\_B[=ZAE&*S%;\HW=]^4ZUOR/K--B_2>T4 KY]^%>EM1A[N$G:MKYT?^#>8
MA=+W/09"@94SR[P0$ C+VM1$Z'L_,K!:1 _096G<5IOBZ&_":8QQ=M;HW;Z]
M/4YID(VW,WI7FO'@3!TT,3E.W#=]0D&'HCIRH&AO=>8.(QV*VXD@T\%-]N5A
MG1R5%5M=_5&O77].[TFR67%.72:""*"8(L6Q$0$T%*'J/$*AYV*7N]".8T_*
M61Y_MM0LU_+.[Y6FUJ1X&E=3PAN,UN1D9@]4#X;JA&%<]CDM:F9FZ;3WF#6Z
M'^\;C+JYO5'NGG8#E?M79T9_K[.F?Z3K^NYV_F:;94(M9%#H$I_@"/BNSP"*
MD L(1E M*2,IXIA+"*V2FUM)7QI[U&HY#\ICKB^_KG=KH72O?E6^H;S+FN]6
M1PY-LRS]JKK2<OO0KL/,"&BR;IB8EO9+SS+3>EFLH:SML-=:K4(KM<<,:.V!
MUK@QK38*S!S6V@.;X\C6/HW8YY-X]^GSS_N;Q^KK*:M$-!DE?%="GV' D?H/
MXF&H5IR^!'Z$?3^ 4GE%1E7Z+@E:&JLI7?^%W#_\Y>>K_47^%H69ITGH1+>;
ME\;$;&(*VL-UK*SE9<B+H)EGEQ@+O)GR2[S;L/66BUP7XFFR+21EB:HF*8^:
M6S?BJ_/')OVZ%ORVS!XAMVO] E>KJ77ZH!U3_8AZGRLOJ<P7(;(F=43]E[)E
M]6,AV-TF^<=6E#\E]SJIG6B21(AO25XF.6LU5;];)Y_0IX7KG6)[I9*->OU!
M>\>ISEN1)[>;,FO$@5XM1?1?]3EB2X7\@@ZE"DO)QC%2N@N3[[4CX47GZ[.E
MO# QHIWTPNCY(6DO=DG%=]D8?$9=SEP,I.=Q@&00 ,(C"+R80 YI$ C?*NWW
M&3F+F].JQ W[B@3#,ET<XVKF9H^ UM2S60^@>B:W. O#^(DMCD6]0%*+L_:>
M3FAQ_O&>V7:9FLFW96!+23/Z]#H3=V*CV;\2V5SL(K' .% ^+Q14K?$Y 23P
M)/ 8D7[H0<\3GE4*75/)2V.-ZX]OWCG719$E=%N4&_-J!OU$.A>3 [$WXY%)
M$)V863K G."JF#5"HR:%-18^;Z976TR.TK=:-V"_)']-\B1/Y2?UZ37+#N48
M?=G>*Q_I*95?E$>=R(01Q8N,Z8-IO1>:KA/63OHL/"^2410#CR()D( <$$$8
M"*.0Q]@7TC=?NH^AT-*(K;1)>_MMJZKHC<JNLOS'WC)G;YK3V&;M0HW6NY>W
M#N;NLXFI\_ON+O--B[F[;:;-C;FZSVK!/2;6'0OS4<3,MH ?$Y3V0G_4=ONY
M_[\DFZ00[]5$S=\I%3:WB7+!JAK7U_?Z_.J_2[7>?M,AK>*_!,E^40-@!1$)
M!/,8@"14:P'/)0 +]9\X"GV*(YT1W2@?^C UEC9_5E: T@QG;T==,_S*:9OB
MU+9<.=H:1YMCMWCHV7-F*XGI^V/BN;&S*ZY*\,O _[8U)EUAO>(8AN28RX^>
MFLRZ%AF&UN'"9&!K]JN4OPFNZ'I=5YBM8WV0\*7+) 9!2'R "'?5JB,0P/5]
M"2&#$$?$=-5Q2L#26+#6L2EU;!DY=1;&R^[]4' FIJ2)<#'WHX?B,Y-?W.!2
MGH$=@392$K)+>'3XKB=?F\T7[5*Z[5MV/C?X7FK5ZF=1ACAM;M]M5%_=E]_%
MZZ?ZCU7:S=@+ I>[OLY,& /$/0PHCWU H >#V.,!E7WOGIKJL#1^;-\O;3[K
MG15.RXRK,BM'\^$/2X9JWF-F#N+$_3 Q%4_3!4,N@=J".-%%3V,U7NHRIRU.
M'1<VK9OJ6667?*MR1K\A6?:D9.CKG^]WQ:%)P%Q.8@(8]W629RI!'# &(I>Y
M,<>,1-@J76*WN*5QX;YR@K ,=[T JQF+C0?6Q(2E2TO46>';JDY4A=L,EE&+
MY'9+G+<\KI'U1X5QS=[J>4A?KEGKP-;=#GJ(<2203X#'8 "0B$,0:W@)C +L
MQ5A&T.@XJU/*TABC":XGI;*VI61/XFAXN#X4G:D/TNM-Q@:@2<JO=F$PZE'Y
M24'S'HMWV7IT!-[Y<,]!G[*D"H MM_W+NR3M0(F;](.R)-T4RJIUZ<"H\2?R
M)GTP\J!@4DJ@O D&D!\+G4#5!S'U<.C&,2.Q7<7K0>HLC49:,0M.%9/]+&K!
MT4FT+;EE6'<9DM!LG3 U6^FPGYTE3FW*42#0<VN<QIPI(H-&0794#ARFT;QD
M.0IZ1ZPZ3JN]]_&Y#IG7PJJ#V3KDOJGI&2$F**<8N%R[7Q@)0'5*8NHQ%$4>
M#2.S>$A3@4NCT&9KMJUT56&V5KO'-1<CX(U/ D:#<Z:3@=F1M#X[& W1F<X2
M1D"VSY&"$4R7CQBZFYG[R,'(J!-'$&;O#2SC6B??+)[J4[&0>1QS'(! " E0
MY"ERUJ5(?.A!B+R(>+'5A?1S@I9&RJU2I#M->Q9M/834S$,= ZB)Z?841A.D
MK;B$Q"2%6@]EO4R5UC,6GRW1>NYY>\]--?8WHO.4-<$7'O&]T(^!'^EJK"(*
M $:0 .H&*("A%R'/V$D[:'MI0U]_SY5^/4(+#G&[[&,-0&.&S?+1@#!WD08
M\A*1%6V41@RJ.(-"5U7Z@S?F*T5_6M5G]>?//-+76]%7U\N[W+^0)/L/LMZ*
M?77JE8MBYKNA!WRNB]KX4@),.0<0^Y(+*@+?M_19NL0MC;ZJ7;ADK[.MV]*)
MK:GS,A9BD[LP.T6O'*VJ4^K:*C\_IA]C LJXWDRGQ)E]&A/KCST;H[=ZIGE.
M'A,N-CQ?1;H>M._Y0$14 ,0X AB3 # 12 ^[6/"06V5R;EI>&CGL%+-,P[Q#
MRFS\][)_XJ%^V73[-,F'9HZ:"7G7^+S)C@]M.LIG?/3 @*JG9710WNPU1))+
MX@O@>A("-8EC$ >8  %1%$@<NJZT*L9\)&%IH[&E8,^\F,<@F@W00=!,/%"M
M4.E7Y/24Y:,7.'TF9/[BIJ=L/%G8].2#O6MU'=Y8_R"*CU*Y_ZN8>B0*/0HB
M&$4 "1H 0B$%, J$)-#GOH=61:H3T1E]PAVRK,;Y3N*$"VDMPV'/#L:3:O.,
M'!S4OB$93W0BZ[\*LB[NKO39[OD<4-:=8,8.(T$[,4\\#S2H-R-_T $'/UXY
M2M^R[A#Y=F6;8J1/L:]+<(U<[.NLN+F+?5VR^T2QKXNOC)!Y6_T@LD?Q.5VO
M?ZDB"%<\\AA#"E#($5'.A8L #5P?,#>*!,=^B+%5L98+\I;F:CQ/,%WKZ_RN
M-79JE8>DY#X!N!G5C CCQ'0S",%AN;K/XS)9SNX3(E\N=_=Y^SMS>'>\-O3B
MUH>TW)@0_)/(RNL.RJBR:%55F>I,_4#,,/,$!%)*'4E(71![,0:0QB3V(\IP
M9+4O.4R=I3&42;G EGE3U OLU:N&"Z[9^FKJU5FKFW:FM#NFKA18=<S,-0"'
M8#O-3;!>&KW0I; AZ)V_'S:H53N>SK-""18;DB7I;YO\0;!$)H+7.R-2!!3Z
M40Q"C^LC;.HK^J4><%$4PXC[4B*C&BR=4I;'JI6BEOM+W4AV4]YH^$S.9*;0
M&#.2D>D=1*/>;Y&,^NF08+H%S,(;1C8V=&#V<#]OK*Y%F]^DUU66[D]9^B"R
MXDG[ +JNP5OUVX?[LJP*<B$1P@,1TS68&&<@#CP(:.CAD$0>H7ZTVHA;[6>8
M^5[FPHV^>%Q]\6T5IOOPKSE/*M=*9U.O]2ZC.46CM)T'9=$39M[2R.C.PR>-
MTAK56FVGT?NJ=$R+*KW]VXLH6[M ]H"-Z>Y82)_5M;%'Y="-Z=&"'9EQD:S>
M*/]'EZ)[DW*QPMP-/5]Z@/)(+1)I$  <Q3&((TR%U&7F0Z- N\.&E^:8:-W*
MJHR.ULZ,;X[ ZF:3(1!,O7=M9KTQ#YPS=3_*\V:8YX+]=)L^OE*O5"-<_>-P
M8!\U-\NP/6=$,RC/_MU^E?!&S7[I.N%EH&!YL[QV;3&&$>&>'GZQ!(@0]2\<
M0<!8Z/HL]".7"--%PCDABQN*;3VK) @]E@MG(;V\6A@#J,D/FWI@9+5NN 3"
MT&7#V?9G6S5<LK"]:+CX[%CW7'3([@JSF,&0N&I!(+F:=%T*,&-$K13\T"<4
M8>8:I1;L%K.T<3_%'9<23C,G?SA($X_YT_=;1HKQ-D-AVKLMI:07OMG2MO;R
MO99G3]M[VC_7]P,^B2Q)^=L-_UDMMU<4(5]X$@,.U<!',4> A%#YW3"D8> J
MKYL:)6$^*V%I []1TJFT_/_)>]<FMW'M;/2OL"I5V3-5C6R"!$$@^=2^S?8I
MS]BOQSNIG/F@PK6M1)8<4?+8^]<?@*3N$@6 ()LY;V7'TW:3Q%H/R >WM9Z5
M&#,3:Z?[+/PZD/>GX[WA&?B3]T;&:X;>Z7V/J?KUYXXV9^]TZWCRWGUAR%[_
M[I#!3!>DU1Z6;^9+MA1SMMC7=VH*O,\$)B77M #"?.ZV]!(S0WR> :QI5A82
M,5DXR;AXMCNU3W]O<'*889F_' J2625'>[+Z>;4PG5#]I=ZM<IT7^':*RT'"
M(% /OUIH4=X;>X"XBB> &8A0_Q,(]R9'/)/PQN'TE,+_]K UR"^KE?QSOE@\
M+B_4U ^I+8?X B*YQB@M 6,I!HB5&2 8<<"YD"7,54FI5XD(O^:GQE\[Z^N-
M](O2$"YY6S'ZQ&V!,QS2 ].7,\B&R88(Z @#+N9:R=."4==08>B<KZT"GQ)&
M>38HV]"JE0=62_'C48CUEBT>&XU/\X]U7M\,$B(ATF:*IGD!$"<:D RE@&@.
M829Q5A+BPW1.K4Z-X*S1R9'526NV'Y^Y >Y&8]%A')B]O!'TYB<O1&+2DEO#
MH[*1%Q;G).1WL[^*R?NO\]5<OF-_5F8-4]73N/90@L%42,4R +." 21A:9:#
M&0,8E9 BKC(BG$M8WFQE:MS2&)KL+&V6) ':'K=A[6:4:& -S"##X^2NAA(%
MKY%T4:[B%D<.Y2X,'<(HM^\=32+EKOG'8BGW+PX,F%NO]'QC.7?&.<PEE+9:
M C%3+9AG@*K<1L4BP@7)E;#94.[)F(='>W'>"+F7-A%0L?72C";57W]:V.Q
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M&\BZC<LQ\!KX4PZ!*B#)LQN'N*F;-]H:.2&SV^/+-,L[U_M'RG\P:P/S0)O
M^4VM?[S85O.EJG;'B[9<>&KW/1!,,X THH#F0@-*$1(*E9 2YY#YSI:FQ@VM
ML<G.VF1G;D!^2S?$W1P1%;B!26(\S-Q#[:-A-U+,?0\,O4+NG7#IB+WOOG^T
M('PG-XZC\=UN")M@_:8VAYS+Q\UF/>?;35W;9'5:'WY7=GM6PI+#PI!J;GX
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MJ"QV>92?W+_ESD:=7N33C,I/(WSA/^V,_OFOQW6X31](E:P/YOM]^-WPN_%
M?S1'K EE8?MI9^G/%L&/#MAY\X03)C%IH[O!45G$R?=S4G&[R3\^[1W[LS)T
M97/R&T7LPBP<M%U6X,R&6&@(*(,I*,L,0TX$H:E3+:4KSY[:G* USU_&X1IN
MW530$XVAMR-B N$>2=8#D)&BQWR \8H<N^%Z1[38^1VC18C=,/4X*NS6)8&;
M'C9ZXX6A.&ESA-2RJCOY<;TV/5.7+*Q>_#A<TV:F/UKAV_=UV&[UB[ER4[UM
MXW?/2M>]_J[68EZI#^NY4+-"REQ#C($VK <03"6PM3D!1M@PGV9F N64]_,,
MMD^-36O+E4Q^,E.&;=7$H]6!:#][;L*,V/V.FSK3[-2A-XFL1X!;EY)COY-C
MQ^VNV_&%K?-)[?U#TOK_D#0(V-ED@\'#9='1'0Y)#43$O:?Q>R_J7M:(YH^[
M-S9^OUSLM3V#"8'1T;7(^QLF[)'#C[:,$T1(\%Q+0$16UYK7@%.: 2DUT5KF
MO$!>Y:6O-3*U4::M/K S,K!*UE4XW0:#OB -S-K>^/A'+G< $#52^5H[XT8F
M=WAZ$8G<=6UH]NI.I/:E%7MDHIY@MR\K(Y@R5*8 ELK6:+&EY2', ,.:R*S4
MR&[\>>6MWFYL:AQPL/4A^<U<%UPJKP-?-S*(A=K I' P,]G9.4@IO/M@Q$U
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M*U6> :5DR0M(8:&=#E<=VYL:$^PJ7[<VVZ.R@]7)'];NI#;<(]C"!?9NLA@
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M#)G*1.@^5AXS(X>'A6])V^)C;/&!?57K7U4M)T"@HA23 F $S62IP/;,O,0
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MWD$T#E\Z ]/!H/>?,1JG.KMSS++N-X6&C381:C8U<BFO;-40*&@A"P5((11
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ME=L7!98;:"O\M4)1GU;OYIOY4]WGOZO-9E$O+V>*Y4KF)09*P0*@@C*K?U<
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MA3TD,--YRROU5&]VO%PMJ]5B+NM=D+<;]:5JPU$1HP55L@!<V-1FH27@)5,
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M&$PRA;(\RU(OUK^.?I9F_9H;/(-+PG;AZ6:W J TL6UJ)(R,B(=[3C?-M:>
MM2KZ80A:JZ*CJWEK5?3K>U:KXLKC?I9 JL+L7 5;W]YM-S4%Q(IBDJ)8:R X
M-8Z13""@.;*[QUC1+*<\ILAE^E]J?&ESOI(OJ@3T"B5=!*Y_GH^%8_(@FS,2
MSG.Z3^731-XU,WFGQ-^_;K__P[QVF,3FA^=S]V*3LTS8/F6:6=K[S+!%^E=5
M%M_9OJKUN=N75:S0[J/JPE4U?7FA=B>FL",-GR5^YR(C &MF[^ZF.<@UTD!+
M\S\A,Y0PK\3"$;(L;>*?5(E:NE1QB*8:VTF=%E&?"T]?\'%T<R!F&IV)[="4
M ^/MC 2 -*3#,D:<69V: +@]=WQ"-#DTF]!J7:R+ZHBF"66]-TI_/C#5?-F>
MJ&IL"+NF=K?5?&@FC><$B<T^S!4"-&44<&.$I:18D]C)D1HKR-)L;QWSY8_1
M)_5M6QXN=M0J^*;D#1P:-XLZ!^ 3F].G*K0B[M4E_5H->ZNFK4A=?2RR"D65
M1@%MZEA0PZ88#I1EYI3$<8B=IS".;&_@]7]QI^3#6GW4U:6=-X]5-.M0R$\F
M-M8D"4CC1 %,- <<2PT2@42*,L$H\ZJ*V-/7TJQA(VK%JVF%M8;Q$-R]5@30
M&V8WLQ<(O(DMVPC<_&\$7D<DZ#6_GN[FO;MW7>^S"WD.KXS="?]1;%1%"+@2
M%*4DT3%@+&;&;N 44&5VN#!5'%*&8(*]BJM?Z&-I]J*U0?K+"GE@LQR\&SUA
MZ;O+'(30?+M')W!&[ C/U)]FIW?JYH5V<&=Z=N_,SA_U#T>_V^R+_>-K*<UG
ML:O_9=M%JY1BDM!< )H06_>').8G)4!.*<=:V)QSY1J7[NQE:;/](&A4BWC3
M_!!5'[?S_=9^8*_'K8/ -?7IU%"DO,+95Y$8$=?N;GNV /=5]=J1[NL/#YW^
M[^Y5::,ZOY7;'_L[RWC%-H\KQK#.4HH YR@'6,3(+/L" @;S1$!,$,ZQGP&X
MV,]"34 C:W00-JJE]34 EZ%U-0&C 9O'"/AB-< $]"(QV@A<;GUF,]"KXKDA
MZ']\DL2^=S_K6A^_;;?R1[%>KW#.C.=/-&!QINQ=/@FH5@1D>4+2-+-GUUX;
M E\!EF8\+,7D2>B@.7KGX+OM(*:$=&+S<CT[+WIUE#]J% AZC6T8=C,FY9W+
ML*2,O$Z$/-/QNML9&QSMJ9QQ".)!EF :$P)@E9Z7)<J>*%$0$YE*A2@B>F"L
M]%K72S-N[1!@;S&:T:'4JX/B&UD-"?6,@=:1*(\(O+H"-DT<]FKO+Q26=46E
M.TKKW,( %IP[5MZ;;^IA7PBVKL^6ZEQ^B+%2*>$ 48F-GY80D&,(049((AF4
M@KI5YKG2S](LUE-1C^>O?G<HKF';;XL"(C:QX9D%+ ]VF3"@S73AMT')%E.)
MNI!\_;,($1QW1*>/^*7G[?G(7:ZK\(3 Q>'Q@=2!Q<98YK>EDL7^/;,G]?O'
M/]G/XO[A_LVV--MKXW>^96;@S=^OJ%2<QA #S6@,C VU8?'$+&<T9\93S"C4
M7G5L?#I?FGFM8KW&33E('S7BVRM3E0+148.H4<&3A]!G9-Q\PJGPGM@XAX3:
MG\QP &9!*0Y]^I^7^'  ,F=TB$/:&&;I7O]@I?QBWK4KT4KJ6,90)2"!R-8P
M5RF@Q-@SPC,99\@8,^;$-76Q]:79JDJXR$IW;1UV0,[-U S&8V);X@Z%MZ6X
MJ')(4_"T@UGG^D7=GD_FRP\-C<:;B;%AZ[H&XF=5?B^$^OW3YYJ4.Z,X2273
M(-8R W:VVC \!0PI)%D<(PZE7_"]M[^ES>CWRD#)UKY!]GY,76/JP9":/(1^
MD#2J18UJ6:-71MI?)B _=X0F;(2\O\N9 ^).^I_'O]U>&QCNMG=7W["=DO:<
M4&UVU6[X=5F:3T79?=2;Q],CM^S1_E5ER9H:_\<K(!\M/^:7.[;Y^,TVL?NP
MK;@RE6R(&FN>QM],T_M?V5Z]9T7Y7VS]H#YMU^OWV]*VNLHUEVFB,$@I-)8+
M8P4HSC. <)[F$.:(YEY7-1:FW](L92,[:$@T*^DC*WYDY8\J!2PGR^&>N6?8
M?EG@KS@FF,&,@%1C!K#6"G")8R XA]32JMHD5:^:O@O3T.?SFJ>6\/^O#\SQ
M\&E94B_()ZG4!MSJ';6QB5K@V-L%[>=J@*(*H9N:ONC)E=4*I6AO8(IJG&ZB
M(U(WT1F1\.5/=(IKK0O]$H(>W2U,Q7G/!Q>F?-<AY$+%#$\")<3#O:74-8*T
MR$]65&(LJ$  94@";(;:. 8, ^,0H(QE@BG*0Q$_719A:8YA2\PGM$'A:)PZ
MAL)M"9T6X(E7N?[<C9O(&_N@1$W]\,U%SM0AQ6((F?I1\B%ANM*2GPW<E?M5
M?4)0AZT(UEF.<PI$G'-CVI($L#1/+?-23@2A&"9.H<"SEI=FL6KAW S4.4[]
M=F>4]A.;D^:<+US$KE/;GMEOWFG-?//;\UE_WN@LD[E3EV:.=C\PS/VX-1BI
MLE2RNG9;^4V[UP_[NVU9_%O)%<D192@E0"MH2T%E"C"B$\"%TD3&64:$5])H
M?W=+FZ1':0\WQ6\..[E==)+8S\&X K:;,Q$.PHEG^@CTO%T$-U!"N@-7>IQU
MZ7?3_ODR[_C6,+MRF3"W7KURDE,J8PTHE@Q@A&- &<5 <::0Q%P+ZG0EUZ6S
MI=D47QIJ?W3=S$@HS"8V(AUP37#@YP)(2 /2V]^LYL-%\^?&P^F=@1&1)LCR
MIV*V'IL-U?R^^?:P;]5H.Y7D@KEF"5<*: B931Y( (WM'RE'DB0Y)]2K'K]7
M[TLS+JT <$M\3^9#/_P=(R!3H3IU\.,BH%59R?;O!U5NHD]*/)2E-53V"3-'
MRN-?_#5)5;1!N :-BG@),&] 9 @V9[&008T,K1BY9\5&R:98=[V>IX32U%8G
MRI!&QEMB&6 QSX$2$*7&ULF4>%FXR]TLS90U4D:-F+XE'B]BZ6:MQB,TL5DZ
M V<"?Z@?A+#E%"_V-'.QQ#YMSTLA]CX]TN\YDA[]43!NTZ@+M:O-C_RX.:XQ
MYH'V"O.&[8JJCLJA+)<D2!&>4:"U01QCGH <ZAP@E"<JQ7G*4Z^DRJ#2+<W8
MG);YFS:U6$O#9KF7EH6L9YFO]!Q182WL1^#IG,T]M+,Y;S..ZG 7+B3ZD[AX
M001\&1<P)+:=+F+03@9R,VFMQ*':><W,_(GMU8%A],%T]O&;*JL3N]V*9THA
MD@DSW) #S 4$U);%XBA)H,**(+\:F.Y=+\WZ'R6/6J3B5OCH:<GC&\M@)+RK
MC7N,B9N]G@;IB8UQ.)#]N:&\\0I*%^7>^[P,4MZHG)%*^;<P\&+S4Y;D#^K'
MVS4K[G?OB[62-8M2#CE.(": <VW,&<P4H)(S(-(493&724:UUWWFZWTNS8Z=
MDW4;J:.#V%$EMQ_QN0_\;I8K,*@3FZP >/I?479'*.C-9(=NY[V0[([#V3UD
MCU<''FZJ_5NVN[LMM]\+J>2;QW_M;*K4[U7VZ!-6F15-)(<8"L S)@%.2 98
MEB1 )80R)K!QP-AJO]VSM>-1IW/77M;I*,"$)WEJ'PDC>O1@\^"+C?FGECEB
M1Z$]CT'=Q\'Q4'02=*<^(C7 6JFC1FQ[Y^#5OPXH_Q(=A6\18 4\-?5&+.@9
MJGOO\YZH>J-R=K[JW\*(*Y7\>C8]?YY-7^?,?WS8[_9L8VL:/LN:_Z1L31M;
M],$>%)LY_L#67U1Y'Z^D$ G&@@&$I0 8\13DE,0@1W&<XXQ(F'K5GGD!'9;F
M^P6XBW2\;=2"X\)]HR,D40N3R((RX#;<S!^>VRJP\,]IXN5DT5_2L#MK+S.6
MP>^ES:S&_'?/7F:<+MXO>R%11E.D7;L;M^NZ'%<3JJ5Q8CY!!#(84X!CQD&N
MT@1D<:9SFFC!D%]!@U"2+6Z];=.(.5C,7:_)'$W9-G+8'=?%EQC,J5>[><=Q
M#(5<&,PG(IP;*=Q+T=.%P;2'S"Y0!Q.5R^GL_53^:R-OS83Y8*907?DV3C2)
MH=" 2J( 3E@*.,D2('*::DV52F$2M.;- "&7MEJT*]5YE2&>="0]=D,O.#X3
M+P ^0Q.^8L8([&8M>S%$SF75KAB!M'<!BC%]C=T!?%*VO(796MC<$O.+*K^K
M-X^VSX_Z[7:W/V7N*TPHCF,)E,AB@#'- <UR#I"6 LF$(*0&^OK.,BS-3K>]
MP3K":MGF#\4-]MLGJ6.O=[NM**K_\J/8WT5/E*Y2R-[=?UMO'Y6M56CW?^8[
M'NK?NP^JKR<_R5#-Z+,_1;U6P/KHE46WA::W]K;8A,3T(["<QA=W%^.%O&YO
MG+K]:_^F_+DEOY3,QG(^/][S[7J%&8&)$!(P"#' )(. Y1P"FL=<Y(1FJ7 Z
MNSAK>6FVL!8N.DCGSA?Y%*Y^>S0*A(FMC*/^7AR0%W4=P?KXM+W9>!XOJM%F
M=KS\P,PU7^MP[+N?JA3%SBX S\*Q]7]1MV4AU(KE!H68,8 2+HT[!&T5ZC@&
M#*4JBX7YO]\UJYGD7IK9:(D=L7VDC!]D5N%OJBRV,GI5;**'G:P*:.ZL\MT<
MAR_Z+03:&<\_PO^+S@9;VE\X&VP0B"H(%E##<MB8+:(VI:?HR]JWAQV/8+4D
M!W8_; E\UO0AA[$.+K>/&W\MU@_FL=/-Y.I*25,)=I50%:=:(8 5I6:%2PG@
MB$&@XY@2X\UJ[+?A#R/6TA:P8PUH5INB3:677<7$]O[>&+O=H8[1]J3A?_@M
M8X'&TVV5FG^4)EZ$SM:*#\<!JBM,M;1Z=KMDDKK(81$.N60$DFS6%2$LFL\-
M?N#6_=E-O["??[*]-62OOY9*M2@E%8(I1(* C$,!,*,,Y&8R@"R',DV%H!EW
MNL'2V\O2K*V]!59+&AU%'<#5V0UKOY4,!M;4T8C)<7)G- V"UTOPF7: &)#.
M]"HT/62FW>_.1F5Z5?PVD>GUAX=YNU_*ZL[T8U66L+I8O<JD4+&2&>#2NJ^2
MI\9SI1@DG".1,YG$>;[:J*_V-.:+NP-[WI/3%TP/7_!9?U/&(@^"-I4T*UG]
M?,X+J'()[<5( V.JH=D4,&H6'/.K8%#)G',L"&Y0O:T".)_WK-S/B.WS7J='
M^";B;&V/ZFSPBJNOQ:9*4#Z&L$:#;K#-98X1T G. 88R!IR97Y.4,(59K%+Y
M#/1W&SD[Y$V?,P/^)%HX&FJW_=% U.8ZA/"9^-X[EV[=0^Y"+O0RZXZB6\OG
MNX.>)X?6=#KPX+XUFPAC1XY5[B6#&A*00P+M48,&7$L)4 IS@5.<<N59F^E"
M+TOS]!LAHW<_BT,%Q0/3D3VF]:Y0>0E5M^D^&JN)9_P1IEK "2J[]4(0MG+0
MI8YFK@#4H^MY)9^^AP=6Y*E+Q)EUM0HRG%)U4I[',4,)(#I) $XLUT5.!2!&
M32*,#>!)ZL?OU]F7S_<]#]/>L7#A;<.E%[W>[\N"/^RKH\/]-GK+2EE8RM?_
M5&R]O[NQA6/^[EEZIQ-\-V,1!-")#<8%)*>I-7L5C*!5<SH[F[=(SC6=SVKB
M7'UA,$V8<9(+MF[1EUTJQYR8S7!"D00\A<:UB#,-<A['(!%$RD0R(5*_<MAN
M_2[.V6C$?D*M>!+<FQC,"7Q'#R0\I%/[)%?0G*JXM1]0@<F^G+J>F^'+!X\+
MM%Y>KP^LU75*D7[[4);VO+PYK^00(BY%;C.LC,,#,04L-@X/U)@(J&2"I1>9
M4'=72S-'M7C1^B2QYY%Q#ZQN5B<,6!,;FI:0-U$#VA1'MM?1"%I=J[NW>8MJ
M7=7ZK);6]3?\$ZK?;?9FD_7Y3JW7-NN&;1Y769*9Z4\I$)(1@ E2($\I HH0
MEA*=Q6GL=*GP<O-+,P<'":-*Q*B6T3W!^@)\_29@/"A3;V%\\/!*N.Y6>T36
M]85&9TN][E:HG7_=\]3 )&SUU?H+G]0W2_II"7_TMKROSF[_.%8;3S%$&B$(
M,J(R@#$B((\) E0GDDC%B19>)3A=.EW:U*YECHY"1RVI1]2%=QH -T\@-*P3
M&X< B/IG"7M %#3%UZ7?>?-S/9 X2Z[U>3<<5]CN6&F]/AC FJI400*(CI4E
MT+%%;0@&B,&,$:*)&8RQ%&'/.UV:73J*-YX+[ Q?UX.7L*A-?@YS(H\X,4-,
M<1CC#LO4Q%UG_;XX7U<7$BXT79WO#BWZ^^.U$-N'JK#P;;G=F!_%H:/;[;H0
MCX<_3]% ##D6,$]!AC(-L)!F3Q.;/V*29PD5FD&_"V6^ BS0!-EU_!1,/&D3
M?;9IMZR4W@6 /<?$S51-B?3$9LM6*&_A^E3XF^@@>/17_>])PK9#T0M;&-A3
MAIG+ P]#Z+Q(\,!V!FX"]VQ?M?Y1'R?Q[7975%>FFF@DC--,,"% C%5B-H%Q
M KBFVFP"81Y3D24(4:]-H$.G2[-T1YEM,MO)WC5BNT0TAP^ XR8P,*Q3;P+'
M(^J_"?2 *.@FT*7?>3>!'DB<;0)]W@V38F,9M<3)(&6*)M!8(*QU##"##.1Y
ME@-.H=2$*(J05['QWMZ69HDJ"A-[V[Y]=3%B+IDVG@=4_8/@9I2"03MUO/HL
MY>:FH@@4D]@A)U2FS+UYVN&+YM]<U/U:#L[EEP;Z0 ]\=PAK[>RUH96$6$&=
M2[.URXR[([#9Y#&1@YAIE8C8DK#ZN3M/VU^:/6F)=^W>E!-\CL[*<%"F]DO<
M\?#W/RYK'=35>-;%O%[%9?W.'(B.Q[KF;WL _C __?-OS=^8/VQ)DG_^[7\
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M<^_ )Q2@C- 0T&DP)='>$;2%K!B ^-OOO$O[;?D^6Z8?%LN,2](EUR\-R_1
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MN9ZF,+NJJY,ZR.B#!O*&(BAG/?A2>_-ES8D92O#[K<QV^@:[GCTR (X7TV)
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MA.7?5M<&V=5U1$(F. \&8@P,%$H%07""$"L8T4@;C?N&Q?FM=W0-I-.%NVC
MZ?ZUV^T->"M0J9W-*2201==!0Z% )"L&4@C:*Z=L&$6][22VE^NCGH[AXR39
M/UI__IQFE^2AOK\),:!P+"MFP.0ZPL9'8BAI-% N"V5]<,$TN9<ZE-"NE><
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M>9KNT',(IY_'SP%D[P$[]X/JU@Y,#7/,9ZMRT?4PJJ!YE@Z"IE=>)4Z$*CP
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MOI[NEU"UY,F1P63 D6R!XG1_MXI7\Z281\.8:[+N=\0[3&L73!=LF H&'4I
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M1?"W6F>PNLGF(CI921J6A"FC!%7W+06A!%B+3KA"FGC;Z!T'/CM/-,TCU@Q
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MN0-[>%=19/$8<G *O/*K&GZRVK@L]#L?94'%%3:9+W!&I:A#&+UG*>H0JG<
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MGK"X,W,V#Z+#F5K"9Q.*;8;)BW9']R??E<!D!9<&K/4UI&9)*;I4E6)04>K
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MTO_]7_\?4$L! A0#%     @ 8H)E45J824<!"   )"<  !<
M ( !     &$R,7$Q,3!Q,#DS,#(P97@S,3$N:'1M4$L! A0#%     @ 8H)E
M47-J[G,%"   FR<  !<              ( !-@@  &$R,7$Q,3!Q,#DS,#(P
M97@S,3(N:'1M4$L! A0#%     @ 8H)E49T>XO?V!   4Q<  !<
M     ( !<!   &$R,7$Q,3!Q,#DS,#(P97@S,C$N:'1M4$L! A0#%     @
M8H)E44YZLLUW&0  @YD  !<              ( !FQ4  &$R,7$Q,3!Q,#DS
M,#(P97@Y.3$N:'1M4$L! A0#%     @ 8H)E4<L@(8'SKP$ DJD3 !
M         ( !1R\  &-A:"TR,#(P,#DS,"YH=&U02P$"% ,4    " !B@F51
M4#6:ICD0   *J   $               @ %HWP$ 8V%H+3(P,C P.3,P+GAS
M9%!+ 0(4 Q0    ( &*"95$S=PB=%AD  +(# 0 4              "  <_O
M 0!C86@M,C R,# Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( &*"95'WVM9SAV$
M $%L!  4              "  1<) @!C86@M,C R,# Y,S!?9&5F+GAM;%!+
M 0(4 Q0    ( &*"95%9.B(VX#   #M!   3              "  =!J @!C
M86@M,C R,# Y,S!?9S$N:G!G4$L! A0#%     @ 8H)E42)8.)Q[3@  ^%T
M !,              ( !X9L" &-A:"TR,#(P,#DS,%]G,BYJ<&=02P$"% ,4
M    " !B@F51>\C/: )"  #J4   $P              @ &-Z@( 8V%H+3(P
M,C P.3,P7V<S+FIP9U!+ 0(4 Q0    ( &*"95%;6=/BRC4  .]$   3
M          "  < L P!C86@M,C R,# Y,S!?9S0N:G!G4$L! A0#%     @
M8H)E47B:2C$@6@  3FD  !,              ( !NV(# &-A:"TR,#(P,#DS
M,%]G-2YJ<&=02P$"% ,4    " !B@F513>C![#)*  "060  $P
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64$L%!@     1 !$ 7P0  *R?!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
